



UNSW
THE UNIVERSITY OF NEW SOUTH WALES

Never Stand Still

Faculty of Medicine

National Centre in HIV Epidemiology and Clinical Research

**NATIONAL CENTRE IN
HIV EPIDEMIOLOGY &
CLINICAL RESEARCH**



ANNUAL REPORT 2010

contents

	Foreword	1
	Research programs	2
	Research studies	7
Surveillance	National surveillance co-ordination and information dissemination	7
	Disease surveillance	8
	Behavioural surveillance	11
	Linkage studies	12
	Reviews, analyses and mathematical modelling	12
Clinical research	HIV: antiretroviral therapy	13
	Viral hepatitis	18
	Sexually transmissible infections	20
	Clinical public health	20
	Diagnostics	22
Epidemiological research	Prevention	23
	Social, behavioural and cultural research	24
	Collaborative projects with Sydney Sexual Health Centre	27
	Clinical epidemiology	28
	Infection-related cancer	28
Laboratory research	Immunopathogenesis and correlates of immunity research	30
	Laboratory service and support	31
	Assay development	32
	Development of new therapeutic modalities	32
	Translational research: host	32
	Translational research: viral	33
	Therapeutic research	34
	Co-infection	34
Aboriginal and Torres Strait Islander health		35
International health	Asia-Pacific region	38
	Cambodia	39
	China	40
	Europe	40
	Fiji	40
	Papua New Guinea	40
	Thailand	41
	Vietnam	41
Commissioned reviews		42
Biostatistics and database support		43
	Advisory committees	44
	External boards, committees and advisory groups	49
	Staff and affiliated researchers	53
	Students and student supervision	57
	Collaborating organisations	60
	Disclosure of financial relationships and consulting	66
	Funding	67
	Research grants	70
	Conference presentations and posters	71
	Publications	80
	Index of studies	89

foreword

The National Centre in HIV Epidemiology and Clinical Research had an excellent year in 2010, with a pleasing result from our grant applications to the National Health and Medical Research Council, and other infrastructure support.

In particular we note funding grants such as an NHMRC Partnership Grant for the Enhancing Treatment of Hepatitis C Opiate Substitution Settings study (ETHOS) and an NHMRC Project Grant to investigate resistance to antivirals in acute HCV; an NHMRC Program Grant in sexually transmissible infections, which funded an expansion of the activities of the Biostatistics and Database Program, in particular the collection of data concerning trends in STI diagnoses in HIV-positive patients; NHMRC Project Grants for very promising work concerning transcriptional silencing of HIV-1 and for the investigation of memory CD4 T-cells that harbour latent HIV infection, as well as an ARC Linkage grant for in vivo molecular imaging.

Major studies have opened and others have closed. After much anticipation we were pleased to see SECOND-LINE study commence recruitment in 49 sites across 18 countries; and the CORAL and Encore2 studies were completed and presented at national and international meetings. The START pilot phase of enrolment was completed in mid 2010. As a consequence of achieving this key milestone, the Division of AIDS at the US NIAID announced in September that the study would proceed into the definitive phase, with the number of sites globally being tripled in order to achieve the target enrolment of 4000 participants before the end of 2012.

The CONNECT project, an NHMRC-funded study of the social norms regarding HIV/STI risk and risk reduction behaviours among MSM, also began in 2010, while the SPARTAC trial, the largest randomised trial conducted at primary HIV infection, was successfully completed. 2010 saw the start of the STRIVE study, a collaboration between three of the National Centre's ten research groups in which an intervention of a sexual health quality improvement program is being rolled out in a clustered randomised community trial in remote communities in Far North Queensland, Western Australia and the Northern Territory.

Substantial work has continued on the collaboration between our organisation and the Universities of Melbourne, Adelaide and Western Australia which started last year as the result of an NHMRC program grant for a program titled HIV and HCV Vaccines and Immunopathogenesis. The five-year grant addresses the development of vaccines and better treatments for HIV and hepatitis C and brings together a team of researchers with skills in basic virology and immunology with those providing expertise in translational lab work.

We also look ahead to the 25th anniversary in 2011 of the establishment of Australia's three National Centres of HIV Research, a bold step by the Federal Government in the face of the emerging pandemic. Of course, over the years, the work of this National Centre has broadened considerably from our HIV base, and we are proud to apply the lessons from HIV to a broad range of infectious diseases, particularly viral hepatitis and sexually transmissible diseases.

The National Centre's achievements can in part be measured by the achievements of our staff in the lists of publications and presentations and other measures of professional recognition noted in this annual report. I thank all of them for their contribution, and I also thank the Faculty of Medicine at The University of New South Wales for its continuing support for our work.



DAVID COOPER



Research programs and program heads

For almost 25 years, the National Centre in HIV Epidemiology and Clinical Research has continued to expand the scope of its research, endeavouring to provide new information to assist in the prevention and treatment of HIV/AIDS, viral hepatitis and sexually transmissible infections.

Led by Professor David Cooper, NCHECR has a leading presence in Australia coupled with a very strong and increasing presence in South East Asia. HIV continues to be a catastrophic issue for our South East Asian neighbours and sub-Saharan Africa. Australia's national interest is served where it intervenes in health issues in its region by leading in developing and delivering solutions.



The Director

Professor David A. Cooper AO FAA has been the primary driver behind the success of the National Centre in HIV Epidemiology and Clinical Research since its inception in 1986. Professor Cooper is one of the world's most eminent and respected HIV clinical scientists. In addition to his

enormous clinical experience Professor Cooper is widely recognised for his contributions to the field in HIV immunology and infectious diseases. This is further exemplified by his role in supporting the disciplines of virological, immunological, pharmacological and neurological research in one organisation. He has assembled a world class research team at NCHECR that influences and supports activities globally through extensive national, regional and international collaborations.

The Therapeutic and Vaccine Research Program

The Therapeutic and Vaccine Research Program (TVRP) conducts a range of clinical trials designed to assess the effectiveness of new HIV therapies or candidate vaccines. These studies often provide not just biomedical data, but also evidence of the impact of policy practice and therapeutic guidelines in both resource-rich and resource-limited settings. TVRP staff provide leadership through the program's role as an International Co-ordinating Centre for the INSIGHT network, a major international collaboration for the conduct of large clinical endpoint strategic trials in HIV disease which has more than 300 sites in 30 countries.

After much anticipation the SECOND-LINE study commenced recruitment in 2010. This clinical trial was designed to investigate the safety and efficacy of ritonavir-boosted lopinavir and 2-3N(t)RTI backbone in participants virologically failing first-line therapy. The study is being conducted in 49 sites across 18 countries. By December, 166 participants were randomised across 13 countries, with 42 sites open. It is planned for the study to be fully recruited by Q3 2011. CORAL was completed and presented at national and international meetings. Encore2, a randomised pharmacokinetic study of a reduced dose versus standard dose 3TC in HIV-negative volunteers, was completed in May 2010. Encore3, a study of the safety and pharmacokinetics of three different doses of lopinavir/ritonavir in HIV-negative volunteers was completed in January. Data were analysed and an abstract presented in November in Glasgow Kingdom.

Progress was made in achieving ethical and regulatory approvals at

many of the 51 sites across five continents involved in the Encore1, a study of a reduced dose versus the standard dose of efavirenz. A protocol amendment allowed inclusion of dried blood spots for analysis of efavirenz concentrations and HIV viral load, vitamin D monitoring and mid-interval monitoring of efavirenz pharmacokinetics within the main protocol, as well as intensive pharmacokinetics and CNS sub-studies. In February 2010, the ALTAIR CNS sub-study was presented at the CROI conference in San Francisco and both data from the primary analysis to week 48 and the CNS effects of study treatment were published in *Clinical Infectious Diseases*. In October, four ALTAIR-related presentations were made at the ASHM conference and the ALTAIR study continued to an extended week 144 visit.

The START pilot phase of enrolment was completed in mid 2010. As a consequence of achieving this key milestone, Division of AIDS, NIAID, announced in September 2010 that that study would proceed into the definitive phase, which is now proceeding with the number of sites globally being tripled in order to achieve the target enrolment of 4000 participants before the end of 2012. In addition, the MARCH study contracts between UNSW and Pfizer/ViiV Healthcare were agreed in principle in October 2010.



Professor Sean Emery is head of the Therapeutic and Vaccine Research Program. He has been at NCHECR for 17 years and is a recognised expert in HIV therapeutic research and the design, conduct and reporting of clinical trials.

The Biostatistical and Database Program

The Biostatistics and Databases Program has a collaborative biostatistical research role across many of the NCHECR's programs and activities. This includes ensuring the statistical design and analysis of clinical trials and epidemiological studies are to appropriate international standards. The program also develops traditional CRF and web-based databases, for research studies and national surveillance activities.

In addition to collaborative activities with other programs, the program has independent research activities in a number of areas. First, the program leads a number of large, observational cohort studies. These include adult HIV cohorts in Australia and Asia, paediatric HIV cohorts in Asia, and an adult HCV cohort in Australia. These studies aim to assess treatment and outcomes in HIV and HCV disease. Second, the program has an active mathematical modelling group. This group is largely focused on transmission, and interventions aimed at preventing transmission, of certain sexually transmissible infections, including HPV, gonorrhoea and chlamydia. Third, the program has an active interest in linkage studies, including linkage of HIV, HBV, HCV and cohort studies to hospitalisation, cancer and death registries. These linkage studies describe longer term outcomes and epidemiological patterns. Highlights of 2010 in the Biostatistics Program include NHMRC program grant funding in sexually transmissible infections, which commenced in 2010. This funded expansion of BDP activities, in particular the collection of STI data in the Australian HIV Observational

Database to allow trends in STI diagnoses in HIV-positive patients to be investigated. Other points of note are the development of mathematical models of HPV transmission which were then applied to investigate the role of vaccinating young males in addition to the current vaccination policy in Australia of vaccinating young females. The models underpinned a submission by CSL Pty Ltd for public funding of an expanded vaccination schedule to include young males. A prominent journal, the *European Journal of Cardiovascular Prevention and Rehabilitation*, published our cardiovascular disease prediction equation based on data from the D:A:D Study (see Publications section). A risk equation specifically for HIV-positive patients will improve of cardiovascular risk assessment in this group, and improve patient management and outcomes.



Professor Matthew Law, head of the Biostatistics Program, has been at the NCHCR for 17 years. His group plays a key support role to other academic programs but has also developed its own areas of responsibility through co-ordination of national and international observational databases.

The HIV Epidemiology and Prevention Program

The HIV Epidemiology and Prevention Program (HEPP) conducts research into the transmission and prevention of HIV and sexually transmissible infections (STIs), and on the natural history of HIV. Our work is multidisciplinary and collaborative. We work in partnership with communities most affected by HIV, particularly the gay community and those people living with HIV. We work across the spectrum of biomedical, behavioural and structural prevention, because effective HIV prevention acknowledges the complexities of everyday life for at-risk communities. Our work includes behavioural risk surveillance, studies of risk behaviour, and studies of use of biomedical preventive interventions. Researchers in HEPP conduct a range of work on the intersection of infection, immunity and cancer to inform our knowledge of how we might prevent cancer in people with HIV. A particular focus is the prevention of anal cancer in gay men. Highlights of 2010 for the HIV Epidemiology and Prevention Program include the commencement of the NHMRC funded CONNECT project. CONNECT is the short title for the NHMRC funded study Social norms regarding HIV/STI risk and risk reduction behaviours among men who have sex with men in Australia. Program head Professor Andrew Grulich was awarded the prize for best overall presentation in epidemiology and public health at the 26th International Papilloma virus conference in Montreal for a presentation entitled A national outcome for quadrivalent HPV vaccination: declining rates of genital warts in Australia (see Presentations section). In 2010, the program co-convened a workshop entitled Treat ASIA symposium on Cancer and HIV in the Asia-Pacific and launched the PASH (Pleasure and Sexual Health) report on the national study of gay men's beliefs about HIV and risk. Program staff members also had a successful year. Patrick McGrath was awarded best presentation in Theme C (prevention) at the AHSM conference in Sydney, and Dr Mary Poynten was awarded her PhD for her thesis Behavioural and biological aspects of HIV prevention.



Professor Andrew Grulich heads the HIV Epidemiology and Prevention Program with a focus on cohort studies in at risk populations linked to behavioural investigations. These types of research are central to the evaluation of biomedical prevention strategies such as vaccines, microbicides and chemoprophylaxis. Professor

Grulich is also a world authority on the serious emerging issue of cancer in HIV. Andrew has been at NCHCR for 17 years.

The Immunovirology and Pathogenesis Program

The Immunovirology and Pathogenesis Program (IVPP) was formed in 2005, resulting from the amalgamation of the Laboratory Support and Primary HIV Infection Research Programs. The group works very closely with the Immunovirology group at the St Vincent's Centre for Applied Medical Research. The activities of the IVPP can be divided into three categories. A substantial proportion of laboratory-based activity is directed towards providing routine or semi-routine laboratory support essential for the successful conduct of clinical trials and epidemiological studies conducted by NCHCR, through specimen processing and conduct of specialised immunological and virological assays. These include immunogenicity assays for vaccine trials. The second component is the conduct of clinical trials and natural history studies in pathogenically informative populations of patients with HIV-infection such as those identified with primary infection and long term non-progressors. Finally, senior scientists and academics within the program are responsible for their own research projects on pathogenesis and development of therapeutics.

Immunopathogenesis work currently relates to CD4 T-cell function in early HIV infection and in natural controllers of the disease. Novel methodologies for the characterisation of antigen-specific T cells and T regulatory cell have been established allowing the functional and molecular characterisation of these difficult to study cells. These novel methodologies have substantial implications for the understanding of the immunopathogenesis of a range of infections apart from HIV infection, including Hepatitis C and autoimmune diseases. It has also allowed us to gain insights into the location of reservoirs of HIV infections. The effect of early therapeutic intervention with integrase inhibitors and other anti-retroviral regimens on these reservoirs is one of the major current focuses within the laboratory.

2010 saw the IVPP successfully complete the SPARTAC trial, the largest randomised trial conducted at primary HIV infection as well as the PriRIS and TBox40 studies. IVPP commenced an NHMRC project grant titled siRNA induced transcriptional silencing of HIV-1: Elucidating the mechanisms and exploring options for delivery as well as an ARC Linkage grant: In vivo molecular imaging using engineered affinity reagents and fluorescent laser scanning confocal endomicroscopy. The program was awarded an additional NHMRC project grant: Antigen specificity and function of memory CD4 T cells that harbour latent HIV infection. Two back-to-back publications were accepted in the *Journal of Immunology*, which define the determinants of late escape in HLA-B27 long term non-progressors.



Professor Tony Kelleher is head of the Immunovirology and Pathogenesis Program, and works closely at a laboratory level with colleagues from SVH. This program gives lab support across the organisation, as well as conducting world-class research, presently focussed on the design and development of novel assays, and the study of micro RNAs, fine mapping of T-cell fn, and the transcriptional gene silencing of HIV by siRNA.

The Viral Hepatitis Clinical Research Program

The Viral Hepatitis Clinical Research Program was formed in 2003 and is a rapidly expanding area of clinical research and development within the NCHECR. The program focuses on therapeutic research in viral hepatitis and the activities of the program can be divided into 3 main areas. Clinical research including clinical trials forms the main part of the program's work. The second component is the recently established viral hepatitis sample repository, HepBank, for molecular virology research. The third component is epidemiological research through data linkage studies and mathematical modelling.

Particular areas of interest for the program are the natural history of newly acquired Hepatitis C (HCV) and treatment of acute and chronic HCV particularly in the setting of injection drug use. The program also has a strong interest in HIV/HCV and HIV/HBV coinfection. Further, a recent focus on HCV reinfection, superinfection and protective immunity has seen the expansion of laboratory based viral hepatitis research. The Viral Hepatitis Clinical Research Program liaises with all other programs within the NCHECR, as well as with hepatologists, infectious disease physicians and primary care networks nationwide.

Future aims of the program include continuing to design and coordinate multi-centre clinical research trials in viral hepatitis and the expansion of the research networks in Australia, Asia and internationally. Additionally, an expansion of the sample repository and molecular virological research is planned.

2010 brought an NHMRC Partnership Grant award for the Enhancing Treatment of Hepatitis C Opiate Substitution Settings study (ETHOS) and enrolment of 216 of 500 subjects. In addition, the National Institute of Drug Abuse ROI awarded the program a renewal grant for the Australian Trial in Acute Hepatitis C study (ATAHC) (see Research studies). A further NHMRC Project Grant was awarded to evaluate naturally occurring resistance to Direct Acting Antiviral drugs in acute hepatitis C. The program oversaw an expansion of the viral hepatitis laboratory research program, including collaborations with several internationally renowned research groups; and there was a publication in Hepatology on the role of Interleukin-28B (IL28B) genotype in recent HCV infection.



Professor Greg Dore heads the Viral Hepatitis Clinical Research Program that investigates new treatments for people infected with hepatitis B or C and particularly those co-infected with HIV in which the hepatic complications represent a significant co-morbidity. He has been at NCHECR for more than 16 years.

The Viral Hepatitis Epidemiology and Prevention Program

The Viral Hepatitis Epidemiology and Prevention Program strives to conduct multidisciplinary public health research that is ethical, innovative and makes a difference. We are proud of, and committed to, working in partnership with affected communities in Australia and internationally to achieve our goals. Key aims of the program are to initiate and undertake epidemiological, social and behavioural research examining viral hepatitis and public health issues associated with drug use and risk behaviour; design and implement trials of behavioural and biomedical prevention interventions designed to prevent viral hepatitis and other infectious diseases in vulnerable populations; to conduct and support surveillance activities including monitoring trends in blood-borne virus incidence, prevalence and risk behaviour among people who inject drugs; to translate research outcomes into evidence-based public health practice; and to build capacity for research, surveillance and harm reduction within Australia and the region through the provision of training and technical assistance.

Highlights of 2010 for VHEPP include the 16th annual Australian Needle and Syringe Program Survey (ANSPS), Australia's internationally recognised surveillance system for monitoring the prevalence of anti-HIV and HCV and associated risk factors among people who inject drugs. A special 16 year report summarising data from 1995 to 2010 will be published in 2011.

In 2010, recruitment to the NHMRC-funded Hepatitis Acceptability and Vaccine Incentives Trial (HAVIT), a two-arm randomised trial examining the efficacy of financial incentives in increasing hepatitis B immunisation completion in people who inject drugs was completed. During the year, recruitment and follow-up continued for the Hepatitis Incidence and Transmission Study – community (HITS-c), a prospective observational study of anti-HCV negative people who inject drugs. Initially funded under the UNSW Hepatitis C Vaccine Initiative, the cohort is now funded by NHMRC as part of a program of HCV Vaccine preparedness research.

Papers published by VHEPP staff and students included a 15 year review of HIV surveillance among people who inject drugs in AIDS, a paper in the British Medical Journal on the impact of opiate substitution treatment on survival and long term injecting cessation, and a review of the challenges and opportunities of conducting candidate HCV vaccine trials with people who inject drugs in Vaccine (see Publications section). International projects in 2010 included a longitudinal study of Culture and HIV Prevention in Cambodia, examining the social and environmental influences on injection drug use conducted with collaborators at the British Columbia Centre for Excellence in HIV/AIDS in Vancouver, and an ARC-funded cluster randomised trial of non-pharmaceutical protection against influenza in Vietnam in collaboration with the School of Public Health and Community Medicine at UNSW.



Professor Lisa Maher is head of the Viral Hepatitis Epidemiology and Prevention Program. Professor Maher conducts ethnographic, epidemiological and clinical research on drug use and related harms and studies of interventions designed to prevent infectious diseases in vulnerable populations, including people who inject drugs (PWID) and female sex workers.

The Surveillance and Evaluation Program for Public Health

The Surveillance and Evaluation Program for Public Health (SEPPH) monitors the pattern of transmission of HIV, viral hepatitis, and specific sexually transmissible infections in Australia, assesses past and expected epidemic trends, and evaluates the epidemiological impact and cost-effectiveness of public health intervention strategies and programs. SEPPH also evaluates HIV epidemics and develops research capacity in Southeast Asia and the Pacific.

Surveillance activities are conducted in collaboration with the Australian Commonwealth Government Department of Health and Ageing, State and Territory health authorities and collaborating networks. Analyses and interpretation of recent trends in new diagnoses of HIV, viral hepatitis and STIs, and estimates of prevalence and incidence in key population subgroups are published in our Annual Surveillance Report. Public release datasets on new HIV and AIDS diagnoses are also available for download. SEPPH, of the National Centre in HIV Epidemiology and Clinical Research, is a collaborating unit of the Australian Institute of Health and Welfare.

SEPPH carries out extensive mathematical modelling research in order to evaluate public health programs, understand drivers of epidemic trends, project future epidemic trajectories, and assess the potential impact of public health strategies. This research is focused on HIV, viral hepatitis, and sexually transmissible infections in Australian populations and on HIV/AIDS in the Southeast Asia and Pacific region. This evaluation is often extended to health economic analyses of different programs or interventions. SEPPH is also involved in building research capacity in the areas of epidemiology, biostatistics, mathematical modelling, and other biomedical research associated with HIV/AIDS in Southeast Asia and the Pacific.

2010 saw the release of the Surveillance Reports, including the fourteenth annual review of available surveillance data pertaining to the occurrence of HIV, viral hepatitis and sexually transmissible infections in Australia, and the fourth annual Bloodborne viral and sexually transmitted infections in Aboriginal and Torres Strait Islander people: Surveillance and Evaluation Report.

Surveillance activities broadened with commencing analyses for the first surveillance report on transfusion transmissible infections in Australia in collaboration with the Australian Red Cross Blood Service. Cross-program contributions including the establishment of the National Trachoma Surveillance and Reporting Unit at UNSW and development of the National BBV and STI Surveillance and Monitoring Plan, as well as the conduct of modelling and acceptability studies of HIV in NSW.

In 2010, SEPPH also organised the NSW HIV and STIs surveillance forum and think tank for around 70 participants at the Australia Technology Park. Internationally, SEPPH broadened in scope and influence in the evaluation of HIV epidemics working closely with the Vietnam Administration for AIDS Control and the Ministry of Health in China. SEPPH has also been developing country-specific models for Indonesia, Cambodia and Papua New Guinea for the interpretation of public health surveillance data. The program's experience evaluating the cost-effectiveness of blood-borne viruses in Australia has been applied to collaborate with 13 countries in Eastern Europe and Central Asia. Major Australian modelling and evaluation activities included the dissemination of recommendations from the National Gay Men's

Syphilis Action Plan and the release of reports on Mapping HIV outcomes: geographical and clinical forecasts of numbers of people living with HIV in Australia and evaluation of HIV in South Australia. In addition, an epidemiological and economic model for evaluating prevention and treatment strategies for responding to hepatitis C epidemics was developed.



Associate Professor David Wilson, head of the Surveillance and Epidemiology Program for Public Health, has presided over a restructure and expansion of our surveillance work in the few short years since he joined us. His program has extended its standing monitoring of HIV, viral hepatitis, and specific sexually transmissible

infections to the assessment of past and expected epidemic trends, and evaluates the epidemiological impact and cost-effectiveness of public health strategies.

The Sexual Health Program

The Sexual Health Program leads and participates in research into the epidemiology, surveillance, microbiology, clinical management, and prevention of sexually transmissible infections (STIs); including, but not limited to, chlamydia, syphilis, gonorrhoea, human papillomavirus infection, herpes simplex virus infection, and HIV infection. Our program is also involved in research into the behaviour and sexual health of priority populations for STI control such as youth, gay men, sex workers, Aboriginal people, prisoners, and travellers.

The Sexual Health Program works closely with several other programs within the Kirby Institute. The program also collaborates with a national network of 25 specialist sexual health services; research laboratories in Sydney, Melbourne, Brisbane and PNG; the School of Population Health at the University of Melbourne; the Burnet Institute in Melbourne; and the Menzies School of Health Research. Methodologies used in the program's research range from descriptive epidemiology with novel analytical techniques, molecular epidemiology, enhanced surveillance strategies, data linkage studies, social and behavioural research, test evaluations, detecting antimicrobial resistance, evaluating and improving health care delivery, legal and policy research, anthropology, and biomedical prevention.

In November, the program published the first report of a national decline in genital warts in young women resulting from the national HPV vaccination program that was launched in 2007. The article, which attracted national and international interest, also found a decline in genital warts amongst heterosexual men, thought to be a result of herd immunity; there was no significant decline among older women and men who have sex with men.

The Law and Sexworker Health (LASH) team, led by Basil Donovan, published a report on The Sex Industry in Western Australia. Funded by the WA Department of Health, the report, which made extensive recommendations for law reform and enhanced health promotion for sex workers, resulted in a review of the WA legislative response to prostitution as well as health services for sex workers.

The ACCESS (Australian collaboration for chlamydia enhanced sentinel surveillance) project produced its first of several reports. The ACCESS project comprises six separate clinical networks and a laboratory network, each providing unique information on testing uptake and positivity for chlamydia in a range of priority populations such as young heterosexuals, men who have sex with men, Aboriginal and Torres Strait Islander people, pregnant women and sex workers.

After years of planning, the ACCEPt (Australian Chlamydia control effectiveness pilot) project finally began recruiting towns for this community-cluster randomised trial of intensified chlamydia screening. In 2010 further funding was granted by the NHMRC to continue the trial to its endpoint of reduced chlamydia prevalence. The ACCEPt trial is led by A/Prof Jane Hocking at the University of Melbourne with input from several NCHCECR programs.



Professor Basil Donovan, head of the Sexual Health Program, has spent decades working in every aspect of sexual health. His program undertakes research and surveillance designed to inform strategies to reduce the impact of sexually transmissible infections (STIs) and HIV, and to conduct trials to directly reduce the impact of STIs.

The Aboriginal and Torres Strait Islander Health Program

The Aboriginal and Torres Strait Islander Health Program was established in 2007. The program works collaboratively across sectors to close the gap in health disparity between Aboriginal and Torres Strait Islander and non-Indigenous people, with a key focus upon sexual health and blood borne viruses. The particular objective of the program is to enhance the capacity of Aboriginal and Torres Strait Islander communities in responding to STIs, HIV and viral hepatitis.

The program has four main domains of activity that aim to increase the level of Sexual Health and BBV knowledge within Aboriginal and Torres Strait Islander communities:

- **Research:** To conduct research in partnership with Aboriginal and Torres Strait Islander communities in the areas of STIs, HIV/AIDS and other BBVs;
- **Surveillance:** To support existing surveillance activities and to identify innovative new areas and methods of surveillance that will benefit Aboriginal and Torres Strait Islander communities;
- **Capacity Building:** To work with existing health services to enhance the capacity of existing systems and workforces in the areas of sexual health and BBV service delivery; research; and surveillance;
- **Information dissemination** through the development of a comprehensive clearinghouse of Aboriginal and Torres Strait Islander Sexual Health initiatives including surveillance and research.

The program works closely with the National Aboriginal Community Controlled Health Organisation, its State and Territory based Affiliate organisations and Aboriginal Community Controlled Health Services to make a difference to the health of indigenous communities.

2010 saw the release of the fourth annual Bloodborne viral and

sexually transmitted infections in Aboriginal and Torres Strait Islander people: Surveillance and Evaluation Report. In addition, two major studies began in Queensland: one of HBV in the Torres Strait Islands and the other aiming to recruit 300 Aboriginal and Torres Strait Islander people who inject drugs. During 2010, Australia's largest randomised cluster trial ever to be conducted in Aboriginal health, named STRIVE, completed baseline prevalence studies for bacterial STI in 67 remote communities and first-year sites were initiated to the intervention arm. Work progressed through 2010 in SHIMMER, a quality improvement project in Aboriginal Community Controlled Health Services in NSW; REACCH, a Centre for Clinical Research Excellence in Aboriginal Community Controlled Health, and GOANNA, a national survey of young Aboriginal and Torres Strait Islander people regarding STI and BBV knowledge risk behaviour and health service access (see Research Programs). The program was also awarded an NHMRC Project Grant to trial the use, effectiveness and feasibility of STI point of care tests in remote Aboriginal communities.



Mr James Ward, head of the Aboriginal and Torres Strait Islander Health Program, brings to this recently created program many years of experience in indigenous health. His program works collaboratively across sectors to address the disparity in health outcomes for indigenous peoples in prevention and treatment of sexually

transmitted infections and blood-borne viruses, through research, surveillance, capacity building and information dissemination.

The Public Health Interventions Research Group

The Public Health Interventions Research Group undertakes a diverse range of projects that focus on the evaluation of strategies to prevent infectious disease. We collaborate extensively, both within NCHCECR and externally, and emphasise research that benefits the health of disadvantaged populations in Australia and the Asia-Pacific Region. Much of our work also has a strong capacity building component. The group is currently involved in projects related to the control of HIV, sexually transmitted infections, viral hepatitis, tuberculosis, scabies and trachoma. Countries of activity include Australia, Papua Guinea, Indonesia, Cambodia and Fiji.

2010 saw the start of the STRIVE program, in collaboration with Sexual Health and Aboriginal and Torres Strait Islander Health Programs. Two new post doctoral fellows joined PHIRG and the group was successful in its bid to host the 2012 International Microbicides Conference. PHIRG was also awarded the contract to develop the new national trachoma unit with SEPPH and ATSI programs; and we undertook a formal collaboration with Papua New Guinea Institute of Medical Research with Andrew Valley being posted in Goroka.



Professor John Kaldor is an NHMRC senior principal research fellow who is committed to the NCHCECR's work in biomedical prevention. Professor Kaldor has been at NCHCECR for two decades.

Surveillance

National surveillance co-ordination and information dissemination

Support for national surveillance committees

Ongoing monitoring of new diagnoses of HIV infection, viral hepatitis and sexually transmissible infections in Australia was co-ordinated by the National Blood Borne Viruses and Sexually Transmissible Infections Surveillance Committee during 2010. The role of the Committee is to develop new initiatives in case surveillance, new analyses of surveillance data, standardise surveillance procedures across State and Territory health jurisdictions and facilitate feedback of surveillance outputs. The Communicable Diseases Network Australia, of which the NBBV&STI Surveillance Committee is a sub-committee, commenced a review of its membership and the role of its sub-committees to ensure that CDNA's objectives are informed by the best advice and that the work of the sub-committees reflects current CDNA priorities.

Status: Ongoing

Personnel: Ann McDonald, Melanie Middleton, Keira Robinson, Libby Topp, Handan Wand, Basil Donovan, John Kaldor, David Wilson

Collaborators: State and Territory health authorities; Australian Government Department of Health and Ageing; Australian Paediatric Surveillance Unit; Australian Institute of Health and Welfare; networks involved in surveillance for HIV, viral hepatitis and sexually transmissible infections.

Funding: Commonwealth Department of Health and Ageing

Location: Surveillance and Evaluation Program for Public Health

HIV, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report

Detailed analyses and interpretations of national surveillance data on HIV, viral hepatitis and sexually transmissible infections are published in *HIV, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2010*.

Status: Ongoing. The *Annual Surveillance*

Report was published for the fourteenth successive year.

Personnel: Ann McDonald, Melanie Middleton, Libby Topp, Handan Wand, David Wilson

Collaborators: State and Territory health authorities; Australian Paediatric Surveillance Unit; Australian Institute of Health and Welfare; networks involved in surveillance for HIV, viral hepatitis and sexually transmissible infections.

Funding: Commonwealth Department of Health and Ageing

Location: Surveillance and Evaluation Program for Public Health


Australian HIV Surveillance Report

The *Australian HIV Surveillance Report* provides quarterly updates on the number of new diagnoses of HIV infection and estimates of HIV incidence and prevalence through a network of sexual health clinics.

Status: Ongoing. The *Australian HIV Surveillance Report*, in its current format, has been published each quarter from July 1990.

Personnel: Ann McDonald, Melanie Middleton

Collaborators: State and Territory health authorities; Australian Paediatric Surveillance



Members of the Surveillance and Evaluation Program for Public Health

Unit; Australian Institute of Health and Welfare; networks involved in surveillance for HIV, viral hepatitis and sexually transmissible infections
Funding: Commonwealth Department of Health and Ageing
Location: Surveillance and Evaluation Program for Public Health

Bloodborne viral and sexually transmitted infections in Aboriginal and Torres Strait Islander People: Surveillance Report 2010

While the pattern of diagnosis of HIV, viral hepatitis and sexually transmitted infections in the Aboriginal and Torres Strait Islander population is reported in the *Annual Surveillance Report*, more detailed analyses and interpretations of national surveillance data for these infections were published separately in a single comprehensive report, for use by organisations and individuals with an interest in the health of Aboriginal and Torres Strait Islander people.

Status: Ongoing. The fourth issue of *Bloodborne viral and sexually transmitted infections in Aboriginal and Torres Strait Islander People: Surveillance Report 2010* was released in October 2010.

Personnel: James Ward, Simon Graham, Ann McDonald, Melanie Middleton

Collaborators: State and Territory health authorities; Australian Paediatric Surveillance Unit; Australian Institute of Health and Welfare; networks involved in surveillance for HIV, viral hepatitis and sexually transmissible infections.

Funding: Commonwealth Department of Health and Ageing

Location: Surveillance and Evaluation Program for Public Health

Merging HIV and AIDS registries

Status: Ongoing, to be finished by June 2011.

Personnel: Tarana Lucky, Ann McDonald, Melanie Middleton, Handan Wand, David Wilson

Funding: DoHA, ARC

Location: Surveillance and Evaluation Program for Public Health

Australian Red Cross Blood Bank Surveillance

Status: Ongoing. The first annual report on Australian blood donors' surveillance to be published by June 2011

Personnel: David Wilson, John Kaldor, Clive Seed, Sue Ismay, Stephen Wroth, June Lee, Anthony Keller, Claire Styles, Hung-Sing Yang, Ann McDonald, Tarana Lucky

Funding: Australian Red Cross, Australian Research Council

Location: Surveillance and Evaluation Program for Public Health

Disease surveillance

Surveillance for HIV

Monitoring cases of AIDS

The past pattern of HIV transmission, the pattern of illness associated with advanced HIV immunodeficiency and the impact of antiretroviral treatment on the pattern of illness is monitored through national AIDS surveillance.

Status: Ongoing. A case for denotification of AIDS has been made by the national bloodborne viral and STI surveillance committee. Until AIDS is denotified its monitoring is ongoing.

Personnel: Ann McDonald, Melanie Middleton

Collaborators: State and Territory health authorities; Australian Paediatric Surveillance Unit; Australian Institute of Health and Welfare; networks involved in surveillance for HIV, viral hepatitis and sexually transmissible infections

Funding: Commonwealth Department of Health and Ageing

Location: Surveillance and Evaluation Program for Public Health

Monitoring cases of newly diagnosed HIV infection

The pattern of HIV transmission is monitored through national surveillance for newly diagnosed HIV infection.

Status: Ongoing

Personnel: Ann McDonald, Melanie Middleton, David Wilson

Collaborators: State and Territory health authorities; Australian Paediatric Surveillance Unit; Australian Institute of Health and Welfare; networks involved in surveillance for HIV, viral hepatitis and sexually transmissible infections

Funding: Commonwealth Department of Health and Ageing

Location: Surveillance and Evaluation Program for Public Health

Monitoring diagnoses of newly acquired HIV infection

Diagnoses of newly acquired HIV infection are monitored to provide an indication of the current pattern of HIV transmission in Australia.

Status: Ongoing

Personnel: Ann McDonald

Collaborators: State and Territory health authorities; Australian Institute of Health and Welfare; networks involved in surveillance for HIV, viral hepatitis and sexually transmissible infections

Funding: Commonwealth Department of Health and Ageing

Location: Surveillance and Evaluation Program for Public Health

Monitoring perinatal exposure to HIV

The extent and outcome of perinatal exposure to HIV in Australia is monitored to indicate the rate of and risk factors for mother-to-child HIV transmission, the impact of interventions for reducing the risk of perinatal HIV transmission and HIV prevalence among women of child-bearing age.

Status: Ongoing

Personnel: Ann McDonald

Collaborators: State and Territory health authorities; Australian Paediatric Surveillance Unit; Australian Institute of Health and Welfare; networks involved in surveillance for HIV, viral hepatitis and sexually transmissible infections

Funding: Commonwealth Department of Health and Ageing

Location: Surveillance and Evaluation Program for Public Health

Monitoring long-term outcome of newly acquired HIV infection

The long-term outcome of HIV infection is monitored among cases with a known date of HIV acquisition.

Status: Ongoing

Personnel: Ann McDonald

Collaborators: State and Territory health authorities; Australian Institute of Health and Welfare; networks involved in surveillance for HIV, viral hepatitis and sexually transmissible infections

Funding: Commonwealth Department of Health and Ageing

Location: Surveillance and Evaluation Program for Public Health

Monitoring HIV transmission through specialised tests for incident HIV infection

Specialised tests for diagnosing incident HIV infection are evaluated by comparison with the results of national surveillance for newly acquired HIV infection.

Status: Ongoing

Personnel: Ann McDonald

Collaborators: NSW State Reference Laboratory for HIV; State and Territory health authorities; Australian Institute of Health and Welfare; networks involved in surveillance for HIV, viral hepatitis and sexually transmissible infections

Funding: Commonwealth Department of Health and Ageing

Location: Surveillance and Evaluation Program for Public Health

Laboratory surveillance of incident HIV infection

Laboratory markers are used to determine incident from established HIV infection to monitor the trends in newly acquired infections, providing an important sentinel surveillance tool. The application of the 'detuned' and BED ELISAs, and analysis of other routine laboratory markers used in the diagnosis of HIV infection, is used in monitoring new infections.

Status: All newly identified cases of HIV infection at the NSW State Reference

Laboratory for HIV at St Vincent's Hospital were analysed on BED assays. During 2010 protocols were developed towards a goal of deriving viral sequence from dried blood spots. This would allow sophisticated molecular epidemiology to be performed even in resource-poor settings.

Personnel: Anthony Kelleher

Collaborators: Philip Cunningham, St Vincent's Hospital, Sydney; Sara Evans, Celine Yang, Kazuo Suzuki, Jane Cornwall, NSW State Reference Laboratory for HIV, St Vincent's Hospital, Sydney

Funding: NSW Health Department

Location: *Immunovirology and Pathogenesis Program*

Surveillance for viral hepatitis

Monitoring cases of newly diagnosed viral hepatitis

The pattern of transmission of viral hepatitis is monitored through national surveillance for newly diagnosed hepatitis B and hepatitis C infection, and newly acquired infections notified to the National Notifiable Diseases Surveillance System. Information on exposure category and country of birth for cases of newly acquired hepatitis B and C notifications is also obtained through NNDSS.

Status: Ongoing

Personnel: Melanie Middleton, Libby Topp, Lisa Maher

Collaborators: State and Territory health authorities; Australian Government Department of Health and Ageing

Funding: Commonwealth Department of Health and Ageing

Location: *Surveillance and Evaluation Program for Public Health*

Monitoring long-term outcomes of chronic hepatitis B and C

Data is obtained from the Australian and New Zealand Liver Transplant Register on number and underlying cause (hepatitis B and C, other) for liver transplants performed.

Status: Ongoing

Personnel: Melanie Middleton, Greg Dore

Collaborator: Australia and New Zealand Liver Transplant Register

Funding: Commonwealth Department of Health and Ageing

Location: *Surveillance and Evaluation Program for Public Health*

Surveillance for sexually transmissible infections

Monitoring HIV prevalence and incidence through sexual health clinics

HIV prevalence and incidence is monitored among people seen at sexual health clinics who are voluntarily tested for HIV antibody as part of their clinical care.

Status: Ongoing

Personnel: Ann McDonald

Collaborators: Collaborative group on sentinel surveillance in sexual health clinics

Funding: Commonwealth Department of Health and Ageing

Location: *Surveillance and Evaluation Program for Public Health*

Monitoring HIV antibody prevalence among prison entrants in Australia

HIV transmission among people entering Australian prisons is monitored through reports received from State and Territory Departments of Corrections of the number of people received into prisons each quarter, the numbers who were voluntarily tested for HIV antibody and the numbers with diagnosed HIV infection.

Status: Ongoing

Personnel: Melanie Middleton, Ann McDonald

Collaborators: State and Territory Departments of Corrections

Funding: Commonwealth Department of Health and Ageing

Location: *Surveillance and Evaluation Program for Public Health*

Monitoring HIV and viral hepatitis among blood donors

Newly emerging patterns of transmission of HIV and viral hepatitis are monitored among blood donors, a subgroup of the population at low risk of infection who are compulsorily tested for blood-borne viruses.

Status: Ongoing

Personnel: Melanie Middleton, Ann McDonald

Collaborator: Australian Red Cross Blood Service

Funding: Commonwealth Department of Health and Ageing

Location: *Surveillance and Evaluation Program for Public Health*

Young Women's Reproductive Health Study

This is a nationally representative survey of young women designed to obtain population-based information on human papillomavirus vaccination coverage, prevalence of genital warts and genital Chlamydia and other issues pertinent to young women's reproductive health such as pregnancy and contraception.

Status: 2010 protocol developed

Personnel: Bette Liu, John Kaldor, Basil Donovan, Julia Brotherton, Marion Saville

Collaborators: Victorian Cytology Service; National HPV Vaccination Register

Funding: NHMRC Program Grant, Victorian Cytology Service

Located: *Public Health Interventions Research Group*

Hepatitis Analysis

Review of hepatitis B from the NNDSS

Status: Ongoing. Data received from NNDSS

Personnel: Keira Robinson, David Wilson

Location: *Surveillance and Evaluation Program for Public Health*

Modelling and economic evaluation of hepatitis C epidemic mitigation strategies in Australia

Status: Ongoing

Funding: National Health and Medical Research Council (NHMRC)

Personnel: David Wilson, Rosie Thein, Murray Krahn, Lisa Maher, Greg Dore, John Kaldor, Shamin Kinathil, Pen Reyes, James Jansson

Location: *Surveillance and Evaluation Program for Public Health*

Epidemiological and economic impact of potential increased hepatitis C treatment uptake in Australia

Status: Report released.

Personnel: David Wilson, Rosie Thein, Greg Dore, M. D. Krahn, Alexander Hoare

Funding: Roche

Location: *Surveillance and Evaluation Program for Public Health*

Developing and validating a scoring tool for identifying people who inject drugs at highest risk of hepatitis C virus infection

Status: To be submitted (after Addiction and JID decisions)

Personnel: Handan Wand, Jenny Iversen, David Wilson, Libby Topp, Lisa Maher

Location: *Surveillance and Evaluation Program for Public Health*

Chronic hepatitis B prevalence in Australia among at-risk populations: results from a systematic review and meta-analysis

Status: Paper produced.

Personnel: Keira Robinson, Rosie Thein, B. Cowie, Lisa Maher, Greg Dore, John Kaldor, David Wilson

Location: Surveillance and Evaluation Program for Public Health

Modelling and impact of hepatitis C treatment in prisons

Status: model developed

Personnel: James Fetherston, David Wilson, Tony Butler

Location: Surveillance and Evaluation Program for Public Health

Syphilis

Developing the National Gay Men's Syphilis Action Plan

Status: Main project completed with the dissemination of the Phase A final report in 2009.

Personnel: David Wilson, Garrett Prestage, Basil Donovan, Richard Gray, Alex Hoare, Ian Down, Jack Bradley

Funding: NSW Health

Location: Surveillance and Evaluation Program for Public Health

Chlamydia

Australian Collaboration on Chlamydia Enhanced Sentinel Surveillance (ACCESS).

Chlamydia is the most commonly notified disease in Australia and is an important cause of pelvic inflammatory disease and tubal infertility in women. Chlamydia notifications have been increasing for over a decade. However, the basis of the increase is not well understood. The ACCESS program determines chlamydia testing and positivity rates in priority populations nationally as well as maintaining an ongoing surveillance system. Populations of interest include young heterosexuals, men who have sex with men, sex workers, pregnant women, and Indigenous people. The program involves national collaborative networks of selected services including sexual health clinics, antenatal clinics, Aboriginal Community Controlled Health Services, family planning clinics, general practices and laboratories.

Status: The first reports were published in 2009 with others in preparation

Personnel: Basil Donovan, Rebecca Guy, John Kaldor, Andrew Grulich, Neil Franklin, Hammad Ali, James Ward, Handan Wand

Collaborators: Margaret Hellard, Caroline Van Gemert, Mark Stoové, Isabel Bergeri, Jane Goller, Fabian Kong, Anna Bowring, Elizabeth Sullivan, Zhuoyang Li, Wayne Dimech, Marcus Chen, Christopher Fairley, Catherine O'Connor, Bridget Dickson, Lewis Marshall, Tony Merritt, Jane Hocking, Marie Pirota, Phyllis Lau,

Douglas Boyle, Helena Britt, Clare Heal, Tom Brett, Caroline Harvey, Robyn Wardle, Kathy McNamee, Lynne Jordan, Anne Stephens, Christine Read, Deborah Bateson, Deborah Wright, Mick Adams, Mark Saunders, Sophie Couzos, Jenny Hunt, Peter Waples-Crowe, David Scrimgeour, Sid Williams, Ana Herceg, Liz Moore, Michael Beckmann, Julie MacPhail, Marian Currie, Zena Robinson, Trent Miller, Megan Halliday, Paul Goldwater

Funding: Commonwealth Department of Health and Ageing Chlamydia Pilot Program

Located: Sexual Health Program; co-located Public Health Interventions Research Group

Surveillance of lymphogranuloma venereum Chlamydia trachomatis types among men who have sex with men

Lymphogranuloma venereum (LGV) is caused by *Chlamydia trachomatis* (CT) serovars L1-L31. These serovars display tropism for the lymphatic system and are clinically much more severe than other chlamydia serovars. Since 2004, there has been a resurgence of LGV proctitis affecting men who have sex with men with HIV infection in the United Kingdom, Western Europe and the North America. The pattern of infection in Australia has not yet been described. The prevalence, clinical spectrum and risk factors of LGV among men who have sex with men attending the Melbourne and Sydney Sexual Health Centres, and the HIM/pH cohorts were investigated.



Members of the Surveillance and Evaluation Program for Public Health

LGV was found to be rare and always associated with symptoms.
Status: The final report was published in 2010
Personnel: Basil Donovan
Collaborators: Sepehr Tabrizi, Jimmy Twin, Susanne Garland, Christopher Fairley, William Rawlinson
Funding: NHMRC Project Grant
Located: *Sexual Health Program*

Eco-pathogenomics of chlamydial infection of the human reproductive tract

Sub-project *Investigating the cellular dynamics of Chlamydia infection*
Status: In vivo data and preliminary in vitro data collected
Personnel: J. Ravel, A. Maurelli, G. Myers, David Wilson, Patrik Bavoil, Roger Rank
Funding: National Institutes of Health (NIH)
Location: *Surveillance and Evaluation Program for Public Health*

Using CD4 counts at diagnosis to estimate incidence

Status: ongoing
Personnel: Fred Wu, Handan Wand, Ann McDonald, David Wilson
Funding: Australian Research Council
Location: *Surveillance and Evaluation Program for Public Health*

HIV treatment failure, therapeutic pathways, and clinical outcomes: understanding the present and planning for the future

Status: ongoing
Personnel: David Wilson, Pen Reyes, Rosie Thein, Lei Zhang
Funding: NAPWA, NHMRC
Location: *Surveillance and Evaluation Program for Public Health*

Genital warts

Long-term surveillance of genital warts through Australian sexual health services.

A national program of human papilloma virus (HPV) vaccination of Australian teenage girls and young women requires systems that can provide long-term surveillance for trends in HPV-related diseases. Genital warts should only be prevented by quadrivalent vaccine that also covers HPV types 6 and 11. We established a network for enhanced sentinel surveillance for genital warts in eight larger sexual health clinics across Australia.
Status: Data collection ongoing
Personnel: Basil Donovan, David Regan,

Andrew Grulich, Hammad Ali, Handan Wand, Rebecca Guy, Neil Franklin
Collaborators: Christopher Fairley, School of Population Health, University of Melbourne, and Melbourne Sexual Health Centre
Funding: CSL Biotherapies Ltd
Located: *Sexual Health Program*

Creutzfeldt-Jakob Disease

Analyses of the National Creutzfeldt-Jakob Disease Registry

Biostatistical and epidemiological advice and support is provided for the analysis and interpretation of Registry data.
Status: Ongoing
Personnel: Handan Wand
Collaborator: The Australia National Creutzfeldt-Jakob Disease Registry
Located: *Biostatistics and Databases Program*

Behavioural surveillance

The Australian Needle and Syringe Program Survey (ANSPS)

The Australian Needle and Syringe Program Survey (ANSPS) forms the basis of Australia's sentinel surveillance of HIV and hepatitis C virus (HCV) prevalence and behaviour indices of risk among people who inject drugs (PWID). Since 1995, all clients attending selected Needle and Syringe Program (NSP) sites during a specified one to two week period are asked to complete a brief self administered questionnaire and to provide a capillary blood sample for HIV and hepatitis C antibody testing. Demographic and behavioural data captured include injecting and sexual behaviour, blood borne virus testing, drug treatment and needle and syringe acquisition. A National Data Report, summarising National and State/Territory data is produced by VHEPP on an annual basis.

Status: Ongoing.
Personnel: Jenny Iversen, Libby Topp, Lisa Maher
Collaborators: Australian State and Territory health authorities; the Collaboration of Australian Needle and Syringe Programs; St Vincent's Centre for Applied Medical Research (AMR) and NSW State Reference Laboratory for HIV at St Vincent's Hospital; Association for Prevention and Harm Reduction Programs Australia (ANEX); Australian Injecting and Illicit Drug Users' League (AIVL), National Drug Research Institute (NDRI), Drug and Alcohol Services, St Vincent's Hospital.
Funding: Australian Government Department of Health and Ageing

Location: *Viral Hepatitis Epidemiology and Prevention Program*

Periodic surveys of HIV risk behaviour

A study of sexual risk behaviour, HIV and STI testing, and illicit drug use among gay men in Australia.
Status: In 2010, over 8,000 behavioural questionnaires surveys were completed in Sydney, Melbourne, Adelaide, Perth, Canberra and Brisbane, as well as in certain regional areas of Queensland. Ongoing analysis and reporting occurred in 2010.
Personnel: Garrett Prestage, Iryna Zablotska, Ian Down, Andrew Grulich
Collaborators: National Centre in HIV Social Research; State AIDS Councils; State PLWHA organisations; State Health Departments
Funding: State and Territory Health Departments
Located: *HIV Epidemiology and Prevention Program*

Behavioural predictors of HIV diagnoses trends (Australian Gay Community Periodic Surveys and HIV surveillance)

An ecological study of trends in sexual risk behaviour and HIV diagnoses among gay men in Australia.
Status: In 2010, 37 820 behavioural questionnaires surveys were completed in Sydney, Melbourne, and Brisbane. Analyses of these surveys were completed in parallel with the analyses of data from the ongoing HIV surveillance. Analysis and reporting occurred in 2010.
Personnel: Iryna Zablotska, Garrett Prestage, Andrew Grulich
Collaborators: National Centre in HIV Social Research; State AIDS Councils; State PLWHA organisations; State Health Departments
Funding: State and Territory Health Departments
Located: *HIV Epidemiology and Prevention Program*

Review of the history and methodology of the Australian behavioural surveillance and its implications for policy and prevention (Australian Gay Community Periodic Surveys)

Repeated cross-sectional surveys of gay-community attached men; review of the history, methodology, behavioural trends and the use of data for policy development
Status: In 2010, we reviewed the history and methodology of the Australian behavioural surveys, compiled the review of behavioural trends and their use in policy development. Analyses were completed in 2010.

Personnel: Iryna Zablotska, Garrett Prestage
Collaborators: National Centre in HIV Social Research; State AIDS Councils; State PLWHA organisations; State Health Departments
Funding: State and Territory Health Departments
Located: *HIV Epidemiology and Prevention Program*

Linkage studies

Morbidity in people with hepatitis B and C in New South Wales:

This is a population-based data linkage study. Notification records for cases of hepatitis B and/or hepatitis C in New South Wales have been linked to their hospital, death, and HIV/AIDS records by The Centre for Health Record Linkage (CHeReL). In 2010, the relative impact of hepatitis B and HIV co-infection on morbidity in people with HCV was examined. HIV or HBV co-infection significantly increased the rates of all cause, illicit drug, and especially liver related hospital admissions. However, the low prevalence of co-infection in Australians with HCV meant that the excess burden at a population-level was minimal. A comparison of hospitalisation rates between people notified with HBV and HCV revealed contrasting trends over time. The burden of non alcoholic liver disease (cirrhosis) and all cause morbidity was two-fold higher in the HCV compared with the HBV cohort, whilst the reverse was true for liver cancer. In addition, hospitalisation rates for non alcoholic liver disease increased by 9% in the HCV cohort but decreased by 14% in the HBV cohort ($P < 0.001$), suggesting an impact of new treatments on liver-related morbidity in patients with HBV.

Personnel: Heather Gidding, Janaki Amin, Matthew Law, Greg Dore

Collaborators: New South Wales Health, Centre for Health Record Linkage (CHeReL)

Funding: University of New South Wales

Located: *Biostatistics and Databases Program*

Reviews, analyses and mathematical modelling

Systematic review and meta-analyses of HIV comorbid conditions

Status: ongoing

Personnel: David Wilson, Jo Watson, James Jansson, Fakhru Islam, Fred Wu

Funding: Australian Research Council (ARC), National Association of People Living with HIV/AIDS (NAPWA)

Location: *Surveillance and Evaluation Program for Public Health*

Review of HIV transmission

Status: complete

Personnel: David Wilson, Victor Jaurejig

Funding: Australian Research Council

Location: *Surveillance and Evaluation Program for Public Health*

Clinical Service Delivery for HIV Positive People in Australia

Status: Ongoing

Personnel: Kylie Mallitt, David Wilson, Handan Wand

Funding: Australian Research Council (ARC)

Location: *Surveillance and Evaluation Program for Public Health*

Mapping HIV outcomes in Australia

Status: Report released

Personnel: David Wilson, James Jansson, Jo Watson

Funding: National Association of People living With HIV/AIDS (NAPWA)

Location: *Surveillance and Evaluation Program for Public Health*

Evaluating the epidemiological benefits of needle and syringe programs in Australia

Status: ongoing

Personnel: David Wilson, J. Anderson, Matthew Law, Lisa Maher, Greg Dore, John Kaldor, Amy Kwon, Rosie Thein, Cliff Kerr, Lei Zhang

Funding: Department of Health and Ageing, UNAIDS

Location: *Surveillance and Evaluation Program for Public Health*

Using mathematical models to assess the impact of interventions to reduce sexually transmitted infections in Australia

Status: ongoing

Personnel: Jane Hocking, David Regan, David Wilson, David Philp, Anthony Smith, Rob Carter, Ben Hui

Funding: National Health and Medical Research Council (NHMRC)

Location: *Surveillance and Evaluation Program for Public Health*

Modelling the interaction between sexually transmitted infections and HIV transmission to inform public health policy

Status: A review of STI, IDU, and HIV in Aboriginal and Torres Strait Islanders is

being conducted, and a model of HIV and STI transmission in Aboriginal populations is being developed

Personnel: David Wilson, Richard Gray, James Ward, Andrew Grulich, Basil Donovan, Sheila Matete-Owiti, Gordana Popovic

Funding: National Health and Medical Research Council (NHMRC)

Location: *Surveillance and Evaluation Program for Public Health*

Modelling HIV in NSW

Status: Study completed

Personnel: David Wilson, Garrett Prestage, Richard Gray, Ian Down, Alex Hoare, Haris Ghaus, Jack Bradley

Funding: NSW Health

Location: *Surveillance and Evaluation Program for Public Health*

Modelling HIV epidemics in South Australia

Status: Complete

Personnel: David Wilson, Kel Heymer, Alex Hoare

Funding: South Australia Health

Location: *Surveillance and Evaluation Program for Public Health*

Clinical research

HIV: antiretroviral therapy

Randomised trial in primary HIV infection looking at three forms of intervention (SPARTAC)

SPARTAC (short pulse antiretroviral treatment at seroconversion) looks at the effect on CD4 T-cells of three interventions at primary HIV infection, either treating with antiretroviral therapy for 12 or 48 weeks or not treating at all until CD4 declines to <350 cells.

Status: Enrolment ceased in June 2007 by which time 37 patients had been screened. 31 patients continue to be followed up with last visits scheduled for December 2010

Personnel: Anthony Kelleher, Pat Grey

Collaborators: Medical Research Council (UK); Jonathon Weber, Sarah Fidler, Imperial College; Robert Finlayson, Taylor Square Private Clinic; Mark Bloch, Holdsworth House Medical Practice; Robert McFarlane, East Sydney Doctors; Cassy Workman, AIDS Research Initiative; Dr Nick Doong, Burwood; Professor David Cooper, St Vincent's Hospital; Mark Kelly, AIDS Medical Unit; Norman Roth,

Prahran Market Clinic; Dr BK Tee, The Centre Clinic; Richard Moore, Carlton Clinic; Philip Cunningham, Kate McGhie, Julie Yeung, St Vincent's Hospital, Sydney

Funding: Wellcome Trust

Location: *Immunovirology and Pathogenesis Program*

PHIDISA Ia

A prospective epidemiological cohort study of HIV and risk-related co-infections in the South African National Defence Force (SANDF).

Status: Recruitment opened January 2004.

Sites: 6 military medical sites in Republic of South Africa

Enrolled/target: 8,439/unlimited

Personnel: Sean Emery

Funding: US National Institutes of Health; US Department of Defense; South African National Defence Force

Location: *Therapeutic and Vaccine Research Program*

PHIDISA II

A randomised, open-label 2x2 factorial study

to compare the safety and efficacy of different combination antiretroviral therapy regimens in treatment-naïve patients with advanced HIV disease and/or CD4+ cell counts < 200 cells/ μ L. **Status:** Completed March 2009, published JID 2010.

Sites: 6 military medical sites in Republic of South Africa

Enrolled/target: 1,771/2,800

Personnel: Sean Emery

Funding: US National Institutes of Health; US Department of Defense; South African National Defence Force

Location: *Therapeutic and Vaccine Research Program*

ALTAIR

A randomised open-label study comparing the safety and efficacy of three different combination antiretroviral regimens as initial therapy for HIV infection.

Status: Recruitment January 2007 to February 2008, week 48 data lead to inclusion of week 144 follow-up visit.

Sites: 37 sites in 15 countries

Enrolled/target: 329/300



Members of the Therapeutic and Vaccine Research Program

Personnel: Rebekah Puls, Christoph Boesecke, Maria Arriaga, Carlo Dazo, Hila Haskelberg, Kathy Petoumenos
Funding: Gilead Sciences
Location: *Therapeutic and Vaccine Research Program*

ALTAIR MRS Sub-study

A randomised open-label study comparing the safety and efficacy of three different combination antiretroviral regimens as initial therapy for HIV infection: CNS metabolite and cognitive impairment.
Status: Recruitment April 2007 to February 2011, week 144 follow-up visit.
Sites: 4 sites in 4 countries
Enrolled/target: 30/300
Personnel: Rebekah Puls, Maria Arriaga, Carlo Dazo, Hila Haskelberg, Kathy Petoumenos, Steve Kerr
Funding: UNSW
Location: *Therapeutic and Vaccine Research Program*

ALTAIR Bone biomarker Sub-study

An analysis of vitamin D and biomarkers related to bone disease in patients recruited and followed in the ALTAIR study.
Status: Analysis of blood stored samples collected at week 0, 12, 24, 48 and 96 within the Altair study
Sites: All sites participating in the main ALTAIR study
Target: All participant storage samples from participants completing week 96
Personnel: Hila Haskelberg, Jenny Hoy, Rebekah Puls, Janaki Amin, Paddy Mallon, Sean Emery
Funding: UNSW
Location: *Therapeutic and Vaccine Research Program*

ALTAIR Renal Sub-study

A randomised open-label study comparing the safety and efficacy of three different combination antiretroviral regimens as initial therapy for HIV infection: analysis of renal outcomes.
Status: Recruitment April 2007 to February 2011, week 144 follow-up visit.
Sites: All sites participating in the main ALTAIR study
Enrolled/target: All participant storage samples from participants completing week 96
Personnel: Rebekah Puls, Maria Arriaga, Carlo Dazo, Hila Haskelberg, Paul Fahey, Janaki Amin, Sean Emery, Christoph Boesecke
Funding: UNSW
Location: *Therapeutic and Vaccine Research Program*

PINT

A study of the effects of the integrase inhibitor, raltegravir, on viral reservoirs in those treated at primary HIV-infection compared to those treated during chronic infection.
Status: The trial was fully enrolled at 16 patients. All patients completed the initial phase of trial (52 weeks) and 15 remain in two-year extension phase which will compete mid 2011.
Personnel: Anthony Kelleher, Linda Gelgor, Pat Grey, Kersten Koelsch, Christophe Boesecke, Sean Emery, Wendy Lee, Janaki Amin, David Cooper
Collaborators: Robert Finlayson, Taylor Square Private Clinic; Mark Bloch, Holdsworth House Private Practice; Robert McFarlane, 407 Doctors; John Zaunders, Kat Marks, Kate McGhie, Julie Yeung, St Vincent's Hospital, Sydney, John Murray, School of Mathematics, Faculty of Science, UNSW
Funding: Merck & Co Inc
Co-located: *Therapeutic and Vaccine Research Program and Immunovirology and Pathogenesis Program*

ENCORE1

A randomised, double-blind, placebo-controlled clinical trial to determine the safety and efficacy of reduced dose efavirenz (400mg qd) versus standard dose efavirenz (600mg qd) as part of combination therapy in treatment naive individuals with HIV infection.
Status: in development
Sites: approximately 50
Target: approximately 700
Personnel: Rebekah Puls, Enmoore Lin, Jessica Taylor, Carlo Dazo, Natalie Espinosa, Janaki Amin
Funding: Bill & Melinda Gates Foundation
Location: *Therapeutic and Vaccine Research Program*

ENCORE1 CNS Sub-study

A randomised, double-blind, placebo-controlled clinical trial to determine the safety and efficacy of reduced dose efavirenz (400mg qd) versus standard dose efavirenz (600mg qd) as part of combination therapy in treatment naive individuals with HIV infection: EFV central nervous system exposure sub-study.
Status: in development
Sites: 6 sites in 4 countries
Target: approximately 40
Personnel: Rebekah Puls, Enmoore Lin, Jessica Taylor, Carlo Dazo, Natalie Espinosa, Janaki Amin
Funding: UNSW
Location: *Therapeutic and Vaccine Research Program*

ENCORE1 Intensive Pharmacokinetics Sub-study

A randomised, double-blind, placebo-controlled clinical trial to determine the safety and efficacy of reduced dose efavirenz (400mg qd) versus standard dose efavirenz (600mg qd) as part of combination therapy in treatment naive individuals with HIV infection: intensive 24 hour pharmacokinetic analysis.
Status: in development
Sites: 4 sites in 4 countries
Target: approximately 40
Personnel: Rebekah Puls, Enmoore Lin, Jessica Taylor, Carlo Dazo, Natalie Espinosa, Janaki Amin
Funding: UNSW
Location: *Therapeutic and Vaccine Research Program*

ENCORE2

Pharmacokinetics of plasma lamivudine (3TC), and its active intracellular anabolite 3TC-triphosphate over a 24 hour dosing interval following administration of 3TC 300 mg and 150 mg once daily to HIV-negative healthy volunteers.
Status: recruitment and follow-up completed 2010, data analyses scheduled for end 2010
Sites: one, Chelsea & Westminster Hospital, London, United Kingdom
Target: 24 HIV-1-negative subjects
Personnel: Rebekah Puls, Janaki Amin, Enmoore Lin, Jessica Taylor, Carlo Dazo, Natalie Espinosa
Funding: Bill & Melinda Gates Foundation
Location: *Therapeutic and Vaccine Research Program*

ENCORE3

Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg, and 200/50 mg twice daily in HIV negative volunteers.
Status: recruitment and follow-up completed 2009, data analyses completed and publication 2010
Sites: one, Chelsea & Westminster Hospital, London, United Kingdom
Target: 24 HIV-1-negative subjects
Personnel: Rebekah Puls, Janaki Amin, Enmoore Lin, Jessica Taylor, Carlo Dazo, Natalie Espinosa
Funding: Bill & Melinda Gates Foundation
Location: *Therapeutic and Vaccine Research Program*

SECOND-LINE

A randomised open-label study comparing the safety and efficacy of ritonavir boosted lopinavir and 2-3N(t)RTI backbone versus ritonavir boosted lopinavir and raltegravir in participants virologically failing first-line

NNRTI/2N(t)RTI therapy.

Status: Open to enrolment in all sites- 150 enrolled

Sites: 48

Target: 550

Personnel: Mark Boyd, Alli Humphries, Natalie Espinosa, Nisha Seneviratne, Torsak Bunupuradah, Maria Arriaga, Rosemary Robson, Wendy Lee

Funding: UNSW, Merck, Abbott, amfAR

Location: *Therapeutic and Vaccine Research Program*

SECOND-LINE Dried Blood Spot sub-study

To test concordance between dried blood spots to assess viral load and genotypes as compared to centrally tested stored samples.

Status: Open to enrolment in all sites

Sites: 48

Target: 550

Personnel: Mark Boyd, Alli Humphries, Natalie Espinosa

Funding: UNSW, Merck, Abbott, amfAR

Location: *Therapeutic and Vaccine Research Program*

SECOND-LINE Body Composition sub-study

To determine the difference in mean limb fat changes and BMD changes at the proximal femur as measured by DXA scan between the 2 study arms in a sub-set of the SECOND-LINE cohort

Status: Open to enrolment in all sites –46 enrolled

Sites: 48

Target: 200

Personnel: Mark Boyd, Alli Humphries, Nisha Seneviratne, Paddy Mallon, Jennifer Hoy, Waldo Bellosa, Samuel Ferret

Funding: UNSW, Merck, Abbott, amfAR

Location: *Therapeutic and Vaccine Research Program*

STALWART

A randomised, open-label, phase II, international study of sc IL-2 with and without concomitant antiretroviral therapy in patients with HIV-1 infection and CD4+ cell counts >300 cells/ μ L: study of aldesleukin with and without antiretroviral therapy.

PURPOSE OF EXTENDED FOLLOW-UP:

To continue unblinded safety assessments of participants in groups that received IL-2 compared to the group that did not receive IL-2.

Status: Enrolment closed 30 June 09. Main study data collection ended on 28 February 2009, extended data collection concluded in 2010

Extended follow-up phase began 01 March 2009 for a further two-year period through until 28 Feb 2011

Sites: 13

Enrolled/target: 267 patients (worldwide) with an equal allocation among the three study groups. All participants randomised into main study are eligible for the extended follow-up. (5 sites in Australia, 3 sites in Thailand, 6 sites in Argentina)

Personnel: Cate Carey, David Courtney-Rodgers

Funding: US National Institutes of Health

Location: *Therapeutic and Vaccine Research Program*

ART Intensification with raltegravir and hyper-immune bovine colostrum (CORAL)

A randomised, double-blind, placebo controlled multi-centre study to measure the effect on CD4+ outcomes of combination antiretroviral therapy intensification with or without passive immunotherapy to reduce immune activation in HIV-infected individuals with persistent CD4+ T-cell count <350 cells/ μ L despite prolonged HIV plasma viraemia <50 copies/mL for at least 12 months on combination antiretroviral therapy.

Status: Analysis completed. All sites closed August 2010. Manuscript in preparation.

Sites: 20 Australian sites

Enrolled/target: 75/72

Personnel: Helen Byakwaga, Hila Haskelberg, Kymme Courtney-Vega, Janaki Amin, Mark Boyd, Sean Emery

Funding: UNSW

Location: *Therapeutic and Vaccine Research Program*

Strategic Timing of Antiretroviral Therapy (START)

An open-label randomised multicentre trial to examine the safety and efficacy of commencing combination antiretroviral therapy at a CD4+ cell count of > 500 cells/mm³ versus commencing at a CD4+ cell count of <350 cells/mm³. This initiative includes several substantial substudies (see below for details) designed to determine the effects of treatment with ART on neurological manifestations of HIV disease, cardiovascular complications, bone mineral metabolism, chronic obstructive pulmonary disease and abbreviated forms of informed consent documentation.

Status: Recruitment opened April 2009. To date 908/4000 enrolled, with 154 in the Sydney region.

Sites: 100 in the pilot phase with 17 sites in the Sydney region (sites coordinated by NCHECR),

to be expanded in the definitive phase (October 2010) with a further 33 sites in the Sydney Region.

Target: pilot phase enrolment 1200 patients with 220 from sites coordinated by NCHECR; enrolment in the definitive phase will be 4000 (with approximately 1000 from sites coordinated by NCHECR)

Personnel: Sarah Pett, Cate Carey, Megan Evans, Simone Jacoby, Sally Hough, Sean Emery, Lara Cassar

Funding: Division of AIDS (DAIDS), The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH); Australian National Health and Medical Research Council (NHMRC); Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS, France); Bundesministerium für Bildung und Forschung (BMBF, Germany); NEAT - European AIDS Treatment Network; Department of Bioethics, The Clinical Center, NIH; Division of Clinical Research, NIAID, NIH; National Cancer Institute (NCI), NIH; National Heart, Lung, and Blood Institute (NHLBI), NIH; National Institute of Mental Health (NIMH), NIH; National Institute of Neurological Disorders and Stroke (NINDS), NIH; National Institute for Arthritis and Multiple Sclerosis (NIAMS), NIH

Location: *Therapeutic and Vaccine Research Program*

Informed Consent Substudy: A substudy of Strategic Timing of AntiRetroviral Treatment (START)

This substudy is evaluating understanding of study information and satisfaction with the consent process among research participants of the START protocol, after receiving information from one of two different types of consent form: a standard or a concise consent.

Status: Recruitment opened April 2009. To date 845/4000 enrolled, with 139 in the Sydney region.

Sites: 75 in the pilot phase with 15 sites in the Sydney region (sites coordinated by NCHECR), to be expanded in the definitive phase (October 2010) with a further 17 sites in the Sydney Region (in Argentina, Thailand, Israel, Mexico, Chile, South Africa, Nigeria, India and Australia).

Target: n=2000.

Personnel: Sarah Pett, Cate Carey, Megan Evans, Simone Jacoby, Sally Hough, Sean Emery, Lara Cassar

Funding: DAIDS; NHMRC; ANRS, France; BMBF, Germany; NEAT - European AIDS Treatment Network; Department of Bioethics, The Clinical Center, NIH

Location: *Therapeutic and Vaccine Research Program*

Genomics: A substudy of Strategic Timing of AntiRetroviral Treatment (START)

The purpose of this substudy is to obtain a whole blood sample from which DNA will be extracted to study validated (present and future) genetic variants that determine the risk of the various primary and secondary outcomes assessed in START.

Status: Recruitment opened April 2009.

To date 666/4000 enrolled, with 91 in the Sydney region.

Sites: as many of the START sites as possible to be involved, to date 78 sites are registered with 13 in the Sydney region

Target: as many of the overall cohort of 4000 START patients as possible.

Personnel: Sarah Pett, Cate Carey, Megan Evans, Simone Jacoby, Sally Hough, Sean Emery, Lara Cassar

Funding: DAIDS; NHMRC; ANRS, France; BMBF, Germany; NEAT - European AIDS Treatment Network; Division of Clinical Research, NIAID, NIH

Location: *Therapeutic and Vaccine Research Program*

Neurology: A substudy of Strategic Timing of AntiRetroviral Treatment (START)

The purpose of the substudy is to determine whether immediate initiation of antiretroviral therapy (ART) in ART-naïve persons with a CD4+ count > 500 cells/mm³ is superior, with respect to neurocognitive function, compared to deferring ART initiation until CD4+ counts decline to 350 cells/mm³.

Status: Recruitment opened April 2009. To date 214/600 enrolled, with 78 in the Sydney region.

Sites: 30 in the pilot phase (10 in Sydney region) expanding to a total of 33 sites

Target: n=600

Personnel: Sarah Pett, Cate Carey, Megan Evans, Simone Jacoby, Sally Hough, Sean Emery, Lara Cassar

Funding: DAIDS; NHMRC; ANRS, France; BMBF, Germany; NEAT - European AIDS Treatment Network; NIMH, NIH; NINDS, NIH

Location: *Therapeutic and Vaccine Research Program*

Arterial Elasticity: A substudy of Strategic Timing of AntiRetroviral Treatment (START)

The arterial elasticity substudy will determine if early initiation of ART is superior to deferred ART in increasing large artery elasticity (LAE) and small artery elasticity (SAE) (i. e. , in reducing arterial stiffness) as measured by pulse wave tonometry.

Status: Recruitment opened September 2009. To date 73/300 enrolled, with 41 in the Sydney region.

Sites: 17 sites in the pilot phase (6 sites in Sydney region), expanding to 21 sites, with one additional site in Sydney region (in India), and 6 sites (in Australia, Thailand and Argentina) contributing patients utilising tonometers located at other sites in the same city

Target: n=300

Personnel: Sarah Pett, Cate Carey, Megan Evans, Simone Jacoby, Sally Hough, Sean Emery, Lara Cassar

Funding: DAIDS; NHMRC; ANRS, France; BMBF, Germany; NEAT - European AIDS Treatment Network and NHLBI, NIH

Location: *Therapeutic and Vaccine Research Program*

Pulmonary Substudy: A substudy of Strategic Timing of AntiRetroviral Treatment (START)

The pulmonary substudy will determine if early initiation of ART is superior to deferred ART in with regards to pulmonary function as assessed by annual spirometry and respiratory health questionnaire.

Status: Recruitment opened January 2010. To date 78/1000 enrolled, with 4 in the Sydney region.

Sites: 45 in the pilot phase with 7 sites in the Sydney region; a further 40 sites will be added for the definitive phase including another 16 sites from the Sydney region.

Target: n=1000

Personnel: Cate Carey, Megan Evans, Simone Jacoby, Sally Hough, Sean Emery, Sarah Pett, Lara Cassar

Funding: DAIDS; NHMRC; ANRS, France; BMBF, Germany; NEAT - European AIDS Treatment Network and NHLBI, NIH

Location: *Therapeutic and Vaccine Research Program*

Bone Mineral Density: A substudy of Strategic Timing of AntiRetroviral Treatment (START)

The bone mineral density substudy will determine if early initiation of ART is superior to deferred ART in with regards to bone health as measured by annual bone mineral density.

Status: Recruitment not yet open, protocol released November 2010.

Sites: 46 with 19 sites in Sydney region (includes pilot sites that are already open and definitive phase sites)

Target: n=400

Personnel: Simone Jacoby, Megan Evans, Sally Hough, Sean Emery, Sarah Pett, Cate Carey, Lara Cassar.

Funding: DAIDS; NHMRC; ANRS, France; BMBF, Germany; NEAT - European AIDS Treatment Network and The National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH.

Location: *Therapeutic and Vaccine Research Program*

STEAL HLA Sub-study

An analysis of HLA-A, HLA-B and HLA-C super-types related to cardiovascular disease and body composition in patients recruited and followed in the STEAL study.

Status: Analysis of stored blood samples

Sites: All that participated in the main STEAL study and collected storage samples

Target: All participant storage samples collected at week 0, 12, 24 and 48

Personnel: Allison Humphries, Sean Emery, Janaki Amin, David Cooper, Damien Cordery

Funding: NCHECR, UNSW

Location: *Therapeutic and Vaccine Research Program*

STEAL Body Composition Sub-study

An analysis of predictors of body composition changes in patients recruited and followed in the STEAL study.

Status: Analysis being conducted on previously collected data.

Sites: All that participated in the main STEAL study and had a DEXA scan completed at baseline

Target: All participants' DEXA scans completed at week 0, 48, and 96

Personnel: Allison Humphries, Sean Emery, Janaki Amin, David Cooper, Mark Bloch

Funding: NCHECR, UNSW

Location: *Therapeutic and Vaccine Research Program*

STEAL Bone biomarker Sub-study

An analysis of biomarkers related to bone disease in patients recruited and followed in the STEAL study.

Status: Analysis of stored blood samples

Sites: All that participated in the main STEAL study and collected storage samples

Target: All participants' storage samples collected at week 0, 12, 24, 48, 72 and 96

Personnel: Hila Haskelberg, Sean Emery, Andrew Carr, Jennifer Hoy, Janaki Amin, Peter Ebeling

Funding: NCHECR, UNSW and Dept Immunology, St Vincent's Hospital

Location: *Therapeutic and Vaccine Research Program*

FLU002

An International Observational Study to Characterize Adults with Influenza A – Pandemic H1N1 (H1N1v) INSIGHT H1N1v Outpatient Study (FLU 002)
Status: vs. 2. 0 06-Nov-2009, open at sites with community transmission of H1N1
Sites: 75 sites globally; in Sydney region: 22 sites (in Thailand, Argentina, Chile and Australia)
Target: 1045/5000; enrolment in Sydney region n=343
Personnel: Sarah Pett, Sean Emery, Rose Robson, Lara Cassar
Funding: NIAID
Location: *Therapeutic and Vaccine Research Program*

FLU003

An International Observational Study to Characterize Adults Who Are Hospitalized with Complications of Influenza A – Pandemic H1N1 (H1N1v) INSIGHT H1N1v Hospitalization Study (FLU 003)
Status: vs. 1. 0 18-Aug-2009, open at sites with community transmission of H1N1
Sites: 88 globally; 18 in Sydney region (in Thailand, Argentina, Chile, Hong Kong and Australia)
Target: 313/1600; total enrolment; enrolment in Sydney region n=39
Personnel: Sarah Pett, Sean Emery, Rose Robson, Lara Cassar

Funding: NIAID

Location: *Therapeutic and Vaccine Research Program*

SPARTA

A randomised, open-label, cross-over study to examine the pharmacokinetics and short-term safety and efficacy of two dosing strategies of raltegravir plus atazanavir in HIV-infected patients.
Status: Recruitment opened July 2009; 48-week follow up will finish April 2011
Sites: two
Target: 24
Personnel: Dianne Carey
Funding: UNSW
Location: *Therapeutic and Vaccine Research Program*

Etravirine+ Raltegravir Study

A randomised, open-label, cross-over study to examine the efficacy, safety and pharmacokinetics of two dosing strategies of etravirine plus raltegravir in HIV-infected individuals.
Status: not yet open to recruitment
Sites: two
Target: 24
Personnel: Dianne Carey
Funding: Tibotec
Location: *Therapeutic and Vaccine Research Program*

LASA

A multicenter randomised study to compare the efficacy and safety of lower dose atazanavir/ritonavir (ATV/r 200/100 mg OD) versus standard dose (ATV/r 300/100 mg OD) in combination with 2NRTIs in well virology suppressed HIV-infected adults.
Status: Protocol and documentation being prepared. Site selection concluded, recruitment to commence 2011 Q1
Sites: up to 15 clinical centres in the Thai National Health Service network
Target: 560
Personnel: Sean Emery, Stephen Kerr, Alli Humphries, Jessica Taylor, Wendy Lee
Funding: NCHCR, HIVNAT, Thai NHSO
Location: *Therapeutic and Vaccine Research Program*

MARCH

A randomised, controlled trial to evaluate the efficacy and safety of maraviroc as a switch for either nucleoside analogue reverse transcriptase inhibitors (N(t)RTI) or boosted HIV protease inhibitors(r/PI) in HIV infected patients with stable, well-controlled plasma HIV-RNA while taking their first N(t)RTI + r/PI regimen of combination antiretroviral therapy (cART) – The MARCH study.
Status: Protocol and documentation being prepared. Site selection concluded, recruitment to commence 2011 Q1
Sites: up to 60 clinical centres in the NCHCR



Members of the Therapeutic and Vaccine Research Program

international network to include Argentina, Australia, Brazil, Canada, Chile, Colombia, Germany, Israel, Mexico, Peru, Spain, UK, Venezuela

Target: 560

Personnel: Sean Emery, Sarah Pett

Funding: ViiV Healthcare

Location: *Therapeutic and Vaccine Research Program*

The Australian HIV Observational Database (AHOD)

Observational cohort study of patients with HIV. Demographic, clinical and treatment data are aggregated twice each year via electronic data transfer.

Status: 3173 patients recruited by 31 March 2010

Personnel: Sadaf Marashi-Pour, Hamish McManus, Stephen Wright, Courtney Bendall, Kathy Petoumenos, Matthew Law

Collaborators: Network of clinical sites (GPs, hospitals and sexual health clinics) throughout Australia

Funding: Foundation for AIDS Research (amFAR) via a US National Institutes of Health grant through the International Epidemiologic Databases Evaluating AIDS collaboration; consortium of pharmaceutical companies
Located: *Biostatistics and Databases Program*

The Data Collection on the Adverse Events of Anti-HIV Drugs Study (D:A:D)

Large, international, collaborative study aimed at assessing the medium to long-term effects of antiviral treatment of people with HIV in terms of possible increased risk of cardiovascular events.

Status: The study combines data from 11 cohorts, including more than 33,000 patients. Australia contributes 706 patients from the Australian HIV Observational Database. Follow up continued through 2010

Personnel: Sadaf Marashi Pour, Hamish McManus, Stephen Wright, Kathy Petoumenos, Matthew Law

Collaborators: Network of clinical sites throughout Australia; Copenhagen HIV Programme, Hvidovre University Hospital
Funding: European Agency for the Evaluation of Medicinal Products (EMA)

Located: *Biostatistics and Databases Program*

Myocardial infarction, assessment of Antiretroviral and Genetic factors in Human Immunodeficiency Virus infection: MAGNIFICENT

International collaborative project of 17 Observational HIV Cohort Studies to evaluate the contribution of single nucleotide

polymorphisms (identified in genome-wide association studies in the general population) and of combination antiretroviral therapy (cART), traditional acute coronary artery disease (CAD) risk factors, and HIV-related factors (CD4+ count, HIV RNA levels) to CAD events in HIV-infected individuals

Personnel: Courtney Bendall, Kathy Petoumenos
Collaborators: Network of clinical sites (GPs, hospitals and sexual health clinics) throughout Australia; Swiss HIV Cohort Study Group
Located: *Biostatistics and Databases Program*

Viral hepatitis

Cancer Council STREP Grant Understanding hepatocellular carcinoma in NSW

Status: Ethics approval for NSW HBV and HCV linkage study (linkage to NSW Central Cancer Registry, Mortality data from Registry of Births Deaths and Marriages and Australian Bureau of Statistics, NSW Admitted Patient Data Collection) was granted from the NSW Population & Health Services Research Ethics Committee and the UNSW HREC during 2009. A probabilistic linkage of NSW Notifiable Diseases Database, Admitted Patient Data Collection, Central Cancer Registry and deaths was completed at the end of 2009. The linkage was carried out by the Centre for Health Record Linkage (CHeReL).

Personnel: Rosie Thein, Heather Gidding, Janaki Amin, Matthew Law, Greg Dore

Collaborators: Kate Ward (NSW Health)

Funding: The Cancer Council NSW

Location: *Viral Hepatitis Clinical Research Program*

Australian Trial in Acute Hepatitis C (ATAHC II)

A prospective longitudinal study of natural history and treatment outcomes following response guided treatment of recent hepatitis C infection.

Status: submitted for ethics review in November 2010

Enrollment target: 120 subjects

Personnel: Gail Matthews, Greg Dore, Barbara Yeung, Pip Marks, Jason Grebely, Tanya Applegate

Collaborators: Macfarlane Burnet Institute for Medical Research and Public Health; St Vincent's Hospital, Sydney; Royal Prince Alfred Hospital; Kirketon Road Centre; Nepean Hospital; School of Medical Sciences, UNSW; School of Biotechnology and Biomolecular Sciences, UNSW; The Alfred Hospital; St. Vincent's Hospital, Melbourne; Royal Melbourne Hospital; Royal Adelaide Hospital;

Princess Alexandra Hospital; Royal Perth Hospital and Murdoch University.

Funding: US National Institutes of Health

Location: *Viral Hepatitis Clinical Research Program*

Enhancing Treatment of Hepatitis C in Opiate Substitution Settings (ETHOS)

The National Centre in HIV Epidemiology and Clinical Research (NCHECR) was awarded an NHMRC Partnership Grant (partner organisations listed below) to address the issue of HCV treatment in the opiate pharmacotherapy setting. The partnership project includes an evaluation of assessment and treatment of HCV in a prospective cohort study – the ETHOS Cohort; patient and provider attitudes and barriers towards the provision of services for assessment and treatment of HCV infection; peer based support as a strategy for enhancing knowledge and uptake of treatment for HCV infection; and cost effectiveness of providing assessment and treatment for HCV infection in the opiate pharmacotherapy setting. The ETHOS cohort aims to examine HCV treatment uptake, treatment response and incidence of reinfection among clients with chronic HCV and a history of injection drug use.

Status (ETHOS cohort): Commenced recruitment February 2009 with more than 200 enrolled to date. Target is 500

Personnel: Greg Dore, Jason Grebely, Alexa Gillman, Pip Marks, Rosie Thein, Amanda Erratt, Marianne Jauncey, Patrick McGrath, Ineke Shaw

Collaborators: National Centre in HIV Social Research (NCHSR), NSW Health Department, Sydney South West Area Health Service (SSWAHS), Hepatitis NSW and NSW Users and AIDS Association (NUAA); Faculty of Medicine, University of Sydney; Australian Injecting and Illicit Drug Users League (AIVL)

Funding: Australian Government Department of Health and Ageing; NSW Health Department
Location: *Viral Hepatitis Clinical Research Program*

Liver Disease and HIV/HBV Coinfection in the era of HAART (COLD)

A prospective cohort of people with HIV/hepatitis B co-infection to examine the impact of highly active antiretroviral therapy on liver disease progression and provide a means for surveillance of resistance to hepatitis B active agents.

Status: Recruitment of 150 individuals completed in Australia and the US in 2004-2006. Cohort expanded to include 47 individuals from Thailand in 2008. Study in final analysis.

Personnel: Gail Matthews, Amanda Erratt, Pip Marks, Patrick McGrath
Collaborators: Johns Hopkins University; Victorian Infectious Diseases Reference Laboratory; The Alfred Hospital; Royal Melbourne Hospital; St Vincent's Hospital, Sydney, HIV-NAT, Bangkok, Thailand
Funding: US National Institutes of Health
Location: *Viral Hepatitis Clinical Research Program*

Defining Risk and Mechanism of Per mucosal Transmission for acute HCV Infection within high-risk populations (RAMPT-C Study)

The study aims to characterise per mucosal transmission of HCV among HIV-positive and HIV-negative MSM, through clinical and molecular epidemiological analysis, with qualitative socio-behavioural and biological studies to explore the transmission mechanisms. The study consists of three parts: Part I – Phylogenetics analysis, Part II – semen analysis, and Part III – Behavioural mechanism interview (see *Epidemiology*). An eligible patient can participate in Part I only or all three parts.

Status: Recruitment started in November 2009 at St. Vincent's Hospital, NSW. The Alfred Hospital, VIC started recruitment in March 2010.
Enrolled/target: Part I – prospective component: 5/50; Part II – 3/65; Part III – 3/20

Personnel: Amanda Erratt, Barbara Yeung, Pip Marks, Gail Matthews, Greg Dore, Tanya Applegate, Garrett Prestage, Jack Bradley, Ian Down

Collaborators: Mark Danta, St Vincent's Clinical School, UNSW; Margaret Hellard, Rose Ffrench, Kylie Goy, The Macfarlane Burnet Institute for Medical Research and Public Health

Funding: National Health and Medical Research Council Project Grant and St. Vincent's Clinic Foundation Research Grant

Co-located: *Viral Hepatitis Clinical Research Program and Immunovirology and Pathogenesis Program*

The International Collaboration of Incident hepatitis C in Injecting Cohorts (InC3) Collaborative Group

The InC³ Collaborative Group was established to create a merged multi-cohort project of pooled data from well characterised cohorts of IDUs with acute HCV infection, facilitate new in-depth studies not possible from each individual study and bring together researchers across disciplines. This collaboration has been successful in pooling behavioural, clinical and virological data on 539 participants with well-defined HCV seroconversion events from eight cohorts in Australia, Canada, Europe and the

United States. This is the largest consortium of investigators assembled to investigate acute HCV infection. The behavioural, clinical and virological data already collected and the access to stored specimens from this merged study has the potential to provide invaluable insight into the control of HCV infection, including the development of novel HCV therapeutics and vaccine strategies.

Status: The first data merger in September 2009

Enrolled: 539 participants

Personnel: Gregory Dore, Jason Grebely, Lisa Maher

Collaborators: University of New South Wales, The Burnet Institute, Université de Montréal, University of California San Francisco, the University of Amsterdam and Public Health Service of Amsterdam, Harvard, Johns Hopkins
Location: *Viral Hepatitis Clinical Research Program*

Hepatitis Acceptability and Vaccination Incentives Trial (HAVIT)

Injecting drug use is the leading exposure category for notifications of newly acquired hepatitis B virus (HBV) in Australia. Funded by the NHMRC, the Hepatitis Acceptability and Vaccination Incentives Trial (HAVIT) is a two-arm open-label randomised controlled trial designed to determine the efficacy of incentive payments to increase HBV vaccine completion in PWID. Secondary endpoints are to evaluate the cost effectiveness of standard care compared to incentive payments as a means of improving HBV vaccination series completion, identify the correlates of immunity and assess hepatitis B knowledge and barriers to immunisation uptake and completion. Using a 3-dose accelerated schedule (0, 7 and 21 days), the trial is being conducted at two inner-Sydney health services which target PWID. To date 414 PWID have been screened with 138 participants eligible and enrolled following baseline serology.

Status: Recruitment completed and data base locked, analyses pending

Personnel: Rachel Deacon, Mofizul Islam, Libby Topp, Lisa Maher

Collaborators: Kirkeaton Road Centre/South Eastern Sydney and Illawarra Area Health Service; Sydney South West Area Health Service; Redfern Drug Health Service/South West Sydney Area Health Service; Discipline of Addiction Medicine, University of Sydney; National Drug and Alcohol Research Centre
Funding: National Health and Medical Research Council Project Grant

Location: *Viral Hepatitis Epidemiology and Prevention Program*

Hepatitis C Vaccine Preparedness Studies

This program of work, which commenced in 2010, continues and extends earlier work conducted under the UNSW HCV Vaccine Initiative. The project aims to establish the feasibility of conducting field trials of candidate HCV vaccines with PWID. Specific aims are to 1) determine HCV incidence and spontaneous clearance in a prospective cohort of uninfected PWID; 2) identify associated risk factors; 3) evaluate retention strategies and factors associated with adherence to the study protocol; and 4) investigate immunisation acceptability, clinical trial literacy and willingness to participate in future vaccine trials in this group. The project includes the Hepatitis C Incidence and Transmission Study – community (HITS-c), an ongoing prospective observational study of HCV antibody negative PWID. By October 2010, 149 participants had been enrolled in the cohort and a total of 10 incident cases of hepatitis C infection had been observed (8. 12 per 100 person years; 95% CI; 4. 23-15. 61).

Status: Ongoing

Personnel: Jarliene Enriquez, Anna Bates, Anh Pham, Len Liao, Ju Park, Bethany White, Lisa Maher.

Collaborators: Academic Medical Centre, University of Amsterdam and Infectious Disease Cluster, GGD Amsterdam Public Health Service; Australian Intravenous and Injecting League (AIVL); Hepatitis Australia; Hepatitis C Council of NSW; Inflammatory Diseases Research Unit, School of Medical Sciences, UNSW; SEALS Microbiology, Prince of Wales Hospital; The Macfarlane Burnet Institute for Medical Research; British Columbia Centre for Excellence in HIV/AIDS; University of California San Francisco

Funding: NHMRC Project Grant

Location: *Viral Hepatitis Epidemiology and Prevention Program*

Data from the highly specialised drugs program

Summary data of patients receiving antiretroviral treatments funded through the Highly Specialised Drugs Program are received from the Australian Government Department of Health and Ageing, and published in annual and biannual surveillance reports.

Status: Ongoing

Personnel: Hamish McManus

Collaborator: Highly Specialised Drugs Program, Special Access and Coordination Section, Pharmaceutical Access and Quality Branch, Australian Government Department of Health and Ageing

Located: *Biostatistics and Databases Program*

Australian Chronic Hepatitis C Observational Study (ACHOS)

ACHOS is a clinic-based observational study of chronically infected hepatitis C patients, and is conducted in collaboration with the Viral Hepatitis Clinical Research Program. The study aims to determine the level of hepatitis C treatment uptake and factors that predict uptake and treatment outcomes. Recruitment of 1261 patients was completed in December 2009. Most patients recruited were male (68%), born in Australia (77%), aged 35-54 years (67%), and past injecting drug users (64%). Seventeen percent had received treatment previously and 49% received treatment at or sometime after enrolment. Among newly referred treatment naive patients, current injecting drug use, past and current treatment for drug dependency and alcohol use above 20 grams per day (OR 0.20, 95% CI 0.08-0.46) were independent predictors of treatment deferral. Follow-up will continue in 2011 when a further analysis will be conducted to examine predictors of treatment success.

Personnel: Heather Gidding, Janaki Amin, Matthew Law, Greg Dore

Collaborators: Network of 25 sites around Australia

Funding: State and Territory Health Departments

Located: *Biostatistics and Databases Program*

Sexually transmissible infections

Syphilis: a trial of chemoprophylaxis to prevent syphilis in men who have sex with men with HIV infection

Given the recent resurgence in syphilis cases in the Western World amongst gay men it is now time to test new strategies such as chemoprophylaxis to control syphilis that would be available to any syphilis outbreaks in both developed and developing countries. The primary aim of the trial is to determine whether chemoprophylaxis with 100mg of oral doxycycline daily can reduce the incidence of syphilis in gay men with HIV infection, compared to those receiving placebo. The secondary aims are to compare the clinical safety and incidence of rectal chlamydia and gonorrhoea of HIV-infected gay men and compare the sexual behaviour of HIV-infected gay men treated with the study drug with their baseline behaviour.

Status: Funding application pending

Personnel: Fraser Drummond, John Kaldor, Basil Donovan, Rebecca Guy, Kathy Petoumenos, Andrew Grulich, David Cooper,

Garrett Prestage, Matthew Law

Collaborators: Chris Bourne, Sydney Sexual Health Centre; Jeff Klausner, CDC Program, South Africa.

Funding: NHMRC project grant application pending

Located: *Sexual Health Program*

Is azithromycin adequate treatment for asymptomatic rectal chlamydia? – an audit

We conducted a retrospective audit of all men who have sex with men (MSM) diagnosed with rectal chlamydia in 2009 to look at the effectiveness of treating with single dose azithromycin.

Status: Final manuscript accepted for publication

Personnel: Fraser Drummond, Handan Wand, Rebecca Guy, Basil Donovan

Collaborators: Nathan Ryder, Anna McNulty, Lynne Wray, Phillip Read

Funding: In-house

Located: *Sexual Health Program*

The Australian HIV Observational Database (AHOD) STI project

Sexual health clinics in AHOD will contribute data on sexually transmissible infections and treatment in patients recruited to AHOD

Status: Protocol agreed with 11 sites involving around 900 patients. Protocol is under review by ethics committees. First data transfer and analysis in March 2011.

Personnel: Kathy Petoumenos, Hamish McManus, Stephen Wright, Courtney Bendall, Matthew Law

Collaborators: Network of 11 sexual health clinics around Australia

Funding: National Health and Medical Research Council, NIH, EMEA and pharmaceutical consortium

Located: *Biostatistics and Databases Program*

Mathematical modelling of human papillomavirus transmission

This research involves the design, implementation and analysis of mathematical models for assessing the health-economic impact of Human papillomavirus (HPV) vaccination, screening and testing policies in Australia.

Status: A general HPV modelling framework has been completed allowing for the transmission of multiple HPV types to be modelled. The model has been used to estimate the long-term impact of the current female-only vaccination programme, and a theoretical male + female vaccination programme, on the incidence of genital warts due to HPV types 6 and 11 as well as the incidence of infection due to HPV types

6, 11, 16, and 18. The model is being further developed to incorporate progression to HPV-related disease (e.g., cervical intraepithelial neoplasia and cervical cancer) and new methodology is under development to facilitate the calibration of the model in a Bayesian framework.

Personnel: David Regan, Matthew Law, Andrew Grulich, John Kaldor, Igor Korostil, Edward Waters

Collaborators: CSL Limited, Victorian Cytology Service Incorporated, Australian National University, University of Melbourne, La Trobe University

Funding: Australian Research Council, CSL Limited, Victorian Cytology Service Inc

Located: *Biostatistics and Databases Program*

Mathematical modelling of bacterial STIs in Australian sub-populations

This research involves the design, implementation and analysis of mathematical models for assessing the health economic impact of public health interventions for the control and prevention of chlamydia, gonorrhoea, syphilis and trichomoniasis in different populations in Australia. The models will address the STIs that are of most importance in heterosexual, MSM, and indigenous populations, respectively.

Status: A range of compartmental and individual-based models have been developed to evaluate a wide range of screening and intervention strategies for the control and prevention of bacterial STIs in remote individual communities and to assess the potential importance of community mobility in sustaining high prevalence of STIs in these communities. A model of gonorrhoea transmission, incorporating infection at different anatomical sites, is in development to assess the potential impact of moving from culture to NAAT as the primary diagnostic test.

Personnel: David Regan, David Wilson, Ben Hui, Matthew Law, Rebecca Guy, Basil Donovan, John Kaldor

Collaborators: UNSW School of Public Health and Community Medicine, University of Melbourne, La Trobe University, Deakin University

Funding: NHMRC

Located: *Biostatistics and Databases Program*

Clinical public health

Australian Chlamydia control effectiveness pilot (ACCEPT) study

Current national guidelines for general

practitioners (GPs) recommend all sexually active people aged 15–29 years old receive annual testing for chlamydia. More than 80% of 15–29 year olds attend a GP each year less however less than 10% are being tested for chlamydia by their GP. ACCEPT involves a multifaceted intervention in the GP setting to maximise testing rates and annual testing in sexually active 16–29 year olds to see if it can reduce the prevalence of chlamydia infections and its associated complications such as PID. GP clinics and Aboriginal Community Controlled Health Services in about 50 towns or regions throughout Vic, NSW and Qld have been invited to take part.

This is the first trial of this nature in Australia and is being led by the Centre for Women's Health, Gender and Society, The University of Melbourne, in collaboration with a large consortium of experts including a number of researchers from NCHECR. In addition, NCHECR has been contracted to develop the protocol for Program Evaluation and Mathematical. The primary aims of this project are to assess the feasibility, acceptability and cost-effectiveness of an organised program for chlamydia testing in general practice. The secondary aim of this project is to increase testing and awareness of chlamydia in the Australian population.

Status: Site recruitment in Vic, NSW, and southern Qld began in 2010

Personnel: John Kaldor, Basil Donovan, David Regan, David Wilson, Matthew Law, Rebecca Guy, Rebecca Lorch, Lisa Edward, James Ward

Collaborators: Jane Hocking (University of Melbourne), Meredith Temple-Smith, Jenny Walker, Simone Poznanski, Alaina Vaisey, Dyani Lewis, Jane Gunn, Christopher Fairley, Nicola Low, Marian Pitts, Marion Saville, Dorota Gertig, Sepehr Tabrizi, Margaret Hellard

Funding: Australian Government Department of Health and Ageing Chlamydia Pilot Program

Co-located: *Sexual Health Program, Aboriginal and Torres Strait Islander Health Program, Surveillance and Evaluation Program for Public Health, Public Health Interventions Research Group, Biostatistics and Databases Program*

REACT study

Chlamydia re-infection is common in women and men. Chlamydia re-infections increase the risk of chlamydia-related sequelae such as pelvic inflammatory disease (PID) and infertility, when compared to initial infection, and in men who have sex with men (MSM) has been associated with an increased HIV seroconversion risk. Clinical guidelines in Australia recommend that for all people treated for chlamydia a repeat test is conducted in six weeks. This randomised controlled trial will

assess the effectiveness of a SMS reminder and home-based self-collected samples (home group) to increase the proportion of patients re-tested after a chlamydia infection, compared to an SMS reminder and clinic testing (clinic group). Approximately 600 patients diagnosed with chlamydia across two sexual health clinics will be randomised to the home group or the clinic group.

Status: Recruitment to commence May-June 2011
Personnel: Rebecca Guy, Handan Wand, Basil Donovan, John Kaldor, Kirsty Smith

Collaborators: Jane Hocking, Anna McNulty, Christopher Fairley, Marcus Chen, Catriona Bradshaw, Sepehr Tabrizi, Suzanne Garland, Simon Wright, Bill Rawlinson, Gary Rickard, Phillip Read, Melbourne Sexual Health Centre, Sydney Sexual Health Centre, University of New South Wales, University of Melbourne, Victorian Cytology Service, Royal Women's and Royal Children's Hospitals

Funding: NHMRC STI Program Grant

Located: *Sexual Health Program*

Uptake and outcomes of chlamydia or gonorrhoea testing programs in non-clinical settings: a systematic review

Primary care clinics play an important role in the prevention and management of sexually transmissible infections (STIs). A large proportion of young people attend primary care clinics each year for one reason or another and most chlamydial infections are diagnosed in this setting. However, despite the central role of primary care in chlamydia management, the proportion of sexually active young people attending these clinics who are offered screening at the time of their visit is suboptimal in many developed countries. This systematic review aims to examine the participation rate and outcomes of chlamydia and/or gonorrhoea testing programs among young people outside of clinical services.

Status: Data extraction almost complete and ready for analysis

Personnel: Rebecca Guy, Muhammad Shahid Jamil, Hammad Ali, John Kaldor

Collaborators: Jane S Hocking, Heidi Bauer, Jennifer Walker, Program Development and Evaluation, STD Control Branch, California Department of Public Health, Richmond, California

Funding: NHMRC Program Grant

Located: *Sexual Health Program*

Syphilis testing in HIV positive men

Clinical guidelines recommend three-monthly syphilis testing in HIV-positive men who have sex with men (MSM) as part of quarterly routine HIV management checks. However not

all men are having quarterly HIV management checks, particular if they have clinically stable for a number of years. This study aims to assess the syphilis testing frequency in HIV positive men against the frequency of HIV management checks at seven clinical sites in Melbourne and Sydney, Australia.

Status: Data received from five sites to date.

Analysis underway

Personnel: Rebecca Guy, Handan Wand
Collaborators: Andrew Carr, John McAllister, Marcus Chen, Chris Bourne, David Baker, Norm Roth, BK Tee, Jenny Hoy, Mark Stooové, Carol El-Hayek, St Vincent's Hospital, Sydney, The Alfred Hospital, Melbourne, Sydney Sexual Health Centre, Sydney, Melbourne Sexual Health Centre; East Sydney Doctors; Prahran Market Clinic, Melbourne; The Centre Clinic, Melbourne; The Burnet Institute, Melbourne

Located: *Sexual Health Program*

Economic, social and cross cultural issues in non-pharmaceutical protection of front line responders to pandemic influenza and emerging infections

Non-pharmaceutical interventions such as face masks are one of the few widely available strategies that can be offered to front line responders (FLR) in outbreak situations and that can be guaranteed to be available regardless of the type of infection. This study aims to 1) determine knowledge, attitudes and practices of FLR related to infection control and barriers to adherence to mask use; 2) conduct the first international RCT of the protection afforded to FLR by face masks against influenza and other respiratory viruses; 3) compare knowledge, attitudes and practices of FLR in Australia and Vietnam, and identify both culturally specific and universal issues that may affect the behaviour of FLRs in an emergency; 4) model the cost-effectiveness of surgical and N95 face masks; and 6) inform disease control policy nationally and internationally on the use of face masks in control of pandemic influenza, emerging infections or a bioterrorist attack.

Status: Ongoing.

Personnel: Lisa Maher

Collaborators: School of Public Health and Community Medicine, UNSW (lead); Imperial College Faculty of Medicine, London; National Institute of Hygiene and Epidemiology (NIHE), Hanoi; Westmead Hospital, Sydney.

Funding: Australian Research Council

Location: *Viral Hepatitis Epidemiology and Prevention Program*

Notifiable Diseases and Reproductive Health

This project uses data linkage in NSW to

examine the effects of commonly notified diseases including Sexually Transmitted Infections and Blood Borne Viruses on reproductive health outcomes in women.

Status: Awaiting linked data

Personnel: Bette Liu, Louisa Jorm, Christine Roberts, John Kaldor

Collaborators: University of Western Sydney; Kolling Institute University of Sydney

Funding: NHMRC Post-doctoral fellowship; NHMRC Program Grant

Located: *Public Health Interventions Research Group*

Identifying predisposing factors for, and the consequences of, common and emerging infectious diseases

This project will involve using the 45 and Up Prospective cohort study and data linkage to examine what factors may predispose adults to certain infections and what the longer term consequences of infections are on health outcomes and health service utilisation.

Status: 2010 Study funding secured, approvals from data custodians obtained

Personnel: Bette Liu, John Kaldor, Emily Banks
Collaborators: Sax Institute; Australian National University

Funding: Ramaciotti Foundation

Located: *Public Health Interventions Research Group*

available RPOC tests for syphilis have been recombinant treponemal antigen assays, which are unable to differentiate between past-treated and recent syphilis, so are likely to result in substantial overtreatment if used in endemic settings. However, technological advances have led to the development of new RPOC tests which detect recent, as distinct from past treated infection. These newer tests will be evaluated in this study and compared with currently available syphilis POC tests and gold standard tests.

Status: Protocol complete and ethics approved; evaluation to commence mid-2011

Personnel: Rebecca Guy, Basil Donovan, John Kaldor, Louise Causer, Fraser Drummond

Collaborators: Peter Robertson, David Leslie, Jennie Leydon, Theo Karapanagiotidis, David Anderson, Mary Garcia, John Reeder, Kit Fairley, Claire Ryan, Tawarot Kurumop; Melbourne Sexual Health Centre, Victorian Infectious Diseases Reference Laboratory (VIDRL), Burnet Institute, Sydney Sexual Health Centre, South East Area Laboratory Service (SEALS), Papua New Guinea Institute of Medical Research (PNGIMR)

Funding: NHMRC STI Program Grant

Co-located: *Sexual Health Program and Public Health Interventions Research Group*

Diagnostics

Evaluation of syphilis PCR

There is a need for rapid and reliable direct tests for syphilis. This study was an audit of the outcomes of testing men who have sex with men with lesions consistent syphilis at the Taylor Square Private Clinic with a new *Treponema pallidum* PCR assay. The test was found to be 90% sensitive for primary syphilis and 50% sensitive for secondary syphilis, and it diagnosed several patients with primary syphilis who had yet to seroconvert to syphilis.

Status: Final report in preparation

Personnel: Rebecca Guy, Basil Donovan

Collaborators: Matthew Shields, Robert Finlayson, Taylor Square Private Clinic; Neisha Jeffreys, ICPMR, Westmead Hospital

Funding: In-house

Located: *Sexual Health Program*

Syphilis point-of-care test evaluation

Rapid point-of-care (RPOC) tests offer a new approach to ensuring that diagnosis and treatment of syphilis is timely across the diverse geographic and social settings of PNG. Until recently, the only commercially

Epidemiological research

Prevention

HIV vaccine preparedness cohort study (Health in Men study)

A vaccine preparedness cohort study of HIV-negative homosexual men.

Status: During 2001-2004, 1,427 HIV negative men were enrolled and active follow up ceased in 2007. In 2010, final data analysis and reporting occurred.

Personnel: Andrew Grulich, Garrett Prestage, Iryna Zablotska, Mary Poynten, David Templeton, Jeff Jin

Collaborators: National Centre in HIV Social Research; Australian Federation of AIDS Organisations; AIDS Council of NSW

Funding: NHMRC; NSW Health Department

Located: HIV Epidemiology and Prevention Program

Modelling interventions to prevent syphilis infection and their acceptability among gay men

This study uses mathematical modelling to estimate the likely impact of a range

of interventions designed to reduce rates of syphilis infection among gay men, and uses both quantitative and qualitative research methods to assess how acceptable such interventions would be to the target population.

Status: Data collection is completed; 2,306, gay men were recruited to answer specific questions about their knowledge of syphilis and their attitudes toward a range of possible interventions through an online survey and were then invited to participate in three focus groups in Sydney and Melbourne. Data from mathematical models were considered alongside the findings from the acceptability study. A report of the findings was published and further data analysis and reporting is ongoing.

Personnel: Garrett Prestage, Jack Bradley, Ian Down

Collaborators: Australian Research Centre in Sex Health and Society

Funding: Commonwealth Department of Health and Ageing, NSW Health Department, Victorian Department of Health

Located: HIV Epidemiology and Prevention Program

Modelling interventions to prevent HIV infection and their acceptability among gay men in NSW

This study uses mathematical modelling to estimate the likely impact of a range of interventions designed to reduce rates of HIV infection among gay men, and uses both quantitative and qualitative research methods to assess how acceptable such interventions would be to the target population. 600 gay men were recruited to answer specific questions about their attitudes toward a range of possible interventions through an online survey and were then invited to participate in five focus groups in Sydney. Data from mathematical models were considered alongside the findings from the acceptability study.

Status: Data collection completed; data analysis and reporting is ongoing

Personnel: Garrett Prestage, Jack Bradley, Ian Down, Steve Frendo

Collaborators: Australian Research Centre in Sex Health and Society

Funding: NSW Health Department

Located: HIV Epidemiology and Prevention Program



Members of the HIV Epidemiology and Prevention Program

Staying safe: How do long term injecting drug users avoid hepatitis C infection?

Using an established longitudinal cohort of people who inject drugs (PWID) this project is looking to develop a new generation of hepatitis C virus (HCV) prevention programs to assist both new and experienced PWID to develop and implement strategies to remain uninfected with HCV. It will assist people who are infected but who clear the virus to continue to inject to avoid re-infection. Comparisons of PWID who have acquired HCV and those who have not over the long term (i. e. those who have "stayed safe") will also be explored.

Status: Ongoing

Personnel: Peter Higgs, Lisa Maher

Collaborators: The Centre for Population Health, Burnet Institute; Harm Reduction Victoria.

Funding: NHMRC Training Fellowship; UNSW Faculty of Medicine Small Grant Scheme

Location: *Viral Hepatitis Epidemiology and Prevention Program*

eTEST An initiative to enhance STI Testing in gay men

Regular testing of sexually active gay men is required to prevent ongoing transmission of STIs. This project assesses whether a multi-faceted intervention which involves software designed to encourage clinicians to test through passive prompts, SMS recall messaging, audit tools, education and incentives for testing can increase testing rates

in general practice. eTEST will take place in Sydney among 10-15 GP clinics with the aim of increasing HIV/STI testing to at least two times per year in high-risk gay men, four times per year in HIV positive men, and re-testing after a chlamydia and gonorrhoea infection. These aims are in accordance with the testing guidelines for men who have sex with men.

Status: Commenced

Personnel: Rebecca Guy, Larissa Lewis, Handan Wand, John Kaldor Basil Donovan

Collaborators: Chris Bourne, Vijay Ramanathan, Jane Hocking, John De Wit, Denton Callander

Funding: NSW Health

Located: *Sexual Health Program*

Social, behavioural and cultural research

HIM (Health in Men) study: per contact probability of HIV transmission

A cohort study to examine the probability of HIV transmission by sexual act.

Status: All 1,427 HIV negative men underwent detailed sexual behaviour interviews. Analysis and final reporting occurred in 2010

Personnel: Andrew Grulich, Garrett Prestage, Iryna Zablotska, Jeff Jin, David Wilson

Collaborators: National Centre in HIV Social Research; Australian Federation of AIDS Organisations; AIDS Council of NSW

Located: *HIV Epidemiology and Prevention Program*

HIM (Health in Men) study: incidence and risk factors for pharyngeal gonorrhoea

A cohort study to examine the incidence and risk factors for pharyngeal gonorrhoea.

Status: All 1,427 HIV negative men underwent detailed sexual behaviour interviews and over 90% were tested for pharyngeal gonorrhoea. Analysis and final reporting occurred in 2010

Personnel: Andrew Grulich, Garrett Prestage, Iryna Zablotska, Jeff Jin, David Wilson

Collaborators: National Centre in HIV Social Research; Australian Federation of AIDS Organisations; AIDS Council of NSW

Located: *HIV Epidemiology and Prevention Program*

HIM (Health in Men) study: defining high HIV incidence subgroups

A cohort study to define high HIV incidence subgroups of homosexual men who could potentially be targeted for HIV prevention trials. 1,427 HIV negative men underwent detailed sexual behaviour interviews. Analyses were performed to identify subgroups with at least a 2% incidence of HIV.

Status: Analysis and final reporting in 2010

Personnel: Andrew Grulich, Mary Poynten, Garrett Prestage, Iryna Zablotska, Jeff Jin

Collaborators: National Centre in HIV Social Research; Australian Federation of AIDS



Members of the Viral Hepatitis Epidemiology and Prevention Program

Organisations; AIDS Council of NSW

Located: HIV Epidemiology and Prevention Program

Risk factors for HIV seroconversion

A study of risk factors for HIV infection among people recently diagnosed with HIV infection.

Status: During 2010, online and direct enrolment continued in Queensland, Victoria, New South Wales, South Australia and Western Australia, and was extended to Tasmania and the Australian Capital Territory. In total, 247 men with recent primary HIV infection were enrolled into the study by the end of June 2010, and an additional 90 individuals, both male and female, were enrolled between July and December 2010. Preliminary analysis and reporting has commenced and is ongoing. Funding has been provided to continue the study through 2012 and extend to include women recently diagnosed with HIV.

Personnel: Garrett Prestage, Ian Down, Jack Bradley, Jeff Jin, Andrew Grulich

Collaborators: National Centre in HIV Social Research; Australian Research Centre in Sex, Health and Society; Curtin University; State AIDS Councils, State PLWHA organisations, and State Health Departments.

Funding: Queensland Health; Victorian Department of Health; NSW Health Department; Western Australian Health Department; South Australia Department of Health; Tasmanian Department of Health; Health Department of the ACT

Located: HIV Epidemiology and Prevention Program

Study of gay community attachment among Australian gay men and its implications for behavioural surveillance and research (Australian Gay Community Periodic Surveys)

Repeated cross-sectional surveys of gay-community attached men (behavioural surveillance); analyses of trends and predictors of gay community attachment and their implications for further behavioural surveillance and research in Australian gay communities.

Status: In 2010, all surveys completed in Sydney, Melbourne, Brisbane, Adelaide, Perth and Canberra were reviewed for the information about gay community attachment. Analyses were completed.

Personnel: Iryna Zablotska, Garrett Prestage

Collaborators: National Centre in HIV Social Research; State AIDS Councils; State PLWHA organisations; State Health Departments

Funding: State and Territory Health Departments

Located: HIV Epidemiology and Prevention Program

Group sex study

A study to investigate the motivations and circumstances of group sex behaviour among gay men, particularly those behaviours that may contribute to HIV transmission.

Status: Data collection is completed: In total, 994 men completed the study questionnaire and sixteen men were interviewed in depth. Analysis and reporting is ongoing.

Personnel: Garrett Prestage, Jack Bradley.

Collaborators: The University of Sydney University of Western Sydney; AIDS Council of New South Wales; Victorian AIDS Council; Queensland Association of Healthy Communities.

Funding: NSW Health Department; Victorian AIDS Council; Queensland Association of Healthy Communities

Located: HIV Epidemiology and Prevention Program

The PASH (Pleasure and Sexual Health) Study: understandings of risk among gay men

A study of beliefs and attitudes about risks and consequences of HIV infection in Australian gay men.

Status: Data collection is completed: In total, 4125 men were referred to the survey, of whom 2306 provided sufficiently complete survey questionnaires for inclusion in analysis. 40 men were interviewed in depth. A comprehensive community report was published in May 2010. Further data analysis and reporting is ongoing.

Personnel: Garrett Prestage, Jack Bradley, Ian Down, Steve Frendo

Collaborators: Australian Research Centre in Sex, Health and Society; Curtin University; National Centre in HIV Social Research; State AIDS Councils, State PLWHA organisations, and State Health Departments.

Funding: Victorian Department of Health; NSW Health Department; Western Australian Health Department; South Australian Department of Health

Located: HIV Epidemiology and Prevention Program

Sexually adventurous men's study

A study to document and record the work of the Sexually Adventurous Men's Projects of the Victorian AIDS Council and PLWHA Victoria, and to investigate the beliefs and behaviours among gay men in sexually adventurous networks in Melbourne.

Status: Processes and record-keeping documentation have been established, and data collection is ongoing. Interview schedules have been developed.

Personnel: Garrett Prestage.

Collaborators: Australian Research Centre in Sex Health and Society; Victorian AIDS Council; PLWHA Victoria.

Funding: Victorian Health Department

Located: HIV Epidemiology and Prevention Program

Defining risk and mechanisms of permucosal transmission of acute HCV infection within high-risk populations

A study of HCV transmission and its risk factors among homosexual men.

Status: The study samples have been stored and will undergo batch analysis in 2010. Recruitment is ongoing.

Personnel: Garrett Prestage, Ian Down, Jack Bradley, Mark Danta, Gail Matthews, Tanya Applegate

Collaborators:

Funding: NHMRC

Located: HIV Epidemiology and Prevention Program

Social norms regarding HIV/STI risk and risk reduction behaviours among men who have sex with men in Australia (CONNECT study)

A cross-sectional quantitative study using respondent-driven sampling to recruit homosexual men in Sydney, Melbourne and Perth to investigate norms regarding sexual practices across different social/sexual networks.

Status: During 2010, the study protocol, data collection instrument and the study procedures were developed and recruitment staff trained.

Recruitment of seeds started in December

Personnel: Iryna Zablotska, Garrett Prestage, Michelle McKechnie, Ben Bavinton

Collaborators: National Centre in HIV Social Research; Curtin University, AIDS Council of NSW (ACON), Victorian AIDS Council (VAC), AIDS Council of Western Australia (WAAC)

Funding: NHMRC (2010-2012)

Located: HIV Epidemiology and Prevention Program

Mapping gay community networks in Sydney, NSW

Mixed-method cross-sectional study involving interviews of opinion leaders representing different networks and organisations of gay men in Sydney to describe the structure and functioning of the Sydney gay community.

Status: The protocol and data collection instrument were developed. Data collection has commenced.

Personnel: Iryna Zablotska, Garrett Prestage, Ben Bavinton

Collaborators: AIDS Council of NSW (ACON)
Funding: NSW Health
Located: HIV Epidemiology and Prevention Program

Out on the Reef 2010

This is a study of the experiences of gay men living with and affected by HIV in North Queensland.

Status: Data collection is completed. Gay men living in North Queensland were invited to participate in three focus groups and in one-on-one key informant interviews in Cairns. Data collected through other studies that include men from this region are being reanalysed to identify specific issues among men in this region. A report of the findings is in preparation. Data analysis and reporting is ongoing.

Personnel: Garrett Prestage, Ian Down

Collaborators: Australian Research Centre in Sex Health and Society

Funding: Queensland Department of Health

Located: HIV Epidemiology and Prevention Program

RAMPT-C

This is a study of the sexual transmission of hepatitis C among HIV-positive gay men.

Status: HIV-positive gay men who have recently been diagnosed with hepatitis C are recruited to answer specific questions about their knowledge of hepatitis C and their beliefs about its

transmission. Data collection is ongoing.

Personnel: Garrett Prestage, Jack Bradley, Ian Down

Collaborators: St Vincents Hospital

Funding: NHMRC

Located: HIV Epidemiology and Prevention Program

Monogamy: meanings and practices among gay men

This is a study of gay men's attitudes toward and beliefs about monogamy, and how that affects the kinds of relationships they form.

Status: Gay men are being interviewed in depth about the concept of monogamy and their own relationships. Data collection is ongoing.

Personnel: Garrett Prestage

Collaborators: Australian Research Centre in Sex Health and Society

Funding: NHMRC

Located: HIV Epidemiology and Prevention Program

A survey of the sexual behaviour and sexual health of Australian prisoners

Little is known about the sexual behaviour, including sexual assault, of Australian prisoners. In addition, the consequences of introducing condoms and dental dams into prisons are unknown. This study was designed to qualify and quantify the sexual behaviour of male and female prisoners in all New South Wales and

Queensland prisons. It also aimed to assess the effects of NSW prisons introducing condoms and dental dams in 1997. This study involves computer-assisted telephone interviews with prisoners and key informant interviews.

Status: Data collection completed in 2008; several reports published 2010 with more in preparation. The second monograph, detailing the Queensland findings, was also published in 2010

Personnel: Basil Donovan, Karen Schneider, Tony Butler

Collaborators: Eva Malacova, Juliet Richters, Luke Grant, Alun Richards, Anthony Smith

Funding: NHMRC Project Grant, NSW Health Department, NSW Department of Corrective Services, Queensland Department of Corrective Services, UNSW

Located: Sexual Health Program

The Law and Sexworker Health (LASH) Project

It has long been suspected that different legal climates have different health and welfare outcomes for sex workers. As its various jurisdictions have different prostitution laws, Australia is an ideal country to study the effects of those laws. Three capital cities were chosen for their different legal climates: Melbourne, where sex work is only decriminalised in licensed brothels (licensing), otherwise it remains illegal; Perth, where sex work remains criminalised; and Sydney, where most



Members of the HITS-c team with Professor Lisa Maher (third from right)

form of adult sex work are decriminalised, without licensing. Through legal research we determined the laws and the level of policing of those laws in Victoria, WA, and NSW. We also mapped the female brothel-based sex industry in each city. Brothels were chosen at random, with a survey target of 200 sex workers in each city. Each brothel was repeated approached until every sex worker consented to participate or refused. Each participating sex worker completed a questionnaire that was available in 4 languages. Those women were then offered testing for chlamydia, gonorrhoea, *Mycoplasma genitalium* infection, and trichomoniasis. Comparisons were made between cities.

Status: Analyses and reporting of the findings underway

Personnel: Basil Donovan, Chris Harcourt, Karen Schneider, Handan Wand, John Kaldor

Collaborators: Sandra Egger, Christopher Fairley, Marcus Chen, Lewis Marshall, Sepehr Tabrizi, Sexual Workers Outreach Project, Sydney; RhED, Melbourne; Magenta, Perth

Funding: NHMRC Project Grant, Victorian Department of Human Services

Located: Sexual Health Program

Exploring the natural history of injection drug use: A qualitative study of social and environmental influences in the VIDUS cohort

This study seeks to: (1) examine the influence of social and environmental factors on critical initiation and transitional events among street youth and adults who inject drugs, including transitions in drug use, initiation into drug scenes and sex work; (2) examine the influence of social and physical context within 'drug scenes' on HIV risk behaviour; (3) refine and document an evolving ethno-epidemiological approach to investigating the natural history of injection drug use. The study employs observational ethnographic activities, in-depth interviews, mapping techniques, photography, and epidemiological data. Observational activities will be conducted in settings where illicit drugs are consumed. Qualitative in-depth interviews will be conducted with individuals who are members of existing cohort studies, and will utilise a longitudinal perspective through annual follow-up of participants.

Status: Ongoing.

Personnel: Lisa Maher

Collaborators: British Columbia Centre for Excellence in HIV/AIDS, Vancouver (lead).

Funding: Canadian Institutes of Health Research

Location: Viral Hepatitis Epidemiology and Prevention Program

Collaborative projects with Sydney Sexual Health Centre

Culturally and linguistically diverse MSM at SSHC: diagnostic and behavioural trends

Differences may exist in both STI risk behaviour and testing practice between the major Culturally and Linguistically Diverse (CALD) groups within Australia. The purpose of this study is to compare practice and trends over time. Data will be analysed by country of birth (Australian born versus overseas born) and language spoken.

Status: Data analysis ongoing

Personnel: Rebecca Guy, Handan Wand, Basil Donovan

Collaborators: Chris Bourne, Phillip Read

Funding: Nil

Located: Sexual Health Program

Unprotected oral sex and sex workers

Unprotected fellatio at work may represent a risk for STI acquisition in the oropharynx, and subsequent onwards transmission. This study seeks to identify the determinants of unprotected fellatio, and where possible correlate this to the presence of gonorrhoea in the oropharynx. Sex workers attending Sydney Sexual Health Centre were asked about their use of condoms for fellatio at work, and swabs were taken for gonorrhoea testing. Preliminary results have been presented at the Australasian Sexual Health Conference 2010, and further analysis will be presented at the ISSTD conference in July 2011 prior to publication.

Status: Preliminary results presented

Personnel: Basil Donovan, Rebecca Guy, Handan Wand

Collaborators: Phillip Read, Anna McNulty

Funding: Nil

Located: Sexual Health Program

Seasonal trends in STI diagnoses: an investigation

Local, state-wide and national notification data for STIs appears to show consistent variation at specific times during the year. The aim of the study is to identify seasonal trends in STI diagnoses, and to correlate this to trends in sexual behaviour, alcohol and drug use. Data from the Sydney Sexual Health Centre database will be used for this analysis.

Status: Data analysis ongoing

Project members: Handan Wand, Basil Donovan, Rebecca Guy

Collaborators: Phillip Read, Anna McNulty

Funding: Nil

Located: Sexual Health Program

Do SMS reminders improve STI testing frequency in men who have sex with men (MSM)?

In late 2008, Sydney Sexual health Centre implemented a reminder system to improve re-testing rates for HIV and sexually transmissible infections (STIs) in men who have sex with men (MSM); 3-6 monthly SMS reminders were recommended for high-risk MSM. We evaluated the impact of the SMS reminder system on HIV/STI testing re-testing rates in MSM attending Sydney Sexual Health Clinic. A controlled observational study design was used.

Status: manuscript accepted for publication

Personnel: Rebecca Guy, Handan Wand

Collaborators: Chris Bourne, Vickie Knight, Heng Lu, Anna McNulty

Funding: None

Located: Sexual Health Program

Do SMS reminders improve retesting rates after chlamydia infection in heterosexuals?

Chlamydia re-infection is common in women and men. By 12 months re-infection rates have been reported to be as high as 22% in a chlamydia re-infection prospective cohort of young women in Australia 2008-2009. In light of the high re-infection rates, clinical guidelines in Australia recommend that any people diagnosed with chlamydia should be re-tested in three months to detect chlamydia re-infections. Despite this, a recent analysis of heterosexuals attending 19 sexual health clinics found that the proportion of patients with chlamydia infection who were re-tested in 1-4 months was 11.9% in heterosexual males and 17.8% in heterosexual females. In late 2008, Sydney Sexual health Centre implemented a SMS reminder system to improve the frequency of the re-testing within three months of a chlamydia infection. We evaluated the impact of the SMS reminder system on chlamydia re-testing within three months of initial infection in heterosexuals attending Sydney Sexual Health Clinic. A controlled observational study design was used.

Status: in progress

Personnel: Rebecca Guy, Handan Wand

Collaborators: Phillip Read, Aurelie Kenigsberg, Vickie Knight, Anna McNulty

Funding: None

Located: Sexual Health Program

Clinical epidemiology

Chlamydia incidence and re-infection study (CIRIS): a longitudinal cohort study of young Australian women

Chlamydia incidence and re-infection rates have never been studied in Australian women. We aimed to determine the incidence of chlamydia in a cohort of young women who initially screen negative, along with determining the re-infection rate of women who initially screen positive, in order to inform future population screening programs. This study involved the establishment of a cohort of young women attending a range of primary health care services who agreed to complete questionnaires and return self-collected vaginal swabs for testing over the next 12 months.

Status: The cohort was closed in 2010.

Analyses are continuing

Personnel: Basil Donovan, John Kaldor

Collaborators: Jane Hocking, Jenny Walker, Christopher Fairley, Marcus Chen, Jane Gunn, Marie Pirotta, V Harindra, L Gurrin L, Sepehr Tabrizi, Suzanne Garland, K McNamee, Hudson Birden, Frank Bowden

Funding: Australian Government Department of Health and Ageing Chlamydia Pilot Program

Located: Sexual Health Program

A longitudinal study of bacterial vaginosis and *Mycoplasma genitalium* in young Australian women

Little is known about the epidemiology and natural history of bacterial vaginosis (BV) and nothing is known about *M genitalium* (MG) infection in Australian women. We seek to determine the prevalence, incidence and persistence of BV and MG in a general population of Australian women using the cohort established by the CIRIS study.

Status: The cohort was closed in 2010. Two reports have been accepted for publication and further analyses are underway

Personnel: Basil Donovan

Collaborators: Jane Hocking, Jenny Walker, Christopher Fairley, Marcus Chen, Catriona Bradshaw, Jane Gunn, Marie Pirotta, V Harindra, L Gurrin L, Sepehr Tabrizi, Suzanne Garland, K McNamee

Funding: NHMRC Project Grant

Located: Sexual Health Program

Examination of injecting drug use life course and estimating prevalence and health consequences of a dynamic population

This project examines longitudinal datasets of injecting drug users from the UK (e. g. Edinburgh Addiction Cohort Study) and

Australia (e. g. Hepatitis Incidence and Transmission Study) taking into account periods of injecting and non-injecting. This will allow for more valid projections of injecting drug use health consequences and associated health impacts and costs of interventions.

Status: Ongoing.

Personnel: Jo Kimber, Lisa Maher

Collaborators: University of Bristol; MRC Biostatistics Unit, Cambridge; Muirhouse Medical Group, Edinburgh; London School of Hygiene and Tropical Medicine

Funding: NHMRC (Sidney Sax) Training Fellowship

Location: Viral Hepatitis Epidemiology and Prevention Program

Infection-related cancer

The SPANC study (Study of the prevention of anal cancer)

A cohort study to examine the prevalence, incidence and risk factors for progression of human papillomavirus infection and anal cancer precursors in HIV positive and HIV negative homosexual men aged 35 and older.

Status: The study team was assembled, collaborative structures formed, study protocol finalised, instruments developed, and the first



Members of the Sexual Health Program

29 participants were recruited.

Personnel: Andrew Grulich, Jeff Jin, David Templeton, Garrett Prestage

Collaborators: Sexually Transmitted Infections Research Centre, Westmead Hospital; St Vincent's Hospital; Melbourne Sexual Health Centre; Royal Women's Hospital, Melbourne; Douglass Hanly Moir Pathology; School of Public Health, University of Sydney

Funding: NHMRC Program Grant

Located: *HIV Epidemiology and Prevention Program*

Review of HPV associated cancers in Australia

A review of Australian cancer registration data to quantify the public health burden associated with HPV-related cancers in Australia.

Status: Analyses and final reporting occurred.

Personnel: Andrew Grulich, Jeff Jin

Collaborators: University of Melbourne, Commonwealth Serum Laboratories

Funding: NHMRC Fellowship

Located: *HIV Epidemiology and Prevention Program*

Geographic variation in anal cancer incidence in New South Wales

A review of NSW data on cancer incidence in those postcodes with a high proportion of homosexually active men.

Status: Analyses of cancer incidence by postcode occurred.

Personnel: Andrew Grulich, Mary Poynten, Jeff Jin

Collaborators: NSW Cancer Registry

Funding: NHMRC Fellowship

Located: *HIV Epidemiology and Prevention Program*

HIM (Health in Men) study: sero-epidemiology of Human papillomavirus (HPV)

A cohort study to describe incidence and risk factors for HPV seropositivity.

Status: All 1,427 HIV negative men underwent detailed sexual behaviour interviews. Stored samples were extracted and shipped to the German Cancer Research Centre where they underwent multiplex serology for HPV. Analyses are ongoing.

Personnel: Andrew Grulich, Mary Poynten, Garrett Prestage, Iryna Zablotska, Jeff Jin

Collaborators: German Cancer Research Centre; National Centre in HIV Social Research; Australian Federation of AIDS Organisations; AIDS Council of NSW

Funding: NHMRC Fellowship; NHMRC program grant

Located: *HIV Epidemiology and Prevention Program*

International pooled analysis of immune risk factors for lymphoma

A pooled analysis of case-control studies of immune risk factors for lymphoma. All twelve member studies sent data on a pooled total of 12,982 cases and 16,441 controls, and results on auto-immune disease as a risk factor for non-Hodgkin lymphoma (NHL) were reported.

Status: Analyses on the association between atopic disease and birth order were reported in 2010, and analyses on infectious conditions and NHL risk were ongoing.

Personnel: Andrew Grulich

Collaborators: UNSW Cancer Research Centre; University of Southern California; German Cancer Research Centre; Feinberg School of Medicine, Northwest University; Centre for Study and Prevention of Cancer; Aviano Cancer Centre; Catalan Institute of Oncology; University of California, San Francisco; David Geffen School of Medicine, University of California, Los Angeles; University of York; British Columbia Cancer Registry; School of Medicine, Yale University

Funding: Leukaemia Foundation of Australia

Located: *HIV Epidemiology and Prevention Program*

Cancer in primary immune deficiency

A project to describe the incidence of malignancies in people with primary (congenital) immune deficiencies and to compare this with the incidence of malignancy in people with HIV/AIDS and in those with organ transplants.

Status: Analysis and final reporting occurred in 2010.

Personnel: Andrew Grulich,

Collaborators: UNSW Cancer Research Centre; Australian Primary Immunodeficiency Disease Register, The University of Sydney

Funding: NHMRC fellowship

Located: *HIV Epidemiology and Prevention Program*

Laboratory research

Immunopathogenesis and correlates of immunity research

Immuno-phenotyping of T-cell subsets

Many NCHECR clinical trial and natural history protocols involve immunological sub studies.

The laboratory supports these sub studies as a semi-routine service.

Status: Routine use of 6-10 colour multiparameter flow cytometry. Intensive assays were performed as part of the PINT and CORAL studies, including analysis of Stem cells. The CORAL study was completed in 2010.

Personnel: Nabila Seddiki, Mee-Ling Munier, Michelle Bailey, Chansavath Phetsouphanh, Yin Xu, Anthony Kelleher
Collaborator: John Zaunders, St Vincent's Hospital, Sydney

Funding: Project-specific grants

Location: Immunovirology and Pathogenesis Program

Primary HIV and early disease research – Australian cohort (PHAEDRA) Extension

A systematic mechanism to follow up the PHAEDRA and CoreO1 cohorts in Sydney and Melbourne with acute and early HIV-1 infection.

Status: 147 patients were enrolled in this extension study by Dec 2010 and follow up is continuing.

Personnel: Pat Grey, Ansari Shaik, David Cooper, Anthony Kelleher.

Collaborators: Robert Finlayson, Taylor Square Private Clinic; Mark Bloch, Holdsworth House General Practice; Cassy Workman, AIDS Research Initiative; Robert McFarlane, East Sydney Doctors; Dr B.K. Tee, The Centre Clinic; Norman Roth, Prahran Market Clinic; Phillip Cunningham, John Zaunders, St Vincent's Hospital, Sydney; The Alfred Hospital; Tim Read, Melbourne Sexual Health; Sydney Sexual Health; John Murray, School of Mathematics, Faculty of Science, UNSW

Funding: NHMRC Program Grant

Location: Immunovirology and Pathogenesis Program


Australian Long-Term Non-progressor Study

The Australian long-term non-progressor cohort study was established in 1994 and is still ongoing. Studies focussing on identifying the reason this rare group of people with prolonged HIV infection remain healthy, with virtually no damage to their immune system are extremely important for understanding the pathogenesis of HIV and for developing new antiretroviral therapy and preventative vaccines.

Status: Of the 141 participants recruited to this cohort 52 individuals (sustained non-progressors) are still treatment naïve. Four new patients were recruited in 2010.

Personnel: Linda Gelgor, Anthony Kelleher, Pat Grey, Ansari Shaik, John Kaldor, David Cooper

Collaborators: Long-Term Non-progressor Study Group, including clinical sites in Sydney, Port Kembla, Canberra, Brisbane and Melbourne; Kat Marks, St Vincent's Hospital, Sydney; Stephen Kent and Ivan Stratov, University of Melbourne. International collaboration includes Elite Controller



Members of the Immunovirology and Pathogenesis Program

Collaborative Project and the International AIDS Vaccine Initiative (IAVI).

Funding: NHMRC

Location: *Immunovirology and Pathogenesis Program*

Evolution of immune responses in primary infection and long-term non-progressors

This study examined the mechanisms of viral escape from cytotoxic T-lymphocyte responses, and particularly the events leading up to escape from the HLA-B27 mediated T-cell response at the level of Tcell receptor usage. It employs samples and data gathered during the follow-up of the long-term non-progressor (LTNP) cohort, and samples collected from the PHAEDRA cohort.

Status: T-cell receptor repertoire studies and viral escape studies completed and results published in 2010

Personnel: Anthony Kelleher, Linda Gelgor, Kathy Petoumenos

Collaborators: Daniel Douek, David Price, Vaccine Research Centre, US National Institutes of Health; Miles Davenport, Vanessa Venturi, Centre for Vascular Research, UNSW

Funding: US National Institutes of Health; NHMRC

Location: *Immunovirology and Pathogenesis Program*

B cell subsets, neutralising antibodies and auto-antibodies at primary HIV-1 Infection

Studies of overlap between neutralising antibodies and auto-antibodies at primary infection and the subsets of B cells producing these responses. Data collection on B cell phenotypes from cryopreserved samples cohorts of patients from Pheadra/coreO1 studies identified at primary infection who control HIV infection and who do not was completed in 2010. Methods for the delineation of Follicular T helper cells and B cell subsets in parallel in humans and macaques were employed to isolate these cells from macaques with SIV infection. These cells are being characterised as a potential reservoir for SIV infection.

Status: Analysis due for completion early 2011.

Personnel: Chris Weatherall, Yin Xu, Anthony Kelleher

Collaborators: John Zaunders, Kazuo Suzuki, St Vincent's Hospital, Sydney; Damian Purcell, Department of Microbiology and Immunology, The University of Melbourne; Stuart Tangye, Immunology and Inflammation Program, Garvan Institute of Medical Research, Stephen Kent, Rob De Rose Department of

Microbiology and Immunology, The University of Melbourne

Funding: NHMRC

Location: *Immunovirology and Pathogenesis Program*

Immunopathogenesis of immune reconstitution disease

Studies of the immunopathogenesis of immune reconstitution disease (IRD) based on the samples studied ex vivo from patients suffering this disease.

Status: A study exploring the causes of this dysregulation, with particular focus on the role of T regulatory cells. Studies commenced in 2006 and were formalised to recruit all patient commencing CART late in the disease with a natural history study called PrIRIS. The study is still ongoing with 20 patients enrolled (aim 20). Assays performed real time aimed to look at the phenotype (8 flow cytometry panels) at intracellular cytokine secretion and at antigen-specific regulatory and effector T cells. Patient will complete the study in Q12011 and there after data analysis will be completed.

Personnel: Nabila Seddiki, Anthony Kelleher, Chansavath Phetsouphanh, Sarah Pett

Collaborator: Debbie Marriott, St Vincent's Hospital, Sydney

Funding: NHMRC

Location: *Immunovirology and Pathogenesis Program*

Viral reservoirs

Currently available antiretroviral therapy has little impact on HIV viral reservoirs. The site, size and components of these reservoirs is poorly understood. Also, the impact of integrase inhibitors on latently infected cells, including residual viraemia, which is tightly connected to these cells, is currently unclear.

Status: Assays to quantify the DNA species of HIV-1 total DNA, integrated DNA and episomal DNA, were established in the laboratory and validation of these assays has been completed. These assays have been used to analyse week 52 patient samples from the PINT study. Also, the analysis from samples of a of a raltegravir switch study has been completed in 2010, using the total HIV-1 DNA and 2-LTR circle assays. Another study commenced in 2009 and now complete, this study was aimed at the preferential infection of CD4+ T cell subsets during chronic HIV infection. A low copy HIV-1 RNA assay (limit of detection 3 copies/ml) has been used for quantitation of low level (below 50 copy) viraemia in patients currently enrolled in the CORAL study, this study has also been completed in 2010. A new and recently

funded study to characterise the antigen specificity, frequency and function of latently HIV-1 infected CD4 T memory cells is in preparation and is due to commence in 2011. In addition more detailed analysis of HIV DNA content in CD4+ T cell subsets from patients enrolled in the PINT study is to commence in 2011.

Personnel: Kersten Koelsch, Michelle Bailey, Kristin McBride, Paul Lam

Collaborators: John Zaunders, Kat Marks, St Vincent's Hospital, Sydney; John Murray, School of Mathematics, UNSW

Funding: NHMRC, Merck

Location: *Immunovirology and Pathogenesis Program*

RESTORE

An observational study to explore reconstitution of immunity in patients with advanced HIV-1-infection commencing combination antiretroviral therapy

Status: start date September 2010.

Sites: one site in Thailand

Target: 13/50 patients

Personnel: Sarah Pett, Sean Emery, Anthony Kelleher

Funding: NHMRC, UNSW

Location: *Therapeutic and Vaccine Research Program*

Laboratory service and support

Specimen receipt and processing for clinical trials and natural history studies

The laboratory provides a service to other NCHECR programs encompassing the separation of blood components including but not limited to; cryopreservation of serum, plasma and PBMC, archiving and on shipping of samples. The service also includes database management of the storage of these samples. Staff also have experience with the implementation of assays which are not offered by local diagnostic laboratories. This service contributes to the overall smooth running of clinical trials and natural history studies.

Status: Ongoing

Personnel: Anthony Kelleher

Collaborators: Kate Merlin, Julie Yeung, Maria Piperias, Bertha Fsadni, St Vincent's Hospital, Sydney

Funding: Project-specific grants

Co-located: *Viral Hepatitis Clinical Research Program and Immunovirology and Pathogenesis Program*

HepBank Clinical Sample Repository & Open Access Substudy database (LabKey)

Establishment of a HCV sample repository that incorporates barcoding to facilitate patient sample and data management. This includes samples from ATAHc and CHARIOT and prospective trials including Sample collection for Prospective cohorts and trials including ACTIVATE / ATAHc II / ETHOS. The web-based LabKey database will link existing clinical, sample repository and laboratory data-sets to allow comprehensive analysis of clinical trial results. This will also strengthen collaborative efforts within NCHCR and with investigators from other leading Research Institutes.

Personnel: Ineke Shaw, Brendan Jacka, Pip Marks, Tanya Applegate, Ansari Shaik, Tony Kelleher

Funding: Program grant

Co-located: *Viral Hepatitis Clinical Research Program and Immunovirology and Pathogenesis Program*

Assay development

Assays of T-cell function, proliferation and cytotoxicity, and identification of antigen-specific T-cells

A range of flow cytometric assays for assessing CD4+ and CD8+ T-cell function are worked up in the laboratory. The measures of antigen-specific T-cells include T cell proliferation, activation and cytokine secretion. Such assays are important for understanding HIV pathogenesis and in responses to vaccines, and therefore are included in the protocols of clinical trials and natural history studies carried out by NCHCR. Intensive assays were performed as part of the phase I trial of PO4112, and the PINT trial of therapy with the integrase inhibitor, Raltegravir. These studies have now also been extended to the PHILDO observational study of primary HIV infection. These assays are also being validated in two clinical trials: assessing latent TB infection; and CMV re-activation and Adenovirus infection following paediatric bone marrow transplantation, respectively.

Status: Continued analysis of samples from PHAEDRA and the long-term non-progressor cohorts.

Personnel: Nabila Seddiki, Mee-Ling Munier, Michelle Bailey, Yin Xu, Chansavath Phetsouphanh, Celine Yan, Anthony Kelleher
Collaborators: John Zaunders, St Vincent's Hospital, Sydney; Mahila Namasivayam, Tony Walls and John Ziegler, Sydney Children's Hospital

Funding: NHMRC, St Vincent's Hospital
Co-located: *Viral Hepatitis Clinical Research Program and Immunovirology and Pathogenesis Program*

HIV drug resistance

This project involves the development of expertise in the application of a number of methods of detecting antiretroviral drug resistance through genotypic testing of HIV isolates. We have three major projects: evaluation and conducting commercially available genotype testing for protease, reverse transcriptase regions; development of new in-house genotyping method from blood dry-spot from the patients as a starting material of genotype assay, which will be transferred to collaborator in south-east countries; and developing assay for the determination of CCR5 tropism of patient's HIV isolates and establishing the HIV tropism genotype test in our laboratory. More than 700 HIV-1 resistance genotypes have been performed based on the commercial based resistant assays. New in-house genotyping method is under development for protease, reverse transcriptase, and Integrase regions. We are confirming sensitivity of the current developed assay and we will start to use dry-blood samples for genotyping assay. We have started evaluation of CCR5 tropism assay. We will compare this new tropism assay to the Trofile™ assay, which is currently used as the standard assay.

Status: evaluation completed of ViralSeq HIV-1 Genotyping kits

Personnel: Anthony Kelleher, Celine Yan, Kerstin Koelsch, Yong Pan

Collaborators: Kazuo Suzuki, Philip Cunningham, Leon McNally, Alexander Carrera, St Vincent's Hospital, Sydney

Funding: NSW Health Department, ViV
Co-located: *Viral Hepatitis Clinical Research Program and Immunovirology and Pathogenesis Program*

Novel real time PCR technology for mixed infection

Development of novel MNzyme technology for the detection and quantification of mixed HCV infection.

Personnel: Brendan Jacka, Tanya Applegate
Collaborators: Alison Todd, Elisa Mokany, SpeedX Pty Ltd, Sydney

Funding: Program grant
Co-located: *Viral Hepatitis Clinical Research Program and Immunovirology and Pathogenesis Program*

Development of new therapeutic modalities

RNA inducing viral latency

This project is related to siRNA gene silencing for HIV-1 and SIV infection. siRNAs targeting viral promoter DNA region induce transcriptional gene silencing (TGS) of viral genes in infected cells. The study has been extended to two major objectives: delivery system of siRNA and mechanism gene silencing. To develop and evaluate delivery system including lentiviral and non-viral delivery system to be used for mouse HIV-1 infection model; and to define the pathways by which dsRNAs targeting the promoter regions of HIV-1 and SIV.

Status: Constructs applicable for use in HIV-1 infection are under development. The constructs will be incorporated into lentiviral delivery vector and the delivery system will be assessed in vitro. Epigenetic changes induced by siRNAs targeting HIV-LTR will be defined. The role of Ago1 in nucleus in this process will be determined by confocal microscope using tagged Ago1 and labelled siRNA.

Personnel: Anthony Kelleher, Chantelle Hood, Sanjay Swaminathan

Collaborators: Kazuo Suzuki, St Vincent's Hospital, Sydney, Takaomi Ishida, Makoto Yamagishi, Toshiki Watanebe, The University of Tokyo

Funding: NHMRC

Co-located: *Viral Hepatitis Clinical Research Program and Immunovirology and Pathogenesis Program*

Translational research: host

In-vivo hepatitis C virus adaptation to host HLA-restricted immune responses in recently acquired HCV (ATAHC)

To characterise HCV adaptation to HLA-restricted immune response and examine the influence of HLA alleles on HCV sequence evolution and escape mutations.

Personnel: Greg Dore, Gail Matthews

Collaborators: Simon Malal and Silvana Gaudieri (CCiBS, Perth) and Andrew Lloyd (UNSW)

Funding: NIH

Co-located: *Viral Hepatitis Clinical Research Program and Immunovirology and Pathogenesis Program*

IP10 & IL28B serum protein levels in recently acquired HCV (ATAHC)

Analysing serum IP-10 and IL28B protein

levels (by ELISA) as a marker of spontaneous and treatment-induced clearance during early HCV infection.

Personnel: Jason Grebely, Tanya Applegate, Greg Dore, Gail Matthews

Collaborators: Jordan Feld, Toronto University; Andrew Lloyd, UNSW

Funding: NIH; program grant

Co-located: *Viral Hepatitis Clinical Research Program and Immunovirology and Pathogenesis Program*

IL28B-associated SNP mutations in recently acquired HCV (ATAHC)

Assessment of human genetic polymorphisms associated with treatment induced and spontaneous clearance of acute HCV infection

Personnel: Jason Grebely, Tanya Applegate, Greg Dore, Gail Matthews

Collaborators: Jacob George, Vijay Suppiah, David Booth, Westmead Millenium Institute

Funding: NIH; program grant

Co-located: *Viral Hepatitis Clinical Research Program and Immunovirology and Pathogenesis Program*

ISG expression profiles within peripheral blood in recently acquired HCV (ATAHC)

Examining the effects of Ribavirin on ISG expression profiles and examine any between those with persistent infection and those with clearance, and Ribavirin mechanism.

Personnel: Jason Grebely, Tanya Applegate, Greg Dore, Gail Matthews

Collaborators: Michael Beard, Edmund Tse, Adelaide University; Nick Shackel, Centenary Institute; Andrew Lloyd

Funding: NIH; program grant

Co-located: *Viral Hepatitis Clinical Research Program and Immunovirology and Pathogenesis Program*

T-cell responses in recently acquired HCV (ATAHC)

To identify the prevalence, magnitude, and breadth of CD4 and CD8 T cell responses to HCV proteins in primary HCV infection and the changes in these responses in subjects with and without treatment,

Personnel: Greg Dore, Gail Matthews, Jason Grebely

Collaborators: Jacqueline Flynn, Rosemary Ffrench, Burnet Institute

Funding: NIH

Co-located: *Viral Hepatitis Clinical Research Program and Immunovirology and Pathogenesis Program*

Characterisation of the humoral immune response in recently acquired HCV (ATAHC)

Development of an inexpensive incidence diagnostic test and investigation of serological markers of clinical outcome

Personnel: Greg Dore

Collaborators: Kim Wilson, National Serology Reference Laboratory

Funding: NIH

Co-located: *Viral Hepatitis Clinical Research*

Program and Immunovirology and Pathogenesis Program

Translational research: viral

Resistance mutations to Directly Acting Antivirals in treatment naïve patients

Identification of the prevalence of pre-existing resistance mutations within the ATAHC cohort, to polymerase and protease inhibitors using deep sequencing analysis.

Personnel: Gail Matthews, Tanya Applegate, Brendan Jacka, Greg Dore

Collaborators: Silvana Gaudieri, Centre for Clinical Immunology and Biomedical Statistics Royal Perth Hospital and Murdoch University

Funding: Program grant, project-specific grants

Co-located: *Viral Hepatitis Clinical Research Program and Immunovirology and Pathogenesis Program*

Characterisation of reinfection/mixed HCV infection in recently acquired HCV (ATAHC)

Analysis of the prevalence and impact of HCV reinfection and mixed infection using direct sequencing and genotype specific PCR

Personnel: Brendan Jacka, Tanya Applegate, Jason Grebely, Greg Dore, Gail Matthews

Collaborators: Sean Pham, Peter White, UNSW

Funding: NIH; program grant

Co-located: *Viral Hepatitis Clinical Research Program and Immunovirology and Pathogenesis Program*



Members of the Immunovirology and Pathogenesis Program

Serotype identification of HCV genotype

Determination of HCV genotypes among participants with negative HCV RNA at enrolment during acute HCV infection using an established HCV Murex HCV Serotyping Kit, within the ATAHC cohort and the broader InC³ Collaborative Group.

Personnel: Brendan Jacka, Tanya Applegate, Jason Grebely, Greg Dore

Collaborators: Janke Schinkel, University of Amsterdam; Naglaa Shoukry, University of Montreal; Andrew Lloyd

Funding: NIH; program grant

Co-located: *Viral Hepatitis Clinical Research Program and Immunovirology and Pathogenesis Program*

Hepatitis C virus transmission dynamics among injection drug users in Vancouver (ARYS / VIDUS Cohort)

To assess HCV transmission dynamics among IDUs, including HCV incidence, phylogenetics and phylodynamics, within well characterised injecting cohorts within Vancouver. To also assess mixed HCV infection/reinfection and mixed HCV infection among IDUs and the associated factors.

Personnel: Jason Grebely, Greg Dore, Tanya Applegate, Brendan Jacka, Gail Matthews

Collaborators: Mel Kraiden, British Columbia Centre for Disease Control; Zabrina Brumme, Simon Fraser University; Richard Harrigan, University of British Columbia, Canada

Funding: Program grant

Co-located: *Viral Hepatitis Clinical Research Program and Immunovirology and Pathogenesis Program*

Therapeutic research

Ribavirin concentrations in with chronic HCV in subjects CHARLOT

Determinants of plasma ribavirin concentration during the first 12 weeks of therapy in CHC genotype 1 patients treated within the CHARLOT study.

Personnel: Gail Matthews, Ineke Shaw, Rachel Ali, Greg Dore

Collaborators: John Ray, St Vincent's Hospital

Funding: Roche

Co-located: *Viral Hepatitis Clinical Research Program and Immunovirology and Pathogenesis Program*

Co-infection

Transmission networks in recently acquired HCV (ATAHC)

Explore clinical and molecular epidemiology of HCV transmission networks in HIV+/- population and assess if networks bridging into HIV- communities through phylogenetic and molecular clock analysis of HCV sequences.

Personnel: Gail Matthews, Tanya Applegate,

Greg Dore, Jason Grebely

Collaborators: Sean Pham, Peter White, UNSW; Lei Zhang

Funding: NIH; program grant

Co-located: *Viral Hepatitis Clinical Research Program and Immunovirology and Pathogenesis Program*

RAMPT-C cohort

Defining risk and mechanisms of percutaneous transmission for acute HCV infection MSM and IDUs within high-risk populations. This includes analysis of transmission events through HCV sequencing, biological and behavioural mechanisms in incident cases.

Personnel: Gail Matthews, Barbara Yeung, Amanda Erratt, Tanya Applegate, Brendan Jacka, Greg Dore.

Collaborators: Mark Danta, St Vincent's Clinical School, UNSW; Margaret Hellard, Rose Ffrench, Kylie Goy, Burnet Institute, Melbourne

Funding: Program grant; project-specific grants

Co-located: *Viral Hepatitis Clinical Research Program and Immunovirology and Pathogenesis Program*



Members of the Viral Hepatitis Clinical Research Program

Aboriginal and Torres Strait Islander health

STRIVE

This study is a clustered randomised community trial with an intervention of a sexual health quality improvement program aimed at reaching best-practice targets in STI control. It is located in 67 remote communities, comprised of 23 clusters of communities, in the Northern Territory, Western Australia and Far North Queensland. Over the next three years eight clusters of communities will be randomly assigned to receive the intervention.

Status: Baseline prevalence data for chlamydia, gonorrhoea and trichomonas has been completed from each of the 67 clinics

Personnel: John Kaldor, James Ward, Alice Rumbold, Rebecca Guy, Robyn McDermott, Lisa Maher, Basil Donovan, Linda Garton, Christopher Fairley, Bronwyn Silver, Janet Knox, Belinda Hengel, David Glance, Skye McGregor, Donna Ah Chee, John Boffa, Steven Skov

Funding: NHMRC Project Grant

Located: *Aboriginal and Torres Strait Islander Health Program*

REACCH: Research Excellence in Aboriginal Community Controlled Health

REACCH brings together the leading Australian institution dedicated to clinical research on sexually transmitted and blood borne viral infections (NCHECR), and the peak organisation for Aboriginal Community Controlled Health Services (NACCHO). Together, NCHECR and NACCHO will develop and implement a clinical research program through five selected ACCHS in urban and regional areas that with an aim of improving clinical practice and program delivery in this sector.

Status: Research being undertaken in each of the partner organisation sites

Personnel: John Kaldor, James Ward, Dea Delaney Thiele, Sophie Couzos, David Scrimgeour, Jenny Hunt, Greg Dore, Basil Donovan, Mary Ellen Harrod, Maurice Shipp

Funding: NHMRC Centre for Clinical Research Excellence (CCRE)

Located: *Aboriginal and Torres Strait Islander Health Program*

GOANNA

The first Australian study assessing knowledge, risk behaviours and health service access in relation to sexually transmissible infections

and blood borne viruses of young Indigenous people. This project will conduct the first-ever Australian study describing levels of knowledge, risk practice and access to health services in relation to sexually transmissible infections (STIs) and blood borne viruses (BBVs) of young Aboriginal and Torres Strait Islander people aged 16 to 30 years.

Status: Currently underway; five of 40 survey collections sites completed

Personnel: James Ward, Heather Worth, Dea Delaney-Thiele, John Kaldor, Smith A, Marion Pitts, Joanne Bryant, Clint Arizmendi

Funding: Australian Research Council (ARC) Linkage Grant

Located: *Aboriginal and Torres Strait Islander Health Program*

HIV Modelling Grant

Modelling the interaction between sexually transmitted infections and HIV transmission to inform public health policy. This project will conduct quantitative analyses using epidemiology, mathematical modelling, and health economics to investigate the impact of sexually transmitted infections (STIs), and where applicable injecting drug use, on population level transmission of HIV.

Status: Literature review complete; models under development

Personnel: David Wilson, Richard Gray, James Ward, Jonathon Anderson, Rob Carter

Funding: NHMRC Project Grant

Located: *Aboriginal and Torres Strait Islander Health Program*

STI Modelling Grant

This grant will use mathematical models to assess the impact of interventions to reduce sexually transmitted infections in Australia. The aims of this project will be to develop dynamic mathematical models to describe the transmission of chlamydia, gonorrhoea and syphilis in Australian populations and to further our understanding of their epidemiology. These will be used to assess the impact of interventions and the cost effectiveness on the incidence and prevalence of chlamydia, gonorrhoea and syphilis in Australian populations.

Status: Several models completed, analysis and interpretation underway

Personnel: Jane Hocking, David Regan, David

Wilson, David Philp, Anthony Smith, Andrew Grulich, James Ward

Funding: NHMRC Project Grants

Located: *Aboriginal and Torres Strait Islander Health Program*

SHIMMER: NSW Aboriginal Health Research Program

This grant aims to develop an Aboriginal Health Research Program within NSW Aboriginal Communities. This grant includes a trial aimed at enhancing clinical practice to reduce STIs in urban and regional Aboriginal primary health care settings in NSW.

Status: Research progressing

Personnel: James Ward, Basil Donovan, Rebecca Guy, Simon Graham, Janet Knox, Handan Wand, John Kaldor

Funding: NSW Health

Located: *Aboriginal and Torres Strait Islander Health Program*

Increasing completeness of 'Aboriginality' in infectious diseases data through record linkage – a feasibility study

The aim of this project is therefore to improve availability and validity of epidemiological data on notifiable diseases in Aboriginal people in NSW so that incidence and prevalence of these diseases can be more accurately estimated. The objective of this project is to link records from the Notifiable Diseases Database (NDD) with other routinely collected population health databases to prepare a de-identified 'snapshot' dataset, with improved completeness of 'Aboriginality'.

Status: Linkage complete; data analysis and interpretation underway

Personnel: Jeremy McAnulty, James Ward

Funding: NSW Health

Located: *Aboriginal and Torres Strait Islander Health Program*

Development and trial of Key Performance Indicators for Sexually Transmitted Infection control in clinical settings with high bacterial prevalence

A review of the literature has revealed a lack of performance indicators relevant to settings with a high prevalence of bacterial STI, such as in the Northern Territory (NT). This project aims to identify, develop, trial and endorse a core set of

key performance indicators (KPI) relevant to STI control in the NT. This will improve monitoring of STI control programs allowing comparison between regions and services.

Status: Completed in 2010

Personnel: Bronwyn Silver, Alice Rumbold, James Ward, John Kaldor, Steven Skov

Funding: NHMRC Program Grant

Located: *Aboriginal and Torres Strait Islander Health Program*

A situational analysis of public health responses to chronic hepatitis B in the Torres Strait:

This study is designed to identify priorities for an effective public health response to chronic hepatitis B in the Torres Strait through describing the impact of chronic hepatitis B infection on people and communities throughout the Torres Strait and to document how health service providers respond.

Status: Data collection underway

Personnel: Patricia Fagan, Cheryl Sendall, Yoko Nakata, Marian Pitts, Jack Wallace, James Ward, Stephen McNally

Funding: Latrobe University

Located: *Aboriginal and Torres Strait Islander Health Program*

Pelvic Inflammatory Disease in the primary health care setting: an investigation of clinical management.

This project is a review of current clinical practice

in relation to the management of women of reproductive age who present to remote community clinics in Central Australia with signs and symptoms of pelvic inflammatory disease and/or urinary tract infection.

Status: Data collection complete, interpretation and analysis and dissemination underway

Personnel: Bronwyn Silver, Alice Rumbold, Kirsty Smith, Janet Knox, James Ward, John Kaldor, Jacqueline Boyle

Funding: NHMRC Program Grant

Located: *Aboriginal and Torres Strait Islander Health Program*

Indigenous injecting use in Queensland (IIDU): a peer based research project

This research aims to explore the patterns of use, risks and outcomes of Indigenous injecting drug users (IDUs) in Queensland.

Status: Data collection currently underway

Personnel: Robert Kemp, Jake Najman, Sidney Williams, James Ward

Funding: Queensland Health

Located: *Aboriginal and Torres Strait Islander Health Program*

The role of resiliency in responding to blood-borne viral and sexually transmitted infections in Indigenous communities

A collaborative project between Australia, Canada and New Zealand to examine resilience to blood-borne viruses (BBVs) and sexually transmissible

infections (STIs) in Indigenous communities.

With a focus on adolescents and young adults in urban settings, the Australian component of the study seeks to identify factors that protect against acquisition of BBV/STI and promote access to prevention and treatment, and provide capacity building opportunities for Indigenous researchers and Aboriginal Community Controlled Health Services. In 2010 the third and final component of the Australian arm was completed, involving more than 300 interviews with young Aboriginal and Torres Strait Islander people in Townsville and Perth.

Status: Ongoing

Personnel: Julie Mooney-Somers, Anna Olsen, Marlene Thompson, Lisa Maher, John Kaldor

Collaborators: Townsville Aboriginal and Islanders Health Service Ltd; The Aboriginal Medical Service Coop Ltd, Redfern; Derbarl Yerrigan Health Service, Perth; Centre for Infectious Disease Prevention and Control, Health Canada; Canadian Aboriginal AIDS Network; University of Ottawa; Ngā Pae o te Māramatanga, University of Auckland; Auckland University of Technology; University of Otago Medical School

Funding: Tripartite Cooperation Agreement between Canadian Institutes of Health Research (CIHR); National Health and Medical Research Council of Australia (NHMRC); Health Research Council of New Zealand (HRC)

Located: *Viral Hepatitis Epidemiology and Prevention Program and Public Health Interventions Research Group*



Members of the Aboriginal and Torres Strait Islander Health Program

Liver Spots: A study of hepatitis B knowledge, treatment and health care among Indigenous Australians

This project aims to engage Indigenous individuals, families and communities affected by hepatitis B, as well as health care providers and policy makers in addressing the social and treatment needs of Aboriginal and Torres Strait Islander people living with chronic hepatitis B. Working with both urban and rural/remote communities, the study will investigate facilitators and barriers to biomedical knowledge, cultural healthcare needs, traditional health beliefs and facilitators and barriers of treatment uptake. Information generated from in-depth interviews and survey data will contribute to meeting the chronic health management and treatment needs of participating individuals and communities as well as providing data to inform the development of culturally appropriate resources and services for Indigenous Australians. Pilot work on the project began in late 2010.

Status: Ongoing

Personnel: Anna Olsen, Lisa Maher

Collaborator: Tullawon Health Service, South Australia

Funding: NHMRC Training Fellowship

Location: *Viral Hepatitis Epidemiology and Prevention Program*

From Broome to Berrima: building Australia-wide research capacity in Indigenous offender health and health care delivery

Australia has the highest Indigenous incarceration rate in the OECD, which impacts profoundly on Indigenous communities. Further, offender populations endure a greater health burden compared with the general community. This project is developing much needed capacity in offender health research, building a team of Indigenous researchers, and creating an Australia-wide network for sharing knowledge in this field. Outcomes will include better Indigenous offender health services and improved well being for this marginalised population.

Status: Ongoing

Personnel: John Kaldor

Collaborators: Tony Butler, Michael Levy, Fadwa Al-Yaman, Kay Wilhelm, Mick Dodson, Dennis Gray, Steve Allsop, Curtin University

Funding: NHMRC Capacity Building Grant

Located: *Public Health Interventions Research Group*

International health

Survey of epidemiological cohort studies and specimen sample sets and development of technical guidance documents for HIV incidence assays

The goal of the project is to advance assay identification and development for both the detection of acutely HIV infected persons and for the identification of specimens from recently HIV infected persons. This project will add to the knowledge of how existing and developing science can lead to such assays and build resources that can be used for the evaluation and validation of assays. A Request for Proposals will be created to stimulate the development of new assays.

Status: Project completed 2010

Personnel: John Kaldor, Joanne Micallef

Collaborators: Timothy Mastro, Connie Sexton, Mary Lynn Baniecki, JMG Garcia, Gaby Vercauteren, Family Health International

Funding: Gates Foundation Grant

Located: *Public Health Interventions Research Group*

Asia-Pacific region

TREAT Asia HIV Observational Database (TAHOD)

Observational cohort study of patients with HIV at 18 sites throughout the Asia-Pacific region. Demographic, clinical and treatment data are aggregated twice each year via electronic data transfer.

Status: At the data transfer in March 2010, baseline and retrospective data from about 5000 patients from 18 sites were aggregated. It is expected that follow up will continue for at least a further three years.

Personnel: Jialun Zhou, Rebecca Oyomopito, Julian Elliott, Preeyaporn Srasuebkul, Matthew Law, David Cooper

Collaborators: Network of 18 clinical sites at countries throughout the Asia-Pacific region

Funding: American Foundation for AIDS Research (amfAR) via a US National Institutes of Health grant through the International Epidemiologic Databases Evaluating AIDS collaboration

Located: *Biostatistics and Databases Program*

TREAT Asia Studies Evaluating Resistance (TASER)

There are two studies: First, a surveillance study (TASER-S) examining rates of transmitted HIV-resistance in newly diagnosed HIV-infected subjects not previously treated with antiretroviral drugs. Second, a monitoring study (TASER-M) assessing rates of developing HIV-resistance in patients starting antiretroviral treatments.

Status: Approximately 1500 naive and experienced patients had been recruited to TASER-M. Enrolment has ceased for the majority of the sites in 2010 with follow up continuing until mid 2011. Two new sites from Malaysia and Thailand have joined TASER-M and recruitment for these two sites will continue until 2011

TASER-S: Approximately 450 patients have been recruited from 5 sites. Recruitment has ceased for this study.

Personnel: Awachana Jiamsakul, Jialun Zhou, Matthew Law

Collaborators: Network of 12 sites in South East Asia

Funding: American Foundation for AIDS



Members of the Public Health Interventions Group

Research (amfAR) via a grant from the government of the Netherlands
Located: Biostatistics and Databases Program

TREAT Asia Paediatric HIV Observational Database (TApHOD)

TREAT Asia Paediatric HIV Observational Database (TApHOD) is a collaborative cohort of HIV-infected children in the Asia-Pacific region. The study participants are recruited from TREAT Asia clinical sites. Demographic, clinical and treatment data are aggregated twice each year via electronic data transfer. Currently, 16 sites in six countries have agreed to participate transferred their data to the NCHECR.

Status: Up to March 2010, 3635 children were recruited into TApHOD. Further recruitment is planned for 2011 and follow-up for at least three years. One new site in Vietnam and one in Indonesia will join TApHOD soon. These two new sites will have their first transfer in March 2011.

Personnel: Azar Kariminia, Matthew Law

Collaborators: Network of 18 sites initially throughout the Asia-Pacific region

Funding: TApHOD is funded by The Foundation for AIDS Research (amfAR), the Austrian AIDS Life Association, and the U. S. National Institute of Child Health and Human Development (NICHD)

Located: Biostatistics and Databases Program

TREAT Asia Quality Assurance Scheme (TAQAS)

To ensure capacity in HIV resistance testing in the Asia-Pacific region, a quality assurance scheme was implemented. Twice a year, HIV-infected blood samples are distributed to laboratories around the region, with returned HIV resistance test results compared to a consensus result.

Status: Two sets of blood samples were circulated in March and October to up to 22 laboratories.

Personnel: Jialun Zhou, Rebecca Oyomopito, Matthew Law

Collaborators: Network of 22 laboratories; National Reference Laboratory, Melbourne; Stanford University

Funding: American Foundation for AIDS Research (amfAR)

Located: Biostatistics and Databases Program

HIV Consortium for Partnerships in Asia and the Pacific

The HIV Consortium for Partnership in Asia and the Pacific was established in 2007 and has nine member organisations comprising a broad range of HIV advocacy and technical expertise from Australia. The Consortium and its members are responsible for implementing AusAID's Regional HIV Capacity Building Program. NCHECR is partnering with academic institutions in Indonesia and Cambodia to build capacity in HIV research methodologies.

Status: Ongoing

Personnel: Louise Causer, John Kaldor, Skye

McGregor, Janaki Amin, Kathy Petoumenos, Sarah Huffam

Collaborators: IHRG, ARCShS, ASHM, Albion Street Centre, NRL, Scarlet Alliance, AFAO, AIVL (Australia); NCHADS (Cambodia); JEN, Udayana University, Gadjah Mada University (Indonesia)

Funding: AusAID

Located: Public Health Interventions Research Group


Cambodia

Culture and HIV Prevention in Cambodia

This study assesses two cultural measures particular to Asian cultures, 'harmonious control' and 'fatalism' and their association with HIV infection and related risk and preventive behaviour, including adherence to a preventive vaccine regimen, among young women working in the sex and entertainment industry in Phnom Penh, Cambodia. Phase 1 consists of a formative qualitative phase to assess the constructs of harmonious control and fatalism, risk behaviours, and attitudes toward biomedical prevention technologies. Phase 2 consists of a prospective observational study with clinical and serological assessments for HIV and other STIs, risk behaviours and measurement of adherence to a multidose preventive HPV vaccine series.

Status: Ongoing

Personnel: Julie Mooney-Somers, John Kaldor, Lisa Maher



Members of the Biostatistics and Database Program

Collaborators: University of California, San Francisco (lead); NCHADS; Cambodian Women's Development Association
Funding: National Institutes of Health
Location: *Viral Hepatitis Epidemiology and Prevention Program*

Cambodian Treatment Access Program (CTAP)

Increasing access to antiretroviral treatment in Cambodia through the establishment of treatment clinics and technical assistance to the national HIV treatment program.

Status: Completed 2010
Personnel: Sarah Huffam, John Kaldor, David Cooper
Collaborators: National Center for HIV/AIDS, Dermatology and STDs; National Institute for Public Health; Phillip Cunningham, St Vincent's Hospital
Funding: Roche
Located: *Public Health Interventions Research Group*

China

Evaluation in China

Review and evaluation of HIV epidemics in China.
Status: Ongoing
Personnel: David Wilson, Lei Zhang, Eric Chow, Zhuang Xun, Lorraine Yap, Zunyou Wu, Jun Zhang, Jun Jing
Funding: World Bank Global HIV/AIDS Program, UNSW, AusAID
Collaborator: China CDC, Tsinghua University

Europe

Staying Safe: A sociology of how injecting drug users avoid viral infection in the long-term

This study aims to reconstruct the life trajectories of injecting drug users to identify social practices and conditions linked to long term avoidance of hepatitis C virus infection. Using qualitative life history studies from long-term PWID who have not been exposed to hepatitis C alongside those who have been exposed; this is the first research in the UK on long-term avoidance of viral infections associated with injecting drug use. To date a total of 13 in-depth qualitative interviews have been conducted.
Status: Ongoing.
Personnel: Lisa Maher
Collaborators: London School Hygiene Tropical Medicine, University of London (lead);

National Development and Research Institutes, New York; National Centre for HIV Social Research; The Burnet Institute.
Funding: Economic and Social Research Council
Location: *Viral Hepatitis Epidemiology and Prevention Program*

An international research workshop focused on newly acquired hepatitis C in injecting drug users

This grant was used to organise and support the 2nd Workshop of the InC3 Collaborative Group held on 15 April 2010 prior to the EASL Congress in Vienna, Austria. The meeting included international researchers across a range of disciplines with cohorts evaluating acute HCV among PWID.
Status: Ongoing
Personnel: Jason Grebely, Lisa Maher, Gregory Dore
Collaborators: Centre de Recherche du CHUM, Canada (lead); University of California San Francisco (UCSF); Amsterdam Public Health Service, The Netherlands; Viral Hepatitis Clinical Research Program; The Burnet Institute; Johns Hopkins University
Funding: Canadian Institutes of Health Research
Location: *Viral Hepatitis Epidemiology and Prevention Program*

Evaluating the effectiveness of needle and syringe programs in Eastern Europe

Status: Data collation tool developed and distributed to six Eastern European countries.
Personnel: David Wilson, Lei Zhang, Amy Kwon
Funding: UNAIDS
Location: *Surveillance and Evaluation Program for Public Health*

Fiji

Scabies - Factors associated with scabies in a highly endemic population

This study has three main objectives: to characterise the participants in a Fiji community survey of scabies; to identify environmental and demographic risk factors for scabies in Fiji; and to provide information on possible preventative measures for scabies.
Status: Commenced late 2010
Personnel: John Kaldor
Collaborators: Lucia Romani, Margot Whitfield, Andrew Steer
Funding: private philanthropy
Located: *Public Health Interventions Research Group*

Papua New Guinea

Women's and men's experiences of preventing mother-to-child transmission (PMTCT) in Papua New Guinea: a gendered socio-cultural analysis of barriers and facilitators for program engagement

PNG is experiencing an expanding heterosexual HIV epidemic, placing an increasing number of newborns at risk of acquiring infection. This research seeks to understand the gendered socio-cultural aspects influencing the uptake and outcomes of PMTCT programs from the perspectives of antenatal women, their partners, and health care workers. It seeks to undertake an assessment of PMTCT programs; examine knowledge, attitudes and decision-making processes regarding PMTCT; test enablers of return for safe delivery and post-natal care; examine experiences of consent, counselling and confidentiality; determine gender-specific barriers/facilitators to accessing PMTCT programs; develop recommendations for improved PMTCT programs.
Status: Commenced late 2009
Personnel: John Kaldor
Collaborators: Heather Worth, Angela Kelly, Barbara Kepa, Martha Kupul, Grace Kariwiga, Glen Mola, Tarcisia Hunhoff, PNG Institute of Medical Research, UNICEF, University of Papua New Guinea, Catholic Health Services, International HIV Research Group, UNSW
Funding: AusAID Australian Development Research Award
Located: *Public Health Interventions Research Group*

Research and education in HIV/AIDS for resource-poor countries: REACH Initiative Diagnosis of tuberculosis in HIV infected and uninfected children in Papua New Guinea with a T-cell based assay: a prospective study

Diagnosis of PTB in children in settings such as Papua New Guinea (PNG) is therefore usually made on the basis of a combination of contact history, clinical findings, tuberculin skin test (TST) and radiological findings if available. This approach can lack sensitivity and specificity, particularly in young children who are the most susceptible group to TB disease in childhood. As a result, children may be either under- or over-treated. The project aims to investigate the role of the QFN test in the management of paediatric TB in PNG.
Status: Ongoing
Personnel: Wari Allison, John Kaldor, Louise Causer

Collaborators: Hong Van Tieu, Dr Jintanat, Dr Thanyawee, John Vince, Prof Tefuarani, Mobumo Kiroamat
Funding: Tibotec Virco Virology BVBA
Located: *Public Health Interventions Research Group*

MCAIS: Male Circumcision Acceptability & Impact Study, PNG

This four-year multi-disciplinary community-based research program is investigating the potential of male circumcision for HIV prevention in Papua New Guinea and has four principal components: ethnographic research; mathematical modelling; health systems research; and longitudinal clinical cohort studies. The study is being carried out among a combination of general and at-risk population cohorts at multiple sites in PNG. A sub-study to investigate the notional acceptability of a vaginal microbicide surrogate for HIV prevention among women and men attending a sexual health clinic in Port Moresby was completed in 2010.

Status: To be completed December 2011

Personnel: Andrew Vallely, John Kaldor, Peter Siba, Angela Kelly, Lisa Fitzgerald, Claire Ryan, James Neo, Martha Kupul, Herick Aeno, Voletta Fiya, Petronia Kaima, Zure Kombati, John Millan, Greg Law, Joyce Sauk, Andrew Page, John Murray, David Wilson, Richard Gray Peter Hill, Anna Tynan

Collaborators: PNG Institute of Medical Research, University of Queensland, Mt Hagen General Hospital, HOPE Worldwide, National Department of Health, PNG.

Funding: AusAID Australian Development Research Award (ADRA)

Located: *Public Health Interventions Research Group*

NACS Masculinities Study, PNG

This two-year multi-disciplinary community-based research program will investigate the role that individual, community and cultural constructs of masculinity, male sexuality and sexual agency have in determining sexual behaviour among young men in PNG, and specifically, their role in promoting behaviours known to increase the risk of HIV and STIs among men and women. The study will be conducted in Eastern and Western Highlands Provinces, PNG where 50 to 60 in-school and out-of school male youth aged 16-17 years will be recruited into a qualitative longitudinal research study and followed up every three months for up to 18 months.

Status: Fieldwork to commence March 2011.

Personnel: Andrew Vallely, Angela Kelly, Lisa Fitzgerald, Peter Siba, Maxine Whittaker, John

Kaldor, John Millan, Joyce Sauk, Herick Aeno, James Neo, Zure Kombati

Collaborators: PNG Institute of Medical Research, University of Queensland.

Funding: National AIDS Council Secretariat, Papua New Guinea (NACS)

Located: *Public Health Interventions Research Group*

HSV-2 / HIV Epidemiology Study, PNG

This project will investigate the epidemiology of Herpes simplex Type-2 (HSV-2) among 100 HIV sero-positive and 200 HIV sero-negative individuals attending sexual health clinics in Goroka and Mt Hagen, PNG; and investigate the performance of different diagnostic assays for the detection of HSV-2.

Status: Fieldwork to commence Feb 2011; study to be completed by Dec 2011

Personnel: Claire Ryan, Peter Siba, Andrew Vallely, John Kaldor, Zure Kombati, Tawarot Kurumop, Petronia Kaima

Collaborators: PNG Institute of Medical Research, Goroka General Hospital, Mt Hagen General Hospital

Funding: National AIDS Council Secretariat, Papua New Guinea (NACS)

Located: *Public Health Interventions Research Group*

Evaluating and predicting the epidemiological impact of health policies for reducing HIV in Melanesian and South-East Asian populations

Personnel: David Wilson, Alexander Hoare, John Murray, John Kaldor, Matthew Law, Richard Gray, Kel Heymer, Amy Kwon, Lei Zhang, Cliff Kerr

Status: Models have been developed

Funding: AusAID

Location: *Surveillance and Evaluation Program for Public Health*

Vietnam

Evaluation of the epidemiological impact of harm reduction programs across Vietnam

This project involves the use of mathematical modelling techniques to evaluate the likely epidemiological impact of peer-education based harm reduction programs (distribution of condoms and needles and syringes) across numerous provinces in Vietnam.

Status: Ongoing

Personnel: David Wilson, Lei Zhang, Richard Gray, Rosie Thein, Amy Kwon

Funding: World Bank, UNSW, NHMRC

Location: *Surveillance and Evaluation Program for Public Health*

Evaluating Needle-Syringe Programs in Vietnam

Status: Analysis complete

Personnel: David Wilson, Lei Zhang, Virginia Loo

Funding: The World Bank

Location: *Surveillance and Evaluation Program for Public Health*

Thailand

Modelling HIV Vaccines (international collaboration with Centers for Disease Control)

Status: Thailand model ongoing. Project complete.

Personnel: Richard Gray, Karen Schneider, Alex Hoare, David Wilson

Funding: nil

Location: *Surveillance and Evaluation Program for Public Health*

Commissioned reviews

Report on the sex industry in New South Wales

This is a state specific report of the Sex Industry in New South Wales that was commissioned by the NSW Health Department.

Status: Report in preparation

Personnel: Basil Donovan, Chris Harcourt, John Kaldor

Collaborators: Sandra Egger, Sepehr Tabrizi, Christopher Fairley

Funding: NSW Health

Located: *Sexual Health Program*

Report on the sex industry in Western Australia

This is a state-specific report of the Sex Industry in Western Australia that was commissioned by the Western Australian Health Department.

Status: Final report submitted 2010

Personnel: Basil Donovan, Chris Harcourt, Karen Schneider, Jody O'Connor

Collaborators: Sandra Egger, Christopher Fairley, Marcus Chen, Lewis Marshall, **Funding:**

Western Australian Health Department

Located: *Sexual Health Program*

NSW Chlamydia review

In October 2009 the NSW Ministerial Advisory Committee on HIV and Sexually Transmissible Infections (CAS) Health Promotion Sub-Committee decided to review the NSW response to chlamydia. A Chlamydia Working Group was established to review the literature and to provide advice and planning support for the creation of NSW Chlamydia strategy.

Status: Report in preparation

Personnel: Hammad Ali, Rebecca Guy, Bette Liu, Basil Donovan, John Kaldor

Collaborators: Jane Hocking, Chris Bourne

Funding: NSW Health

Located: *Sexual Health Program*

Biostatistics and database support

Writing clinical trial databases, and providing biostatistical input to the design and analysis of all NCHECR projects.

Status: During 2010, members of the Program actively contributed to the design of, or analysed data from, the ALTAIR, ENCORE, SMART, ESPRIT, SILCAAT, Second line, Lipodystrophy Case Definition and MARCH studies (see *Therapeutic and Vaccine Research Program*); the ATAHc study (*Viral Hepatitis Clinical Research Program*); the ACCEPT study (*Sexual Health Program*); the STRIVE study (*Aboriginal and Torres Strait Islander Study*); the NSP survey (*Viral Hepatitis Epidemiology and Prevention Program*); and national surveillance activities (*Surveillance and Evaluation Program for Public Health*).

Personnel: Noorul Absar, Amit Achhra, Janaki Amin, Rossitza Chevkenova, Paul Fahey, Kathy Petoumenos, Handan Wand, Jialun Zhou

Collaborators: Other programs at NCHECR

Funding: Project-specific grants

Located: *Biostatistics and Databases Program*



Members of the Biostatistics and Database Program

Advisory committees

Surveillance Committees

Annual Surveillance Report Advisory Committee

John Kaldor PhD (Chair)

NCHECR

Basil Donovan MB BS, MD, Dip Ven (London), FACHSHM, FAFPHM, FRCPI

NCHECR

Andrew Grulich MB BS, MSc, PhD, FAFPHM

NCHECR

Phillip Keen BA, Dip Comm Ser (CommWork)

HIV Education and Health Promotion Officer, Campaign and Resource Development, Gay Men's Education, Australian Federation of AIDS Organisations, Sydney

Lisa Maher PhD

NCHECR

Ann McDonald BSc, MPH

NCHECR

Tadgh McMahan DrPH

Manager, Multicultural HIV/AIDS and Hepatitis C Service, Sydney

Rhonda Owen BSc (Hons), Grad Dip Business, Grad Dip Clin Epid

Epidemiologist, Surveillance Systems and Policy Section, Surveillance Branch, Office of Health Protection, Department of Health and Ageing

Cindy Shannon BA, Grad Dip Ed (Tert), MBA, DSocScChair, Indigenous Australians' Sexual Health Committee; Professor and Director, Centre for Indigenous Health, University of Queensland
Helen Tyrrell RN, BA (Hons), MBA, FACHSE, CHE
Chief Executive Officer, Hepatitis Australia, Canberra**Robert van der Hoek**

Senior Research Analyst, Australian Institute of Health and Welfare, Canberra

Russell Waddell MB BS, BSc, FACHSHM

Director, STD Services, Royal Adelaide Hospital

Handan Wand MA, MSc, PhD

NCHECR

Iryna Zablotska MD, PhD

Research Fellow, National Centre in HIV Social Research, UNSW

Melanie Middleton BMedSc, MPH (Secretary)

NCHECR

Footnote *Subcommittee of the Communicable Diseases Network Australia

National Bloodborne Virus and Sexually Transmissible Infections Surveillance Committee

John Kaldor PhD (Chair)

NCHECR

Mark Bartlett BSc, Dip Ed, RGN, MPH, Grad Dip App Epi (to April)

Senior Surveillance Officer, Communicable Diseases Branch, NSW Health

Frances Birrell MPH, MAppEpid, GCSc(Stats) (to December)

Epidemiologist, Communicable Disease Unit, Queensland Health

Barry Combs PhD (to December)

Senior Project Officer, HIV Surveillance, Communicable Disease Control Directorate, Department of Health, Perth

Joy Copland MSc, MPH

Manager, Disease Surveillance and Investigation Section, Communicable Disease Control Branch, Department of Health, Adelaide

Maureen Davey (from May)

Specialist Medical Advisor, Population Health, Department of Health and Human Services, Hobart

Tess Davey Grad Dip (HealthCoun), Grad Dip Clin Epi, Cert Nursing

Manager, Surveillance Section, STD Services, Royal Adelaide Hospital

John Daye OAM

Co-convenor, Health, Treatments and Research Portfolio, National Association of People Living with HIV/AIDS, Sydney

Basil Donovan MB BS, MD, Dip Ven (London), FACHSHM, FAFPHM, FRCPI

NCHECR

Dominic Dwyer BSc(Med), MB BS, MD, FRACP, FRCPA

Staff Specialist, Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Sydney

Carol El-Hayek BSc MAE

Centre for Epidemiology and Population Health Research, Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne

Christopher Fairley MB BS, PhD, FRACP,**FACHSHM, FAFPHM**

Professor of Sexual Health, University of Melbourne; Director, Melbourne Sexual Health Centre

Catherine Farrell (from July)

Director, BBV and STIs Section, Targeted Prevention Programs Branch, Population Health Division, Department of Health and Ageing

Lisa Hall (from May)

Epidemiologist, Communicable Disease Unit, Queensland Health

Carolien Giele RN, RM, BSc(Hons), Grad Dip Clin Epi, MPH

Epidemiologist, Communicable Disease Control Directorate, Department of Health, Perth

Andrew Grulich MB BS, MSc, PhD, FAFPHM

NCHECR

Rebecca Guy BAppSc(Med Lab Sc),**MAppEpid PhD**

NCHECR

Margaret Hellard MB BS, FRACP, PhD,**FAFPHM**

Head, Centre for Epidemiology and Population Health Research, Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne

Nasra Higgins BHLthSc(EnvHlth), Grad Dip Epid & Biostat, MEpid

Surveillance Officer, Epidemiology and Surveillance Program, Communicable Disease Control Unit, Public Health Branch, Department of Human Services, Melbourne

Kellie Kwan

Senior Research Officer, Sexually Transmitted Infections and Blood Borne Viruses, Communicable Disease Control Directorate, Department of Health, Perth

Annie Madden BA (Gender Studies & Asian Studies), Cert IV Community Work

Executive Officer, Australian Injecting and Illicit Drug Users League, Canberra

Paul Magnus MB BS

Medical Adviser, Australian Institute of Health and Welfare, Canberra

Lisa Maher PhD

NCHECR

Ann McDonald BSc, MPH

NCHECR

Joanne Micallef, BMedSc(Hons), PhD (from June)

BBV and STI Epidemiologist, Communicable Diseases Branch, NSW Health

Anthony Moore (from January)

Public Health Registrar, Health Protection Service, ACT Health

Jo Murray RN, RM, Grad Dip Nursing

Clinical Nurse Consultant, AIDS Medical Unit, Queensland Health

Rhonda Owen BSc(Hons), Grad Dip Business, Grad Dip Clin Epid (to March)

Epidemiologist, Surveillance Systems and Policy Section, Surveillance Branch, Office of Health Protection, Department of Health and Ageing

Kate Robinson (from April)

Epidemiologist, Surveillance Systems and Policy Section, Surveillance Branch, Office of Health Protection, Department of Health and Ageing

Cindy Shannon BA, Grad Dip Ed (Tert), MBA, DSocSc

Chair, Indigenous Australians' Sexual Health Committee;

Professor and Director, Centre for Indigenous Health, The University of Queensland

Jiunn-Yih Su MB, MPH

Surveillance Project Officer, Sexual Health and Blood Borne Viruses Unit, Centre for Disease Control, Northern Territory Department of Health and Community Services

John Tapsall MB BS, MD, FRCPA (from August)

Director, WHO Collaborating Centre for STD, Microbiology Department, The Prince of Wales Hospital, Sydney

Helen Tyrrell RN, BA(Hons), MBA, FACHSE, CHE

Chief Executive Officer, Hepatitis Australia, Canberra

Russell Waddell MB BS, BSc, FACHSHM

Director, STD Services, Royal Adelaide Hospital

James Ward

NCHECR

Kate Ward MPH

Blood Borne Viruses and Sexually Transmitted Infections Epidemiologist, Communicable Diseases Branch, NSW Health

Matthias Wentzclaff-Eggebert MMgt (Comm Mgt)

Manager, HIV/Hepatitis C Policy and Programs, Communicable Disease Control Branch, Department of Health, Adelaide

Melanie Middleton BMedSc, MPH (Secretary)

NCHECR

Australian Needle and Syringe Program Survey Advisory Group

Alex Wodak MB BS, FRACP, FACHAM (Chair)

Director, Alcohol and Drug Service, St Vincent's Hospital, Sydney

Danielle Bament BA, MPH

Manager, Clean Needle Program, Drug and Alcohol Services South Australia, Southern Adelaide Health Service

Jude Bevan BAppSc, Grad Dip HSC

Senior Policy and Planning Officer (Hepatitis C), Sexual Health and Blood Borne Virus Program, Department of Health, Perth

Tony Butler PhD

Associate Professor, National Drug Research

Institute, Curtin University of Technology, Perth

Tracy Dobie

Manager, Needle and Syringe and Pharmacy Program, Directions, Canberra

Greg Dore MB BS, BSc, PhD, FRACP, MPH

NCHECR

Tania Hunt Dip Soc Sc

Harm Reduction Coordinator, Tasmanian Council on AIDS, Hepatitis and Related Diseases

Roland Jauernig BA(Psych), MAppSc

Manager, Health Protection Services, Department of Human Services, Melbourne

John Kaldor PhD

NCHECR

Robert Kemp

Manager, Queensland Needle and Syringe Program, Queensland Health

Shayne Kilford

Needle and Syringe Program Coordinator, Northern Territory AIDS and Hepatitis Council

Stephen Lymb BA, Grad Dip Soc Sc

Manager, Harm Reduction, Drug and Alcohol Services South Australia, Southern Adelaide Health Service

Lisa Maher PhD

NCHECR

Greg Perry RN, RPN, Grad Dip Soc Sc

Nurse Unit Manager, Biala, Alcohol and Drug Service, The Prince Charles Hospital Health Service District, Queensland Health

Fiona Poeder

Hepatitis C Education Program Manager; Australian Injecting and Illicit Drug Users League (AIVL), Canberra

John Ryan BA, LLB

Chief Executive Officer, Association for Prevention and Harm Reduction Programs Australia (Anex), Melbourne

Francine Smith

Acting State Coordinator, Population Health, Department of Health and Human Services, Hobart

Libby Topp BSc(Psychol)(Hons), PhD

NCHECR

Owen Westcott BA

Senior Policy Analyst, Harm Minimisation, AIDS/Infectious Diseases Branch, NSW Health

Jenny Iversen BAppSc (Secretary)

NCHECR

NCHECR Working Groups

The Antiretroviral Working Group

Janaki Amin BSc(Hons), MPH(Hons), PhD

NCHECR

Jason Appleby

Policy Analyst, Australian Federation of AIDS Organisations, Sydney

Mark Bloch MB BS, MMed

General Practitioner, Holdsworth House General Practice, Sydney

Mark Boyd BA, BM, BS, DCTM&H, MHID, MD, FRACP (Convenor)

NCHECR

Suzanne Crowe MB BS, FRACP, MD

Professor and Head, AIDS Pathogenesis and Clinical Research Program, Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne

William Donohue MB BS, BMedSc

Director, The Care and Prevention Programme, Adelaide University

Dominic Dwyer BSc (Med), MB BS, FRACP, FRCPA

Staff Specialist, Medical Virology and Clinical Microbiology, Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Sydney

Sian Edwards RGN, BSc, MSc

HIV Research Nurse, Northside Clinic, Melbourne

Julian Elliott MB BS, FRACP

Assistant Head, Clinical Research, Infectious Diseases Unit, The Alfred Hospital, Melbourne

Beng Eu MB BS

General Practitioner and Director, Prahran Market Clinic, Melbourne

Martyn French MB ChB, FRACP, MD,

FRCPATH, FRCP (Chair)

Clinical Director, Department of Clinical Immunology and Biochemical Genetics, Royal Perth Hospital; Clinical Professor in Immunology, University of Western Australia

Adeeba Kamarulzaman MB BS, FRACP

Consultant Physician in Infectious Diseases, Clinical Investigations Centre, University of Malaya Medical Centre, Kuala Lumpur, Malaysia

Graham Mills MB ChB, MTH, FRACP

Infectious Disease Physician, Respiratory and Infectious Diseases, Waikato Hospital, Hamilton NZ

Richard Moore MB BS, Dip RACOG, FRACGP, Dip Ven

General Practitioner, Carlton Clinic, Melbourne; Sessional HIV Specialist, Melbourne Sexual Health Centre

Clinical Assistant, Infectious Diseases Unit, The Alfred Hospital, Melbourne

Catriona Ooi BSc(Med), MB BS, FACHSHM, MM (HIV/STIs)

Staff Specialist, Hunter New England Health Service

Jeffrey Post MBBS (Hons 1) PhD FRACP

Senior Staff Specialist, Department of Infec-

tious Diseases and Albion Street Centre, Prince of Wales Hospital, Randwick NSW Conjoint Senior Lecturer, UNSW

John Quin MB BS (Hons), PhD, FRACP, FRCPA (Deputy Chair)

Director of Clinical Immunology, HIV Medicine and Sexual Health, Liverpool Hospital, Sydney

Brett Ritchie BSc (Hons), MB BS, FRACP

Infectious Diseases Physician, Infectious Diseases Unit, Royal Adelaide Hospital, Adelaide

Don Smith MB ChB, MD

Associate Professor and Head of Research Development, Albion Street Centre, Sydney

Gilda Tachedjian PhD, BSc (Hons)

Head, Molecular Interactions Group, Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne

Olga Vujovic MB BS, FRACP

Infectious Diseases Physician, Infectious Diseases Unit, The Alfred Hospital, Melbourne

Bill Whittaker AM

Co-convenor, Health and Treatments Portfolio, National Association of People Living with HIV/AIDS, Sydney

Biomedical Prevention Working Group

Basil Donovan MB BS, MD, DipVen, FACHSHM, FAFPHM, FRCP NCHCECR

Christopher (Kit) Fairley FRACP PhD

Director, Melbourne Sexual Health Centre

Janelle Fawkes BA

Manager, Scarlet Alliance, Australian Sex Workers Association, Sydney

Andrew Grulich MB BS, MSc, PhD, FAFPHM NCHCECR

Rebecca Guy MAppSc, MAppEpid, PhD (Acting Convenor)

NCHCECR

Jane Hocking BAppSc; MPH; MHLthSc; PhD

Senior Lecturer, Centre for Women's Health, Gender and Society, Melbourne School of Population Health, University of Melbourne

John Kaldor PhD

NCHCECR

Bernard Kealey

Vice President, National Association of People Living with HIV/AIDS, Sydney

Mike Kennedy

Executive Director, Victorian AIDS Council/Gay Men's Health Centre, Melbourne

Tadgh McMahon DrPH

Manager, Multicultural HIV/AIDS and Hepatitis C Service, Sydney

Lisa Maher PhD

NCHCECR

Adrian Mindel MB BCh, MSc (CTM), MD, FRCP, FRACP, FACHSHM

Professor of Sexual Health Medicine, University of Sydney Director, Sexually Transmitted Infections Research Centre, Westmead Hospital, Sydney

Kathy Petoumenos BSc, MA, MPH (Hons), PhD NCHCECR

Anna Pierce MB BS, FRACP (Deputy Chair)

Clinical Research Fellow, The Alfred Hospital, Melbourne

Mark Saunders

Policy Officer, NACCHO

Mark Stoové PhD

Head, BBV/STI Research, Centre for Population Health, Burnet Institute

Andrew Vallely MBBS MRCP DTMH MSc PhD NCHCECR

James Ward

NCHCECR

David Wilson BSc, BInfTech, BAppSc(Hons), GradCert(Biostats), PhD

NCHCECR

John de Witt

Director NCHSR

Primary HIV Infection Working Group

Chris Birch BSc, MSc, PhD (Chair)

Senior Scientist, Victorian Infectious Diseases Reference Laboratory, Melbourne

Peter Canavan

Senior Co-ordinator Health Treatments & Research Unit, NAPWA

Doris Chibo BAppsSc (Hons), PhD

Senior Scientist, Victorian Infectious Disease Reference Laboratory (VIDRL), Melbourne

Nicky Cunningham RGN, Dip, BSc (Hons)

Clinical Research Manager, Holdsworth House Medical Practice, Sydney

Phillip Cunningham BAppSc (Med)

Chief of Operations, St Vincent's Centre for Applied Medical Research, Sydney

Simon Donohoe

Manager, AFAO/NAPWA Education Team and AFAO National Aboriginal and Torres Strait

Islander HIV & Sexual Health Project

Robert Finlayson MB BS, Dip Ven, FACHSHM

General Practitioner, Taylor Square Private Clinic, Sydney

Patricia Grey BA, Post Grad Dip App Sci, CNS, Dip (Counselling) (Convenor)

NCHCECR

Dale A. McPhee BSc Hons (Science), PhD

Research Coordinator, National Serology Reference Laboratory, St Vincent's Institute, Fitzroy, Victoria

John Murray BSc (Hons), MSc, PhD

Senior Lecturer, School of Mathematics, Faculty of Science, UNSW, Sydney

Cathy Pell MB BS, MM (Deputy Chair)

Specialist General Practitioner, Taylor Square Private Clinic, Sydney

Norman Roth MB BS, Dip Av Med, Dip Ven, FACHSHM

General Practitioner, Prahran Market Clinic, Melbourne

John Zaunders BSc (Hons)

Senior Scientist, Centre for Immunology, St Vincent's Hospital, Sydney

Toxicology/Pharmacology Working Group

Andrew Carr MD, FRACP, FRCPA

Associate Professor and Senior Staff Specialist, HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent's Hospital, Sydney

Catherine Cherry MB BS, PhD, FRACP, Grad Dip (Clin Epi) (Chair)

Infectious Diseases Physician and Senior Burnet Fellow, Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne

John Daye

Convenor, Health and Treatments Portfolio, NAPWA

Jennifer Hoy FRACP, MB BS, GradDipEpiBio (Deputy Chair)

Head, Clinical Research, Infectious Diseases Unit, The Alfred Hospital

Debbie Marriott BSc (Med), FRACP, FRCPA

Senior Staff Specialist, Clinical Microbiology and Infectious Diseases, St Vincent's Hospital, Sydney

Elizabeth J. Phillips, MD, FRCPC, FRACP

Professor & Director, Centre for Clinical Pharmacology & Infectious Diseases, Murdoch University, Perth; Consultant, Departments of Clinical Immunology & Infectious Diseases, Sir Charles Gairdner Hospital, Perth; Department of Clinical Immunology and Immunogenetics, Royal Perth Hospital, Perth

Rebekah Puls BSc(Hons), PhD (Convenor)

NCHCECR

Tim Read MB BS, FACHSHM

Sexual Health Physician, Melbourne Sexual Health Centre

Robyn Richardson, RN

Project Manager, Clinical Research Program, Centre for Applied Medical Research, St Vincent's Hospital

Handan Wand MA, MSc, PhD

NCHCECR

Ian Woolley MB BS, FRACP

Deputy Director, Infectious Diseases Department, Monash Medical Centre, Melbourne

Phillip Keen

HIV Educator- Gay men, AFAO

Oncology Working Group

Michael Boyle BMedSci, MB BS, MD, FRACP, FRCPA

Staff Specialist, Immunology and Infectious Diseases, John Hunter Hospital, Newcastle, NSW; Conjoint Associate Professor, University of Newcastle, Newcastle, NSW

Mitchell Chipman MB BS, FRACP

Medical Oncologist, The Alfred Hospital, Melbourne

Lyndal Daly BN Grad Dip (Crit Care)

Clinical Practice Consultant, Infectious Diseases Unit, Royal Adelaide Hospital, Adelaide

Grant Davies

Investigation's Manager, Office of the Aged Care Commissioner, Melbourne

Fraser Drummond MBChB DA(UK) MRCA (Convenor)

NCHECR

Andrew Grulich MB BS, MSc, PhD, FAFPHM NCHECR

Richard Hillman BSc(Hons), MD, FRCP, FACHSHM (Chair)

Senior Lecturer and Senior Staff Specialist, Sexually Transmitted Infections Research Centre, Westmead Hospital, Sydney

David Menadue BA, BAEd

Vice President, National Association of People Living with HIV/AIDS, Melbourne

Sam Milliken MB BS, FRACP, FRCPA

Senior Lecturer and Senior Staff Specialist, Department of Haematology, St Vincent's Hospital, Sydney

Dave Templeton MBChB DipVen

MForensMed PhD MFFLM MACLM FACHSHM

NCHECR

Jialiun (Julian) Zhou, BMed, MPH, PhD

NCHECR

Immune-Based Therapies Working Group

Paul Cameron BMedSci (Hons), MB BS, PhD, FRACP, FRCPA (Deputy Chair)

Immunopathologist, Department of Pathology, The Alfred Hospital, Melbourne

Robert Center BSc, PhD

Senior Research Officer, Department of Microbiology and Immunology, University of Melbourne, Melbourne

John Chuah BSc(Med)(Hons), MB BS, FACHSHM

Director, Gold Coast Sexual Health, Miami, Qld

Miles Davenport MB BS (Hons), DPhil

Senior Research Fellow, Centre for Vascular Research, UNSW

Roger Garcia MB BS (Hons), PhD, FRACP, FRCPA (Chair)

Director of Clinical AIDS Services and Staff Specialist in Immunology, Department of Clinical Immunology, Royal Prince Alfred Hospital, Sydney

Phillip Habel BSc (Hons), RN

Trial Nurse, ACT Division of General Practice HIV Program

Mina John MB BS, FRACP, FRCPA

Clinical Immunologist and Immunopathologist, Royal Perth Hospital

Anthony Kelleher BSc (Hons), MB BS (Hons), PhD, FRACP, FRCPA

NCHECR

Mark Kelly MB BS (Hons), FRACP

Senior Medical Officer, AIDS Medical Unit, Queensland Health

Stephen Kent MB BS, FRACP, MD

Associate Professor, Department of Microbiology and Immunology, University of Melbourne

Matthew Law MA, MSc, PhD

NCHECR

Sharon Lewin MB BS (Hons), FRACP, PhD

Director, Infectious Diseases Unit, The Alfred Hospital, Melbourne; Professor, Department of Medicine, Monash University, Melbourne

Jenny McDonald Grad Dip Diets, BSc, Post Grad Dietetics

Treatment Officer, National Association of People Living with HIV/AIDS, Sydney

Dean Murphy BA (Hons)

Education and Biomedical Prevention Consultant, Australian Federation of AIDS Organisations, Sydney & Research Associate, National Centre in HIV Social Research, UNSW

Patricia Price PhD

Associate Professor, School of Surgery and Pathology, University of Western Australia

Damian Purcell PhD

Senior Lecturer in Virology Head, Molecular Virology Laboratory, University of Melbourne

John Sullivan PhD, MPH

Principal Scientist, Australian Red Cross Blood Service, Sydney;

Associate Professor, Transfusion Medicine and Immunogenetics Research Unit, Central Clinical School, Faculty of Medicine, University of Sydney

Sarah Pett BSc (Hons), MB BS(Hons),

DTM&H, MRCP (UK), FRACP (Convenor)

NCHECR

Neurology Working Group

Margaret Bain BSc (Psych), MCLinPsych, MCLinNeuropsych

Neuropsychologist, HIV Neuropsychology Service, St Vincent's Hospital, Sydney

Bruce Brew MB BS (Hons), MD, FRACP

Professor and Head, Department of

Neurosciences and Neurology, St Vincent's Hospital, Sydney

Michael Buckland BSc (Med), MB BS, PhD, FRCPA

Head, Department of Neuropathology, Royal Prince Alfred Hospital, Sydney

Cate Carey RN, BA, MAppSc (Convenor) NCHECR

Melissa Churchill BSc (Hons), PhD

Senior Research Fellow, Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne

Lucette Cysique PhD N. Psych

Postdoctoral Fellow, Brain Sciences UNSW; St Vincent's Clinical School, Sydney

Ian Paul Everall MB ChB (Hons), PhD,

FRCPath, FRCPsych

Cato Professor and Head, Department of Psychiatry, Faculty of Medicine, Dentistry & Health Sciences, University of Melbourne

Paul Gorry PhD (Chair)

Head, HIV Molecular Pathogenesis Laboratory, Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne

Matthew Law MA, MSc, PhD

NCHECR Patrick Li MB BS, FHKCP, FHKAM, FRCP, FRCP (Deputy Chair)

Chief of Service, Department of Medicine, Queen Elizabeth Hospital, Hong Kong

Marilyn McMurchie OAM

Adjunct Associate Professor, Central Clinical School, Faculty of Medicine, University of Sydney and

Director, East Sydney Doctors

Paul Maruff BSc PhD

Chief Science Officer CogState Ltd & Professor, Centre for Neuroscience, University of Melbourne

Maggie Piper RN, BA, MBioEthics

Clinical Trials Co-ordinator, Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Sydney

Nitin Saxena PhD

Chief Scientist, Head of Retroviral Genetics Division, CVR, WMI, Westmead

Peter Sternhell MB BS

Lecturer, School of Psychiatry, St Vincent's Hospital, Sydney

Jo Watson

Executive Officer, National Association of People Living with HIV/AIDS, Sydney

Peter Watts

Health Promotion and Treatments Officer, Queensland Positive People, Brisbane

Edwina Wright MB BS, FRACP

Infectious Diseases Specialist, Department of Infectious Diseases and Microbiology, The Alfred Hospital, Melbourne

Viral Hepatitis Working Group

Anthony Allworth MB BS, FRACP, FRCPA, FACTM, MASM

Director, Infectious Diseases Unit, Royal Brisbane and Women's Hospital

David Baker MB ChB, DCH, Dip Med (Sexual Health)

General Practitioner, East Sydney Doctors, Sydney

Michael Beard PhD, NHMRC Senior Research Fellow

Head, Hepatitis C Virus Research Laboratory, SA Pathology and School of Molecular and Biomedical Science, University of Adelaide

Scott Bowden PhD

Head of the Molecular Microbiology Laboratory, Victorian Infectious Diseases Reference Laboratory, Melbourne

Erol Digiusto BSc (Hons), PhD

Senior Research Fellow, National Drug and Alcohol Research Centre, UNSW

Nicholas Doong MBBS, MPH, DipObs, FRACGP

General Practitioner, Burwood Road General Practice

Greg Dore MB BS, BSc, PhD, FRACP, MPH
NCHECR

Michelle Giles MB BS (Hons) FRACP PhD

Infectious Diseases Physician, Infectious Diseases Unit, The Alfred Hospital, Melbourne

Margaret Hellard MB BS, FRACP, PhD, FAFPHM (Chair)

Head, Centre for Epidemiology and Population Health Research, Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne

David Iser MB BS (Hons), BSc (Med), FRACP

Hepatology Fellow, Infectious Diseases Unit, Alfred Hospital, Melbourne and Gastroenterology Unit, St. Vincent's Hospital, Melbourne

Andrew Lloyd MB BS, MD, FRACP

Professor and Consultant Infectious Diseases Physician, Department of Infectious Diseases, Prince of Wales Hospital, Sydney

Stuart Loveday

Executive officer, Hepatitis C Council of NSW, Sydney

Gail Matthews MB ChB, MRCP (Convenor)

NCHECR

Kathy Petoumenos BSc, MA, MPH (Hons), PhD

NCHECR

Zoë Potgeiter RN, CNS

Clinical Trial Co-ordinator, Immunology B Ambulatory Care Clinic, St Vincent's Hospital, Sydney

Stuart Roberts MB BS, FRACP, MD

Deputy Director, Department of Gastroenterology, The Alfred Hospital, Melbourne

Joe Sasadeusz MB BS, FRACP, PhD

Infectious Diseases Physician, Royal Melbourne Hospital and The Alfred Hospital, Melbourne

David Shaw MB BS, FRACP

Director, Infectious Diseases and Infection Prevention Units, Royal Adelaide Hospital

Carla Treloar BSc (Hons), PhD

Deputy Director, National Centre in HIV Social Research, UNSW

Kumar Visvanathan MB BS, PHD, FRACP

Head of Research and ID Physician, Department of Infectious Diseases, Monash Medical Centre, Southern Health, Melbourne

Bethany White MPH, PhD candidate

NCHECR

Amany Zekry MBBS, PhD, FRACP

Head of Gastroenterology and Hepatology Department, St George Hospital, Senior Lecturer of Medicine, UNSW

NCHECR Working Groups ex officio

David Cooper AO, BSc (Med), MB BS, MD,

DSc, FAA, FRACP, FRCPA, FRCP

NCHECR

Levinia Crooks AM, BA (Hons), Dip Ed

Chief Executive Officer, Australasian Society for HIV Medicine, Sydney

Anthony Cunningham MB BS, BMedSci

(Hons), MD, FRACP, FRCPA, FASM

Director, Westmead Millennium Institute for Medical Research, Sydney; Director, Centre for Virus Research, Westmead Millennium Institute for Medical Research, Sydney

John de Wit MSc, PhD

Director NCHSR

Sean Emery BSc (Hons), PhD

NCHECR

John M Kaldor PhD

NCHECR

Matthew Law MA, MSc, PhD

NCHECR

External boards, committees and advisory groups

- 10th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV Organising Committee (David Cooper)
- 11th Bangkok Symposium on HIV Medicine Organising Committee (David Cooper)
- 12th IUSTI World Congress, Melbourne, 2012, Organising Committee (Basil Donovan)
- 2012 International Microbicides Conference – M2012 (John Kaldor, Chair, Andrew Vallely, Organising Committee Member)
- 20th Annual Meeting of the International Harm Reduction Association, International Program Advisory Group (Lisa Maher)
- 3rd Coalition for Research to Improve Aboriginal Health (CRIA) Conference Scientific Advisory Committee (James Ward)
- 9th International Congress on Drug Therapy in HIV Infection Scientific Committee (HIV9) (David Cooper)
- Aboriginal Sexual Health and Hepatitis Advisory Committee (James Ward)
- ACCESS Aboriginal Community Controlled Health Service steering committee (James Ward, John Kaldor)
- ACCESS family planning network steering committee (Basil Donovan, Rebecca Guy)
- ACCESS general practice network steering committee (Basil Donovan, Rebecca Guy)
- ACCESS sexual health service network steering committee (Hammad Ali, Basil Donovan, Rebecca Guy, John Kaldor)
- AH&MRC Hepatitis C Reference Group (James Ward)
- AIDS Council of New South Wales Board (Garrett Prestage)
- AIDS Council of New South Wales Ethics Review Committee (Garrett Prestage chair, Ian Down member)
- AIDS Council of New South Wales HIV and Sexually Transmissible Infections Working Group (Garrett Prestage)
- AIDS Council of New South Wales Lesbian Health Board Advisory Committee (Julie Mooney-Somers)
- AIDS Council of New South Wales Research and Policy Advisory Committee (Garrett Prestage)
- Alcohol and Drug Foundation NSW, Kathleen York House (Libby Topp, Director)
- Altair Trial Protocol Steering Committee (David Cooper, Sean Emery, Kathy Petoumenos, Rebekah Puls)
- Anex Research Advisory Committee (John Kaldor)
- Annecy HIV group for international HIV surveillance (David Wilson, Australian representative)
- Asian Pacific Journal of Tropical Biomedicine* Editorial Board (David Wilson)
- Australasian Health and Research Data Managers Association Executive Committee (Pip Marks)
- Australasian Sexual Health Conference Sydney 2010 (Fraser Drummond)
- Australasian Sexual Health Conference Sydney 2010 (Fraser Drummond)
- Australasian Society for HIV Medicine, Antiretroviral Guidelines Panel (Fraser Drummond)
- Australasian Society for HIV Medicine, *ASHM Journal Club* Editorial Committee (Peter Higgs)
- Australasian Society for HIV Medicine, Board member (Mark Boyd)
- Australasian Society for HIV Medicine, Education and Training Committee (Sarah Pett)
- Australasian Society for HIV Medicine, Education Resources Advisory Committee (James Ward)
- Australasian Society for HIV Medicine, Expert Advisory Committee Aboriginal and Torres Strait Islander Health (James Ward)
- Australasian Society for HIV Medicine, *Hepatitis B for Primary Care Providers Monograph* Editorial Committee (Gail Matthews)
- Australasian Society for HIV Medicine, HIV and the Body Steering Committee (Sarah Pett)
- Australasian Society for HIV Medicine, National Clinical Subcommittee (Fraser Drummond)
- Australasian Society for HIV Medicine, NSW Hepatitis B Reference Committee (Gail Matthews)
- Australasian Society for HIV Medicine, NSW Hepatitis C Reference Committee (Gail Matthews)
- Australasian Society for HIV Medicine, NSW Hepatitis Reference Committee (Greg Dore)
- Australasian Society for HIV Medicine, NSW Viral Hepatitis Program Advisory Committee (Alexa Gillman)
- Australasian Society for HIV Medicine, President and Board member (Greg Dore)
- Australasian Society for HIV Medicine, Program Building Committee (Anthony Kelleher)
- Australasian Society for HIV Medicine, reviewer of abstracts (Anthony Kelleher)
- Australasian Society for Infectious Diseases Annual Scientific Meeting Organising Committee (Chris Weatherall)
- Australian Chlamydia Control Effectiveness Pilot (ACCEPT) Project Executive Committee (Basil Donovan, Rebecca Guy, John Kaldor)
- Australian Collaboration for Chlamydia Enhanced Sentinel Surveillance (ACCESS) Coordinating Committee (Basil Donovan, Rebecca Guy, John Kaldor, James Ward)
- Australian Government Department of Health and Ageing Ministerial Advisory Committee on Blood Borne Viruses and Sexually Transmissible Infections (Andrew Grulich member)
- Australian Hepatitis Council Health Reference Group (Lisa Maher)
- Australian HIV Observational Database Steering Committee (Matthew Law, Kathy Petoumenos, Hamish McManus)
- Australian Injecting and Illicit Drug Users League, Vietnamese Hepatitis C and Injecting Drug Use Project Reference Group (Lisa Maher)
- Australian Institute of Policy and Science (David Wilson, associate member)
- Australian New Zealand Breast Cancer Trials Group Independent Data Safety and Monitoring Committee (Matthew Law)
- Australian NSP Survey National Advisory Group (Lisa Maher)
- Australian Radiation Protection and Nuclear Safety Agency Radiation Health and Safety Advisory Council (John Kaldor)
- Australian Red Cross Blood Service (David Wilson, monitoring advisor)

Australian Society of Immunology Conference, Abstract Review Committee (Nabila Seddiki)	<i>Current HIV/AIDS Reports</i> Editorial Board (David Cooper, Honorary Member)	<i>Harm Reduction Journal</i> Editorial Board (Lisa Maher)
Australian Society of Immunology Conference, Poster Judging Committee (Nabila Seddiki)	<i>Current Opinion in HIV and AIDS</i> (David Cooper, co-editor)	Hepatitis C Victoria Research Advisory Committee (Peter Higgs, chair)
Australian Technical Advisory Group on Immunisation (ATAGI) Working Party on HPV (Basil Donovan)	<i>Current Opinion in HIV and AIDS</i> Editorial Board (John Kaldor)	Hepatitis C Victoria, Board of Directors (Peter Higgs, president)
Biomedical Prevention Working Group (<i>ex officio</i>) (Basil Donovan, Andrew Grulich, Rebecca Guy, John Kaldor, James Ward, Iryna Zablotska)	Department of Human Services Victorian HIV Taskforce (James Ward)	Hepatitis NSW Medical Research Advisory Panel (Greg Dore)
Cancer Working Group, international epidemiologic databases to evaluate AIDS (Andrew Grulich)	Developing Papua New Guinea's National HIV Strategy 2011-2015, Expert Reviewer (David Wilson)	HIV Consortium for Partnership in Asia and the Pacific Management Committee (John Kaldor, Louise Causer)
Centre for Immunology UNSW Research degree review committee (Tony Kelleher)	<i>Drug and Alcohol Review</i> Editorial Board (Lisa Maher)	HIV DART 2008 Conference Organising Committee (David Cooper co-chair)
CHEST Management Committee (Bette Liu)	<i>Drug and Alcohol Review</i> Editorial Board (Peter Higgs, Lisa Maher)	HIV Netherlands, Australia, Thailand Research Collaboration (HIV-NAT) International Advisory Board (David Cooper, Co-Director, Chris Duncombe)
Closing the Gap Evidence Working Group (James Ward)	<i>eJournal of the International AIDS Society</i> Editorial Board (John Kaldor)	HIV Star Data Safety Monitoring Board Committee (Matthew Law, Stephen Kerr)
Cochrane Collaborative Review Group on HIV infection and AIDS, Biomedical Interventions Reviews Editor (John Kaldor)	Enhancing Hepatitis C Treatment Uptake and Outcomes in Opiate Dependency Pharmacotherapy Settings Steering Committee (<i>ex officio</i>) (John Kaldor)	<i>HIV Therapy</i> Editorial Board (David Cooper, John Kaldor)
<i>Communicable Diseases Intelligence</i> Editorial Board (John Kaldor)	Estimation of HIV Prevalence for European Countries Working Group (David Wilson)	HIVNAT International Advisory Board (Sean Emery)
Communicable Diseases Network Australia (John Kaldor)	European Developing Country Clinical Trials Partnership (EDCTP) microbicide trial feasibility study, East Africa Steering Committee (Andrew Vallely)	IAS (International Aids Society) Conference Organising Committee Co-chair, Basic Science Track Committee, International AIDS Conference (Anthony Kelleher)
Communicable Diseases Network Australia Working Group Leader Aboriginal and Torres Strait Islander working group National Surveillance and Monitoring Plan (James Ward)	Evaluation Advisory Group - Drug Policies and Services within the Alexander Maconochie Centre (Peter Higgs)	IeDEA Cancer Working Group (Matthew Law, Stephen Kerr)
Communicable Diseases Network Australia, Human Papillomavirus (HPV) Surveillance Working Party (John Kaldor)	Expert Working Group to provide advice on Australian Government Department of Health and Ageing-funded HIV/AIDS, hepatitis C and sexually transmissible infections education and health promotion materials (John Kaldor)	IeDEA Data Harmonization Working Group (Jialun Zhou, Rebecca Oyomopito)
Communicable Diseases Network Australia, New Developments in HIV Surveillance Committee (John Kaldor, Chair)	Faculty of Medicine, Expert Review Panel (Sean Emery)	IeDEA Executive Committee (David Cooper, Matthew Law)
Communicable Diseases Network Australia, Subcommittee on Surveillance of Bloodborne Viral and Sexually Transmitted Infections (John Kaldor, David Wilson, Tarana Lucky, Keira Robinson, Melanie Middleton, Ann McDonald, Rebecca Guy, Basil Donovan, James Ward)	Faculty of Medicine, Research Management Committee (Anthony Kelleher)	IeDEA Pharmacovigilance and Adverse Events Working Group (Jialun Zhou)
Communicable Diseases Network of Australia (CDNA), National Strategies HIV STI BBV Subcommittee, subcommittee to develop a national surveillance and monitoring plan for the HIV, STI, Hepatitis B and Hepatitis C and National Aboriginal and Torres Strait Islander STI and BBV Strategies (Lisa Maher)	Family Planning NSW Scientific Advisory Committee (John Kaldor)	Immunovirology Research Network Steering Committee (Anthony Kelleher)
Comprehensive International Program for Research on AIDS (CIPRA) HIV Research Program in Thailand and Cambodia International Steering Committee (David Cooper)	Family Planning NSW Scientific Advisory Group (Donovan B)	<i>Infectious Disease Reports</i> Editorial Board (David Wilson)
	FOXFIRE Data Safety and Monitoring Committee (Matthew Law)	INSIGHT network, Executive Committee (David Cooper, Sean Emery)
	Gardasil Advisory Board, CSL Ltd (Andrew Grulich, Basil Donovan)	INSIGHT network, Infrastructure Committee (Sarah Pett, Cate Carey)
	Gastroenterology Metropolitan Committee on Hepatitis C (Greg Dore co-chair)	INSIGHT network, Monitoring Group Committee (David Courtney-Rodgers, Nisha Seneviratne)
	Genital Warts Surveillance Network (Hammad Ali, Basil Donovan, Neil Franklin, Rebecca Guy, David Regan)	INSIGHT network, Quality Oversight and Performance Evaluation Committee (David Courtney-Rodgers)
		INSIGHT network, Training Committee (Cate Carey)

Intensive Insulin Therapy Trialists' Collaboration Steering Committee (Bette Liu)	Ministerial Advisory Committee on AIDS, Sexual Health and Hepatitis (MACASHH), Hepatitis C Subcommittee (Greg Dore)	NHMRC Grant Review (Immunology) (Anthony Kelleher)
International AIDS Society Meeting, Epidemiology and Prevention Stream, Vienna, Austria, Rapporteur (David Wilson)	Multicultural HIV and Hepatitis Service Advisory Group (Lisa Maher, Chair)	NSW Chapter of Sexual Health Medicine Annual Scientific Meeting Organising Committee (Fraser Drummond)
International Centre for Science in Drug Policy, Technical Advisor (Lisa Maher)	NACCHO Sexual Health and Bloodborne Virus Advisory Committee (James Ward)	NSW Chief Health Officer Report Special Topic: STI (Basil Donovan, David Wilson, advisory group members)
International Conference on the Reduction of Drug-related Harm Scientific -Program Committee (Lisa Maher)	NAPWA Treatments Policy Advisory Group (Fraser Drummond, Sarah Pett)	NSW Department of Corrective Services Ethics Committee (John Kaldor)
International Epidemiologic Databases to Evaluate AIDS Cancer Working Group (Stephen Kerr)	National Association of People Living with HIV/AIDS, HIV Medication Working Group (Dianne Carey)	NSW Health Aboriginal Sexual and Reproductive Health Program Advisory Group (James Ward)
<i>International Journal of Drug Policy</i> Editorial Board (Jo Kimber, Lisa Maher)	National Breast Cancer Foundation Register4 Epidemiological Questionnaire Design Advisory Group (Bette Liu)	NSW Health Advisory Group for the Chief Health Officer (CHO) Report, special topic on sexually transmissible infections (James Ward)
<i>International Journal of STD & AIDS</i> Editorial Board (Basil Donovan)	National Centre for HIV/AIDS, Dermatology and STD (NCHADS) Steering Committee for Cambodian Treatment Access Program (CTAP) and AusAID funded HIV projects (John Kaldor)	NSW Health CAS Health Promotion Sub-Committee Chlamydia Working Group (James Ward)
International Union against Sexually Transmitted Infections, Executive Committee (Basil Donovan, Senior Counsellor)	National Centre for Immunisation Research and Surveillance of Vaccine Preventable Disease Scientific Advisory Committee (John Kaldor)	NSW Health Fixing the Gap In the patient Journey: Improving access to hepatitis C treatment among Aboriginal people. Project Advisory Committee (James Ward)
<i>Journal of Acquired Immune Deficiency Syndromes</i> Editorial Board (David Cooper)	National Centre in HIV Social Research (NCHSR) Scientific Advisory Committee (Lisa Maher)	NSW Health HCV Prevention Campaign Advisory Committee (Bethany White)
<i>Journal of AIDS and Clinical Research</i> Editorial Board (David Wilson)	National Gay Men's Syphilis Action Plan NSW Implementation Committee (Rebecca Guy)	NSW Health Member Mid Term Review Committee, NSW HIV, STI, HCV and Aboriginal Implementation Plan (James Ward)
<i>Journal of Criminology and Criminal Justice</i> International Advisory Board (Lisa Maher)	National Gay Men's Syphilis Action Plan Steering Committee and Monitoring and Evaluation Subcommittee (David Wilson, Rebecca Guy)	NSW Health Panel Member, Statewide Review of AIDS Funded Services (James Ward)
<i>Journal of Drug Issues</i> Editorial Board (Lisa Maher)	National Gay Men's Syphilis Action Plan Technical Working Group (Basil Donovan, Andrew Grulich, Rebecca Guy, Garrett Prestage, David Wilson)	NSW Health Shared Scientific Advisory Committee (Fraser Drummond expert reviewer)
<i>Journal of Hepatology</i> Editorial Board (Greg Dore)	National Health and Medical Research Council Centres of Research Excellence Grant Review Panel (John Kaldor)	NSW Health Shared Scientific Assessment Committee (Fraser Drummond)
<i>Journal of HIV Therapy</i> Current Trends Advisory Board (David Cooper)	National Health and Medical Research Council Project Grant Review Panel, Indigenous Health (John Kaldor)	NSW Health Statewide Review of AIDS Funded Services (James Ward)
Lao People's Democratic Republic National Strategy and Action Plan on HIV/AIDS/STI 2011-2015 (David Wilson expert reviewer)	National HIV/STI and BBV Surveillance Committee (Basil Donovan, Rebecca Guy, John Kaldor, Lisa Maher, Ann McDonald, Melanie Middleton, Libby Topp, James Ward, David Wilson)	NSW Ministerial Advisory Committee on Hepatitis (MACH) (Lisa Maher, Greg Dore, James Ward)
Lionel Murphy Foundation (Board of Trustees) (Lisa Maher)	National Strategies HIV STI BBV Working Group, HCV Working Group (Lisa Maher, Chair)	NSW Ministerial Advisory Committee on HIV/AIDS and Sexually Transmissible Infections (James Ward)
Lotus House Refuge Management Committee (Lisa Maher)	National Strategies STI HIV BBV project working groups (Rebecca Guy, John Kaldor, Garret Prestage, James Ward)	NSW Ministerial Advisory Committee on HIV/AIDS and Sexually Transmissible Infections, Health Promotion Subcommittee (Andrew Grulich chair, Garrett Prestage member)
<i>Medicine Today</i> Board of Editorial Consultants (Basil Donovan)	Netherlands AIDS Foundation Grant Scheme (David Wilson, reviewer)	NSW Population and health services research ethics committee (Andrew Grulich member)

NSW Users and AIDS Association Expert Advisory Committee (Lisa Maher)	SPARTAC Trial Steering Committee (David Cooper, Anthony Kelleher)	UNSW Academic Board Committee Member (John Kaldor)
NUAA Policy & Campaigns Advisory Committee (Ian Down)	SSDV Interagency (Ian Down)	UNSW Academic Board High Degree Research Committee (John Kaldor)
OpiCare Leadership Team (Greg Dore, Jason Grebely)	St Vincent's Centre for Applied Medical Research/UNSW Research degree review committee (Anthony Kelleher)	UNSW Faculty of Medicine Postdoctoral Advisory Committee (Mary Poynten)
Papua New Guinea HIV Modelling Reference Group (John Murray)	St Vincent's Hospital Campus Institutional Biosafety Committee (Anthony Kelleher)	UNSW Faculty of Medicine Research Grant/ Early Career Grant Review (Anthony Kelleher)
Positive Life (NSW) Board Advisory Group (Garrett Prestage, Mark Boyd)	St Vincent's Hospital Human Research Ethics Committee (Claire Vajdic, Deputy Chair; Kathy Petoumenos, Handan Wand)	UNSW Faculty of Science, Promotion to Professor Committee (Lisa Maher)
Practical Advances in Treating HIV (PATH II) Steering Committee (Sean Emery, Chair)	St Vincent's Research & Biotechnology Precinct Hub Governance Council (David Cooper)	UNSW Health Data Linkage committee (Matthew Law)
Prevention Science Track Committee, International AIDS Society Conference, Vienna, 2010 (Andrew Grulich)	Steering Committee for NHMRC grant under the International Collaborative Indigenous Health Research Partnership (John Kaldor)	UNSW Hepatitis C Vaccine Initiative Steering Committee (John Kaldor)
Primary HIV Infection Advisory Committee (John Murray)	STIGMA - NSW Implementation committee for the National Syphilis Action Plan (Rebecca Guy)	UNSW Human Research Ethics Advisory Panel: Medical/Community (Greg Dore, Jo Kimber, Lisa Maher, Mark Boyd)
Project Management Group Randomised Control Trial, Tobacco Control AHE&MRC (James Ward)	STIGMA (Iryna Zablotska)	VAC/GMHC Sexually Adventurous Men's Project Committee (Garrett Prestage)
Project Reference Group NSW STI Campaign (James Ward)	Suicide Prevention Australia Reference Group on Suicide and self-harm amongst the GLBTI communities (Garrett Prestage)	Vietnamese Australian Buddhist Assistance Trust (Lisa Maher)
ProPrems Trial Data Safety Monitoring Committee (John Kaldor)	Surveillance and Monitoring Plan for national strategies HIV STI BBV Sub-Committee of the Communicable Disease Network of Australia Committee (David Wilson)	Working Group, International Agency for Research on Cancer Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 100: A Review of Human Carcinogens (Andrew Grulich)
Public Health Association of Australia - Justice Health Special Interest Group (Peter Higgs)	Sydney HIV Interagency (Garrett Prestage)	World Health Organisation Global Consultation on MSM and Transgender People (Mary Poynten, Advisor)
Queensland Ministerial Advisory Committee on HIV/AIDS, Hepatitis C and Sexual Health Member (Andrew Valley)	Thai A/E Clade HIV Vaccine Trial Protocol Steering Committee (David Cooper, Sean Emery, Anthony Kelleher, Rebekah Puls)	World Health Organisation Strategic and Technical Advisory Committee for HIV/AIDS (David Cooper)
Repatriation Medical Authority (John Kaldor)	The Cancer Council NSW Cancer Research Committee (Andrew Grulich)	World Health Organisation Working Group on Incidence Assays for HIV Infection (John Kaldor co-Chair)
Review panel for Sydney University Master of Medicine (HIV/STI) degree program (David Templeton committee member external)	The Data Collection on Adverse Events of Anti-HIV Drug Study International Steering Committee (Matthew Law)	World Health Organisation/UNAIDS HIV Vaccine Advisory Committee (David Cooper, Chair)
Sax Institute (David Wilson representative for NCHECR)	The HIV/AIDS Legal Centre (HALC) Management Board (Iryna Zablotska)	XVIII International AIDS Conference Abstract Reviewer (Lisa Maher)
<i>Sexual Health</i> (David Cooper, Editor)	The Sax Institute (Andrew Grulich)	
<i>Sexual Health</i> Editorial Board (Basil Donovan, Andrew Grulich, John Kaldor, Garrett Prestage)	TREAT Asia HIV Observational Database Steering Committee (Matthew Law, Jialun Zhou)	
Sexually Transmitted Infections in Gay Men Action Group (Jeff Jin)	TREAT Asia Paediatric HIV Observational Database Steering Committee (Matthew Law)	
Sexually Transmitted Infections Programs Unit Advisor Group, NSW (Rebecca Guy)	TREAT Asia Quality Assurance Scheme Steering Committee (Matthew Law, Jialun Zhou)	
<i>Sexually Transmitted Infections</i> , Editorial Board (David Cooper)	TREAT Asia Steering Committee (David Cooper)	
<i>Sexually Transmitted Infections</i> , Elsevier, New Delhi (Basil Donovan, Section Editor)	TREAT Asia Studies Evaluating Resistance Steering Committee (Matthew Law)	
Sidney Myer Health Scholarship Selection Committee (Peter Higgs)	UNAIDS Estimation of Australia's HIV/AIDS indicators (David Wilson)	
SIRFLOX Independent Data and Safety Monitoring Board Committee (Matthew Law)		

Staff

Director's office

Director and Scientia Professor of Medicine
David Cooper AO, BSc(Med), MB BS, MD, DSc, FAA, FRACP, FRCPA, FRCP

Executive Assistant
Janette Button

Research Assistant
Damien Cordery BSc(Hons), MPH, PhD

Vaccines program grant co-ordinator
John Wilkinson BSc(Hons), PhD

Manager, Research Communication
Louisa Wright M Journalism, MPH

Therapeutic and Vaccine Research Program

Head and Professor
Sean Emery BSc(Hons), PhD

Senior Lecturer
Mark Boyd BA, BM, BS, DCTM&H, MHID, MD, FRACP

Lecturers
Helen Byakwaga MB ChB
Dianne Carey BPharm, MPH
Sarah Pett BSc(Hons), MB BS(Hons), DTM&H, MRCP (UK), FRACP

Rebekah Puls BSc(Hons), PhD
Senior Clinical Project Co-ordinators
Cate Carey RN, BA, MAppSc(Research)
Allison Humphries BSc, MSc(Med), Grad Dip PH

Senior Coordinator - Regulatory Compliance
David Courtney-Rodgers

Clinical Project Co-ordinators
Maria Arriaga BSc, MScMed(STD/HIV)
Carlo Dazo BMedSc(Hons)
Megan Evans BappSc HIM (Health Information Management)

Natalie Espinosa BS (Biomed), MA AppSc (Ex&Sc)
Hila Haskelberg BSc
Sally Hough BAppSci, Grad Cert PM (from July)
Enmoore Lin BA/BSc(Hons), PhD (from March)
Simone Jacoby BSc, Dip Nutrition, Adv Dip Bot Med

Nisha Seneviratne BMedSc, BBus
Jessica Taylor BNurs (from Jan)

Program Manager
Cathy Sajjadi Dip Bus

Data Managers
Kymme Courtney-Vega Dip Sp Th
Wendy Lee

Jose Aurelio Vieira Vulcao BA
Administrative Assistants
Maja Berilazic BEd

Lara Cassar
Rosemary Robson
Alexis Shambrook

HIV Epidemiology and Prevention Program

Head and Professor
Andrew Grulich MB BS, MSc, PhD, FAFPHM

Senior Lecturers
Mary Poynten MBBS, DCH, MPH(Hons), PhD
Garrett Prestage BA(Hons), PhD
David Templeton MB ChB, Dip Ven, Grad Cert ForensMed, MACLM, FACHSHM
Iryna Zablotska PhD, MD, MPH

Post Doctoral Research Fellow
Jeff Jin BMed, MPH, PhD

Research Assistants
Brian Acraman (from March)
Ian Down MPH
Michelle McKechnie BMedSci(Hons), PhD (from May)
Patrick McGrath BA, Dip Ed (from December)

Project Officer
Jack Bradley
Administrative Assistant
Ali Ayoub



The Director's Unit with Professor David Cooper (second from right)

Viral Hepatitis Clinical Research Program

Head and Associate Professor

Greg Dore MB BS, BSc, PhD, FRACP, MPH

Senior Lecturers

Gail Matthews MBChB, MRCP(UK), FRACP PhD

Tanya Applegate, BSc(Hons), PhD

Viral Hepatitis Clinical Research Fellow

Rachel Ali BMBS, BMedSci(Hons),

MRCP(London)

Lecturers

Marianne Jauncey BMed, Grad Dip App Epi,

MPH(Hons), FAFPHM (part time)

Rosie Thein MD, MPH, PhD (to October)

Jason Crebely, BSc, PhD

Clinical Trials Manager

Pip Marks BSc

Clinical Project Co-ordinators

Alexa Gillman BSc(Hons)

Ineke Shaw BSc, Grad Cert BioStats (to October)

Barbara Yeung RN, BHSc(Nursing), MPH

Senior Research Assistant

Brendan Jacka BSc(Hons)

Research Assistants

Amanda Erratt ADip (Admin)

Maryam Salehi Alavi (BSc), (MSc)

Data Manager

Patrick McGrath BA, Dip Ed (to December)

Administrative Assistant

Jennifer Moore

Viral Hepatitis Epidemiology and Prevention Program

Professor and Head

Lisa Maher PhD

Senior Lecturer

Libby Topp BSc(Psychol)(Hons), PhD (from Feb)

Lecturer

Anna Olsen

Post Doctoral Research Fellow

Peter Higgs PhD, MA, BSW

Joanne Kimber BSc, PhD

Qualitative Research Co-ordinator

Julie Mooney-Somers BSc(Hons), PhD

Clinical Trial Co-ordinator

Kathy Barnes RN (to March)

Research Assistants

Anna Bates BA

Rachel Deacon BSc, PhD

Jarliene Enriquez

Mofit Islam

Jenny Iversen BAppSc

Ju Park BSc(Hons) (from May)

Anh Pham

Len Liao

Kerri Shying (to March)

Administrative Assistant

Rachel McCleave BA(Hons), BEd(Prim)

Project co-ordinator/ PhD candidate

Bethany White BA (Psych), MPH

Research Assistant

Heidi Coupland

Surveillance and Evaluation Program for Public Health

Head and Associate Professor

David Wilson BSc, BInfTech, BAppSc(Hons),

GradCert(Biostats), PhD

Lecturer

Richard Gray BSc(Hons), PhD

Lei Zhang BSc(Adv Hons), MSc, PhD, MPH

Post Doctoral Research Fellow

Josephine Reyes BS, MS, PhD (from May)

Coordinator HIV Surveillance

Ann McDonald BSc, MPH

HIV Surveillance Officer

Melanie Middleton BMedSci, MPH

Tarana Lucky MBBS, MPH, MHM (student)

Research Officers

Md. Fakhru Islam BSc(Hons), MSc(Stat), MIS,

MBiostat (from July)

Cliff Kerr BSc(Hons), DipArts, PhD (from July)

Kylie-Ann Mallitt BSc(Hons) PhD student (from July)

Keira Robinson BSc(Hons), MSc (from Feb)

Research Assistants

Eric Chow BSc, MApplSc(Bioinf) (from March)

Charisse Farr (to July)

Haris Ghaus

Kel Heymer BMath, BAppSci(Hons) (to April)

Alex Hoare BSc(Hons)

James Jansson BTeach, BSc(Hons) (part-time)

Victor Jaurejig

Shamin Kinathil BE(Hons), BSc

Amy Kwon BSc (Applied Mathematics)

Sheila Matete-Owiti BSc MIS MPH (from July)

Karen Schneider

Jianyun (Fred) Wu BSc MAActSt, PDipStats (from Feb)

Program Coordinator

Megan Brennan (from October)

Administrator

Mia Giatsios (to August)

Biostatistics and Databases Program

Head and Associate Professor

Matthew Law MA, MSc, PhD

Associate Professor

John Murray BSc(Hons), MSc, PhD (part time)

Senior Lecturer

Janaki Amin BSc(Hons), MPH(Hons), PhD

David Regan BA, BSc(Hons), PhD

Handan Wand MA, MSc, PhD

Stephen Kerr BPharm(Hons), MIPH, PhD (HIV-

NAT, Thailand)

Lecturers

Azar Kariminia BSc, MSc, PhD

Kathy Petoumenos BSc, MA, MPH(Hons), PhD

Jialun Zhou BMed, MPH, PhD

Associate Lecturers

Ben Hui BE(computer engineering), MBIomedE

Igor Korostil MSc (from May)

Statisticians

Heather Gidding BAppSc, Grad Dip Epid

Biostats, MAppEpid, MPHAA

Paul Fahey BSc, MMedStat (from April)

Awachana Jiamsakul BSc, MS

Sadaf Marashi Pour BSc, MSc (to February)

Hamish McManus BEcon, BActS, MBIOS

Rebecca Oyompito BSc, Grad Dip Med Stat

Stephen Wright BMath, MAppStat

Computer Systems Officers

Noorul Absar BTech, Grad Dip(Inf Sc),

MComp(SW Eng)

Rossitza Chevenova BSc

Research assistant

Greg Londish BSc(Hons) (to May)

David Philp (from July)

Program co-ordinator

Courtney Bendall DipBus

Administrative assistant

Supreet Mehik B Homeopathic Medicine and

Surgery (from October)

Immunovirology and Pathogenesis Program

Head and Senior Lecturer

Anthony Kelleher BSc(Hons), MB BS(Hons),

PhD, FRACP, FRCPA

Lecturers

Linda Gelgor PhD, MSc

Kersten Koelsch MBBS, MD

Nabila Seddiki PhD (to October)

Senior Scientist

Nigel McCarthy BSc(Hons), MSc (to January)

Clinical Project Co-ordinators

Patricia Grey BA, Post Grad Dip App Sci, CNS,

Dip (Counselling)

Research Assistants

Michelle Bailey BSc(Hons)

Chantelle Hood PhD

Susanna Ip BSc

Chansavath Phetsouphanh BSc, MSc (to April)

Yin Xu MSc (Research), MSc

Data Administrator

Ansari Shaik BA, MBA

Administrative assistants

Lucy Watchirs-Smith BA

Lydia Jauncey BA (to June)

Sexual Health Program

Head and Professor of Sexual Health

Basil Donovan MB BS, DipVen (Lond), MD,

FAPPHM, FRCPI, FACHSHM

Senior Lecturer and NHMRC Post-doctoral Fellow

Rebecca Guy BAppSc, MAppEpid, PhD

Lecturer

Fraser Drummond MB ChB, MRCA, DA (UK)

Joanne Micallef PhD

Associate Lecturer

Hammad Ali BSc, MBBS, MPH (from June)

Project Co-ordinator

Lisa Edwards BNurs MPH (from August)

Neil Franklin BSc(Hons), MPH (to July)

Rebecca Lorch DipAdultNurs BSc(Hons)(from August)

Research Assistants

Kel Heymer BMath, BAppSci(Hons)(Part time)

Karen Schneider BSc(Hons), MPH (Part-time)

Rashmi Fotedar PhD

Administrative assistant

Candace Mitchell

Aboriginal and Torres Strait Islander Program Manager

Head and Senior Lecturer

James Ward

Research Manager

Simon Graham MAppEpid

National Co-ordinator

Clint Arizmendi PhD

Clinical Project Leader

Mary Ellen Harrod BA, Dip Arts, M Prelim, PhD (from June)

Project Coordinator

Lind Garton RN, Grad Cert Advanced Practice, Sexual Health (from November)

Research assistants

Snehal Akre MBBS, MPH (to October)

Sheila Matete-Owiti BSc, MIS, MPH (from July)

Administrative assistant

Candace Mitchell

Finance and Administration

Business Manager

Annie Tung MPA

Finance Managers

Gina Lam BA(Hons), EMBA

Patricia Xu BEc, EMBA, CPA (to April)

Jence Oesman (from May)

Finance Administrator

Teresa Wong BAcc, CPA

Librarian

Coralie Kronenberg BA, Dip IM Lib, AALIA

IT Specialist

Sergio Sandler MSc, EE, Dip. Ed (from September)

Computer Systems Officers

Lisa Howard Dip IT

Charles Tran BCompSc

Manager, Human Relations

Brigitte Sharp BA(Hons)

Manager, Administration

Tricia Koh BA, MA (from May)

Yvette Toole (maternity leave)

Administrative Officers

Ian Brodie BEc, Grad Dip Ed, Ass Dip Hlth Sc

Dhara Kothary

Morgan Stewart BA(Hons)

Receptionist

Rata Joseph

Public Health Interventions Research Group

Head and Professor of Epidemiology

John Kaldor PhD

Associate Professor

Andrew Vallerly MBBS, MRCP, MSc, DTMH, PhD (from July)

Senior Lecturer

Bette Liu MBBS(Hons) MPH(Hons) DPhil (from June)

Lecturer

Louise Causer MB BS, MSc, DTM&H

Program co-ordinator

Skye McGregor BA, BSc, MA

Researchers affiliated to NCHECR

Visiting Professor

Jennifer Hoy MB BS, Grad Dip Epi Bio, FRACP


Senior Visiting Fellow

Philip Cunningham BAppSc(Med)

Chief of Operations, St Vincent's Centre for

Applied Medical Research

St Vincent's Hospital, Sydney



Members of the Administration and IT Units

Visiting Fellows

Bruce Brew MB BS(Hons), MD, FRACP
Professor of Medicine
St Vincent's Hospital, Sydney

Nick Crofts MB BS, MPH, FAFPHM
Professor and Director
Turning Point Alcohol and Drug Centre,
Melbourne

Cathy Pell MB BS, MM
Specialist General Practitioner
Taylor Square Private Clinic, Sydney

Don Smith MB ChB, MD
Associate Professor and Head of Research
Development
Albion Street Centre, Sydney

Mark Sullivan BSc
Chief Operating Officer
VivaGel™ Microbicide Development
Consortium
Medicines Development Limited, Melbourne

Alex Wodak MB BS, MRACP, FRACP, MRCP,
FAFPHM, FACHAM
Director
Alcohol and Drug Service
St Vincent's Hospital, Sydney

Postgraduate students and student supervision

Doctorates awarded

Kathleen Falster (UNSW)

Treatment experience and long term morbidity and mortality outcomes among a cohort of HIV-infected patients in Australia and the Asia-Pacific region in the era of combination antiretroviral treatment

Supervisors: Matthew Law, Basil Donovan

Susan Hudson (UNSW)

Sex, drugs and 'ugly mugs': an ethnographic study of women who inject psychostimulants and engage in street-based sex work in Kings Cross, Sydney

Supervisor: Lisa Maher

Mary Poynten (UNSW)

Biological and behavioural methods of prevention of HIV/AIDS transmission

Supervisors: Andrew Grulich, Jeff Jin

Supervisors David Cooper; Janaki Amin; Matthew Law

Jonathan Anderson

The role of economic evaluation in decision-making about HIV

Supervisors: David Cooper; Sean Emery; Kathy Petoumenos

Helen Byakwaga

Antiretroviral therapy and the management of HIV/AIDS

Supervisors: Sean Emery; David Cooper; Mark Boyd

Dianne Carey

Optimising therapeutic outcomes in HIV-infected subjects

Supervisors: Sean Emery, David Cooper

Eric Pui Fung Chow

Understanding the past, forecasting the future - investigating the epidemiology of HIV/AIDS in China

Supervisors: Lei Zhang, David Wilson

Paul Clark

Genomics to predict the complications of chronic hepatitis C and its treatment

Supervisors: Greg Dore, Alex Thompson (St Vincent's Hospital, Melbourne)

Laura Cook

Characterisation of T regulatory cells

Supervisors: Tony Kelleher, Nabila Seddiki

Fraser Drummond

Chemoprophylaxis for syphilis in MSM - a trial of systemic chemoprophylaxis for syphilis in HIV positive men who have sex with men

Supervisors: Basil Donovan; John Kaldor; Rebecca Guy.; Jeff Klausner

Heather Gidding

Hepatitis C-related morbidity and treatment in Australia

Supervisors: Matthew Law; Greg Dore; Janaki Amin

Simon Graham

An Intervention to improve sexually transmitted infection control and management in selected Aboriginal Community Controlled Health Services in New South Wales

Supervisors: Basil Donovan; Rebecca Guy; Handan Wand

Hila Haskelberg

Antiretroviral toxicity in HIV-infected patients

Supervisors: Sean Emery; Andrew Carr (St Vincent's Hospital); Janaki Amin

Kelly Jean Heymer

PhD candidates at NCHCR

Amit C Achhra

Bio-markers and other predictors of AIDS and non-AIDS diseases in HIV observational (cohort) studies



Postgraduate students at Darlinghurst

Using modelling to evaluate drivers and predict trajectories of HIV and STI epidemics in South East Asia and Australasia
Supervisors: David Wilson, Phillip O'Neil (University of Nottingham)

Denise Chee Hsu

Using novel biomarkers to define the role of TB specific effector T cell and TB specific regulatory T cell in patients with Mycobacterium tuberculosis (TB) and HIV co- infection

Supervisors: David Cooper, Tony Kelleher

Jennifer Lynne Iversen

Enhanced sentinel sero-surveillance among people who inject drugs in Australia
Supervisors: Lisa Maher, Libby Topp; Handan Wand

Amy Kwon

Mathematical modelling of viral epidemics among injecting drug users in the Asia-Pacific region

Supervisors: David Wilson, Rosie Thein; Cliff Kerr

Kylie-Ann Mallitt

Geospatial Models of HIV Transmission
Supervisors: Handan Wand, David Wilson

Allison Martin (Humphries)

Toxicities associated with antiretroviral treatment of HIV-1 antiretroviral treatment effects on HIV Infection

Supervisors: Sean Emery, Janaki Amin

Sheila Matete-Owiti

Modelling HIV epidemics in Indigenous communities

Supervisors: Richard Gray; David Wilson; James Ward

Kristin McBride

Studies of the latent reservoirs of HIV-1
Supervisors: David Cooper; Tony Kelleher; Kersten Koelsch

Mee Ling Munier

The role of HIV-specific CD4+ T-cells at primary infection

Supervisors: Tony Kelleher; Bill Sewell; John Zaunders

Rebecca Akao Ojomopito

HIV-1 drug resistance in treatment-naïve and combination antiretroviral therapy exposed patients in Asia

Supervisors: Matthew Law, Tony Kelleher

Sarah Pett

Aspects of HIV-1 treatment: An exploration of the positive and negative physiological aspects of host-directed treatments for HIV-1 infection
Supervisors: David Cooper; Tony Kelleher; Sean Emery

Suzanne Polis

Adherence to hepatitis B antiviral therapies
Supervisors: Lisa Maher, Armany Zekry (St George Hospital)

Karen Schneider

Mathematical modelling of HIV epidemiology, treatment and drug-resistance in Thailand
Supervisors: David Wilson; Basil Donovan; Matthew Law

Sanjay Swaminathan

Role of miRNAs in HIV-1 pathogenesis
Supervisor: Tony Kelleher

Winnie Wing Yin Tong

Measurement of immune responses to

clinically significant viral pathogens in immunocompromised adults
Supervisors: Andrew Carr (St Vincent's Hospital), Tony Kelleher

Edward (Ned) Waters

The analysis, ecology and implications of HPV variants in HPV related cancers
Supervisors: David Regan, David Philp (SPHCM); Andrew Grulich

Chris Weatherall

Characterisation of B-lymphocyte responses in primary HIV infection-neutralising antibodies and immune tolerance

Supervisors: Tony Kelleher, David Cooper

Bethany White

Hepatitis C vaccine preparedness
Supervisors: Lisa Maher, Greg Dore

Masters students at NCHCECR

Tarana Lucky Masters by Research

Quantitative techniques to improve monitoring and evaluation of HIV epidemics and to determine trends in transfusion transmissible infections (by producing a national surveillance report with Blood Service) in Australia
Supervisors: David Wilson, Handan Wand

Skye McGregor M. Phil

Health priority setting in developing countries
Supervisors: John Kaldor, Rosie Thein

Chansavath Phetsouphanh Masters by Research
Re-characterising Antigen specific CD4+ T Cells to HIV



Postgraduate students at Coogee

Supervisors: Tony Kelleher, Nabila Seddiki

Lucia Romani M. Phil

Factors associated with scabies in a highly endemic population

Supervisors: John Kaldor, Andrew Steer (Murdoch Childrens Research Institute)

Bronwyn Silver Masters by Research

Reproductive health at risk: exploring the interface between sexual and reproductive health in Indigenous women in remote communities

Supervisors: John Kaldor; Rebecca Guy; Alice Rumbold (Menzies School of Health Research)

Honours students at NCHCR

Lim Steven

Supervisors: Tony Kelleher, Kazuo Suzuki

Characterisation of promoter targeted siRNAs during transcription gene silencing of HIV-1

Murray Daniel

Supervisors: Tony Kelleher, Sanjay

Swaminathan

Mapping miRNA changes in the monocytes of HIV-1 infected patients

Influences on changes in HIV incidence rates in young men in Australia

Co-supervised by Iryna Zablotska

Othman Loay (La Trobe University), PhD

Candidate

HIV and stigma in the United Arab Emirates

Supervised by Garrett Prestage

Somanadhan Sowbhagya

Influence of civil society on HIV policies and services in India and the participation of people living with HIV/AIDS

Supervised by Lisa Maher

Zou Huachun (University of Melbourne), PhD

Candidate

HPV infection in young men who have sex with men

Co-supervised by Andrew Grulich

Supervision of non-National Centre students

Botes Leon Pierre (The University of Sydney)

PhD Candidate

Validation of the acceptability and reliability of self collected anal swabs used for cytological screening, to detect anal squamous intra-epithelial lesions in HIV-positive men who have sex with men

Supervised by Richard Hillman; co-supervised by Jeff Jin

Fetherston James (Curtin University)

Modelling hepatitis C transmission in Australian prisons

Co-supervised by David Wilson

Lam Paul (UNSW Faculty of Medicine)

Supervisors: Kersten Koelsch, Tony Kelleher
HIV DNA dynamics in patients switching to a raltegravir-containing regimen

Lambert Stephen (University of Queensland)

Supervisors: Scott Kitchener (UQ), Basil Donovan

Chlamydia in the Australian Defence Forces

Londish Gregory (on leave of absence)

Supervisors: John Murray, Matthew Law

The Impact of a Male Circumcision Intervention on HIV Epidemics

Read Tim (Melbourne University), PhD Candidate

Sexually transmitted viruses in men having sex with men

Co-supervised by Andrew Grulich

O'Dwyer Matthew (University of Sydney), u/g

Public Health Honours

Collaborating organisations

National

Association for Prevention and Harm Reduction Programs (ANEX), Melbourne
Australasian Chapter of Sexual Health Medicine, Sydney
Australasian Professional Society on Alcohol and other drugs (APSAD)
Australasian Society for HIV Medicine, Sydney
Australasian Society of Clinical Immunology and Allergy (ASCIA) Primary Immunodeficiency Register, Sydney
Australia and New Zealand Cardiothoracic Transplant Registry, Sydney
Australia and New Zealand Dialysis and Transplant Registry (ANZDATA), Adelaide
Australia and New Zealand Liver Transplant Registry, Brisbane
Australian Agency for International Development (AusAID), Canberra
Australian Centre for Hepatitis and HIV Virology Research (ACH²), UNSW, Sydney
Australian Federation of AIDS Organisations, Sydney
Australian Gonococcal Surveillance Program, Sydney
Australian Government Department of Health and Ageing, Canberra
Australian Injecting and Illicit Drug Users League (AIVL), Canberra
Australian Institute of Health and Welfare, Canberra
Australian Liver Association, Sydney
Australian Paediatric Surveillance Unit and its contributors, Sydney
Australian Red Cross Blood Service, Melbourne
Australian Red Cross Blood Service, Sydney
Australian Research Centre in Sex, Health and Society, La Trobe University, Melbourne
Communicable Diseases Network Australia, Canberra
Drug and Alcohol Nurses of Australasia (DANA)
Federal Department of Health and Ageing, Canberra
Hepatitis Australia, Canberra
Immunovirology Research Network (IVRN), UNSW, Sydney
National Aboriginal Community Controlled

Health Organisation, Canberra
National Association of People Living with HIV/AIDS, Sydney
National Drug Research Institute, Curtin University of Technology, Perth
National Centre for Epidemiology and Population Health, Australian National University, Canberra
National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, Sydney
National Centre in HIV Social Research, UNSW, Sydney
National Drug and Alcohol Research Centre, UNSW, Sydney
National Serology Reference Laboratory, Australia, Melbourne
Office of Aboriginal and Torres Strait Islander Health (OATSIH), Canberra
Phase Forward Pty Ltd, Sydney
Royal Australian and New Zealand College of Psychiatrists
Therapeutic Goods Administration, Canberra

Australian Capital Territory

ACT Corrective Services, Canberra
ACT Health
Canberra Sexual Health Centre
Canberra Sexual Health Clinic, Canberra Hospital
Communicable Disease Control Program, ACT Health, Canberra
Directions ACT, Canberra
Interchange General Practice, Canberra
John Curtin School of Medical Research, Australian National University, Canberra
Sexual Health and Family Planning ACT
The Canberra Hospital, Canberra

New South Wales

Aboriginal Health and Medical Research Council of NSW
Aboriginal Medical Service Co-op Ltd, Sydney
Aboriginal Medical Service Western Sydney, Mount Druiitt Village
AIDS Council of NSW (ACON), Sydney, Lismore,

Newcastle, Penrith, Port Macquarie and Wollongong
AIDS Research Initiative, Sydney
Albion Street Centre, Sydney
Albury Community Health Centre, Albury
Area Health Services, NSW Health, Sydney
Armajun Aboriginal Health Service Incorporated, Inverell
Bigge Park Medical Centre, Sydney
Blacktown Methadone Unit, Blacktown
Blacktown Needle and Syringe Program Services, Sydney
Blue Mountains Sexual Health Clinic, Katoomba
Brindabella Family Practice, Queanbeyan
Burwood Road General Practice, Sydney
Central Access Service, Sydney (*formerly St George Hospital Needle and Syringe Program*)
Centre for Addiction Medicine, Westmead Hospital
Centre for Health Research in Criminal Justice, Justice Health, NSW Health Department, Sydney
Centre for Infection and Inflammation Research, School of Medical Sciences, UNSW
Centre for Immunology, St Vincent's Hospital, Sydney
Centre for Transplant and Renal Research, Westmead Millennium Institute for Medical Research, Sydney
Centre for Values, Ethics and the Law in Medicine, University of Sydney
Charlestown Family Medical Services, Charlestown
Communicable Diseases Branch, NSW Health Department, Sydney
Coffs Harbour Sexual Health Clinic
Concord Hospital, Sydney
Dubbo Sexual Health Centre, Dubbo
Durri Aboriginal Corporation Medical Service, Kempsey
East Sydney Doctors, Sydney
Faculty of Science, University of Sydney
Fleet Street Opioid Treatment Unit, Parramatta
First Step Program, Port Kembla and Nowra
Galambila Aboriginal Health Service Inc, Coffs Harbour
Garvan Institute of Medical Research, Sydney
Gateway Opioid Treatment Service Clinic,

Nepean Hospital
 Goulburn River Group Practice, Goulburn
 General Medical Practice, Coffs Harbour
 Grafton Sexual Health Clinic, Grafton
 Greater Southern Area Health Service
 Harm Reduction Program, Liverpool
 Harm Minimisation Program, Newcastle
 Health ConneXions, Sydney
 Hepatitis NSW (formerly Hepatitis C Council of NSW), Sydney
 Holden Street Clinic, Gosford
 Holdsworth House Medical Practice, Sydney and Byron Bay
 Hunter Harm Reduction Services, Newcastle
 Hunter New England Sexual Health Service
 Illawarra Aboriginal Medical Service Aboriginal Corporation, Wollongong
 Illawarra Sexual Health, Port Kembla
 Indo-Chinese Outreach Network (ICON), Sydney
 John Hunter Hospital, Newcastle
 Justice Health, NSW Health Department, Sydney
 K2 Health Service, Sydney
 Kellyclose Mt DrUITT Needle and Syringe Program Services, Sydney
 Kirketon Road Centre, Sydney
 Kite Street Community Health Centre, Orange
 Laverty Pathology
 Lismore Base Hospital, Lismore
 Lismore/ Tweed Heads Sexual Health & AIDS Services
 Liverpool Hospital, Sydney
 Liverpool Sexual Health Clinic, Sydney
 Livingstone Road Sexual Health Centre, Marrickville
 Manly Sexual Health Clinic
 Multicultural HIV/AIDS and Hepatitis C Service, Sydney
 Needle and Syringe Program, Gosford and Long Jetty
 Nepean Hospital, Sydney
 Nepean Sexual Health Clinic
 Newcastle FPNSW Centre, Cooks Hill
 Newcastle Pharmacotherapy Services, Newcastle
 North Coast Area Health Service, Harm Reduction Services
 North Sydney Medical Practice, North Sydney
 Northern Sydney Central Coast Area Health Service, NSW Health Department, Sydney
 Northern Sydney Sexual Health Service, St Leonards
 NSW Centre for Health Record Linkage, Sydney
 NSW Department of Corrective Services

NSW Health Department, Sydney
 NSW Health Department, AIDS and Infectious Disease Branch, Sydney
 NSW State Reference Laboratory for HIV/AIDS, St Vincent's Hospital, Sydney
 NSW Users and AIDS Association (NUAA), Sydney
 Orange Sexual Health Clinic
 Parramatta Needle and Syringe Program Services, Sydney
 Perinatal and Reproductive Epidemiology Research Unit, incorporating the National Perinatal Statistics Unit, UNSW
 Positive Life NSW
 Prince of Wales Hospital, Sydney
 Rankin Court Treatment Centre, Sydney
 Resource and Education Program for Injecting Drug Users (REPIDU), Sydney
 Responsive User Services in Health (RUSH), Sydney
 Royal North Shore Hospital, Sydney
 Royal Prince Alfred Hospital, Sydney
 Royal Prince Alfred Hospital Clinic 36 Outreach Clinic, Sydney
 Royal Prince Alfred Hospital (RPA) Drug Health Services, Sydney
 Royal Prince Alfred Hospital Regent House Outreach Clinic, Sydney
 Royal Prince Alfred Hospital (RPA) Sexual Health Clinic, Sydney
 Sax Institute, Sydney
 School of Medical Sciences, UNSW, Sydney
 School of Public Health, University of Sydney
 School of Public Health and Community Medicine, UNSW, Sydney
 Sex Workers Outreach Project (SWOP), Sydney
 Sexual Health and Infectious Diseases Service (SHAIDS), Lismore
 Sexually Transmitted Infections Research Centre, Westmead Hospital, Sydney
 South Court Primary Care Needle and Syringe Program, Sydney
 South Eastern Area Laboratory Services (SEALS), Prince of Wales Hospital
 South Eastern Sydney and Illawarra Area Health Service, NSW Health Department, Sydney
 South Eastern Area Laboratory Services, South Eastern Sydney and Illawarra Area Health Service, Sydney
 South West Area Health Service, Eastern Division
 South West Area Health Service, Western Division
 St George Hospital, Sydney
 St George Hospital Short Street Sexual Health Clinic

St Vincent's Hospital, Sydney
 St Vincent's Centre for Applied Medical Research
 St Vincent's Medical Imaging, Sydney
 Sydney Medically Supervised Injecting Centre, Sydney
 Sydney Sexual Health Centre, Sydney
 Sydney South Illawarra Health Service
 Sydney South West Area Health Service, Sydney
 Sydney West Area Health Service, Sydney
 Sydney West Area Health Service HIV/Hepatitis C Prevention Service, Auburn, Blacktown, Merrylands, Mt DrUITT and Parramatta
 Sydney West Area Health Service Clinical Sexual Health Services
 SydPath, Sydney
 Tamworth Sexual Health Service, Tamworth
 Taree Manning Clinic
 Taylor Square Private Clinic, Sydney
 The Byrne Surgery, Sydney
 The Cancer Council NSW, Sydney
 The Cancer Institute NSW, Sydney
 Tweed Heads Sexual Health Service
 University of Sydney – Discipline of Addiction Medicine, Sydney
 UNSW Cancer Research Centre, integrated cancer research group
 Wellington Aboriginal Corp Health Service, Wellington
 Western Sydney Aboriginal Medical Service Mt DrUITT
 Westmead Hospital, Sydney
 Westmead Millennium Institute for Medical Research, Sydney
 Woodlands Clinic, Blue Mountains Anzac Memorial Hospital, Katoomba

Northern Territory

Aboriginal Medical Services Alliance Northern Territory, Darwin
 AIDS/STI Program, Disease Control, Department of Health and Community Services, Darwin
 Alice Springs Hospital
 Alice Springs Harm Reduction Program, Alice Springs
 Alice Springs Sexual Health Service Clinic 34
 Communicable Disease Centre, Royal Darwin Hospital, Darwin
 Danila Dilba Health Service, Darwin
 Darwin Harm Reduction Program, Darwin
 Darwin Sexual Health Service
 Family Planning Northern Territory, Coconut Grove

Menzies School of Health Research, Casuarina
 Northern Territory Sexual Health and BBV Unit
 Northern Territory AIDS and Hepatitis C Council,
 Alice Springs, Darwin and Palmerston
 Northern Territory Correctional Services
 Department of Justice, Darwin
 Northern Territory Department of Health and
 Families
 Palmerston Needle and Syringe Program,
 Palmerston
 Royal Darwin Hospital

Queensland

AIDS Medical Unit, Queensland Health,
 Brisbane
 Apunipima Cape York Health Council,
 BungalowBiala Alcohol and Drug Services,
 Brisbane
 Brisbane Sexual Health Clinic, Brisbane
 Cairns Base Hospital, Cairns
 Cairns Base Hospital NSP Services, Cairns
 Cairns Sexual Health Service, Cairns Base
 Hospital, Cairns
 Carbal Medical Service, Toowoomba
 Chancellor Park Family Medical Practice, Sippy
 Downs
 Clinic 87, Sunshine Coast-Wide Bay Health
 Service District, Nambour
 Communicable Disease Unit, Queensland
 Health, Brisbane
 Department of Corrective Services, Brisbane
 Dolls House Sexual Health Clinic, Cairns
 Family Planning Queensland, Toowoomba
 Gladstone Road Medical Centre, Brisbane
 Gold Coast Hospital, Southport
 Gold Coast Sexual Health Clinic, Miami
 Goondir Health Service, Dalby
 Kewarra Family Practice, Kewarra Beach
 Kobi House, Toowoomba
 Nambour Medical Centre, Nambour
 Prince Charles Hospital, Brisbane
 Princess Alexandra Hospital, Brisbane
 Princess Alexandra Sexual Health, South
 Brisbane
 Queensland Aboriginal and Islander Health
 Council, Brisbane
 Queensland Health, Brisbane
 Queensland Injectors Health Network (QUIHN),
 Brisbane, Gold Coast and Sunshine Coast
 Queensland Medical Laboratory (QML),
 Brisbane
 Queensland University of Technology, Brisbane
 Royal Brisbane and Women's Hospital, Brisbane

School of Population Health, University of
 Queensland
 Sunshine Coast and Cooloola HIV/Sexual Health
 Service, Nambour
 Townsville Aboriginal and Islanders Health
 Services Ltd, Townsville
 Townsville ATODS
 Townsville Health Services
 West Moreton Sexual Health Service, QLD

South Australia

Aboriginal Health Council of South Australia, Inc.
 Adelaide
 AIDS Council of South Australia (ACSA), Adelaide
 Drug and Alcohol Services South Australia
 (DASSA), Adelaide
 The Care and Prevention Program, Adelaide
 University, Adelaide
 Clinic 275, Adelaide
 Communicable Disease Control Branch, SA
 Health
 Department of Health
 Flinders Clinical Trials Pharmacy, Adelaide
 Flinders Medical Centre, Adelaide
 Harm Minimisation Program, Hindmarsh Centre,
 Adelaide
 Infectious Diseases Laboratories, Institute of
 Medical and Veterinary Science, Adelaide
 Noarlunga Community Health Service, Adelaide
 Northern Metropolitan Community Health
 Service NSP and Shopfront, Salisbury; SA
 Nunkuwarrin Yunti of South Australia Inc,
 Adelaide
 O'Brien Street Practice, Adelaide
 Parks Community Health Service, Adelaide
 Port Adelaide Community Health Service, Port
 Adelaide
 Royal Adelaide Hospital, Adelaide
 Royal Adelaide Hospital Clinic 275
 Sexually Transmitted Diseases (STD) Services,
 Internal Medicine Service, Royal Adelaide
 Hospital
 Shine SA (Sexual Health Information Networking
 and Education Inc)
 South Australian Health Department
 South Australian Voice for Intravenous Education
 (SAVIVE) Noarlunga, Norwood, Parks, Port
 Adelaide
 Shopfront Youth Health and Information
 Services, Adelaide
 South Australian Prison Health Services, Adelaide
 Women's and Children's Hospital Adelaide

Tasmania

Clarence Community Health Service, Hobart
 Corrective Services Division, Department of
 Justice, Hobart
 Department of Health and Human Services
 Tasmania
 Devonport Community Health Centre,
 Devonport
 Family Planning Tasmania, Hobart
 Hobart, Devonport and Launceston Sexual
 Health Service
 Hobart Sexual Health Service
 Royal Hobart Hospital
 Salvation Army Launceston, Launceston
 Tasmanian Council on AIDS, Hepatitis and
 Related Diseases (TasCAHRD), Hobart and
 Glenorchy
 Tasmanian Aboriginal Centre, Hobart
 The Link Youth Health Service, Hobart

Victoria

Association for Prevention and Harm Reduction
 Programs Australia (Anex), Melbourne
 Barwon Drug and Alcohol Services, Geelong
 Bendigo NSP Services, Bendigo
 Brighton Medical Clinic, Brighton
 Centre for Population Health, Burnet Institute,
 Melbourne
 Centre for Women's Health, Gender and Society,
 Melbourne School of Population Health,
 University of Melbourne
 Darebin Community Health Centre, Northcote
 Deakin Health Economics Unit, Deakin
 University, Melbourne
 Department of Human Services, Victoria
 Department of Microbiology and Immunology,
 The University of Melbourne, Melbourne
 Genesis Medical Centre, Brighton
 Health Information Exchange, Salvation Army,
 Melbourne
 Health Works, Footscray
 Inner Space, Melbourne
 Key Centre for Women's Health in Society,
 University of Melbourne, Melbourne
 Macfarlane Burnet Institute for Medical
 Research and Public Health, Melbourne
 Melbourne Pathology, Melbourne
 Melbourne Sexual Health Centre
 The Microbiological Diagnostic Unit, University
 of Melbourne
 Middle Park Clinic, Melbourne

Monash Medical Centre, Melbourne
 Monash University, Melbourne
 Mooroopna Medical Centre, Mooroopna
 Nexpep, Victoria
 North Richmond Drug Safety Program, Melbourne
 Northcote Clinic, Melbourne
 Northcote Needle and Syringe Program Services, Melbourne
 Northside Clinic, Fitzroy North
 People Living with HIV/AIDS (PLWHA), Melbourne
 Prahran Market Clinic, Melbourne
 Royal Melbourne Hospital, Melbourne
 Royal Women's Hospital, Melbourne
 School of Population Health, The University of Melbourne, Melbourne
 Southern Hepatitis/HIV/AIDS Resource and Prevention Service (SHARPS), Melbourne
 South East Alcohol and Drug Service, Dandenong
 St Vincent's Hospital, Melbourne
 The Alfred Hospital, Melbourne
 The Carlton Clinic, Melbourne
 The Centre Clinic, Melbourne
 Victorian Aboriginal Community Controlled Health Organisation, Melbourne
 Victorian Aboriginal Health Service, Fitzroy
 Victorian AIDS Council/Gay Men's Health Centre (GMHC), Melbourne
 Victorian Cytology Service Inc, Melbourne
 Victorian Infectious Diseases Reference Laboratory, Melbourne
 Wellness Centre Medical Clinic, Malvern East
 Walter and Eliza Hall Institute, Melbourne, Victoria

Western Australia

Aboriginal Health Council of Western Australia, Perth
 AK medical/dental Clinic, Kelmscott
 Centre for Clinical Immunology and Biomedical Statistics, Perth
 Communicable Diseases Control Directorate, Department of Health, Perth
 Curtin University of Technology
 Data Linkage Western Australia, Perth
 Department of Corrective Services, Perth
 Department of Health, Western Australia
 Derbarl Yerrigan Health Service, Perth
 Duncraig Medical Centre, Duncraig
 Fremantle Hospital

Fremantle Hospital Sexual Health Service
 Geraldton Regional Aboriginal Medical Service, Geraldton
 Kimberley Aboriginal Medical Services Council, Broome
 Kimberley Population Health Unit, Broome
 Murdoch University, Perth
 National Drug Research Institute, Curtin University of Technology
 Quarry Health Centre for under 25s, Fremantle;
 Royal Perth Hospital, Perth
 Royal Perth Hospital Sexual Health Clinic
 Royal Perth Hospital, Department of Clinical Immunology
 Sexual Health and Blood Borne Virus Program, Department of Health, Perth
 University of Western Australia, Perth
 Western Australian AIDS Council (WAAC), Perth
 Western Australia Country Health Service (WACHS), Perth
 Western Australian Substance Users Association (WASUA), Perth

International

Academic Medical Centre, University of Amsterdam, Amsterdam
 AIDS Clinical Centre, International Medical Centre of Japan, Tokyo
 AIDS Malignancy Consortium, Birmingham, USA
 American Foundation for AIDS Research (amfAR), New York
 Angkor Hospital for Children, Siem Reap, Cambodia
 Arkansas Children's Hospital
 Aviano Cancer Centre, Aviano, Italy
 Bamrasnaradura Hospital, Bangkok
 Beijing Ditan Hospital, Beijing
 British Columbia Cancer Registry, Vancouver
 British Columbia Centre for Disease Control, Vancouver, Canada
 British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
 Brown University, Providence, USA
 Calgary Regional Health Authority, Canada
 Cambodia NCHADS
 Canadian Trials Network (CTN), Vancouver
 Catalan Institute of Oncology, Barcelona
 Centre for Research on Drugs and Health Behaviour, London School of Hygiene & Tropical Medicine, UK
 Centro de Asistencia e Investigacion Clinica de Inmunocomprometidos (CAICI), Rosario, Argentina

Chelsea and Westminster Hospital, London
 Chaing Mai University, Chaing Mai, Thailand
 Chiang Rai Regional Hospital, Chiang Rai, Thailand
 Children Hospital No. 1, Ho Chi Min City, Vietnam
 Chinese Center for Disease Control and Prevention, Beijing
 Chonburi Regional Hospital, Chonburi, Thailand
 Chris Hani Baragwanath Hospital, Soweto, South Africa
 Chulalongkorn Hospital, Bangkok
 Cipto Mangunkusumo General Hospital, Jakarta
 Community Research Initiative of New England, Boston
 Concerted Action on Seroconversion to AIDS and Death in Europe (CASCADE) and its contributors, Coordinating Unit, London
 Copenhagen HIV Programme, Hvidovre University Hospital, Copenhagen
 Cornell University, New York
 Department of HIV/GUM Research, Brighton, UK
 Department of Life Science & Medical Bio-Science, School of Advanced Science and Engineering, Waseda University, Tokyo, Japan
 Department of Social Medicine, University of Bristol, UK
 Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul
 Division of Statistics, School of Public Health, University of Minnesota, Minneapolis, USA
 Evangel Hospital, Jos, Nigeria
 Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA
 Faculty of Medicine, Udayana University and Sanglah Hospital, Denpasar, Bali, Indonesia
 Fred Hutchinson Cancer Research Center, Seattle
 Fundacion Arriaran, Santiago, Chile
 Fundacion Centro de Estudios Infectologicos (FUNCEI), Clinica La Sagrada Familia, Buenos Aires
 Gemeinschaftspraxis Jessen, Berlin, Germany
 geneOmbio Technologies Pvt Ltd, Pune, India
 German Cancer Research Center, Heidelberg
 Hadassah Medical Centre, Jerusalem
 Harvard University, Boston
 HIV Netherlands, Australia, Thailand Research Collaboration (HIV-NAT), Bangkok
 Hôpital Saint-Louis, Paris
 Hospital Almenara, Lima, Peru
 Hospital Central, Mendoza, Argentina
 Hospital de Clinicas Jose de San Martin, Buenos Aires

Hospital Dos de Mayo, Lima, Peru

Hospital de Enfermedades Infecciosas FJ Muniz, Buenos Aires

Hospital General de Agudos JM Ramos Mejia, Buenos Aires

Hospital General de Agudos Juan A Fernandez, Buenos Aires

Hospital General de Agudos Teodoro Álvarez, Buenos Aires

Hospital General de Guadalupe, Mexico

Hospital General de Leon, Mexico

Hospital Interzonal de Agudos San Juan de Dios, La Plata, Argentina

Hospital Interzonal General de Agudos Oscar Alende, Mar del Plata, Argentina

Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

Hospital Kuala Lumpur, Malaysia

Hospital Paroissien, Buenos Aires, Argentina

Hospital Pulau Pinang, Malaysia

Hospital Likas, Kota Kinabalu, Malaysia

Hôpital Pitié-Salpêtrière, Paris

Hospital Nacional Prof Dr Alejandro Posadas, Buenos Aires

Hospital Raja Perempuan Zainab II, Kelantan, Malaysia

Hospital Rawson, Bajada Pucara, Argentina

Hospital San Borja-Arriaran, Santiago, Chile

Hospital Sungai Buloh, Kuala Lumpur

Imperial College, St Mary's Hospital, London

Infections and Immunity, Avenir Group, Hôpital Pitié Salpêtrière, Université Pierre et Marie Curie-Paris, France

Institute of Infectious Disease, Pune, India

Instituto de Medicina Tropical Alexander von Humboldt, Lima, Peru

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubrián, Mexico City

Integrated Treatment Centre, Hong Kong

International AIDS Society, Geneva

International Consortium of Investigators Working on Non-Hodgkin's Lymphoma Epidemiologic Studies (InterLymph)

Johns Hopkins University, Baltimore

Joint Clinical Research Centre, Kampala, Uganda

Jos University Teaching Hospital, Jos, Nigeria

JOSHUA Research, Bloemfontein, South Africa

JW Goethe Universität, Frankfurt

Kaplan Medical Centre, Rehovot, Israel

Khon Kaen University, Khon Kaen, Thailand

Kumamoto University, Japan

Laboratory of Tumour Cell Biology, Department of Medical Genome Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan

Massachusetts General Hospital, Boston

Mater Misericordiae University Hospital, Dublin

McGill University

Medical Group Practice, Berlin

Medical Research Council, Durban, South Africa

Medical Research Council Clinical Trials Unit, London

Ministry of Public Health, Bangkok

Muirhouse Medical Group, Edinburgh, UK

Nagoya Medical Center, Nagoya, Japan

National Cancer Institute, National Institutes of Health, Bethesda, USA

National Center for AIDS/STD Control and Prevention, Beijing, China

National Center for HIV/AIDS, Dermatology and STDs (NCHADS), Phnom Penh

National Center for Tuberculosis and Leprosy Control, Phnom Penh, Cambodia

National Health Laboratory Services, University of Witwatersrand, Johannesburg

National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, USA

National Hospital of Pediatrics, Hanoi

National Institute for Public Health, Phnom Penh

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA

National Institute of Infectious Disease, Tokyo

National Institute on Drug Abuse, National Institutes of Health, Bethesda, USA

National Pediatric Hospital, Phnom Penh

National Taiwan University Hospital, Taipei

New Hope for Cambodian Children, Phnom Penh

Nuffield Department of Medicine, University of Oxford

Osaka National Hospital, Japan

Papua New Guinea Institute for Medical Research, Goroka, Papua New Guinea

Papua New Guinea National AIDS Council

Partners AIDS Research Center, Boston

Pediatric Institute, Hospital Kuala Lumpur, Kuala Lumpur

Penang Hospital, Malaysia

Plateau State Specialist Hospital, Jos, Nigeria

Port Moresby General Hospital, Papua New Guinea

Providence Health Care, Vancouver

Public Health Service (GGD), Amsterdam, the Netherlands

Queen Elizabeth Hospital, Hong Kong

Queen Mary Hospital, Hong Kong

Ragon Institute of MGH, MIT and Harvard, Boston, USA

Ramathibodi Hospital, Mahidol University, Bangkok

Rambam Medical Centre, Haifa, Israel

Research Institute for Health Science, Chiang Mai, Thailand

Research Institute for Tropical Medicine, Manila

Rikshospitalet, Oslo, Norway

Shanghai Municipal Center for Disease Control and Prevention, China

Siriraj Hospital, Bangkok

Srinagarind Hospital, Khon Kaen, Thailand

Stanford University, Stanford, USA

State Key Laboratory of Virology, Wuhan University, China

Swiss HIV Cohort Study, Copenhagen

Taipei Veterans General Hospital and AIDS Prevention and Research Centre, National Yang-Ming University, Taipei, Taiwan

Tan Tock Seng Hospital, Singapore

Tel Aviv Sourasky Medical Centre, Israel

Thai Red Cross Society, Bangkok

Toronto General Research Institute, Toronto, Canada

Toronto Health Economics and Technology Assessment Collaborative (THETA), Toronto, Canada

Toronto Western Hospital, Toronto, Canada

Toronto Hospital, Canada

TREAT Asia, American Foundation for AIDS Research (amFAR), Bangkok, Thailand and New York, USA

Udayana University, Sanglah Hospital, Bali

UNAIDS, Geneva

Université de Montréal, Montreal, Canada

University Health Network, Toronto, Canada

University of Malaya Medical Centre, Kuala Lumpur

University of Basel, Switzerland

University of British Columbia

University of California, Los Angeles

University of California, San Francisco

University of California, San Francisco, Vietnam Campus, Ho Chi Min City, Vietnam

University of Detroit

University of Guelph, Ontario, Canada

University of Indonesia, Jakarta

University of Maryland, Baltimore, USA

University of Minnesota, Minneapolis, USA

University of Toronto, Canada

University of Waterloo, Canada

Vietnam AIDS Council

Waikato Hospital, Hamilton NZ
Wayne State University, Detroit, USA
The World Bank
The World Health Organisation, Geneva
Worldwide Orphans Foundation (WWO), Ho Chi
Min City
Wuhan University, Wuhan, China
YRC Centre for AIDS Research and Education,
Chennai, India

Pharmaceutical and biomedical industry

Abbott Australasia Pty Ltd, Sydney
Boehringer Ingelheim Pty Ltd, Sydney
Bristol-Myers Squibb Pharmaceuticals,
Melbourne
Calimmune, USA
CSL Limited, Melbourne
Gilead Sciences, Foster City, California
GlaxoSmithKline Australia, Melbourne
Janssen-Cilag Pty Ltd, Sydney
Johnson & Johnson Research Pty Ltd, Sydney
Merck Research Laboratories, West Point, USA
Merck Sharp and Dohme, Sydney
Pfizer Australia Pty Ltd, Sydney
Roche Pharmaceuticals
Roche Products Pty Ltd, Sydney
Schering Plough Pty Ltd, Sydney

Disclosure of financial and other relationships

In relation to the companies indicated, staff members listed below either served on advisory boards or received individual travel grants, consultancy payments or honoraria during 2010. No staff member was a personal recipient of a tied or untied grant or had ownership in intellectual property related to any company that funded NCHECR's research program during 2010. Abbreviated forms of the company names have been used for ease of recognition.

Mark Boyd

MSDA
Bristol-Myers Squibb Australia

Di Carey

Boehringer-Ingelheim

David Cooper

Abbott
Bristol-Myers Squibb
Gilead
Janssen-Cilag
Merck
Pfizer
Tobira
ViiV

Basil Donovan

CSL
Sanofi-Pasteur MSD

Greg Dore

Bristol-Myers Squibb
Gilead
Janssen-Cilag
Merck
Roche

Sean Emery

Abbott
BMS Australia
Gilead
GlaxoSmithKline
MSDA
Tibotec
ViiV

Jason Grebely

Merck Sharp and Dohme
Schering-Plough

Andrew Grulich

CSL
Merck Sharp and Dohme

Anthony Kelleher

Becton Dickenson
Merck Sharp & Dohme
ViiV
Virax

Matthew Law

DLA Phillips
NSW Health
Sirtex Technology Pty Ltd

Pip Marks

Roche

Gail Matthews

Bristol-Myers Squibb
Gilead
Merck Sharp & Dohme
Roche

Sarah Pett

Boehringer-Ingelheim
Gilead Sciences
Merck Sharp & Dohme
ViiV

Funding

Australian Government Department of Health and Ageing	
Research activities for blood borne virus and sexually transmissible infections	5,871,235
The Australian Collaboration for Chlamydia Enhanced Sentinel Surveillance (ACCESS) Project	141,265
Other grants and contracts from public sources – American Foundation for AIDS Research:	
TREAT Asia Studies to Evaluate Resistance (TASER)	231,449
TREAT Asia Quality Assurance Scheme (TAQAS)	194,502
TREAT Asia Pediatric HIV Observational Database (TApHOD)	189,896
AusAID:	
Evaluating and predicting the epidemiological impact of health policies for reducing HIV in Melanesian and South-East Asian populations	152,558
Australian Research Council (ARC):	
Planning female and male vaccination and cervical screening strategies to achieve optimal prevention of HPV-related disease (Project)	122,358
Planning female and male vaccination and cervical screening strategies to achieve optimal prevention of HPV-related disease (APAI)	40,292
Sexual health and relationships in young Indigenous people	208,284
Using mathematical modelling to inform HIV/AIDS public health policy	178,710
Understanding spatial trends in HIV/AIDS infections in South Africa and Australia	81,660
Australian Society for HIV Medicine:	
A Prospective cohort study of Hepatitis C treatment delivery in primary care settings	29,385
Consortium to Implement AusAID's Regional Capacity Building Program 2007-2011 - Cambodia	199,786
Consortium to Implement AusAID's Regional Capacity Building Program 2007-2011 - Indonesia	192,743
Department of State and Regional Development to Industry and Investment NSW - Infrastructure Funding agreement with St Vincent's Hospital	3,050,053
European Medicines Evaluation Agency: Data Collection on Adverse Events of Anti-HIV Drugs Study	44,420
Family Health International Subcontract funded from the Bill and Melinda Gates Foundation: Development of Assays for Acute HIV Infection and Estimation of HIV Incidence in Populations	66,207



Head of Finance, Annie Tung (second from left) with members of the Finance Unit

Medical Research Council, UK: SPARTAC Study	24,507
NHMRC:	
CCRE in Aboriginal Health: Blood borne viral and sexually transmitted infection	227,273
Program Grant - HIV & HCV vaccines and immunopathogenesis	1,898,983
Program Grant - Sexually Transmitted Infections	1,075,032
Project Grant - Defining risk and mechanisms of permucosal transmission for acute HCV infection within high-risk populations	128,368
Project Grant - Hepatitis C Vaccine Preparedness Study	249,894
Project Grant - Modelling and economic evaluation of hepatitis C epidemic mitigation strategies in Australia	152,339
Project Grant - Modelling the interaction between sexually transmitted infections and HIV transmission to inform public health policy	162,529
Project Grant - Randomised controlled trial of Hepatitis B Vaccine Completion in Injecting Drug Users	85,042
Project Grant - Randomised trial to determine the safety and efficacy of early versus deferred treatment of adult HIV infection (START)	137,545
Project Grant - Social norms regarding HIV/STI risk and risk reduction behaviours among men who have sex with men in Australia	189,596
Research Fellows:	
Practitioner Fellowship for Basil Donovan	102,893
Practitioner Fellowship for Greg Dore	85,774
Practitioner Fellowship for Tony Kelleher	73,520
Public Health Fellowship for Bette Liu	80,008
Public Health Fellowship for Rebecca Guy	72,508
Public Health Fellowship for Peter Higgs	72,508
PRF - Andrew Grulich	138,074
SPRF - John Kaldor	156,161
SPRF - Lisa Maher	114,128
Postgraduate Scholarship for Bethany White	18,647
Sidney Sax Fellowship - Joanne Kimber	72,508
NHMRC - Program Grant Subcontract	
University of Sydney: Mathematical Modelling for improved planning of infectious disease control policy	30,000
University of Sydney: Building research capacity for health interventions to improve Aboriginal health	56,750
University of Melbourne: Using mathematical models to assess the impact of interventions to reduce sexually transmitted infections in Australia	110,000
NSW Health Department	
Australian Chronic Hepatitis C Observational Study (ACHOS)	74,500
Expert services in HIV/AIDS, viral hepatitis and sexually transmissible diseases	50,000
HIV Seroconversion Study	21,378
Increasing access to HCV treatment in NSW through opiate pharmacotherapy settings - pilot clinics project (ETHOS)	60,000
NSW Gay Men's HIV Prevention Modelling Project	50,000
Sexual health and relationships in young Indigenous People (ARC Linkage Partner)	41,000
ACT Health	
Sexual health and relationships in young Indigenous People (ARC Linkage Partner)	1,000
Queensland Health	
Australian Chronic Hepatitis C Observational Study (ACHOS)	117,874
Sexual health and relationships in young Indigenous People (ARC Linkage Partner)	12,500
Study of risk factors for HIV seroconversion	11,150
South Australia Health	
Evaluation of the South Australian HIV Epidemic	17,096
Tasmania Health & Human Services	
Sexual health and relationships in young Indigenous People (ARC Linkage Partner)	3,000
Victoria Health	
Sexual health and relationships in young Indigenous People (ARC Linkage Partner)	15,500
Western Australia Health	
Sexual health and relationships in young Indigenous People (ARC Linkage Partner)	1,500
Study of risk and HIV among men who have sex with men in Western Australia	11,955
The Cancer Council NSW	
Strategic Research Partnership Grant with University of Sydney - Towards a strategic partnership (STREP)	50,000
The University of Melbourne	
Collaborative Agreement from Department of Health & Ageing - Evaluation of Chlamydia Pilot in General Practice (ACCEPT)	159,200
UNAIDS	
Evaluating the effectiveness of needle and syringe programs in Eastern Europe	33,668

US National Institutes of Health	
Treatment of recently acquired hepatitis C virus infection (ATAHC 2)	183,140
US National Institutes of Health subcontracts	
American Foundation for AIDS Research: TREAT Asia HIV Observational Database (APHOD)	424,714
Thai Red Cross Research Centre: HIV Research Program in Thailand and Cambodia	85,472
University of California, San Francisco Institute for Global Health : Culture and HIV Prevention in Cambodia	27,136
University of California, San Francisco: Syphilis chemoprophylaxis in homosexual men with HIV infection using doxycycline	30,375
University of Minnesota: INSIGHT - Leadership	415,190
University of Minnesota: INSIGHT - FLU 002 & FLU 003	184,711
University of Minnesota: START Study	222,008
University of Minnesota: STALWART Study	80,134
Victorian Cytology Service	
Planning female and male vaccination and cervical screening strategies to achieve optimal prevention of HPV-related disease (ARC Linkage Partner)	4,620
Pharmaceutical Industry Funding	
Abbott Australasia Pty Ltd	200,000
CSL Limited	104,545
CSL Limited (ARC Linkage Partner)	67,167
Gilead Science Inc	511,405
Gilead Science Pty Ltd	535,000
GlaxoSmithKline Pty Ltd	25,000
Janssen-Cilag Pty Ltd	5,369
Merck Sharp & Dohme	258,213
Pfizer Australia Pty Ltd	3,380
Pfizer Inc via Quintiles Pty Ltd	31,154
Quintiles Pty Ltd	6,665
Tibotec Pharmaceuticals Ltd via Quintiles Pty Ltd	11,925
Total	20,658,034

Research grants

Cooper D, Emery S. Abbott Australasia Pty Ltd. A randomised open-label study comparing the safety and efficacy of ritonavir boosted lopinavir and 2N9t) RTI backbone versus the same ritonavir boosted lopinavir and raltegravir in patients virologically failing first-time NNRTI/2N(t)RTI therapy: the SECOND-LINE study. \$ 600,000 (2010-2012)

Cooper D. NSW Office for Science and Medical Research/NSW Medical Research Support Program. Institute of Virology Infrastructure Funding. \$ 4,577,278 (2010-2011)

Dore G. Australasian Society for HIV Medicine. A Prospective cohort study of Hepatitis C treatment delivery in primary care settings (GP Pilot). \$60,295 (2010-2012)

Dore G. NIH. Treatment of recently acquired hepatitis C virus infection (ATAHC 2). USD 353,564 (2010-2011)

Emery S. American Foundation for AIDS Research. A randomised open-label study of second-line combination ART. \$125,000 (2010-2014)

Gulich A. NHMRC Program Grant: Sexually Transmitted Infections: Causes Consequences and Interventions (SPANC). \$1,779,120 (2010-2014)

Kaldor J. NHMRC Program Grant: Sexually Transmitted Infections: Causes Consequences and Interventions. \$1,779,120 (2010-2014)

Kaldor J. NHMRC Program Grant: Sexually Transmitted Infections: Causes Consequences and Interventions (Contingency) \$50,000 (2010-2014)

Kelleher A. NHMRC Project Grant: siRNA Induced transcriptional silencing of HIV-1: Elucidating the mechanisms and exploring options for delivery. \$494,500 (2010-2012)

Law M. NHMRC Program Grant: Sexually Transmitted Infections: Causes Consequences and Interventions. \$1,779,120 (2010-2014)

Liu B. NHMRC Australian Based Public Health Training Fellowship: Notifiable communicable diseases and reproductive health. \$300,032 (2010-2013)

Liu B. NHMRC Australian Based Public Health Training Fellowship: Notifiable communicable diseases and reproductive health (Direct

Research Costs). \$20,000 (2010-2013)

Maher L. NHMRC Project Grant: Hepatitis C Vaccine Preparedness Study: Investing in Infectious Disease Prevention. \$692,350 (2010-2012)

Matthews G. Gilead Science Pty Ltd. Variation in serum levels of HBsAg and eAg following initiation of HBV-active HAART in HIV-HBV co infected individuals and the relationship with subsequent long-term virological and serological outcomes. \$61,690 (2010)

Olsen A. NHMRC Training Fellowship for ATSI Health Research: Liver spots: A study of hepatitis B knowledge, treatment and health care among Indigenous Australians (Training Support Package). \$265,000 (2010-2013)

Olsen A. NHMRC Training Fellowship for ATSI Health Research: Liver spots: A study of hepatitis B knowledge, treatment and health care among Indigenous Australians (Direct Research Costs). \$20,000 (2010-2013)

Prestage G. NSW Health. HIV Seroconversion Study \$21,378 (2010)

White B. NHMRC Dora Lush Standard Postgraduate Scholarship: Hepatitis C vaccine preparedness: feasibility of field-based vaccine trials. \$56,188 (2010-2012)

Wilson D. ARC Discovery Project: Understanding spatial trends in HIV/AIDS infections in South Africa and Australia. \$225,000 (2010-2012)

Wilson D. Australian Agency for International Development (AusAID). Improving HIV/AIDS surveillance and evaluation in China. \$33,770 (2010)

Wilson D. NHMRC Project Grant: Modelling and economic evaluation of hepatitis C epidemic mitigation strategies in Australia. \$448,500 (2010-2012)

Wilson D. NHMRC Project Grant: Modelling the interaction between sexually transmitted infections and HIV transmission to inform public health policy. \$523,750 (2010-2012)

Wilson D. NSW Health. NSW Gay Men's HIV Prevention Modelling Project. \$50,000 (2010)

Wilson D. UNAIDS. Evaluating the effectiveness of needle and syringe programs in Eastern Europe \$67,362 (2010-2011)

Zablotska-Manos I. NHMRC Project Grant: Social norms regarding HIV/STI risk and risk reduction behaviours among men who have sex with men in Australia. \$667,563 (2010-2012)

Conference presentations

Australian Antiretroviral Guidelines Consortium Sydney, January

Law M. Advice to Consortium regarding when to start antiretrovirals.

Vietnam HIV/AIDS Evaluation Conference Hanoi, January

Wilson DP. Introduction to modelling evaluation of HIV epidemics.

Wilson DP. Data and inputs for Vietnam Epidemic Model for evaluation of provincial harm reduction programs.

Wilson DP. Vietnam impact assessment of harm reduction programs.

17th Conference on Retroviruses and Opportunistic Infections (CROI 2010) San Francisco, February

Petoumenos K, Worm SW, Reiss P, De Wit S, D'Arminio Monforte A, Sabin C, Friis-Møller N, Weber R, Mercie P, Pradier C, El-Sadr W, Kirk O, Lundgren J, Law M. On behalf of the D:A:D Study Group. Rates of Cardiovascular Disease Following Smoking Cessation in Patients with HIV Infection: Results from the D:A:D Study.

Winston A, **Duncombe C, Li P, Gill J, Kerr S, Puls R, Petoumenos K, Taylor-Robinson S, Emery S, Cooper D,** and the Altair Study Group. cART Alters Changes in Cerebral Function Testing after 48 Weeks in Treatment-naïve, HIV-1-infected Subjects Commencing cART.

Wright E, B Grund B, Robertson K, Roediger M, Brew B, **Drummond F, Pumpradit W, Shlay J, Penalva de Oliveira A, Price R,** for the INSIGHT SMART Study Group. CVD and CVD Risk Factors Are Associated with Lower Baseline Neurocognitive Performance in the SMART Neurology Substudy.

2010 Canadian Association for the Study of the Liver Banff (Canada) February

Grebely J, Petoumenos K, Hellard M, Matthews GV, Marks P, Haber P, Rawlinson W, Lloyd A, White PA, Kaldor JM, Dore GJ on behalf of the ATAHC Study Group. Spontaneous clearance and viral dynamics during recent hepatitis C virus infection.

World Congress of Internal Medicine Melbourne, March

Templeton D. Sexually transmitted infections in

men who have sex with men.

Udayana University Workshop on capacity building in HIV clinical and epidemiological research Yogyakarta, March

Kaldor JM. Longitudinal methods in clinical and public health research.

Australian Federation of AIDS Organisations HIV Educators Conference Sydney, March

Wilson DP. Current epidemiological trends in blood-borne viral and sexually transmitted infections.

World Congress of Internal Medicine Melbourne, March

Templeton D. Sexually transmitted infections in men who have sex with men.

Evolving Knowledge and Practice: 11th Social Research Conference on HIV, Hepatitis C and Related Diseases Sydney, April

Coupland H, Maher L. Adjudicating injecting drug users' candidacy for hepatitis C treatment: Conflicting provider, patient and public health realities?

Deacon RM, Newland J, Harris M, Treloar C, Maher L. Hepatitis C seroconversion: Using qualitative research to enhance surveillance.

Down I, Bradley J, McCann P, Brown G, Hurley M, Prestage G. Meanings of HIV in a changing epidemic.

McInnes D, **Prestage G, Bradley J.** Responsibility, risk and negotiation in the discourse of gay men's group sex.

Polis S, Zekry A, Maher L. Patient experiences of adherence to hepatitis B anti viral medications.

Poynten IM, Jin FY, Prestage GP, Kaldor JM, Imrie J, Grulich AE. Attitudes towards biomedical HIV prevention technologies among a cohort of HIV negative gay men in Sydney, Australia.

Prestage G, Hurley M, Brown G, Down I, Bradley J, McCann P. Reasoning risk-reduction.

Prestage G. Enlightened self-interest or 'cultures of care'?

Sacks-Davis R, Gold J, **Higgs P, Hellard M.**

Treating drug users for hepatitis C: Myths and realities, evolving knowledge and practice.

Wilson DP. Modelling the impact of changes in HIV testing rates and estimating the outcomes from the introduction of rapid HIV testing in Australia

Wilson DP. Rapid HIV Testing: it's about time!

Zablotska I, Down I. Pilot study of Respondent-Driven Sampling among gay men in Sydney: lessons learnt.

Zablotska I. HIV testing among gay men/MSM in Australia.

Zablotska I. Surveys of gay men in metropolitan Sydney and rural/regional NSW: comparison of indicators.

2010 International Liver Congress Vienna, April

Grebely J, Dore GJ, Schim van der Loeff M, Cox AL, Bruneau J, Kim AY, Lloyd AR, Maher L, Hellard M, Page K, Prins M, on behalf of the InC3 Collaborative Group. Factors associated with spontaneous clearance during acute hepatitis c virus infection.

Matthews GV, Grebely J, Hellard M, Yeung B, Marks P, Rawlinson W, Kaldor JM, Dore GJ on behalf of the ATAHC Study Group. Differences in early virological decline in individuals treated within the Australian Trial in Acute HCV suggest a potential benefit for the use of ribavirin.

Matthews GV, Grebely J, Hellard M, Yeung B, Marks P, Rawlinson W, Kaldor JM, Dore GJ on behalf of the ATAHC Study Group. Week 4 HCV RNA is the optimal predictor of SVR in both HIV positive and negative subjects within the Australian Trial in Acute HCV.

21st International Harm Reduction Association Conference Liverpool UK, April

Couture MC, Sapphon V, Phal S, Sothy NS, Sichan K, Stein E, Evans J, Kaldor J, Vun MC, Page K, Maher L. Incidence of HIV and sexually transmitted infections and yama use among young sex workers in Phnom Penh, Cambodia.

Grebely J, Hellard M, Bryant J, Hull P, Lavis Y, Hopwood H, Dore GJ, Treloar C. Assessment and treatment of hepatitis C virus infection among people who inject drugs in Australia

Harris M, Treloar C, **Maher L**. Agency, strategy and upbringing: Long-term injectors staying safe from hepatitis C in Sydney.

Higgs P, Aitken C, Hellard M, **Maher L**. Luck, chance and good fortune: Accounts of long-term injectors staying safe from hepatitis C in Melbourne.

Olsen A, Banwell C, Dance P, **Maher L**. "It's just one of those things": Living with hepatitis C and contextual meaning of health among women who inject drugs.

Multinational Influenza Seasonal Mortality Study Copenhagen, May

Davey R, Dwyer D, Losso M, Lynfield R, Cozzi-Lepri A, Gey D, Herman-Lamin K, Hoppe A, Neaton J, **Pett S**, Standridge B, Uyeke T, Wentworth D, Lundgren J on behalf of the INSIGHT FLU 002 & 003 Study Groups. Ongoing Global Assessment of Severity of the 2009 H1N1v Influenza A pandemic: INSIGHT (International Network for Strategic Initiatives in Global HIV Trials) FLU 002 and 003 protocols.

Microbicides 2010 Conference Pittsburgh, May

Lees S, Mtolela G, Selestine V, Barberousse C, Masanja J, **Valley A**, Moffat V, Harvey S, Hayes RJ. Uptake of referrals to HIV care and treatment services in Mwanza, Tanzania during the MDP 301 Phase III clinical trial of PRO 2000 microbicide gel.

16th International Union against sexually transmitted infections (IUSTI) Bali, May
Wilson DP. Developing a national strategy for reducing syphilis epidemics among gay men.

Donovan B. Chlamydia (invited seminar presentation)

Donovan B. Should males be vaccinated against HPV? (invited plenary).

4th Annual Rural Health Conference, Broome, May

Ward J, **Kaldor JM**, **Guy R**, Rumbold A, Skov S, **Maher L**, **Donovan B**, **McDermott R**. STRIVE: STI in remote communities improving and enhancing primary health care.

Health in Difference, Aboriginal Lesbian, Gay and Sistergirl Health Issues – Sameness or Difference Sydney, May

Ward J. Keynote speaker

AFAO HIV Educators' Conference, Sydney, May

Brown G, Ellard J, **Mooney-Somers J**, **Prestage J**. 'Living a life less ordinary': Risk perspectives of

men acquiring HIV while travelling and working overseas.

Prestage G, Brown G, Hurley M. PASHing with the results – implications and application of the results of the PASH study.

Advances in Public Health and Health Services Research at UNSW 2nd Annual Symposium May

Kaldor JM. Collaborative research on the prevention of HIV and other sexually transmitted infections in Papua New Guinea.

Australian Centre for HIV & Hepatitis Virology Research (ACH2) 6th National Workshop Yarra Valley, Victoria, June

Jacka B, **Mokany E**, **Pham ST**, **Carrera A**, **Kelleher A**, **Matthews G**, **Dore G**, **Applegate T**. MNAzyme qPCR used to quantify multiple genotypes in Hepatitis C infection.

Grebely J, **Petoumenos K**, **Hellard M**, **Matthews GV**, **Suppiah V**, **Applegate T**, **Yeung B**, **Marks P**, **Rawlinson W**, **Lloyd AR**, **Booth D**, **Kaldor JM**, **George J**, **Dore GJ** for the ATAHc Study Group. Potential role for IL28B genotype in treatment decision-making in recent hepatitis C virus infection.

Australia's health 2010: Australian Institute of Health and Welfare Canberra, June

Wilson DP. Infectious diseases: sexually transmissible infections in Australia.

Australian Centre for HIV & Hepatitis Virology Research (ACH2) Conference Melbourne, June

Flynn JK, **Dore GJ**, **Hellard M**, **Yeung B**, **White PA**, **Lloyd AR**, **Ffrench RA**, on behalf of the ATAHc Study Group. Altered cytokine responses in HCV-infected subjects treated with interferon.

Grebely J, **Petoumenos K**, **Hellard M**, **Matthews GV**, **Suppiah V**, **Applegate T**, **Yeung B**, **Marks P**, **Rawlinson W**, **Lloyd AR**, **Booth D**, **Kaldor JM**, **George J**, **Dore GJ** for the ATAHc Study Group. Potential role for IL28B genotype in treatment decision-making in recent hepatitis C virus infection.

International HIV & Hepatitis Virus Drug Resistance and Curative Strategies Workshop, Dubrovnik, June

Koelsch KK, **Xu Y**, **Bailey M**, **McBride K**, **Seddiki N**, **Suzuki K**, **Murray J**, **Cooper DA**, **Kelleher AD**, **Zaunders J**. A detailed analysis of T cell subsets and their susceptibility for infection with HIV and the possibility for HIV persistence in those cells.

12th International Symposium on Chlamydial Infections, Salzburg, June

Hocking JS, **Low N**, **Temple-Smith M**, **Donovan B**, **Gunn J**, **Law M**, **Kaldor JM**, **Guy R**, **Poznanski S**, **Fairley CK** on behalf of the ACCEPt Consortium. ACCEPt (Australian Chlamydia Control Effectiveness Pilot): design of a chlamydia testing cluster randomized controlled trial in general practice.

National Indigenous Drug and Alcohol Committee Conference Injecting drug use and Aboriginal Communities Adelaide, July

Ward J. Keynote speaker

XVIII International AIDS Conference Vienna, July

Cooper DA. New drug developments and future options in antiretroviral therapy.

Couture MC, **Sansothy N**, **Stein ES**, **Evans J**, **Sichan K**, **Maher L**, **Page K**. (on behalf of the Young Women's Health Study Collaborative). Amphetamine-type stimulant use increases HIV risk among young women engaged in sex work in Phnom Penh, Cambodia.

Jin J. Transmission risks for MSM

Jin F, **Jansson J**, **Law M**, **Prestage GP**, **Zablotska I**, **Imrie JCC**, **Kippax SC**, **Kaldor JM**, **Gulich AE**, **Wilson DP**. Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART.

Koelsch KK, **Xu Y**, **Bailey M**, **McBride K**, **Seddiki N**, **Suzuki K**, **Murray J**, **Cooper DA**, **Kelleher AD**, **Zaunders J**. A detailed analysis of T cell subsets and their susceptibility for infection with HIV and the possibility for HIV persistence in those cells.

Koelsch KK, **Xu Y**, **Bailey M**, **McBride K**, **Seddiki N**, **Suzuki K**, **Murray J**, **Cooper DA**, **Kelleher AD**, **Zaunders J**. Most HIV DNA in PBMC is present in non-gut homing, resting memory CD4 T cells with $\beta 7$ -CD38-CD127high phenotype.

Maher L, **Phlong P**, **Mooney-Somers J**, **Sichan K**, **Masy T**, **Stein E**, **Couture MC**, **Sansothy N**, **Page K**. [on behalf of the Young Women's Health Study Collaborative]. "It makes us dare to do what we did not dare to do before": Amphetamine-type stimulant use and HIV/STI risk behaviour among young female sex workers in Phnom Penh, Cambodia.

Poynten IM, **Jin FY**, **Prestage GP**, **Kaldor JM**, **Kippax S**, **Gulich AE**. Defining high HIV incidence subgroups of Australian homosexual men: implications for conducting HIV prevention trials in low HIV prevalence settings.

Wilson DP. Development of Australia's syphilis plan

Wilson DP. Evaluating the cost-effectiveness of needle and syringe programs in Australia.

Wilson DP. Reducing syphilis among HIV-infected and -uninfected gay men in Australia.

Wilson DP. Serosorting is not a safe strategy for reducing HIV in most contexts.

NCHECR International Clinical Research Network Meeting Vienna, July

Puls R. Altair Week 96 data update and EncoreI study update

China T Regs 2010 Conference Shanghai, July

Seddiki N, Cook L, Phetsouphanh C, Xu Y, Brown K, Cooper DA, Tye-Din J, Anderson B, Zaunders J, Kelleher AD. Measuring Antigen-Specific CD39+OX40+CD25+ Regulatory and CD39-OX40+CD25+ Effector CD4+ T Cell in viral infections (HIV, CMV) and in autoimmunity (celiac disease)

HIV and Ageing Symposium, National Association for People Living with HIV/AIDS Sydney, June

Murray M. HIV The ageing of the HIV epidemic in Australia.

26th International Papillomavirus Conference Montreal, July

Botes L, Pett S, Marriott D, Carr A, Cooper DA, Hillman R. High acceptability of self-collected anal swabs and High Resolution Anoscopy (HRA).

Conway EL, Stein AN, Hocking JS, Brotherton J, **Regan DG, Grulich AE.** Increasing burden of HPV-associated anal cancer in Australia.

Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Wand H, Fairley CK. A national outcome for quadrivalent HPV vaccination and genital warts in Australia. [Awarded best epidemiology presentation]

Grulich AE. A national outcome for quadrivalent HPV vaccination: declining rates of genital warts in Australia.

Jin F, van Leeuwen M, Vajdic C, McHugh L, Prestage GP, Botes L, Zablotska I, Medley G, Tabrizi S, Kippax SC, Grulich AE, Hillman R. High-grade anal intra-epithelial neoplasia in homosexual men: data from two community-based cohorts.

Sydney Cancer Conference 2010 Sydney, July

Botes L, Hillman R, Jin J, Carr A, Cooper DA,

Marriott D, Pett S, Brew B, Matthews G. Risk factors among HIV-infected men who have sex with men (MSM) for developing high-grade anal squamous cytological abnormalities - results from the Blokes with Anal Squamous Intraepithelial Lesions (BASIL) study.

PHAA 12th National Immunisation Conference Adelaide, August

Conway EL, Stein AN, Hocking JS, Brotherton J, **Regan DG, Grulich AE.** Increasing burden of HPV-associated anal cancer in Australia.

Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Wand H, Fairley CK. A national outcome: quadrivalent HPV vaccination and genital warts in Australia.

Stein AN, Conway EL, Brotherton J, **Regan DG, Grulich AE, Hocking JS.** Burden of potentially HPV-associated oral cavity and oropharyngeal cancer in Australia.

5th International Conference on Interdisciplinary Social Sciences Cambridge, August

Prestage G, Wilson D. The Goals of Australia's National Syphilis Action Plan Are Based in Interdisciplinary Research Findings.

NRL Annual Conference, Melbourne, August

Dimech W, **Guy R, Bergeri I, Kong F, Boyle D, Donovan B, Hellard M** on behalf of the ACCESS collaboration. ACCESS Laboratory Network results: first results after 2 years of operation (2008-2009)

Primary Health Care Conference, Darwin, August 2010.

Temple-Smith M, Hocking J, Gunn J, Donovan B, Guy R, Kaldor J, Low N, Fairley C. ACCEPTing the challenge: launching the Australian Chlamydia Control Effectiveness Pilot (ACCEPT).

17th International Meeting on Hepatitis C Virus and Related Viruses Yokohama, September

Grebely J, Petoumenos K, Hellard M, Matthews GV, Suppiah V, Applegate T, Yeung B, Marks P, Rawlinson W, Lloyd AR, Booth D, Kaldor JM, George J, Dore GJ on behalf of the ATAHc Study Group. Potential role for IL28B genotype in treatment decision-making in recent hepatitis C virus infection.

Jacka B, Mokany E, Pham ST, Carrera A, Kelleher A, Matthews G, Dore GJ, Applegate T. MNAAzyme qPCR used to quantify multiple genotypes in Hepatitis C infection.

Vital signs: Engaging research imaginations, Manchester, September
Mooney-Somers J, Olsen A, Scott R, Akee A, Maher L. Participation, authenticity and rhetoric: Community-based Participatory Research with an Australian Indigenous community.

7th Australasian Viral Hepatitis Conference Melbourne, September

Alavi M, Grebely J, Matthews G, Petoumenos K, Haber P, Yeung B, Lloyd A, Hellard M, van Beek I, Maher L, Kaldor J and Dore GJ on behalf of the ATAHc Study Group. Impact of pegylated interferon alpha-2a treatment on depression during recent HCV infection: the Australian Trial in Acute Hepatitis C (ATAHC).

Alavi M, Grebely J, Matthews G, Petoumenos K, Haber P, Yeung B, Lloyd A, Hellard M, van Beek I, Maher L, Kaldor J and Dore GJ on behalf of the ATAHc Study Group. Mortality among participants with recent hepatitis C virus infection in Australia: the Australian Trial in Acute Hepatitis C (ATAHC).

Balcomb AC, Buckerfield J, Lynch TF, D'Aquino F, **Gillman A and Dore GJ** 'Clinic 96' Update - A Community based hepatitis C treatment service in regional NSW and an ETHOS rural site.

Deacon RM, Topp L, Wand H, Day CA, Rodgers C, Haber PS, van Beek I, Maher L, (on behalf of the Hepatitis Acceptability and Vaccine Incentives Trial (HAVIT) Group). Correlates of hepatitis B vaccination status among injecting drug users: a comparison of eligible and ineligible participants in the HAVIT trial.

Erratt A, Grebely J, Jauncey M, Gillman A, Hill S, Day C, Dore GJ. Knowledge and barriers to referral for HCV assessment and treatment among practitioners in the drug and alcohol setting.

Everingham H, Hazelwood S, Tierney R, **Grebely J, Gillman A, Crawford S, Bath N and Dunlop A** Enhanced treatment for hepatitis C in opioid substitution settings (ETHOS) - Exploring the role of peer support in the delivery of hepatitis C treatment.

Gillman AB, Grebely J, Jauncey M, Day C, Dunlop A, Haber P, Wodak A, Balcomb AC, Weltman MD and Dore GJ. Assessment and treatment of chronic hepatitis C virus (HCV) in a prospective, observational cohort of injection drug users (IDUs): The ETHOS Cohort.

Grebely J, Bryant J, Hull P, Hopwood M, Lavis Y, Dore GJ and Treloar C. Specialist assessment and treatment of hepatitis C virus infection among injection drug users in New South Wales, Australia

Grebely J, Dore GJ, Schim van der Loeff M, Cox AL, Bruneau J, Kim AY, Lloyd AR, Maher L, Hellard M, Page K and Prins M on behalf of the InC3 Collaborative Group. Hepatitis C virus genotype and female sex are independently associated with spontaneous clearance during acute infection - findings from an international collaboration (InC3)

Grebely J, Dore GJ, Schim van der Loeff M, Cox AL, Bruneau J, Kim AY, Lloyd AR, **Maher L**, Hellard M, Page K, Prins M (on behalf of the InC3 Collaborative Group). Hepatitis C virus genotype and female sex are independently associated with spontaneous clearance during acute infection-findings from an international collaboration (INC3).

Grebely J, Petoumenos K, Hellard M, **Matthews GV**, Suppiah V, **Applegate T**, **Yeung B**, **Marks P**, Rawlinson W, Lloyd AR, Booth D, Kaldor JM, George J, and **Dore GJ** on behalf of the ATAHC Study Group. Potential role for IL28B genotype in treatment decision-making in recent hepatitis C virus infection

Jacka B, Mokany E, Pham ST, Carrera A, **Kelleher A**, **Matthews G**, **Dore GJ**, **Applegate T**. MNazyme qPCR used to quantify multiple genotypes in Hepatitis C infection.

Maher L. Hepatitis B and people who inject drugs: Challenges, innovations and opportunities.

Matthews GV, **Grebely J**, Hellard M, **Yeung B**, **Marks P**, Rawlinson W, Kaldor JM, **Dore GJ** on behalf of the ATAHC Study Group. Differences in early virological decline in individuals treated within the Australian Trial in Acute HCV suggest a potential benefit for the use of ribavirin

Wilson DP. Evaluating the cost-effectiveness of needle and syringe programs in Australia for preventing hepatitis C infection among people who inject drugs.

Making Sense of Health, Illness & Disease Oxford, September

Mooney-Somers J, **Olsen A**, Scott R, Akee A, **Maher L**. Learning from the past: Indigenous young people's accounts of sexually transmitted infections as resilience narratives.

AIDS Vaccine 2010 Atlanta, September

Wilson DP. The projected impact of implementation of the RV144 HIV vaccine in Thailand.

Australasian Viral Hepatitis Conference Melbourne, September

Gidding HF, **Amin J**, **Dore GJ**, Ward K, **Law MG**. Trends in all cause and liver-related hospital admissions in people notified with hepatitis B

and C in New South Wales, Australia.

Australasian Epidemiological Association Conference Sydney, September-October

Gidding HF, **Dore GJ**, **Amin J**, **Law MG**. Linked hospitalisations for people diagnosed with hepatitis C in NSW: methodological issues and the added burden of HIV and hepatitis B co-infection.

Gulich AE. Is the reported association between birth order and risk of non-Hodgkin lymphoma due to selection bias?

Cervical and other HPV Related Cancers – Not Yet Beaten: AOGIN Australia Meeting, Melbourne, October

Gulich AE, Stein AN, **Jin F**, Hocking JS, Brotherton J, **Regan DG**, Conway EL. The epidemiology of anal cancer in Australia: implications for the development of anal cancer prevention services.

Hocking JS, **Philp DJ**, **Law MG**, **Regan DG**. What is modelling telling us about vaccination of males?

Anex 2010 Australian Drugs Conference: Public Health and Harm Reduction Melbourne, October

Wilson DP. Evaluating the cost-effectiveness of needle and syringe programs in Australia.

Society for the Study of STDs in Ireland Annual Conference, Dublin, October

Donovan B. The Australian experience with HPV vaccination (invited plenary).

Joint Australasian Sexual Health Congress and ASHM Conference session, Sydney, October

Bradshaw C, Hart G (for), **Donovan B**, Pickett J (against) (invited debate). This house believes that STI control should be a priority in HIV control.

Australasian Sexual Health Conference Sydney, October

Achhra AC, **Zhou J**, Choi JY, Hoy J, Zhang F, **Templeton DJ**, Merati T, Woolley I, **Petoumenos K**, **Amin J**. The clinical significance of cd4+ t-cell counts in Asian and Caucasian HIV-infected populations: results from TAHOD and AHOD.

Botes LP, Ribbons E, McHugh L, **Pett S**, Marriott D, Carr A, Carbone S, **Cooper DA**, Hillman RJ. Anal cytology: a poor predictor of severe anal dysplasia in HIV positive men who have sex with men (MSM).

Bowring A, Goller JL, Berger I, **Guy RJ**, **Donovan B**, Harvey C, Wardle R, McNamee K, Stephens A, Bateson D, Read C, Wright D, Schmidt M,

Boyle D, Hellard MA. Chlamydia in family planning clinics: results from the Australian Collaboration for Chlamydia Enhanced Sentinel Surveillance.

Donovan B, **Franklin N**, **Guy R**, **Gulich AE**, **Regan DG**, **Wand H**, Fairley CK. A national program with a nations impact: quadrivalent HPV vaccination and genital warts in Australia.

Donovan B. Female sex workers in Asia and the Pacific Region (invited symposium presentation). **Drummond F**, Ryder N, Wand J, **Guy RJ**, Read P, McNulty AM, Wray L, **Donovan B**. Is azithromycin effective for asymptomatic rectal chlamydia in men? An audit.

Goller JL, **Ward J**, Saunders M Bergeri I, **Kaldor J**, Williams S, Waples-Crowe P, Moore E, Hunt J, Scrimgeour D, Boyle D, S Couzos, **Donovan B**, Hellard MA. A snapshot of Chlamydia testing and positivity in eight Aboriginal Community Controlled Health Services: useful information for local quality improvement.

Gulich AE, Stein AN, **Jin F**, Hocking JS, Brotherton J, **Regan DG**, Conway EL. Increasing burden and geographical clustering of HPV-associated anal cancer in Australia.

Gulich AG. Session Chair: sexual health closing plenary/debate.

Guy R, **Wand H**, Franklin N, Fairley CK, Chen MY, O'Connor CC, Marshall L, **Gulich AE**, **Kaldor JM**, Hellard M, **Donovan B** on behalf of the ACCESS Collaboration. Testing for chlamydia re-infection at sexual health services in Australia, 2004-2008.

Guy R. HIV/STI point-of-care plenary session. (session chair) Franklin N, **Guy R**, Fairley CK, **Wand H**, Chen MY, Dickson B, O'Connor CC, Marshall L, **Gulich AE**, Hellard M, **Donovan B**, on behalf of the ACCESS Collaboration. Chlamydia trends in young heterosexuals attending sexual health services in Australia, 2004-2008: the access system.

Guy R. SMS reminders increase HIV/STI re-testing rates among men who have sex with men at Sydney Sexual Health Centre.

Kong FYS, **Guy R** Boyle D, Merritt T, Spelman T, Bergeri I, Hocking JS, Britt H, Lau P, Pirota MV, Heal C, Brett T, **Kaldor JM**, **Donovan B**, Hellard M.. Testing for chlamydia at Australian general practices: the Australian collaboration for chlamydia enhanced sentinel surveillance (ACCESS).

Law MG, Woolley I, **Templeton DJ**, Roth N, Chuah J, Mulhall B, Canavan P, **McManus H**, **Cooper DA**, **Petoumenos K** on behalf of the Australian HIV Observational Database (AHOD). Trends in detectable viral load by calendar year

in the Australian HIV observational database.

McKechnie ML. The role of Multiplex PCR (mPCR) in the diagnosis of STIs.

Read P, McNulty AM, **Donovan B.** Unprotected fellatio between sex workers and clients: is it a problem?

Shields M, **Guy RJ**, Jeoffreys N, **Donovan B.** Evaluation of *Treponema* PCR in the diagnosis of early syphilis.

Stein AN, Conway EL, Brotherton J, **Regan DG**, **Gulich AE**, Hocking JS. The burden of potentially HPV-associated oral cavity and oropharyngeal cancer in Australia is increasing.

Templeton DJ, Manokaran N, O'Connor CC. Prevalence and predictors of chlamydia co-infection among gonorrhoea-infected patients attending a metropolitan sexual health clinic.

Templeton DJ, **Prestage GP**, **IM Poynten**, **Jin F**, **Zablotska I**, **Gulich AE.** Prevalence, incidence and predictors of sexual assault in the community-based him cohort of Sydney homosexual men.

Twin J, Moore EE, Garland SM, Stevens MP, Fairley CK, **Donovan B**, Rawlinson W, Tabrizi SN. *Chlamydia trachomatis* genotype based on clinical samples from men who have sex with men in Melbourne and Sydney.

Walker J, Fairley CK, Bradshaw CS, Tabrizi SN, Chen MY, Twin J, Taylor N, **Donovan B**, **Kaldor JM**, McNamee K, Urban E, Walker S, Currie M, Birden H, Bowden F, Gunn J, Pirota M, Gurrin L, Harindra V, Garland SM, Hocking JS. The incidence of genital *Chlamydia trachomatis* in a cohort of young Australian women.

Ward J, **Akre S**, **Guy R**, **Donovan B**, **Kaldor JM**, **Middleton M**, Su J-Y, Knox J, Russell D. A good news story in Aboriginal and Torres Strait Islander health: is it possible to eliminate syphilis? (invited symposium presentation).

Ward J, Goller J, Bergeri I, Kong F, Ali H, **Franklin N**, Sullivan L, Dimech W, **Kaldor JM**, **Donovan B**, Hellard M, **Guy R.** Understanding epidemiology of Chlamydia related to Aboriginal and Torres Strait Islander people: first results from the ACCESS network project.

Ward J. The use of health services for STIs and BBVs among NSW Aboriginal people aged 16-30.

Wilson DP. STI modelling and syphilis modelling.

Wilson DP. Using mathematical modelling to predict HIV incident cases among Aboriginal and Torres Strait Islander people who inject drugs.

22nd Annual Australasian Society for HIV Medicine Conference Sydney, October

Botes LP, Ribbons E, McHugh L, **Pett S**, Marriott D, Carr A, Carbone S, **Cooper DA**, Hillman RJ. Esoteric sex practices: correlation with anal cytological findings.

Boyd MA (Session chair). ASHM Conference Case Presentation Breakfast.

Bradley J, **Prestage G.** Rapid HIV testing: what we want, and when we want it.

Brown G, Ellard J, **Mooney-Somers J**, **Prestage G.** 'I was not some young tourist': Acquisition of HIV among Australian men while travelling and working overseas.

Byakwaga H. Antiretroviral therapy intensification with raltegravir or anti-lipopolysaccharide immunoglobulin from hyper-immune bovine colostrum in antiretroviral-treated patients exhibiting a suboptimal CD4+ T-cell response: the CORAL Study.

Carey C, Wright E, Hoy J, Roth N, Baker D, Vlahakis E, **Evans M**, **Jacoby S**, **Pett S**, **Emery S**, **Cooper DA** for the INSIGHT START Study Group. A tale of five substudies: in the Strategic Timing Of Antiretroviral Treatment (START) trial.

Carey D, **Amin J**, **Boyd M**, **Petoumenos K**, **Emery S.** Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir in randomised trials: systematic review and meta-analysis of randomised controlled data.

Donovan B, Franklin N, **Guy R**, **Gulich AE**, **Regan DG**, **Ward H**, Fairley CK. A national outcome for quadrivalent HPV vaccination: declining rates of genital warts in Australia.

Down I, **Bradley J**, **Gray R**, **Hoare A**, **Wilson D**, **Prestage G.** What would gay men be prepared to do to reduce rates of HIV?

Fitzgerald L, Wojciechowski L, Keeley S, Reynolds S, Howard C, O'Donnell V, Scherman J, Lambert S, **Vallely A.** Social isolation for People living with HIV/AIDS in South East Queensland: Determinants and Consequences.

Goller JL, **Ward J**, Saunders M Bergeri I, **Kaldor J**, Williams S, Waples-Crowe P, Moore E, Hunt J, Scrimgeour D, Boyle D, S Couzos, **Donovan B**, Hellard MA. A snapshot of Chlamydia testing and positivity in eight Aboriginal Community Controlled Health Services: useful information for local quality improvement.

Graham S, **Middleton M**, **Guy R**, **MacDonald A**, **Ward J.** Trends in chlamydia and gonorrhoea notifications in the Aboriginal and Torres Strait Islander population, 2005-2009.

Gray R, **Hoare A**, **Ghaus MH**, **Down I**, **Bradley**

J, **Prestage GP**, **Wilson DP.** Which public health strategies will likely have the greatest impact in reducing HIV incidence among gay men in NSW?

Gulich AE. Cancer prevention in people with HIV.

Gulich AG. Session Chair: Issues in HIV prevention in Gay Men 2.

Guy R. SMS reminders increase HIV/STI re-testing rates among men who have sex with men at Sydney Sexual Health Centre.

Haskelberg H, **Puls R**, **Petoumenos K**, Pussadee K, Delfino MA, **Emery S**, **Cooper DA** for the Altair Study Group HIV Drug Resistance among Treatment-naïve Patients Randomised to Three Different Combination Antiretroviral Regimens in the Altair Study

Hood CL, Lim HGW, **Suzuki K**, **Cooper DA**, **Kelleher AD.** Promoter-targeted siRNA colocalizes with Argonaute 1 and 2 during RNA-induced transcriptional gene silencing of retroviral infections.

Jansson, J. Evaluating and forecasting the medical outcomes and geographical distributions of people living with HIV in Australia.

Jin F, **Jansson J**, **Law M**, **Prestage GP**, **Zablotska I**, Imrie JCC, Kippax SC, **Kaldor JM**, **Gulich AE**, **Wilson DP.** Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART.

Kaldor JM. Interdisciplinary research on HIV prevention: A work in progress.

Kaldor JM. Recent microbicide clinical trials and trials expected to report in the near future.

Kaldor JM. Regional Issues in HIV Prevention: chair.

Kariminia A. Survival of HIV-infected children: a cohort study from the Asia-Pacific region.

Kelly M, French MA, Lewin SR, **Kelleher AD**, **Amin J**, Garsia R, **Haskelberg H**, **Byakwaga H**, **Boyd MA**, **Cooper DA**, Purcell D, **Emery S** on behalf of the CORAL Study Group Antiretroviral therapy intensification with raltegravir or hyper-immune bovine colostrum in Antiretroviral-treated Patients Exhibiting a Suboptimal CD4+ T Cell Response: THE coral STUDY.

Kupul M, Kelly A, Aeno H, Neo J, Naketrumb R, Fitzgerald L, **Kaldor J**, Siba P, **Vallely A.** More than a cut: acceptability of male circumcision for HIV prevention in Papua New Guinea.

Kwon A. The impact of needle syringe

programs on HIV risk behaviours among IDUs in Jakarta, Indonesia.

Law MG, Woolley J, Templeton DJ, Roth N, Chuah J, Mulhall B, Canavan P, McManus H, Cooper DA, Petoumenos K on behalf of the Australian HIV Observational Database. Trends in detectable viral load by calendar year in the Australian HIV Observational Database.

Law MG. When to start – Interpreting cohort studies – a guide for the non-expert; the Australian Antiretroviral Guidelines session.

Lumbiganon P, **Kariminia A**, Aupibul L, Hansudewechakul R, Puthanakit T, Kurniati N, Kumarasamy N, Chokeyhaibulkit K, Yusoff N, Vonthanak S, Siew Moy F, Razali K, Nallusamy R, Sohn AH for the TREAT Asia Pediatric HIV Observational Database (TAPHOD) (**Law M** a member of the TAPHOD steering committee). Survival of HIV-infected children: a cohort study from the Asia-Pacific region.

Maher L, Hudson S. Sex/drug synergies and the street sex work environment.

McBride K, Xu Y, Bailey M, Seddiki N, Suzuki K, Murray J, Cooper DA, Kelleher AD, Koelsch KK, Zaunders J. Majority of HIV DNA in the HIV Reservoir located in the non-gut homing resting memory CD4+ T Cell subset.

McGrath P. Self-based rationales are important primary motivators for volunteers in HIV research.

Petoumenos K, Worm S, Reiss P, De Wit S, D'Arminio Monforte A, Sabin C, Friis-Moller N, Weber R, Mercie P, Pradier C, El-Sadr W, Kirk O, Lundgren J, Law M on behalf of the D:A:D Study Group. Rates of Cardiovascular Disease Following Smoking Cessation in Patients with HIV Infection: Results from the D:A:D Study.

Pett S, Carey C, Hoy J, Roth N, Baker D, Vlahakis E, Evans M, Jacoby S, Cooper DA, Emery S on behalf of the INSIGHT START Study Group. Considerations in the rationale, design and methods of the Strategic Timing of Antiretroviral Treatment (START) trial.

Pett S, Wand H, Kedem E, Markowitz N, Goetz M, Mathiesen L, Cooper DA, Law M, Emery S on behalf of the INSIGHT/ESPRIT Study Group. Impact of Antiretroviral class on CD4+ T-cell changes and clinical outcomes in ESPRIT (Evaluation of Proleukin® in an International Trial).

Prestage G. Disclosing HIV status to casual partners.

Puls R, Sraseubkul P, Petoumenos K, Emery S, Cooper D on behalf of the Altair study group. Anthropometric and metabolic outcomes in a 48 week randomized, open-label study

of three different combination antiretroviral regimens as initial therapy for HIV infection.

Sasson SC, Zaunders JJ, Seddiki N, Bailey M, McBride K, Koelsch KK, Smith D, Cooper DA and Kelleher AD. Progressive activation of CD127+I32- Recent thymic emigrants into terminally differentiated CD127-I32+ T-cells in HIV-1 infection.

Sauk J, Fiya V, Aeno H, Kupul M, Kelly A, Neo J, Millan J, Fitzgerald L, **Kaldor J, Siba P, Vallely A.** Intravaginal hygiene and menstrual practices: implications for HIV/STI prevention and future microbicide acceptability in Papua New Guinea.

Schneider, K. Economic evaluation of monitoring virologic responses to antiretroviral therapy in HIV-infected children in a resource-limited setting: Thailand.

Suzuki K, Yamagishi M, Ishida T, Swaminathan S, Hood C, Cooper DA, Watanebe T, Kelleher AD. Sequence specific induction of HIV-1 transcriptional gene silencing targeting NF- κ B sequences by siRNA without any off-target effects of other NF- κ B driven genes.

Ward J, Bryant J, Worth H, Hull P, Solar S, Bailey S. Use of health services for STIs and BBV infections by young Aboriginal People in NSW.

Ward J, Goller J, Bergeri, I, Kong F, Ali H, Franklin N, Sullivan L, Dimech W, Kaldor JM, Donovan B, Hellard M, Guy R. Understanding epidemiology of Chlamydia related to Aboriginal and Torres Strait Islander people: first results from the ACCESS network project.

Ward J, Guy R, Akre S, Middleton M, Giele C, Su JY, Davis C, Knox J, Fagan P, Donovan B, Kaldor JM, Russell D. Potential elimination of infectious syphilis from Aboriginal and Torres Strait Islander Communities.

Ward J, McDonald A, Kaldor JM for the National Bloodborne Viruses and Sexually Transmissible Infections Surveillance Committee. Trends in newly diagnosed HIV infection in the Aboriginal and Torres Strait Islander and non-Indigenous populations, 1992-2009.

Ward J, Rumbold A, Guy R, Silver B, Taylor Thompson D, McDermott R, Maher L, Donovan B, Law M, Fairley C, Scov S, Boffa J, Ah Chee D, Hengel B, Knox J, Kaldor J. Strive: STI in remote communities improving and enhancing primary health care.

Wilson DP. HIV prevention issues in the region.

Winston A, **Duncombe C, Li PCK, Gill JM, Kerr SJ, Puls R, Petoumenos K, Taylor-Robinson SD, Emery S, Cooper DA** for the Altair Study Group. Two patterns of cerebral metabolite abnormalities are detected on proton magnetic

resonance spectroscopy in HIV+ subjects electively commencing ART.

Winston A, **Duncombe C, Li PCK, Gill MJ, Kerr SJ, Puls R, Petoumenos K, Taylor-Robinson SD, Emery S, Cooper DA** for the Altair Study Group. Choice of combination antiretroviral therapy (CART) alters changes in cerebra function testing after 48 weeks in treatment-naïve HIV-1 infected subjects commencing CART: A randomised controlled study.

Yan C, Carrera A, Kelleher AD, McNally LP, Cunningham PH. Dried Blood Spots Represents A Convenient Alternative Specimen to Plasma For HIV Drug Resistance Genotyping and Subtyping in Resource-limited Settings.

Zablotska I, Holt M, Mao L, Prestage G. Australian gay men never tested for HIV.

Zablotska I, Holt M, Mao L, Prestage G. Contemporary trends in HIV related behaviours among gay men in three Australian states; NSW, Victoria and Queensland.

Zablotska I, Prestage G, Jin F, Fairley C, Triffitt K, Slavin S, Grulich AE. Antiretroviral therapy (ART) as HIV prevention among gay men: building the evidence base.

Zaunders JJ, Seddiki N, Brown K, Cook L, Phetsouphanh C, Pett S, Cooper DA, Kelleher AD. Identification isolation and expansion of antigen specific CD4 T lymphocytes.

Zhou J, Sirisanthana T, Kiertiburanakul S, Chen YMA, Han N, Lim PL, Kumarasamy N, Choi JY, Merati TP, Yunihastuti E, Law MG on behalf of The TREAT Asia HIV Observational Database. Trend of CD4 cell count in HIV-infected patients with HIV viral load monitoring while on combination antiretroviral treatment: results from the Treat Asia HIV Observational Database (TAHOD).

The Society for Medical Decision Making Conference Toronto, October

Schneider, K. Economic evaluation of monitoring virologic responses to antiretroviral therapy in HIV-infected children in a resource-limited setting: Thailand.

2010 National Drug Trends Conference, Sydney, October

Topp L, Iversen J, Nathani J, Poeder F, Maher L (on behalf of the Collaboration of Australian Needle and Syringe Programs). Prevalence and methods of reuse and cleaning of needles and syringes: Results from the 2008 ANSPS.

10th International Congress on Drug Therapy in HIV Infection Glasgow, November

Jackson AGA, Hill A, Else LJ, Back DJ, Morley R, **Puls R**, **Amin J**, **Lin E**, Boffito M. Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100, 200/150, and 200/50 mg twice daily in HIV negative volunteers.

12th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV London, November

Puls R, Brown D, **Fahey P**, **Amin J**, Breit S, Carr A for the HIV Lipodystrophy Case Definition Study Group. Macrophage inhibitory cytokine 1 (MIC-1) serum levels in the Lipodystrophy Case Definition Study

Treat ASIA symposium on Cancer and HIV in the Asia-Pacific Bangkok, November

Grulich AG. The evolving global epidemiology of cancer and HIV.

Grulich AG. Anal cancer epidemiology in immune deficient populations.

Annual Meeting of the Australasian Flow Cytometry Group Sydney, November

Zaunders J, **Seddiki N**, Brown K, **Cook L**, **Phetsouphanh C**, **Pett S**, **Cooper DA**, **Kelleher AD**. Identifying, Isolating And Expanding Antigen-Specific Effector And T Regulatory CD4 Cells.

5th Australian Health and Medical Research Congress Melbourne, November

Kelleher AD. New insights into antiviral CD4+ T cell responses: Identifying, isolating and expanding human antigen-specific effector and regulatory CD4 T cells.

30th Australasian Professional Society on Alcohol and other Drugs (APSAD) Conference Canberra, November

Applegate T, Birkett DJ, Mcintyre GJ, Jaramillo AB, Symonds G, **Murray JM**. In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy.

Dore GJ, **Grebely J**, **Gillman A**, **Thein R**, Day, Ryan L, Treloar, Haber P. Overview of treatment of hepatitis C (HCV) in the opiate pharmacotherapy setting and the Enhancing Treatment of Hepatitis C in the Opiate Substitution Setting (ETHOS) Partnership Initiative.

Everingham H, Hazelwood S, Tierney R, **Grebely J**, **Gillman A**, Crawford, Bath N, Dunlop A. Peer-based support for HCV assessment at Hunter Pharmacotherapy.

Higgs P, Winter R. Film as a tool of reducing

drug related harm.

Papanastasiou C, Dietze P, Jenkinson R, **Higgs P**. IDU experience of assault: results from the Melbourne Injecting Drug User Cohort Study (MIX).

Australian Chlamydia Conference Brisbane, November

Donovan B. The Australian Collaboration for Chlamydia Enhanced Sentinel Surveillance Project (opening plenary).

Wilson DP. Describing and interpreting the epidemiology of Chlamydia nationally and in the Queensland and international context.

European Scientific Conference on Applied Infectious Disease Epidemiology Lisbon, November

Bergeri I, **Guy R**, Boyle D, Kong F, Goller J, Bowring, Franklin N, Sullivan E, **Ward J**, **Kaldor JM**, Dimech W, **Donovan B**, Hellard M. A multi-network automated surveillance system to tackle STIs? Lesson learned after 3 years from ACCESS (the Australian Collaboration for Chlamydia/STIs Enhanced Sentinel Surveillance).

8th Dangerous Consumptions Conference, ANU, Canberra, December

Higgs P. Film and photos: Tools for reducing drug related harm.

Australian Consortium for Social and Political Research (ACSPRI) Social Science Methodology Conference Sydney, December

Mooney-Somers J, **Olsen A**, Scott R, Akee A, **Mahe L**. Questions of pragmatism in Community-based Participatory Research with an Indigenous community.

4th National Scientific Conference on HIV/AIDS Hanoi, December

Kaldor JM. Biomedical strategies for preventing HIV infection: recent developments and future challenges.

Conference posters

17th Conference on Retroviruses and Opportunistic Infections (CROI 2010) San Francisco, February

Botes L, **Cooper D**, **Marriott D**, **Pett S**, Carr A, Carbone S, Kumaradeva N, Hillman R. High Levels of Severe Dysplasia Detected in Anal Biopsies from HIV-Infected Men Who Have Sex

With Men in Sydney, Australia.

Reddy S, Center R, Tan J, Suzuki K, Gorry P, Sterjovski J, Ramsland P, **Cooper DA**, **Kelleher AD**, **Kramski M**, Purcell D. Oligomeric Env gp140 from HIV-1 Pre-seroconversion Strains and Brain as a Vaccine Immunogens For Broad Neutralising Antibody

Seddiki N, **Phetsouphanh C**, **Xu Y**, Lloyd A, Cameron B, **Cooper DA**, **Zaunders J** and **Kelleher AD**. Preferential depletion of Peripheral Memory CD4+CD73+ T Cells by Human Immunodeficiency Virus Type 1 Infection

Seddiki N, **Phetsouphanh C**, **Munier ML**, **Xu Y**, Brown K, **Cook L**, **Cooper DA**, **Zaunders J** and **Kelleher AD**. Gag-specific CD39+OX40+CD25+ Regulatory and CD39-OX40+CD25+ Effector T Cell Frequencies Are Inversely Correlated in HIV Infected Patients.

14th International Workshop on HIV observational databases Barcelona, March

Achhra AC, **Zhou J**, Choi JY, Hoy J, Zhang F, **Templeton DJ**, Merati T, Woolley I, **Petoumenos K**, and **Amin J** for TAHOD and AHOD (**Law M** PI for AHOD and member of steering committee for AHOD and TAHOD). Clinical significance of CD4+ counts in Asian and Caucasian HIV-infected population: results from TAHOD and AHOD.

Zhou J, Sirisanthana T, Kiertiburanakul S, Chen YMA, Han N, Lim PL, Kumarasamy N, Choi JY, Merati TP, Yuniastuti E, **Law M** on behalf of The TREAT Asia HIV Observational Database. CD4 Cell Count Slope in Asian HIV-Infected Patients with HIV Viral Load Monitoring While on First Combination Antiretroviral Treatment.

The International Liver Congress, 45th Annual Meeting of the European Association for the Study of the Liver, Vienna, April

Grebely J, Dore GJ, Schim van der Loeff M, Cox AL, Bruneau J, Kim AY, Lloyd AR, Hellard M, Page K, Prins M. (on behalf of the InC3 Collaborative Group). Factors associated with spontaneous clearance during acute hepatitis C virus infection.

Hellard M, Sacks-Davis R, **Higgs P**, Bharadwaj M, Bowden DS, Drummer H, Aitken C. Elispot testing shows very few injecting drug users avoid hepatitis C virus exposure.

21st International Harm Reduction Association Conference, Liverpool UK, April

White B, Dore G, **Mahe L**. (on behalf of the UNSW HCV Vaccine Initiative). Low hepatitis B virus vaccine coverage in young people who inject drugs in Sydney.

Advances in Public Health and Health Services Research: 2nd Annual Symposium UNSW, May

Poynten IM, Jin FY, Prestage G, Mao L, Kippax S, Kaldor J, Grulich AE. Non-Occupational Post Exposure Prophylaxis Against HIV (NPEP) and Subsequent HIV Infection in Homosexual Men: Final Data from the HIM Cohort.

AIDS 2010 Pre-conference workshop Vienna, July

Hood CL, Lim HGW, Suzuki K, **Cooper DA** and **Kelleher AD**. Promoter-targeted siRNA colocalizes with Argonaute 1 and 2 during RNA-induced transcriptional gene silencing of simian immunodeficiency virus infection

XVIII International AIDS Conference Vienna, July

Brockman MA, Miura T, Sela J, Brumme CJ, Markle T, Rosato P, Streeck H, Block BL, Kadie CM, Jessen H, Rychert J, Rosenberg E, Heckerman D, Markowitz M, **Kelleher AD**, Altfeld M, Harrigan PR, Walker BD, Allen TM, Brumme ZL. Recombinant HIV viruses encoding gag/protease from individuals expressing protective HLA class I alleles exhibit reduced replication capacity in acute/early but not chronic infection.

Keo S, Tony M, Kien SP, Cockroft M, Page K, Stein E, **Mahe L**, Couture MC. The Cambodian Anti-Trafficking Law: Implications for Community-Based Sex Worker HIV Prevention, Care and Research.

Lee MP, **Zhou J**, Messerschmidt L, Honda M, Ditango R, Li PCK on behalf of the TREAT Asia HIV Observational Database. Impact of sex on long-term treatment outcomes of highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database.

Oyomopito R, Phanuphak P, Sungkanuparph S, Kumarasamy N, Sirisanthana T, Li PCK, Kantipong P, Lee CKC, Kamarulzaman A, Singtoroj T, Chen YMA on behalf of the TREAT Asia Studies to Evaluate Resistance (TASER). The TREAT Asia Studies to Evaluate Resistance Monitoring Study (TASER-M) - HIV Drug Resistance in the Asia-Pacific.

Prestage G, Down I. Reasoning risk-reduction.

Sutherland R, Lake R, **Prestage G**. The development of an HIV risk reduction framework for gay and other men who have sex with men (MSM) in New South Wales, Australia.

Thein R. Current and projected cases of hepatitis C co-infected with HIV among Australian injecting drug users: The impact of needle and syringe programs.

White B, Bates A, Donald A, Enriquez J, Liao L, Pham S, Maher L. (on behalf of the UNSW HCV vaccine Initiative). Acceptability and willingness to participate in vaccine trials among young people who inject drugs in Sydney, Australia.

Zablotska I. Sexual practices of gay men in their home communities and while travelling: Gay Community Periodic Surveys in NSW, Australia, 2009.

Zablotska IB, Prestage G, Middleton M, Wilson D, Grulich AE. HIV notification trends in Australia mirror trends in unprotected anal intercourse among gay men.

26th International Papillomavirus Conference Montreal, July

Couture MC, Sansothy N, Stein ES, Sichan K, Palefsky J, Page K. on behalf of the Young Women's Health Study Collaborative (Kaldor J, Phal Kien S, **Mahe L**, Nemoto T, Page K, Palefsky J, Sapphon V, Chhi Yun M). Human papillomavirus infection among young women engaged in sex work in Phnom Penh, Cambodia.

2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Boston, September

Lim PL, **Zhou J**, Ditango R, Sungkanuparph S, **Law M** on behalf of the TREAT Asia HIV Observational Database. Lack of Prophylaxis against Pneumocystis Pneumonia and Mortality: Results from the TREAT Asia HIV Observational Database (TAHOD).

7th Australasian Viral Hepatitis Conference Melbourne, September

Higgs P, Aitken C, Hellard M, **Mahe L**. More than a little luck: Long term injectors who avoid HCV in Melbourne.

Newland J, Harris M, **Deacon R**, Treloar C, **Mahe L**. Social network influences on hepatitis C risk.

Olsen A, Mahe L. Liver Spots: A study of hepatitis C knowledge, treatment and health care among Aboriginal and Torres Strait Islanders.

Polis S, Zekry A, **Mahe L**. Factors associated with non adherence to hepatitis B viral medications.

White B, Enriquez J, Mahe L. [on behalf of the UNSW HCV vaccine Initiative]. Acceptability and Willingness to Participate in Future Hepatitis C Vaccine Trials among Young People who Inject Drugs in Sydney.

St Vincent's Hospital, Sydney symposium Sydney, September

McBride K, Xu Y, Bailey M, Seddiki N, Suzuki K, Murray J, Cooper DA, Kelleher AD, Koelsch KK, Zaunders J. Majority of HIV DNA in the HIV reservoir located in the non-gut homing resting memory CD4+ T Cell subset.

Yan C, Carrera A, Kelleher AD, McNally LP, Cunningham PH. Dried Blood Spots Represents A Convenient Alternative Specimen to Plasma For HIV Drug Resistance Genotyping and Subtyping in Resource-limited Settings.

Ip S, Leeman C, Huynh I, Hickey R, Xu Y, Bailey M, Hsu D, Zaunders J, Kelleher AD. Assessing the performance of a possible new diagnostic test for latent tuberculosis.

Bailey M, Marks K, Xu Y, Zaunders J, Seddiki N, Danta M, Boesecke C, Gelgor L, Cooper DA, Emmerly S, Kelleher AD and PINT Study Group. Isolation of CD4+T cells from the Gut Associated Lymphoid Tissue (GALT) of patients with Primary HIV Infection (PHI) and Chronic HIV infection (CHI) using a high speed cell sorter.

Hood C, Lim HGW, Suzuki K, **Cooper DA** and **Kelleher AD**. Promoter-targeted siRNA colocalizes with Argonaute 1 and 2 during RNA-induced transcriptional gene silencing of simian immunodeficiency virus infection.

Phetsouphanh C, Seddiki N, Xu Y, Zaunders JJ, Procopio F, Sekaly R, Kelleher AD. Re-characterizing Antigen Specific CD4+ T cells using the Ox40/CD25 assay and Single-cell RT-PCR.

Murray D, Swaminathan S, Kelleher AD. A systems biology approach to mapping microRNA changes in monocytes during HIV-1 infection.

19th Australasian Epidemiological Association Annual Scientific Meeting Sydney, September

Poynten IM, Jin F, Prestage GP, Kaldor JM, Kippax S, Grulich AE. Defining high HIV incidence subgroups of Australian homosexual men: implications for conducting HIV prevention trials in low HIV prevalence settings.

Australasian Sexual Health Conference Sydney, October

Bergeri I, **Guy RJ**, Goller J, Kong F, Franklin N, Sullivan L, **Ward J**, Dimech W, **Kaldor JM, Donovan B**, Hellard M. A multi-networks sentinel surveillance system to tackle STIs: the Australian Collaboration for Chlamydia Enhanced Sentinel Surveillance.

Drummond F. Is azithromycin effective for asymptomatic rectal chlamydia in men? An audit.

Fairley CK, Hocking J, Gurrin L, Chen MY,

Donovan B, Bradshaw CS. Continued rapid decline in warts after national quadrivalent HPV vaccine program.

Healey LM, **Templeton DJ**. HIV results: practice at public sexual health clinics.

Jin F, **Templeton DJ**, **Prestage G**, **Zablotska I**, Kippax S, **Donovan B**, Taylor J, Cunningham A, Mindel A, **Kaldor J**, **Gulich AE**. Prevalent and incident herpes simplex virus infections in homosexual men: data from two community-based cohort studies.

McKechnie ML, **Down I**, **Zablotska I**. The use of respondent-driven sampling (RDS) among gay men in Sydney: Lessons from pilot study.

Templeton DJ, **Jin F**, **Poynten IM**, **Prestage GP**, **Zablotska I**, **Gulich AE**. Prevalence, incidence and predictors of sexual assault in the community-based HIM cohort of Sydney homosexual men.

Templeton DJ, **Twin J**, **Jin F**, **Gulich AE**, **Garland SM**, **Tabrizi SN**. Chlamydia trachomatis serovars in community-based HIV-positive and HIV-negative men who have sex with men in Sydney.

Walker S, Walker J, Fairley CK, Chen MY, Bradshaw CS, Urban E, Pirota M, Gurrin L, Harindra V, Tabrizi SN, **Donovan B**, **Kaldor JM**, McNamee K, Currie M, Birken H, Bowden F, Garland S, Gunn J, Hocking J. Young Australian women's experiences of chlamydia screening: a comparison between women who test negative and women who test positive.

Wang Y, Manokaran N, Higgins AN, **Templeton DJ**. Self-collected anal swabs in men who have sex with men: what would be missed?

Ward J, **Rumbold A**, **Guy RJ**, Silver B, Taylor Thompson D, **Donovan B**, **Law M**, **McDermott R**, **Maher L**, Fairley CK, Skov S, Boffa J, Ah Chee D, Hengel B, Knox J, **Kaldor JM**. STRIVE: STI in remote communities improving and enhancing primary health care.

Ward J. The first ever national survey of young Aboriginal and Torres Strait Islander sexual health: knowledge, risk practice and health service access.

Waters EK, Smith AMA, Philp DJ, **Regan DG**. Proposed surveillance of genital warts among men who have sex with men.

Zablotska I. Pleasure and sexual health: familiarity with casual partners, knowledge of HIV status and condom use.

Australasian HIV/AIDS Conference 2010 (22nd Annual Conference of the Australasian Society for HIV Medicine)

Sydney, October

Achhra AC, **Zhou J**, Choi JY, Hoy J, Zhang F, **Templeton DJ**, Merati T, Woolley I, **Petoumenos K**, **Amin J** for TAHOD and AHOD. The clinical significance of CD4+ t-cell counts in Asian and Caucasian HIV-infected populations: results from TAHOD and AHOD (oral)

Aeno H, Fitzgerald L, Fiya V, Kelly A, Sauk J, Kupul M, Neo J, Millan J, Nair S, **Kaldor J**, Siba P, **Vallely A**. Vaginal microbicide acceptability in Papua New Guinea: results of a qualitative study among women and men attending a sexual health clinic in Port Moresby.

Aeno H, Kelly A, Kupul M, Naketrumb R, Neo J, Fitzgerald L, Hill P, **Kaldor J**, Siba P, **Vallely A**. Mapping penile cutting and insert practices in Papua New Guinea.

Chow E. The coming era of HIV/AIDS in China: rapid transmission of HIV among men who have sex with men.

Down I, **Bradley J**, **Prestage G**. Current risk factors for HIV seroconversion among gay men.

Gray R. Forecasting the Population-level Impact of Reductions in HIV Antiretroviral Therapy in Papua New Guinea.

Gray R. What interventions are likely to reduce rates of HIV in gay men?

Hill P, Tynan A, Law G, Milan J, Browne K, Sauk J, Kelly A, Kupul M, Aeno H, Siba P, **Kaldor J**, **Vallely A**. A typology of penile cutting in Papua New Guinea: results of a Modified Delphi study among sexual health clinicians.

Jiamsakul A, Sungkanuparph S, Phanuphak P, Sirisanthana T, Li PCK, Lee CKC, Kantipong P, Ditangco R, Kamarulzaman A, Mustafa M, Merati T, Singtoroj T, Messerschmidt L, **Zhou J**, **Law M**. TAsER-M: a review of the cohort and genotype sequence file transfers – a data management perspective.

McKechnie M, **Down I**, **Zablotska I**. CONNECT: The study of contemporary norms in networks and communities.

McManus H, Li PCK, Nolan D, Bloch M, Kiertiburanakul S, Choi JY, Mulhall B, **Petoumenos K**, **Zhou J**, **Law M**, Brew B, Wright E. Does use of antiretroviral therapy regimens with high central nervous system penetration improve survival in HIV-infected adults?

Murray J. Ageing and current antiretroviral levels are insufficient to reduce the number of people living with HIV in Australia for the foreseeable future (oral)

Oyomopito R, Lee M, Phanuphak P, Lim P, Ditangco R, **Zhou J** and Li PCK on behalf of The TREAT Asia HIV Observational Database.

Frequency of site-reported viral load monitoring predicts HIV disease progression following highly active antiretroviral therapy (HAART).

Oyomopito R, Phanuphak P, Sungkanuparph S, Kumarasamy N, Chen YMA on behalf of the TREAT Asia Studies to Evaluate Resistance (TAsER) (**Law M** a member of TAsER steering committee). The TREAT Asia Studies to Evaluate Resistance Monitoring Study (TAsER-M) – Cohort Profile.

Prestage G, **Down I**, **Bradley J**, **Hurley M**, **Brown G**. Reasoning risk-reduction.

Vallely A, Kaima P, Neo J, Kombati Z, Toliman P, Ryan C, Law G, Kelly A, Millan J, Mek T, Lawi R, Kipani B, Tingetaut T, Aeno H, Fiya V, Kupul M, Forsyth S, Page A, **Kaldor J**, Siba P. A longitudinal clinical pilot study among men and women attending a sexual health clinic in Mt Hagen, Papua New Guinea (oral).

Wu JF. Seasonal differences in vitamin D levels in an HIV positive cohort.

12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV London, November

Puls R, **Brown D**, **Fahey P**, **Amin J**, **Breit S**, **Carr A** for the HIV Lipodystrophy Case Definition Study Group. Macrophage inhibitory cytokine 1 (MIC-1) serum levels in the Lipodystrophy Case Definition Study.

Annual Meeting of the Australasian Flow Cytometry Group Sydney, November

Bailey M, **Zaunders J**, **Xu Y**, **Seddiki N**, **Geigor L**, **Cooper DA**, **Kelleher AD** and PINT Study Group. Characterization of activated CD38+ CD45+ Memory CD4 and CD8 T-Cells during HIV infection using multiparameter flow cytometry.

McBride K, **Xu Y**, **Bailey M**, **Seddiki N**, **Suzuki K**, **Murray J**, **Cooper DA**, **Kelleher AD**, **Koelsch KK**, **Zaunders J**. Majority Of HIV DNA In The HIV Reservoir Is Located In The Non-Gut Homing Resting Memory CD4+ T Cell Subset.

Australasian Professional Society on Alcohol and Drugs Conference Canberra, November

Kimber J, Copeland L, Hickman M, Macleod J, McKenzie J, De Angelis D, Robertson JR. Health related quality of life in a primary care based sample of injection drug users and non drug-injecting controls.

Publications

A

Achhra AC, Amin J, Law MG, Emery S, Gerstoft J, Gordin FM, Vjecha MJ, Neaton JD, **Cooper DA** for INSIGHT ESPRIT & SILCAAT study groups. Immunodeficiency and the risk of serious clinical endpoints in a well-studied cohort of treated HIV-infected patients. *AIDS* 2010;24:1877-1886.

Achhra AC, Zhou J, Dabis F, Pujari S, Thiebaut R, **Law MG**, Bonnet F. Difference in absolute CD4+ count according to CD4 percentage between Asian and Caucasian HIV-infected patients. *J AIDS Clinic Res* 2010;1(1):1000101. doi:10.4172/2155-6113.1000101.

Amin J, De Lazzari E, **Emery S**, Martin A, Martinez E, Carr A, Gatell J, **Cooper DA**. Simplification with fixed-dose tenofovir-emtricitabine or abacavir-lamivudine in treatment experienced, virologically suppressed adults with HIV infection: combined analysis of two randomised, non-inferiority trials Bicombo and Steal. *J AIDS Clinic Res* 2010; 1(1):1000103. doi:10.4172/2155-6113.1000103.

Amin J, Martin A, Bloch M, Carr A. Efficacy of tenofovir-emtricitabine versus abacavir-lamivudine; Reply to Landman and Soonawala. *Clin Infect Dis* 2010;50:1200-1201 (letter).

Ananworanich J, Apornpong T, Kosalaraksa P, Jaimulwong T, Hansudewechakul R, Pancharoen C, Bunupuradah T, Chandara M, Puthanakit T, Ngampiyasakul C, Wongsawat J, Kanjanavanit S, Luesomboon W, Klangsinirikul P, Ngo-Giang-Huong N, **Kerr SJ**, Ubolyam S, Mengthaisong T, Gelman RS, Pattanapanyasat K, Saphonn V, Ruxrungtham K, Shearer WT, on behalf of the PREDICT Study Group. Characteristics of lymphocyte subsets in HIV-infected, long-term nonprogressor, and healthy Asian children through 12 years of age. *J Allergy Clin Immunol* 2010;126:1294-1301.

Applegate TL, Birkett DJ, McIntyre CJ, Jaramillo AB, Symonds G, **Murray JM**. In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to antiretroviral therapy. *Retrovirology* 2010;7:83.

Arnott A, Jardine D, Wilson K, Corry PR, **Merlin K, Grey P, Law MG**, Dax EM, **Kelleher AD, Smith DE**, McPhee DA and the Pulse Study Team (**Smith D, Petoumenos K, Grey P, Munro R, Law M, Kaldor J, Cooper D, Pett S** members). High viral fitness during acute HIV-1 infection. *PLoS ONE* 2010;5(9): e12631.

Asmuth DM, Goodrich J, **Cooper DA**, Haubrich R, Rajcic N, Hirschel B, Mayer H, Valdez H. CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2. *J Acquir Immune Defic Syndr* 2010;54:394-397.

Audsley J, Littlejohn M, Yuen L, Sasadeusz J, Ayres A, Desmond C, Spelman T, Lau G, **Matthews GV**, Avihingsanon A, Seaberg E, Philp F, Saulynas M, Ruxrungtham K, **Dore GJ**, Locarnini SA, Thio CL, Lewin SR, Revill PA. HBV mutations in untreated HIV-HBV co-infection using genomic length sequencing. *Virology* 2010; 405:539-547.

Avihingsanon A, Lewin SR, Kerr S, Chang JJ, Piyawat K, Napissanant N, **Matthews GV, Dore GJ**, Bowden S, Lange J, Ruxrungtham K. Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naïve HIV-HBV coinfection in Thailand. *Antivir Ther* 2010;15:917-922.

B

Baker JV, Neuhaus J, Duprez D, Kuller LH, Tracy R, Bellosso WH, De Wit S, **Drummond F**, Lane HC, Ledergerber B, Lundgren J, Nixon DE, Paton NI, Neaton JD for the INSIGHT SMART study group. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. *J Acquir Immune Defic Syndr* 2010; Epub ahead of print.

Boyd MA. Current and future management of treatment failure in low- and middle-income countries. *Curr Opin HIV AIDS* 2010;5:83-89.

Boyd MA, Hill AM. Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era. *Pharmacoeconomics* 2010;28 Suppl 1:17-34.

Boyd MA, Nwizu CA. Operational research in HIV priority areas: the African way. *Lancet* 2010;376:4-5 (comment).

Brockman MA, Brumme ZL, Brumme CJ, Miura T, Sela J, Rosato PC, Kadie CM, Carlson JM, Markle TJ, Streeck H, **Kelleher AD**, Markowitz M, Jessen H, Rosenberg E, Altfeld M, Harrigan PR, Heckerman D, Walker BD, Allen TM. Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection. *J Virol* 2010;84:11937-11949.

Bryant J, Topp L, Hopwood M, **Iversen J**, Treloar C, **Maher L**. Is point of access to needles and syringes related to needle sharing? Comparing data collected from pharmacies and needle and syringe programs in south east Sydney. *Drug Alcohol Rev* 2010;29:364-370.

Bunupuradah T, Suntarattiwong P, Li A, Sirivichayakul S, Pancharoen C, Boonrak P, Puthanakit T, **Kerr SJ**, Ruxrungtham K, Chotpitayasunondh T, Hirschel B, Ananworanich J on behalf of the HIV-NAT O13 study team. Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors. *Int J Infect Dis* 2010;e311-e316.

C

Calmy A, Bloch M, **Wand H**, Delhumeau C, Finlayson R, Rafferty M, Norris R, Hirschel B, **Cooper DA**, Carr A for the URISTAT study group. No significant effect of uridine or pravastatin treatment for HIV lipodystrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial. *HIV Med* 2010;11:493-501.

Campillo-Gimenez L, Cumont MC, Fay M, Kared H, Monceaux V, Diop O, Müller-Trutwin M, Hurtrel B, Lévy Y, Zaunders J, Dy M, Leite-de-Moraes MC, Elbim C, Estaquier J. AIDS progression is associated with the emergence of IL-17 producing NKT cells early after SIV infection. *J Immunol* 2010;184:984-92.

Campillo-Gimenez L, Laforge M, Fay M, Brussel A, Cumont MC, Monceaux V, Diop O, Lévy Y, Hurtrel B, Zaunders J, Corbeil J, Elbim C, Estaquier J. Nonpathogenesis of simian immunodeficiency virus infection is associated with reduced inflammation and recruitment of plasmacytoid dendritic cells to lymph nodes, not to lack of an interferon type I response, during the acute phase. *J Virol* 2010;84:1838-1846.

Carey D, **Amin J**, Boyd M, **Petoumenos K**, **Emery S**. Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomised controlled trials. *J Antimicrob Chemother* 2010;65:1878-88.

Chen MY, **Donovan B**, Harcourt C, Morton A, Moss L, Wallis S, Cook K, Batras D, Groves J, Tabrizi SN, Garland S, Fairley CK. Estimating the number of unlicensed brothels operating in Melbourne. *Aust NZ J Public Health* 2010;34:67-71.

Cheng WSC, Roberts SK, McCaughan G, Sievert W, Weltman M, Crawford D, Rawlinson W, Marks PS, Thommes J, Rizkalla B, Yoshihara M, **Dore GJ**, on behalf of the CHARIOT Study Group. Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. *J Hepatol* 2010;53:616-623.

Chow EPF, **Wilson DP**, **Zhang L**. The next era of HIV in China: rapidly spreading epidemics among men who have sex with men. *J Acquir Immune Defic Syndr* 2010;55:e32-e33.

Cooper DA, Heera J, Goodrich J, Tawadrous M, Saag M, DeJesus E, Clumeck N, Walmsley S, Ting N, Coakley E, Reeves JD, Reyes-Teran G, Westby M, Van Der Ryst E, Ive P, Mohapi L, Mingrone H, Horbar A, Hackman F, Sullivan J, Mayer H. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naïve subjects with CCR5-tropic HIV-1 infection. *J Infect Dis* 2010;15:201:803-813.

Cooper DA, Wodak AD, Morris BJ. The case for boosting infant male circumcision in the face of rising heterosexual transmission of HIV. *Med J Aust* 2010;193:318-319 (editorial).

Cordery D, **Cooper DA**. Clinical research in NSW: its role in HIV care and prevention. *N S W Public Health Bull* 2010;21:93-95.

Corderoy DV, Hesse K, **Amin J**, **Cooper DA**. Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients. *Antivir Ther* 2010;15:1035-1038.

Couldwell DL, Gidding HF, Freedman EV, McKechnie ML, Biggs K, Sintchenko V, Gilbert GL. *Ureaplasma urealyticum* is significantly associated with non-gonococcal urethritis in heterosexual Sydney men. *Int J STD AIDS* 2010;21:337-341.

Crane M, Sirivichayakul S, Chang JJ, Avihingsanon A, Ubolyam S, Buranapraditkun S, Thantiworasit P, Wightman F, Locarnini S, **Matthews G**, **Dore GJ**, Ruxrungtham K, Lewin SR. No increase in hepatitis B virus (HBV)-specific CD8⁺ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy. *J Virol* 2010;84:2657-2665.

Cysique LA, **Murray JM**, Dunbar M, Jeyakumar V, Brew BJ. A screening algorithm for HIV-associated neurocognitive disorders. *HIV Med* 2010;11:642-649.

D

DART Trial Team (**Byakwaga H** member of the DART Trial Team). Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. *Lancet* 2010;375:123-131.

The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group (**Law M** member of Writing Committee; **Law M** member of D:A:D Steering Committee; **Petoumenos K** D:A:D data manager; **Law M**, **Petoumenos K**, Central Coordinators of AHOD, a participating cohort;

Cooper D participating physician). Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. *AIDS* 2010;24:1537-1548.

The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. Writing Committee: Weber R, Sabin C, Reiss P, de Wit S, Worm SW, Law M, Dabis F, D'Arminio Monforte A, Fontas E, El-Sadr W, Kirk O, Rickenbach M, Phillips, Ledergerber B, Lundgren J (**Law M** member of D:A:D Steering Committee; **Petoumenos K** D:A:D data manager; **Law M**, **Petoumenos K**, **Marashi Pour S** Central Coordinators of AHOD, a participating cohort; **Cooper D** participating physician). HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: The D:A:D Cohort Study. *Antivir Ther* 2010;15:1077-1086.

Day CA, **White B**, **Dore GJ**, van Beek I, Rodgers C, **Cunningham P**, Wodak A, **Maher L**. Hepatitis B virus among injecting drug users in Sydney, Australia: Prevalence, vaccination and knowledge of status. *Drug Alcohol Depend* 2010;108:134-137.

Degenhardt L, Bruno R, **Topp L**. Is ecstasy a drug of dependence? *Drug Alcohol Depend* 2010;107:1-10.

de Wit JB, **Prestage GP**, Duffin IR. Gay men: current challenges and emerging approaches in HIV prevention. *N S W Public Health Bull* 2010;21:65-68.

Dolan K, Teutsch S, Scheuer N, Levy M, Rawlinson W, **Kaldor J**, Lloyd A, Haber P. Incidence and risk for acute hepatitis C infection during imprisonment in Australia. *Eur J Epidemiol* 2010;25:143-148.

Donovan B, Harcourt C, Egger S, Fairley CK. Improving the health of sex workers in NSW: maintaining success. *N S W Public Health Bull* 2010;21:74-77.

Dore GJ, Hellard M, **Matthews GV**, **Grebely J**, Haber PS, **Petoumenos K**, **Yeung B**, **Marks P**, van Beek I, McCaughan G, White P, French R, Rawlinson W, Lloyd AR, **Kaldor JM** for the Australian Trial In Acute Hepatitis C Study Group. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. *Gastroenterology* 2010;138:123-135.

Dore GJ, Soriano V, Rockstroh J, Kupfer B, Tedaldi E, Peters L, Neuhaus J, Puoti M, Klein MB, Mocroft A, Clotet B, Lundgren JD for the SMART INSIGHT study group. Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. *AIDS* 2010;24:857-865.

Drummond F, **Guy R**, **Kaldor JM**, **Donovan B**. The intersection between HIV and syphilis in men who have sex with men: some fresh perspectives. *HIV Therapy* 2010;4:661-673.

Dunbar M, **Murray JM**, Cysique LA, Brew BJ, Jeyakumar V. Simultaneous classification and feature selection via convex quadratic programming with application to HIV-associated neurocognitive disorder assessment. *Eur J Oper Res* 2010;206:470-478.

Duncombe C, **Kerr SJ**, Liddy J, Avihingsanon A, Ruxrungtham K, Phanuphak P. Efficacy and tolerability of zidovudine 200 mg BID as part of combination antiretroviral therapy for 96 weeks. *J Acquir Immune Defic Syndr* 2010;54:e19-e20.

E

Eron JE, Young B, **Cooper DA**, Youle M, DeJesus E, Andrade-Villanueva J, Workman C, Zajdenverg R, Faetkenheuer G, Berger DA, Kumar PN, Rodgers AJ, Shaughnessy MA, Walker ML, Barnard RJO, Miller MD,

DiNubile MJ, Nguyen B-Y, Leavitt R, Xu X, Sklar P for the SWITCHMRK 1 and 2 Investigators. Switch to a raltegravir-based regimen versus continuation of a lopinavir/ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. *Lancet* 2010;375:396-407.

F

Fairley CK, **Donovan B**. What can surveillance of genital warts tell us? *Sex Health* 2010; 7:325-327 (editorial review).

Falster K, **Wand H, Donovan B**, Anderson J, Nolan D, Watson J, **Law MG** on behalf of the Australian HIV Observational Database (**Cooper DA, Petoumenos K, Pour SM, Bendall C, Templeton D** members of AHOD; **Templeton D** Cause of Death reviewer for AHOD). Hospitalizations in a cohort of HIV patients in Australia, 1999-2007. *AIDS* 2010;24:1329-1339.

Farr AC, **Wilson DP**. An HIV epidemic is ready to emerge in the Philippines. *J Int AIDS Soc* 2010;13:16.

Feigin A, **Higgs P**, Hellard M, Dietze P. Further research required to determine link between khat consumption and driver impairment. *Bull World Health Organ* 2010;88:480.

Franklin N, O'Connor CC, Shaw M, **Guy R, Grulich A**, Fairley CK, Chen MY, Hellard M, Dickson B, Marshall L, **Donovan B** on behalf of the ACCESS Collaboration. Chlamydia at an inner metropolitan sexual health service in Sydney, NSW: Australian Collaboration for Chlamydia Enhanced Sentinel Surveillance (ACCESS) Project. *Sex Health* 2010;7: 478-483.

French MA, Tanaskovic S, **Law MG**, Lim A, Fernandez S, Ward LD, **Kelleher AD, Emery S**. Vaccine-induced IgG2 anti-HIV p24 is associated with control of HIV in patients with a 'high-affinity' Fc RIIa genotype. *AIDS* 2010;24:1983-1990.

Frisz-Moller N, Thiebault R, Reiss P, Weber R, D'Arminio Monforte S, De Wit S, El-Sadr W, Fontas E, Worm S, Kirk O, Phillips A, Sabin CA, Lundgren JD, **Law M** on behalf of the D:A:D Study Group (**Law M** member of Writing Committee; **Law M** member of D:A:D Steering Committee; **Petoumenos K** D:A:D data manager; **Law M, Petoumenos K**, Central Coordinators of AHOD, a participating cohort; **Cooper D** participating physician). Predicting the risk of cardiovascular disease in HIV-infected patients. The Data collection on Adverse Effects of Anti-HIV Drugs Study. *Eur J Cardiovasc Prev Rehabil* 2010;17:491-501.

G

Gao Z, **Gidding HF**, Wood JG, MacIntyre CR. Modelling the impact of one-dose vs. two-dose vaccination regimens on the epidemiology of varicella zoster virus in Australia. *Epidemiol Infect* 2010;138:457-468.

Gidding HF, Amin J, Dore CJ, Ward K, **Law MG**. Hospital-related morbidity in people notified with hepatitis C: A population-based record linkage study in New South Wales, Australia. *J Hepatol* 2010;53:43-49.

Goller JL, **Guy RJ**, Gold J, Lim MSC, El-Hayek C, Stooze MA, Bergeri I, Fairley CK, Leslie DE, Clift P, White B, Hellard ME. Establishing a linked sentinel surveillance system for blood-borne viruses and sexually transmissible infections: methods, system attributes and early findings. *Sex Health* 2010;7:425-433.

Gray RT, Hoare A, Prestage GP, Donovan B, Kaldor JM, Wilson DP. Frequent testing of highly sexually active gay men is required to control syphilis. *Sex Transm Dis* 2010;37:298-305.

Gray R, Wilson D. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. *N Eng J Med* 2010;362:1740 (letter).

Grebely J, Knight E, Genoway KA, Viljoen M, Khara M, Elliott D, Gallagher L, Storms M, Raffa JD, DeVlaming S, Duncan F, Conway B. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. *Eur J Gastroenterol Hepatol* 2010;22:270-277.

Grebely J, Knight E, Ngai T, Genoway KA, Raffa JD, Storms M, Gallagher L, Krajden M, **Dore GJ**, Duncan F, Conway B. Reinfection with hepatitis C virus following sustained virological response in injection drug users. *J Gastroenterol Hepatol* 2010;25:1281-1284.

Grebely J, Matthews GV, Petoumenos K, Dore GJ. Spontaneous clearance and the beneficial impact of treatment on clearance during recent hepatitis C virus infection. *J Viral Hepat* 2010;17:896 (letter).

Grebely J, Petoumenos K, Hellard M, **Matthews GV**, Suppiah V, **Applegate T, Yeung B, Marks P**, Rawlinson W, Lloyd AR, Booth D, **Kaldor JM**, George J, **Dore GJ** for the ATAC Study Group. Potential role for *Interleukin-28B* genotype in treatment decision-making in recent hepatitis C virus infection. *Hepatology* 2010;52:1216-1224.

Grebely J, Petoumenos K, Matthews GV, Haber P, **Marks P**, Lloyd AR, **Kaldor JM, Dore GJ**, Hellard M for the ATAC Study Group. Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAC Study. *Drug Alcohol Depend* 2010;107:244-249.

Grulich AE, Jin F, Conway EL, Stein AN, Hocking J. Cancers attributable to human papillomavirus infection. *Sex Health* 2010;7:244-52.

Grulich AE, Vajdic CM, Falster MO, Kane E, Smedby KE, Bracci PM, de Sanjose S, Becker N, Turner J, Martinez-Maza O, Melbye M, Engels EA, Vineis P, Costantini AS, Holly EA, Spinelli JJ, La Vecchia C, Zheng T, Chiu BCH, Franceschi S, Cocco P, Maynadie M, Foretova L, Staines A, Brennan P, Davis S, Severson RK, Cerhan JR, Breen EC, Birmann B, Cozen W. Birth order and risk of non-hodgkin lymphoma – true association or bias? *Am J Epidemiol* 2010;172:621-630.

Grulich A, O'Donnell D, de Wit JB. Surveillance, epidemiology and behavioural research to guide HIV prevention policy. *NSW Public Health Bull* 2010;21:96.

Grulich AE, Wilson DP. Is antiretroviral therapy modifying the HIV epidemic? *Lancet* 2010;376:1824 (letter).

Grulich AE, Zablotska I. Commentary: Probability of HIV transmission through anal intercourse. *Int J Epidemiol* 2010;39:1064-1065.

Guy RJ, Goller JL, Spelman T. Does the frequency of HIV and STI testing among men who have sex with men in primary care adhere with Australian guidelines? *Sex Transm Infect* 2010;86:371-376.

Guy RJ, Kong F, Goller J, Franklin N, Bergeri I, Dimech W, Reilly N, Sullivan E, **Ward J, Kaldor JM**, Hellard M, **Donovan B**. New national Chlamydia sentinel surveillance system in Australia: Evaluation of the first stage of implementation. *Comm Dis Intell* 2010;34: 319-328.

H

Hansudewechakul R, Sirisanthana V, Kurniati N, Puthanakit T, Lumbiganon P, Saphonn V, Khairulddin N, Yusoff N, Kumarasamy N, Fong SM, Nallusamy R, Srasuebkul P, **Law M**, Sohn AH, Chokephailbulkit K for the TREAT Asia Pediatric HIV Observational Database (**Cooper DA, Law MG, Kariminia A** members of the TREAT Asia Pediatric HIV

Network). Antiretroviral therapy outcomes of HIV-infected children in the TREAT Asia Pediatric HIV Observational Database. *J Acquir Immune Defic Syndr* 2010;55:503-509.

Harcourt C, O'Connor J, Egger S, Fairley CK, **Wand H**, Chen MY, Marshall L, **Kaldor JM**, **Donovan B**. The decriminalisation of prostitution is associated with better coverage of health promotion programs for sex workers. *Aust NZ J Public Health* 2010;34:482-486.

Healey LM, O'Connor CC, **Templeton DJ**. HIV result giving. Is it time to change our thinking? *Sex Health* 2010;7:8-10.

Hemachandra A, **Puls RL**, **Kerr S**, Sirivichayakul S, Thantiworasit P, Ubolyam S, **Cooper DA**, **Emery S**, Phanuphak P, **Kelleher A**, Ruxrungtham K. An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection. *Hum Vaccin* 2010;6:835-840.

Heymer K, **Wilson DP**. Available evidence does not support serosorting as an HIV risk reduction strategy. *AIDS* 2010;24:935-936 (letter).

Higgs P, **Maher L**. Older injectors: An emerging and under-recognised public health issue. *Drug Alcohol Rev* 2010;29:233-234 (editorial).

Hoare A, **Kerr SJ**, Ruxrungtham K, Ananworanich J, **Law MG**, **Cooper DA**, Phanuphak P, **Wilson DP**. Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia. *PLoS ONE* 2010;5(6):e10981.

Hong A, **Gulich A**, Jones D, Lee S, Garland S, Dobbins T, Clark J, Harnett G, Milross C, O'Brien C, Rose B. Oropharyngeal cancer. Australian data show increase. *BMJ* 2010;340:c2518 (letter).

Hong AM, **Gulich AE**, Jones D, Lee CS, Garland SM, Dobbins TA, Clark JR, Harnett GB, Milross CG, O'Brien CJ, Rose BR. Squamous cell carcinoma of the oropharynx in Australian males induced by human papillomavirus vaccine targets. *Vaccine* 2010;28:3269-3272.

Horyniak D, **Guy RJ**, Prybylski D, Hellard M, **Kaldor JM**. The utility of voluntary counselling and testing data as a source of information on HIV prevalence: a systematic review. *Int J STD AIDS* 2010;21:305-311.

Horyniak D, **Higgs P**, Lewis J, Winter R, Dietze P, Aitken C. An evaluation of a heroin overdose prevention and education campaign. *Drug Alcohol Rev* 2010;29:5-11.

The International HIV Controllers Study (**Cooper DA** – member, HIV controllers referral team). The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. *Science* 2010;330:1551-1557.

Iversen J, **Wand H**, Gonnermann A, **Maher L**. Gender differences in hepatitis C antibody prevalence and risk behaviours amongst people who inject drugs in Australia 1998-2008. *Int J Drug Policy* 2010;21:471-476.

Jin F, **Jansson J**, **Law M**, **Prestage GP**, **Zablotska I**, Imrie JCC, Kippax SC, **Kaldor JM**, **Gulich AE**, **Wilson DP**. Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART. *AIDS* 2010;24:907-913.

Jin F, **Prestage GP**, Imrie J, Kippax SC, **Donovan B**, **Templeton DJ**, Cunningham A, Mindel A, **Cunningham PH**, **Kaldor JM**, **Gulich AE**. Anal

sexually transmitted infections and risk of HIV infection in homosexual men. *J Acquir Immune Defic Syndr* 2010;53:144-149.

Jin F, **Prestage GP**, **Matthews G**, **Zablotska I**, Rawstone P, Kippax SC, **Kaldor JM**, **Gulich AE**. Prevalence, incidence and risk factors for hepatitis C in homosexual men: data from two cohorts of HIV-negative and HIV-positive men in Sydney, Australia. *Sex Transm Infect* 2010;86:25-28.

K

Kaldor JM, **Wilson DP**. How low can you go: The impact of a modestly effective HIV vaccine compared with male circumcision. *AIDS* 2010;24:2573-2578.

Kent SJ, **Cooper DA**, Vun MC, Shao Y, **Zhang L**, Ganguly N, Bela B, Tamashiro H, Ditango R, Rerks-Ngarm S, Pitisuttithum P, Van Kinh N, Bernstein A, Osmanov S, for the AIDS Vaccine for Asia Network investigators and supporters. AIDS Vaccine for Asia Network (AVAN): Expanding the regional role in developing HIV vaccines. *PLoS Med* 2010;7(9):e1000331.

Kerr SJ, **Ananworanich J**, Ruxrungtham K. Changing evidence on HIV treatment and prevention strategies: Implications and advice for healthcare workers and National Treatment Programmes in Asia. *Asian Biomed* 2010;4:501-503.

Kerr S, J; Sayer, G.P.; Whicker, S.D.; Rowett, D.S.; Saltman, D.C & Mant, A. All-cause mortality of elderly Australian veterans using COX-2 selective or non-selective NSAIDs: a longitudinal study. *Br J Clin Pharmacol* 2010 May 6; doi: 10.1111/j.1365-2125.2010.03702.x.

Kimber J, Copeland L, Hickman M, Macleod J, McKenzie J, De Angelis D, Robertson JR. Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. *Br Med J* 2010; 340:c3172.

L

Lampe FC, Duprez DA, Kuller LH, Tracy R, Otvos J, Stroes E, **Cooper DA**, Hoy J, Paton NI, Friis-Møller N, Neuhaus J, Liappis AP, Phillips AN for the INSIGHT SMART Study Group. Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapy. *J Acquir Immune Defic Syndr* 2010;54:275-284.

Lifson AR and INSIGHT Endpoint Review Committee Writing Group: Belloso WH, Davey RT, Duprez D, Gatell JM, Hoy JF, Krum EA, Nelson R, Pedersen C, Perez G, Price RW, Prineas RJ, Rhamé FS, Sampson JH, and Worley J for the INSIGHT Study Group (**Emery S**, **Cooper D**, **Pett S**, **Drummond F** INSIGHT collaborators). Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials. *HIV Clin Trials* 2010;11:205-219.

Lifson AR, Neuhaus J, Arribas JR, van den Berg-Wolf M, Labriola AM, Read TRH for the INSIGHT SMART Study Group (**Cooper DA**, **Emery S**, **Drummond FM** members of the SMART study group; **Emery S**, **Cooper D**, **Pett S**, **Drummond F** INSIGHT collaborators). Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. *Am J Pub Health* 2010;100:1896-1903.

Londish CJ, **Kwon JA**, **Wilson DP**. Equivalence of two mathematical models of injecting drug use, using Cauchy's theorem. *AMS Gazette* 2010;37:105-109.

Londish CJ, **Templeton DJ**, **Regan DG**, **Kaldor JM**, **Murray JM**. Minimal impact of circumcision on HIV acquisition in men who have sex with men.

Sex Health 2010;7:463-70.

Lutgehetmann M, Volz T, Köpke A, Broja T, Tigges E, Lohse A, Fuchs E, **Murray JM**, Petersen J, Dandri M. In vivo proliferation of hepatitis B virus-infected hepatocytes induces loss of the covalently closed circular DNA in mice. *Hepatology* 2010;52:16-24.

M

Macleod J, Copeland L, Hickman M, McKenzie J, **Kimber J**, DeAngelis D, Robertson JR. The Edinburgh Addiction Cohort: recruitment and follow-up of a primary care based sample of injection drug users and non drug-injecting controls. *BMC Public Health* 10:101.

Maher L, White B, Donald A, Bates A, Enriquez J, Pham S, Liao L. Using ethnographic fieldwork to inform hepatitis C vaccine preparedness studies with people who inject drugs. *Int J Drug Policy* 2010;21:194-201.

Maher L, White B, Hellard M, Madden A, Prins M, Kerr T, Page K. Candidate hepatitis C vaccine trials and people who inject drugs: Challenges and opportunities. *Vaccine* 2010;28:7273-7278.

Martin A, **Amin J, Cooper DA,** Carr A, **Kelleher AD,** Bloch M, Baker D, Woolley I, **Emery S** on behalf of the STEAL Study Group. Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial. *AIDS* 2010;24:2657-2663.

Martinez E, Visnegarwala F, Grund B, Thomas A, Gibert C, Shlay J, **Drummond F,** Pearce D, Edwards S, Reiss P, El-Sadr W, Carr A. The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters. *AIDS* 2010;24:353-363.

McNulty AM, Egan C, **Wand H, Donovan B.** The behaviour and sexual health of young international travellers (backpackers) in Australia. *Sex Transm Infect* 2010;86:247-250.

Merrall ELC, **Kariminia A,** Binswanger IA, Hobbs MS, Farrell M, Marsden J, Hutchinson SJ, Bird SM. Meta-analysis of drug-related deaths soon after release from prison. *Addiction* 2010;105:1545-1554.

Milner K-L, van der Poorten D, Trenell M, Jenkins AB, Xu A, Smythe G, **Dore GJ,** Zekry A, Weltman M, Fragomeli V, George J, Chisolm DJ. Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. *Gastroenterology* 2010;138:932-941.

Miura T, Brumme ZL, Brockman MA, Rosato P, Sela J, Brumme CJ, Pereyra F, Kaufmann DE, Trocha A, Block BL, Daar ES, Connick E, Jessen H, **Kelleher AD,** Rosenberg E, Markowitz M, Schafer K, Vaida F, Iwamoto A, Little S, Walker BD. Impaired replication capacity of acute/early viruses in persons who become HIV controllers. *J Virol* 2010;84:7581-7591.

Moore D, Dray A, Green R, **Hudson SL,** Jenkinson R, Siokou C, Perez P, Bammer G, **Maher L,** Dietze P. Extending drug ethno-epidemiology using agent-based modelling. *Addiction* 2010;104:1991-1997.

Mooney-Somers J, Ussher JM. Sex as commodity: Single and partnered men's subjectification as heterosexual men. *Men and Masculinities* 2010;12:353-373.

Murray JM, Vallely A, Page A. When the presumption of innocence is not beneficial: periodic presumptive treatment for STIs and HIV in female sex workers. *Sex Transm Infect* 2010;86:161-162 (commentary).

N

Nathani J, Iversen J, Shying K, Byrne J, **Maher L.** Qualitative accounts of

needle and syringe cleaning techniques among people who inject drugs in Sydney, Australia. *Drug Alcohol Rev* 2010;29:413-419.

Neaton JD, Neuhaus J, **Emery S.** Soluble biomarkers and morbidity among people infected with HIV: summary of published reports from 1997 to 2010. *Curr Opin HIV AIDS* 2010;5:480-490.

Neuhaus J, Angus B, Kowalska JD, La Rosa A, Sampson J, Wentworth D, Mocroft A for the INSIGHT SMART and ESPRIT Study Groups (**Cooper DA, Emery S, Drummond FM,** members of the SMART study group; **Emery S, Cooper D, Pett S, Drummond F** INSIGHT collaborators; **Cooper DA, Emery S** members of the ESPRIT Executive Committee). Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. *AIDS* 2010;24:697-706.

Neuhaus J, Jacobs Jr. DR, Baker JV, Calmy A, Duprez D, La Rosa A, Kuller LH, **Pett SL,** Ristola M, Ross MJ, Shlipak MG, Tracy R, Neaton JD for the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT), Strategies for Management of Anti-Retroviral Therapy (SMART), Multi-Ethnic Study of Atherosclerosis (MESA), and Coronary Artery Development in Young Adults (CARDIA) Research Groups (**Cooper DA, Emery S, Drummond FM** members of the SMART study group; **Emery S, Cooper D, Pett S, Drummond F** INSIGHT collaborators). Markers of inflammation, coagulation and renal function are elevated in adults with HIV infection. *J Infect Dis* 2010;201:1788-1795.

O

O'Brien AP, Cross WM, **Higgs P,** Munro I, Bloomer MJ, Cho KR. Australians living with and managing hepatitis C. *Issues in Mental Health Nursing* 2010;31:520-524.

O'Connor MB, O'Connor C, Saunders JA, Sheehan C, Murphy E, Horgan M, Carr A, **Cooper DA.** Substance use among HIV patients. *Ir J Med Sci* 2010;179:467-468 (letter).

O'Donnell D, **Gulich A,** Garsia R, Parkhill N, Browne K. HIV in NSW in 2010: sustaining success in an evolving epidemic. *N S W Public Health Bull* 2010;21:49-53 (editorial).

Oliver BG, Elliott JH, Price P, Phillips M, Saphonn V, Chhi Yun M, **Kaldor JM, Cooper DA,** French MA. Mediators of innate and adaptive immune responses differentially affect immune restoration disease associated with *Mycobacterium tuberculosis* in HIV patients beginning antiretroviral therapy. *J Infect Dis* 2010;202:1728-1737.

O'Loughlin J, Millwood IY, McDonald HM, Price CF, **Kaldor JM,** Paull JRA. Safety, tolerability, and pharmacokinetics of SPL7013 Gel (VivaGel®): A dose ranging, phase I study. *Sex Trans Dis* 2010;37:100-104.

Oyomopito R, Lee MP, Phanuphak P, Lim PL, Ditangco R, **Zhou J,** Sirisanthana T, Chen YMA, Pujari S, Kumarasamy N, Sungkanuparph S, Lee CKC, Kamarulzaman A, Oka S, Zhang FJ, Mean CV, Merati T, Tau G, Smith J, Li PCK on behalf of The TREAT Asia HIV Observational Database (**Cooper DA, Law MG, Oyomopito R, Zhou J** members of the TREAT Asia HIV Observational Database; **Law MG, Zhou J** members of the TAHOD Steering Committee). Measures of site resourcing predict virologic suppression, immunologic response and HIV disease progression following highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database (TAHOD). *HIV Med* 2010;11:519-529.

P

Petoumenos K, Hui E, Kumarasamy N, **Kerr SJ,** Choi JY, Chen YA, Merati

T, Zhang F, Lim P-L, Sungkanuparph S, Pujari S, Ponnampalavanar S, Ditangco R, Lee CKC, **Grulich A, Law MG**, TREAT Asia HIV Observational Database (TAHOD) (**Cooper DA, Law MG, Zhou J, Jiamsakul A** members of the TREAT Asia HIV Observational Database; **Law MG, Zhou J** members of the TAHOD Steering Committee). Cancers in the Treat Asia HIV Observational Database (TAHOD): A retrospective analysis of risk factors. *J Int AIDS Soc* 2010;13:51.

Pett SL, Emery S, Kelleher AD, Cooper DA. Antiretroviral agents: Focus on maraviroc for the treatment of HIV-1-infected adults. *Clinical Medicine Insights: Therapeutics* 2010;2: 697-713 (invited review).

Pett SL, Kelleher AD, Emery S. Role of interleukin-2 in patients with HIV infection. *Drugs* 2010;70:1115-1130.

Pett SL, Zaunders J, Bailey M, Murray J, MacRae K, Emery S, Cooper DA, Kelleher AD. A novel chemokine-receptor-5 (CCR5) blocker, SCH532706, has differential effects on CCR5⁺CD4⁺ and CCR5⁺CD8⁺ T cell numbers in chronic HIV infection. *AIDS Res Human Retroviruses* 2010;26:653-661.

Phidisa II Writing Team for Project Phidisa; Ratsela A, Polis M, Dhlomo S, **Emery S**, Grandits G, Khabo P, Khangile T, Komati S, Neaton JD, Naidoo LC, Magongoa D, Qolohle D. A randomized factorial trial comparing 4 treatment regimens in treatment-naïve HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/ μ L in South Africa. *J Infect Dis* 2010;202:1467-1469.

Poynten IM, Jin F, Prestage GP, Kaldor JM, Imrie J, Grulich AE. Attitudes towards new HIV biomedical prevention technologies among a cohort of HIV negative gay men in Sydney, Australia. *HIV Med* 2010;11:282-288.

Poynten IM, Jin F, Prestage GP, Kaldor JM, Kippax S, Grulich AE. Defining high HIV incidence subgroups of Australian homosexual men: implications for conducting HIV prevention trials in low HIV prevalence settings. *HIV Med* 2010;11:635-641.

Prasitsuebsai W, Bowen AC, Pang J, Hesp C, **Kariminia A**, Sohn AH. Pediatric HIV Clinical Care Resources and Management Practices in Asia: A Regional Survey of the TREAT Asia Pediatric Network. *AIDS Patient Care STDs* 2010;24:127-131.

Puls RL, Srasuebkul P, Petoumenos K, Boesecke C, **Duncombe C**, Belloso WH, Molina JM, Li L, Avihingsanon A, Gazzard B, **Cooper DA, Emery S** for the Altair Study Group (**Cooper D** (cochair), **Emery S, Petoumenos K, Puls R**, Altair Protocol Steering Committee; **Emery S, Puls RL**, Boesecke C, **Petoumenos K, Drummond F, Haskelberg H, Srasuebkul P, Courtney-Vega K, Berilazic M** members Altair Study Team; **Cooper DA** Altair site investigator). Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naïve, HIV-infected subjects: week 48 data from the Altair Study. *Clin Infect Dis* 2010;1;51:855-864.

Q

Quinn HE, McIntyre PB, Backhouse JL, **Gidding HF**, Brotherton J, Gilbert GL. The utility of seroepidemiology for tracking trends in pertussis infection. *Epidemiol Infect* 2010;138:426-433.

Raboud JM, Diong C, Carr A, Grinspoon S, Mulligan K, Sutinen J, Rozenbaum W, Cavalcanti RB, **Wand H**, Costagliola D, Walmsley S for the Glitazone and Lipatrophy Meta-Analysis Working Group. A Meta-Analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipatrophy. *HIV Clin Trials* 2010;11:39-50.

R

Regan DG, Philp DJ, **Waters EK**. Unresolved questions concerning human papillomavirus infection and transmission: a modelling perspective. *Sex Health* 2010;7:368-375.

Reks-Ngarm S, Pitisuttithum P, Ganguly N, **Zhang L**, Tamashiro H, **Cooper DA**, Van MC, Bela B, Ditangco R, Van Kinh N, Bernstein A, Osmanov S, Mathieson B, **Kent SJ**, Shao Y. Defining the Objectives of the AIDS Vaccine for Asia network: report of the WHO-UNAIDS/Global HIV vaccine enterprise regional consultation on expanding AIDS vaccine research and development capacity in Asia. *Curr Opin HIV AIDS* 2010;5:435-452.

Richters J, **Prestage G, Schneider K**, Clayton S. Do women use dental dams? Safer sex practices of lesbians and other women who have sex with women. *Sex Health* 2010;7:165-169.

S

Salmon AM, van Beek I, **Amin J, Kaldor J, Maher L**. The impact of a supervised injecting facility on ambulance call-outs in Sydney, Australia. *Addiction* 2010;105:676-683.

Sasson SC, Smith S, **Seddiki N, Zaunders JJ**, Bryant A, **Koelsch KK**, Weatherall C, **Munier M-L**, McGinley C, **Yeung J**, Mulligan SP, Moore J, **Cooper DA**, Milliken S, **Kelleher AD**. IL-7 receptor is expressed on adult B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers. *Cytokine* 2010;50:58-68.

Seed CR, Kee G, Wong T, **Law M**, Ismay S. Assessing the safety and efficacy of a test based, targeted screening strategy to minimise transfusion transmitted malaria. *Vax Sang* 2010;98:e182-e192.

Seed CR, Kiely P, **Law M**, Keller AJ. No evidence of a significantly increased risk of transfusion-transmitted human immunodeficiency virus infection in Australia subsequent to implementing a 12-month deferral for men who have had sex with men. *Transfusion* 2010;50:2722-2730.

Shen M, Menashe I, Morton LM, Zhang Y, Armstrong B, Wang SS, Lan Q, Hartge P, Purdue MP, Cerhan JR, **Grulich A**, Cozen W, Yeager M, Holford TR, Vajdic CM, Davis S, Leaderer B, Krickler A, Severson RK, Zahm SH, Chatterjee N, Rothman N, Chanock SJ, Zheng T. Polymorphisms in DNA repair genes and risk of non-Hodgkin lymphoma in a pooled analysis of three studies. *Br J Haematol* 2010;151:239-244.

Steigbigel RT, **Cooper DA**, Tepler H, Eron JJ, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Katlama C, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Clotet B, Zhao J, Wan H, Rhodes RR, Strohmaier KM, Barnard RJ, Isaacs RD, Nguyen BYT for the BENCHMRK Study Teams. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV Infection: Week 96 results of the BENCHMRK 1 and 2 Phase III Trials. *Clin Infect Dis* 2010;50:605-612.

Stevens MP, Twin J, Fairley CK, **Donovan B**, Tan SE, Yu J, Garland SM, Tabrizi SN. Development and evaluation of an ompA quantitative real-time PCR assay for *Chlamydia trachomatis* serovar determination. *J Clin Microbiol* 2010;48:2060-2065.

Sturgiss EA, **Jin F**, Martin SJ, **Grulich A**, Bowden FJ. Prevalence of other sexually transmitted infections in patients with newly diagnosed anogenital warts in a sexual health clinic. *Sex Health* 2010;7:55-59.

Suzuki K, Kelleher AD. Lessons from viral latency in T cells: manipulating HIV1 transcription by siRNA. *HIV Therapy* 2010;4:199-213.

T

Tavel JA, INSIGHT STALWART Study Group (**Cooper D, Emery S** members of the INSIGHT Executive Committee; **Carey C** member of the STALWART Study Group Protocol Team; **Carey C, Cooper D, Courtney-Rodgers D, Emery S** members of the STALWART Study Group Sydney International Coordinating Center; **Anderson J, Cooper DA** STALWART clinical site principal investigators). Effects of intermittent IL-2 alone or with pericycle antiretroviral therapy in early HIV infection: the STALWART study. *PLoS One* 2010;5(2):e9334.

Templeton DJ. Male circumcision to reduce sexual transmission of HIV. *Curr Opin HIV AIDS* 2010;5:344-349.

Templeton DJ, Jin F, McNally LP, Imrie JCC, Prestage GP, Donovan B, Cunningham PH, Kaldor JM, Kippax S, Grulich AE. Prevalence, incidence and risk factors for pharyngeal gonorrhoea in a community-based HIV-negative cohort of homosexual men in Sydney, Australia. *Sex Transm Infect* 2010;86:90-96.

Templeton DJ, Millett GA, Grulich AE. Male circumcision to reduce the risk of HIV and sexually transmitted infections among men who have sex with men. *Curr Opin Infect Dis* 2010;23:45-52.

Templeton DJ, Tyson BA, Meharg JP, Habgood KE, Bullen PM, Malek S, McLean R. Aboriginal health worker screening for sexually transmissible infections and blood-borne viruses in a rural Australian juvenile correctional facility. *Sex Health* 2010;7:44-48.

Templeton DJ, Williams A, Healey L, Odell M, Wells D. Male forensic physicians have an important role in sexual assault care. *J Forensic Leg Med* 2010;17:50-52 (letter).

Tong WW, McAllister J, White PA, **Kelleher AD, Carr A**. Transmission of triple-class, drug resistant HIV-1 in Australia. *Intern Med J* 2010;40:657-661.

Topp L, Hudson S, Maher L. Mental health symptoms among street-based psychostimulant injectors in Sydney's Kings Cross. *Subst Use Misuse* 2010;45:1180-1200.

Treloar C, Byron P, McCann P, **Maher L**. "Fitness for duty": social, organisational and structural influences on the design and conduct of candidate hepatitis C vaccine trials involving people who inject drugs. *Vaccine* 2010;28:5228-5236.

Treloar C, Newland J, Harris M, **Deacon R, Maher L**. A diagnosis of hepatitis C: Insights from a study on patients' experiences. *Aust Fam Physician* 2010; e155868:589-592.

V

Vallely A, Page A, Dias S, Siba P, Lupiwa T, Law G, Millan J, Wilson DP, Murray JM, Toole M, Kaldor JM. The prevalence of sexually transmitted infections in Papua New Guinea: A systematic review and meta-analysis. *PLoS One* 2010;5:e15586.

Vajdic CM, Mao L, van Leeuwen MT, Kirkpatrick P, **Grulich AE, Riminton S**. Are antibody deficiency disorders associated with a narrower range of cancers than other forms of immunodeficiency? *Blood* 2010;116:1228-1234.

Vajdic CM, van Leeuwen MT, Turner JJ, **McDonald AM, Webster AC, McDonald SP, Chapman JR, Kaldor JM, Grulich AE**. No excess risk of follicular lymphoma in kidney transplant and HIV-related immune deficiency. *Int J Cancer* 2010;127:2732-2735.

van de Laar TJ, **Matthews GV, Prins M, Danta M**. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. *AIDS* 2010; 24:1799-1812 (editorial review).

van Leeuwen MT, Webster AC, McCredie MRE, Stewart JH, McDonald SP, **Amin J, Kaldor JM, Chapman JR, Vajdic CM, Grulich AE**. Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. *Br Med J* 2010;340:c570; doi: 10.1136/bmj.c570.

W

Wand H, Ramjee G. Targeting the hotspots: Investigating spatial and demographic variations in HIV infection in small communities in South Africa. *J Int AIDS Soc* 2010;13:41.

Wand H, Yan P, Wilson D, McDonald A, Middleton M, Kaldor J, Law M. Increasing HIV transmission through male homosexual and heterosexual contact in Australia: results from an extended back-projection approach. *HIV Med* 2010;11:395-403.

Ward J, Akre SP, Kaldor JM. Guarding against an HIV epidemic within an Aboriginal community and cultural framework; lessons from NSW. *N S W Public Health Bull* 2010;21:78-82.

Wilson DP. European Christians are at the forefront in accepting evolution: results from an internet-based survey. *Evol Dev* 2010;12:537-540.

Wilson DP. Evidence is still required for treatment as prevention for riskier routes of HIV transmission. *AIDS* 2010;2891-2892 (letter).

Wilson DP. Interpreting sexually transmissible infection prevention trials by adjusting for the magnitude of exposure. *Clin Trials* 2010;7:36-43.

Wilson DP, Heymer KJ, Anderson J, O'Connor J, Harcourt C, Donovan B. Sex workers can be screened too often: a cost-effectiveness analysis in Victoria, Australia. *Sex Transm Infect* 2010;86:117-125.

Wilson DP, Hosein SR. It is too early to discuss HIV elimination. *Public Health Reports* 2010;125:786.

Wilson DP, Jin F, Jansson J, Zablotska I, Grulich AE. Infectiousness of HIV-infected men who have sex with men in the era of highly active antiretroviral therapy. *AIDS* 2010;24:2420-2421 (letter).

Wilson DP, Regan DG, Heymer KJ, Jin F, Prestage GP, Grulich AE. Serosorting may increase the risk of HIV acquisition among men who have sex with men. *Sex Transm Dis* 2010;37:13-17.

Winston A, **Duncombe C, Li PC, Gill JM, Kerr SJ, Puls R, Petoumenos K, Taylor-Robinson SD, Emery S, Cooper DA** for the Altair Study Group. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. *Clin Infect Dis* 2010;50:920-929.

Wodak A, **Maher L**. The effectiveness of harm reduction in preventing HIV among injecting drug users. *N S W Public Health Bull* 2010;21:69-73.

Wongsawat J, Puthanakit T, Kanjanavanit S, Hansudewechakul R, Ngampiyaskul C, **Kerr SJ, Ubolyam S, Suwanlerk T, Kosalaraksa P, Luesomboon W, Ngo-Giang-Huong N, Chandara M, Saphonn V, Ruxrungtham K, Ananworanich J** on behalf of the PREDICT study group. CD4 cell count criteria to determine when to initiate antiretroviral therapy in children. *Pediatr Infect Dis J* 2010;29:966-968.

Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, **Law M, D'Arminio Monforte A, Friis-Moller N, Kirk O, Fontas E, Weller**

I, Phillips A, Lundgren J for the D:A:D Study Group (**Law M** member of Writing Committee; **Petoumenos K** D:A:D data manager; **Law M, Petoumenos K**, Central Coordinators of AHOD, a participating cohort; **Cooper D** participating physician). Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. *J Infect Dis* 2010;201:318-330.

Wright EJ, Grund B, Robertson K, Brew BJ, Roediger M, Bain MP, **Drummond F**, Vjecha MJ, Hoy J, Miller C, Penalva de Oliveira AC, Pumpradit W, Shlay JC, El-Sadr W, Price RW for the INSIGHT SMART Study Group (**Cooper DA** clinical site investigator for the SMART Neurology substudy; **Cooper DA, Emery S, Drummond FM**, members of the SMART study group; **Emery S, Cooper D, Pett S, Drummond F** INSIGHT collaborators). Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. *Neurology* 2010;75:864-873.

Y

Yan CS, Hanafi I, **Kelleher AD**, Carr AD, **Amin J**, McNally LP, **Cunningham PH**. Lack of correlation between three commercial platforms for the evaluation of human immunodeficiency virus type 1 (HIV-1) viral load at the clinically critical lower limit of quantification. *J Clin Virol* 2010;49:249-253.

Yap L, Richters J, Butler T, **Schneider K**, Kirkwood K, **Donovan B**. Sexual practices and dental dam use among women prisoners – a mixed methods study. *Sex Health* 2010; 7: 170-176.

Z

Zablotska IB, Prestage G, Middleton M, Wilson D, Grulich AE. Contemporary HIV diagnoses trends in Australia can be predicted by trends in unprotected anal intercourse among gay men. *AIDS*; 2010;24:1955-1958 (research letter).

Zeiler I, Langlands T, **Murray JM**, Ritter A. Optimal targeting of hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance treatment. *Drug Alcohol Depend* 2010;110:228-233.

Zheng H, Ehrlich F, **Amin J**. Economic evaluation of the direct healthcare cost savings resulting from the use of walking interventions to prevent coronary heart disease in Australia. *Int J Health Care Finance Econ* 2010;10:187-201.

Zheng H, Ehrlich F, **Amin J**. Productivity loss resulting from coronary heart disease in Australia. *Appl Health Econ Health Policy* 2010;8:179-189.

Zhou J, Li PCK, Kumarasamy N, **Boyd M**, Chen YMA, Sirisanthana T, Sungkanuparph S, Oka S, Tau G, Phanuphak P, Saphonn V, Zhang FJ, Omar SFS, Lee KKC, Ditangco R, Merati TP, Lim PL, Choi JY, **Law MG**, Pujari S on behalf of the TREAT Asia HIV Observational Database. Deferred modification of antiretroviral regimen following documented treatment failure in Asia: results from the TREAT Asia HIV Observational Database (TAHOD). *HIV Med* 2010;11:31-39.

Zhou J, Sirisanthana T, Kiertiburanakul S, Chen YM, Han N, Lim PL, Kumarasamy N, Choi JY, Merati TP, Yunihastuti E, Oka S, Kamarulzaman A, Phanuphak P, Lee CK, Li PC, Pujari S, Saphonn V, **Law MG**. Trends in CD4 counts in HIV-infected patients with HIV viral load monitoring while on combination antiretroviral treatment: results from The TREAT Asia HIV Observational Database. *BMC Infect Dis* 2010;10:361.

Non-peer reviewed

Australian Chlamydia Control Effectiveness Pilot Executive (**Donovan B, Guy R** – members). General practices to accept the challenges. *Primary Times* (The Journal of the Australian Practice Nurses Association) 2010 June; 8:19.

Boyd MA, Crowe SM. Indinavir. In: Grayson ML, Crowe SM, McCarthy JS, Mills J, Mouton JW, Norrby SR, Paterson DL, Pfaller MA, eds. *Kucers' the Use of Antibiotics: A clinical review of antibacterial, antifungal, antiparasitic and antiviral drugs*. 6th ed. London: Hodder Arnold; 2010: 2776-2787.

Butler T, Richters J, Yap L, Papanastasiou C, Richards A, **Schneider K**, Grant L, Smith AMA, **Donovan B**. *Sexual health and behaviour of Queensland prisoners: with Queensland and New South Wales comparisons*. Perth and Sydney: National Drug Research Institute, Curtin University, and School of Public Health and Community Medicine, University of New South Wales; 2010.

Chute RS, **Templeton DJ**. Management of abnormal vaginal discharge. *Modern Medicine of South Africa* 2010 (July);43-45.

Commonwealth of Australia (**Donovan B** – expert writing panel). *Australasian Contact Tracing Manual*. 4th ed. Sydney: Australasian Society for HIV Medicine; 2010.

Cooper DA, Matthews G. Tenofovir. In: Grayson ML, Crowe SM, McCarthy JS, Mills J, Mouton JW, Norrby SR, Paterson DL, Pfaller MA, eds. *Kucers' the Use of Antibiotics: A clinical review of antibacterial, antifungal, antiparasitic and antiviral drugs*. 6th ed. London: Hodder Arnold; 2010: 2613-2626.

Donovan B, Dayan L. Syphilis. In: Warrell DA, Cox TM, Firth JD, eds. *Oxford Textbook of Medicine*. 5th ed. Oxford: Oxford University Press; 2010: 885-896.

Donovan B. Sex work and law reform. *Government Gazette* (Centre for Parliamentary Studies, London) 2010; Sept: 30 (invited editorial).

Donovan B, Harcourt C, Egger S, Schneider K, O'Connor J, Marshall L, Chen MY, Fairley CK. *The sex industry in Western Australia: a report to the Western Australian Government*. Sydney: National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales; 2010.

Donovan B, Knight V. What's happening in sexual health? *Primary Times* (The journal of the Australian Practice Nurses Association) 2010 June; 8: 8-9.

Feigin A, **Higgs P**, Hellard M, Dietze P. Further research required to determine link between khat consumption and driver impairment. *Bull World Health Org* 2010;88:480.

Grebely J, Dore G. Protease and polymerase inhibitors for the treatment of hepatitis C virus infection. In: Grayson ML, Crowe SM, McCarthy JS, Mills J, Mouton JW, Norrby SR, Paterson DL, Pfaller MA, eds. *Kucers' the Use of Antibiotics: A clinical review of antibacterial, antifungal, antiparasitic and antiviral drugs*. 6th ed. London: Hodder Arnold; 2010:2976-2989.

Grebely J, Dore G. Pegylated interferon alfa. In: Grayson ML, Crowe SM, McCarthy JS, Mills J, Mouton JW, Norrby SR, Paterson DL, Pfaller MA, eds. *Kucers' the Use of Antibiotics: A clinical review of antibacterial, antifungal, antiparasitic and antiviral drugs*. 6th ed. London: Hodder Arnold; 2010:2959-2957.

Higgs P. Women, ageing and hepatitis C. *Good Liver* 2010; Winter:5.

National Centre in HIV Epidemiology and Clinical Research. *Australian NSP Survey National Data Report 2005-2009*. National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW; 2010. Available at: <http://www.nchechr.unsw.edu.au>

National Centre in HIV Epidemiology and Clinical Research. *Bloodborne viral and sexually transmitted infections in Aboriginal and Torres Strait Islander People: Surveillance and Evaluation Report 2010*. National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, NSW; 2010. Available at: <http://www.nchechr.unsw.edu.au>

National Centre in HIV Epidemiology and Clinical Research. *Epidemiological and economic impact of potential increased hepatitis C treatment uptake in Australia 2010*. National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, NSW; 2010. Available at: <http://www.nchechr.unsw.edu.au>

National Centre in HIV Epidemiology and Clinical Research. *HIV, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2010*. National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, NSW; 2010. Available at: <http://www.nchechr.unsw.edu.au>

National Centre in HIV Epidemiology and Clinical Research. *Epidemiological and economic impact of potential increased hepatitis C treatment uptake in Australia 2010*. National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, NSW; 2010. Available at: <http://www.nchechr.unsw.edu.au>

Olsen A, Mooney-Somers J, Topp L, Maher L. *Sexual Health through the Eyes of Indigenous Youth: Conducting Survey Research Training Manual*. National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW; 2010.

Pett SL, Emery S. Atazanavir. In: Grayson ML, Crowe SM, McCarthy JS, Mills J, Mouton JW, Norrby SR, Paterson DL, Pfaller MA, eds. *Kucers' the Use of Antibiotics: A clinical review of antibacterial, antifungal, antiparasitic and antiviral drugs*. 6th ed. London: Hodder Arnold; 2010: 2830-2841.

Ryder N, **Donovan B.** The management and prevention of recurrent genital herpes. *Modern Medicine South Africa* 2010; Sept: 24-28.

Treloar C, Newland J, Harris M, **Deacon R, Maher L.** How did I get hepatitis C? *User's News* 2010;60(10):26-28.

Wilson DP, Heymer KJ. *Evaluation of HIV in South Australia*. Technical Report. Sydney: National Centre in HIV Epidemiology and Clinical Research, University of New South Wales; 2010.

Index of studies

ACCEPT: Australian Chlamydia control effectiveness pilot study	20
ACCESS: Australian Collaboration on Chlamydia Enhanced Sentinel Surveillance	10
ACHOS: Australian Chronic Hepatitis C Observational Study	20
AHOD: The Australian HIV Observational Database	18
AHOD: The Australian HIV Observational Database STI project	20
ALTAIR	13
ALTAIR Bone biomarker Sub-study	14
ALTAIR MRS Sub-study	14
ALTAIR Renal Sub-study	14
Analyses of the National Creutzfeldt-Jakob Disease Registry	11
ANSPS: The Australian Needle and Syringe Program Survey	11
Assays of T-cell function, proliferation and cytotoxicity, and identification of antigen-specific T-cells	32
ATAHC: Characterisation of reinfection/mixed HCV infection in recently acquired HCV	33
ATAHC: Characterisation of the humoral immune response in recently acquired HCV	33
ATAHC: IL28B-associated SNP mutations in recently acquired HCV	33
ATAHC: In-vivo hepatitis C virus adaptation to host HLA-restricted immune responses in recently acquired HCV 42	32
ATAHC: IPI0 & IL28B serum protein levels in recently acquired HCV	32
ATAHC: ISG expression profiles within peripheral blood in recently acquired HCV	33
ATAHC: T-cell responses in recently acquired HCV	33
ATAHC: Transmission networks in recently acquired HCV	34
ATAHC II: Australian Trial in Acute Hepatitis C	18
Australian HIV Surveillance Report	7
Australian Long-Term Non-Progressor Study	30
Australian Red Cross Blood Bank Surveillance	8
B cell subsets, neutralising antibodies and auto-antibodies at primary HIV-1 infection	31
Behavioural predictors of HIV diagnoses trends (Australian Gay Community Periodic Surveys and HIV surveillance)	11
Bloodborne viral and sexually transmitted infections in Aboriginal and Torres Strait Islander People: Surveillance Report 2010	8
Cambodian Treatment Access Program (CTAP)	39
Cancer Council STREP Grant	18
Cancer in primary immune deficiency	29
CHARIOT: Ribavirin concentrations in with chronic HCV in subjects	34
Chlamydia incidence and re-infection study (CIRIS): a longitudinal cohort study of young Australian women	28
Chronic hepatitis B prevalence in Australia among at-risk populations: results from a systematic review and meta-analysis	10
Clinical Service Delivery for HIV Positive People in Australia	12
COLD: Liver Disease and HIV/HBV Coinfection in the era of HAART	18
CONNECT: Social norms regarding HIV/STI risk and risk reduction behaviours among men who have sex with men in Australia	25
CORAL: ART Intensification with raltegravir and hyper-immune bovine colostrum	15
Culturally and linguistically diverse MSM at SSHC: diagnostic and behavioural trends	26
Culture and HIV Prevention in Cambodia	39
D:A:D: The Data Collection on the Adverse Events of Anti-HIV Drugs Study	18
Data from the highly specialised drugs program	19
Defining risk and mechanisms of per mucosal transmission of acute HCV infection within high-risk populations	25
Developing and validating a scoring tool for identifying people who inject drugs at highest risk of hepatitis C virus infection	9
Developing the National Gay Men's Syphilis Action Plan	10
Development and trial of Key Performance Indicators for Sexually Transmitted Infection control in clinical settings with high bacterial prevalence	36
Do SMS reminders improve retesting rates after chlamydia infection in heterosexuals?	27
Do SMS reminders improve STI testing frequency in men who have sex with men (MSM)?	27
Economic, social and cross cultural issues in non-pharmaceutical protection of front line responders to pandemic influenza and emerging infections	21
Eco-pathogenomics of chlamydial infection of the human reproductive tract	11
ENCORE1	14

ENCORE1 CNS Sub-study	14
ENCORE1 Intensive Pharmacokinetics Sub-study	14
ENCORE2	14
ENCORE3	14
Epidemiological and economic impact of potential increased hepatitis C treatment uptake in Australia	9
eTEST: An initiative to enhance STI Testing in gay men	24
ETHOS: Enhancing Treatment of Hepatitis C in Opiate Substitution Settings	18
Etravirine + Raltegravir Study	17
Evaluating and predicting the epidemiological impact of health policies for reducing HIV in Melanesian and South-East Asian populations	41
Evaluating Needle-Syringe Programs in Vietnam	41
Evaluating the effectiveness of needle and syringe programs in Eastern Europe	40
Evaluating the epidemiological benefits of needle and syringe programs in Australia	12
Evaluation in China	40
Evaluation of syphilis PCR	22
Evaluation of the epidemiological impact of harm reduction programs across Vietnam	41
Evolution of immune responses in primary infection and long-term non-progressors	31
Examination of injecting drug use life course and estimating prevalence and health consequences of a dynamic population	28
Exploring the natural history of injection drug use: A qualitative study of social and environmental influences in the VIDUS cohort	27
FLUOO2	17
FLUOO3	17
From Broome to Berrima: building Australia-wide research capacity in Indigenous offender health and health care delivery	37
Geographic variation in anal cancer incidence in New South Wales	29
GOANNA	35
Group sex study	25
HAVIT: Hepatitis Acceptability and Vaccination Incentives Trial	19
Hepatitis C Vaccine Preparedness Studies	19
Hepatitis C virus transmission dynamics among injection drug users in Vancouver (ARYS / VIDUS Cohort)	34
HepBank Clinical Sample Repository & Open Access Substudy database (LabKey)	31
HIM (Health in Men) study: defining high HIV incidence subgroups	24
HIM (Health in Men) study: incidence and risk factors for pharyngeal gonorrhoea	24
HIM (Health in Men) study: per contact probability of HIV transmission	24
HIM (Health in Men) study: sero-epidemiology of Human papillomavirus	29
HIV Consortium for Partnerships in Asia and the Pacific	39
HIV drug resistance	32
HIV Modelling Grant	35
HIV treatment failure, therapeutic pathways, and clinical outcomes: understanding the present and planning for the future	11
HIV vaccine preparedness cohort study (Health in Men study)	23
HIV, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report	7
HSV-2 / HIV Epidemiology Study, PNG	41
Identifying predisposing factors for, and the consequences of, common and emerging infectious diseases	22
Immunopathogenesis of immune reconstitution disease	31
Immuno-phenotyping of T-cell subsets	30
InC3: International Collaboration of Incident hepatitis C in Injecting Cohorts Collaborative Group	19
Increasing completeness of 'Aboriginality' in infectious diseases data through record linkage – a feasibility study	36
Indigenous injecting use in Queensland (IIDU): a peer based research project	36
International pooled analysis of immune risk factors for lymphoma	29
International research workshop focused on newly acquired hepatitis C in injecting drug users	40
Is azithromycin adequate treatment for asymptomatic rectal chlamydia?	20
Laboratory surveillance of incident HIV infection	9
LASA	17
LASH: The Law and Sexworker Health Project	26
Liver Spots: A study of hepatitis B knowledge, treatment and health care among Indigenous Australians	37
Longitudinal study of bacterial vaginosis and Mycoplasma genitalium in young Australian women	28
Long-term surveillance of genital warts through Australian sexual health services	11
MAGNIFICENT: Myocardial infarction, assessment of Antiretroviral and Genetic factors in Human Immunodeficiency Virus infection	18
Mapping gay community networks in Sydney, NSW	25

Mapping HIV outcomes in Australia	12
MARCH	17
Mathematical modelling of bacterial STIs in Australian sub-populations	20
Mathematical modelling of human papillomavirus transmission	20
MCAIS: Male Circumcision Acceptability & Impact Study, PNG	41
Merging HIV and AIDS registries	8
Modelling and economic evaluation of hepatitis C epidemic mitigation strategies in Australia	9
Modelling and impact of hepatitis C treatment in prisons	10
Modelling HIV epidemics in South Australia	12
Modelling HIV in NSW	12
Modelling HIV Vaccines (international collaboration with Centers for Disease Control)	41
Modelling interventions to prevent HIV infection and their acceptability among gay men in NSW	23
Modelling interventions to prevent syphilis infection and their acceptability among gay men	23
Modelling the interaction between sexually transmitted infections and HIV transmission to inform public health policy	12
Monitoring cases of AIDS	8
Monitoring cases of newly diagnosed HIV infection	8
Monitoring cases of newly diagnosed viral hepatitis	9
Monitoring diagnoses of newly acquired HIV infection	8
Monitoring HIV and viral hepatitis among blood donors	9
Monitoring HIV antibody prevalence among prison entrants in Australia	9
Monitoring HIV prevalence and incidence through sexual health clinics	9
Monitoring HIV transmission through specialised tests for incident HIV infection	8
Monitoring long-term outcome of newly acquired HIV infection	8
Monitoring long-term outcomes of chronic hepatitis B and C	9
Monitoring perinatal exposure to HIV	8
Monogamy: meanings and practices among gay men	26
Morbidity in people with hepatitis B and C in New South Wales	12
NACS Masculinities Study, PNG	41
Notifiable Diseases and Reproductive Health	21
Novel real time PCR technology for mixed infection	32
NSW Chlamydia review	42
Out on the Reef 2010	26
PASH (Pleasure and Sexual Health) Study: understandings of risk among gay men	25
Pelvic Inflammatory Disease in the primary health care setting: an investigation of clinical management	36
Periodic surveys of HIV risk behaviour	11
PHAEDRA: Primary HIV and early disease research: Australian cohort extension	30
PHIDISA Ia	13
PHIDISA II	13
PINT	14
RAMPT-C cohort	34
RAMPT-C study: Defining risk and mechanism of per mucosal transmission for acute HCV infection within high-risk populations	19
RAMPT-C: sexual transmission of HCV among HIV-positive gay men	26
REACCH: Research Excellence in Aboriginal Community Controlled Health	35
REACH Initiative: Research and education in HIV/AIDS for resource-poor countries	40
REACT study	21
Report on the sex industry in New South Wales	42
Report on the sex industry in Western Australia	42
Resistance mutations to Directly Acting Antivirals in treatment naïve patients	33
RESTORE	31
Review of hepatitis B from the NNDSS	9
Review of HIV transmission	12
Review of HPV associated cancers in Australia	28
Review of the history and methodology of the Australian behavioural surveillance and its implications for policy and prevention (Australian Gay Community Periodic Surveys)	11
Risk factors for HIV seroconversion	25
RNA inducing viral latency	32

Role of resiliency in responding to blood-borne viral and sexually transmitted infections in Indigenous communities	36
Scabies - Factors associated with scabies in a highly endemic population	40
Seasonal trends in STI diagnoses: an investigation	27
SECOND-LINE	14
SECOND-LINE Body Composition sub-study	15
SECOND-LINE Dried Blood Spot sub-study	15
Serotype identification of HCV genotype	34
Sexually adventurous men's study	25
SHIMMER: NSW Aboriginal Health Research Program	36
Situational analysis of public health responses to chronic hepatitis B in the Torres Strait	36
SPANC: Study of the prevention of anal cancer	28
SPARTA	17
SPARTAC: Randomised trial in primary HIV infection looking at three forms of intervention	13
Specimen receipt and processing for clinical trials and natural history studies	31
STALWART	15
START: Strategic Timing of Antiretroviral Therapy	15
START: Arterial Elasticity: A substudy of Strategic Timing of AntiRetroviral Treatment	16
START: Bone Mineral Density: A substudy of Strategic Timing of AntiRetroviral Treatment	16
START: Genomics: A substudy of Strategic Timing of AntiRetroviral Treatment	16
START: Informed Consent Substudy: A substudy of Strategic Timing of AntiRetroviral Treatment	15
START: Neurology: a substudy of Strategic Timing of AntiRetroviral Treatment	16
START: Pulmonary Substudy: A substudy of Strategic Timing of AntiRetroviral Treatment	16
Staying Safe: A sociology of how injecting drug users avoid viral infection in the long-term	40
Staying safe: How do long term injecting drug users avoid hepatitis C infection?	24
STEAL Body Composition Sub-study	16
STEAL Bone biomarker Sub-study	16
STEAL HLA Sub-study	16
STI Modelling Grant	36
STRIVE	35
Study of gay community attachment among Australian gay men and its implications for behavioural surveillance and research (Australian Gay Community Periodic Surveys)	25
Support for national surveillance committees	7
Surveillance of lymphogranuloma venereum Chlamydia trachomatis types among men who have sex with men	10
Survey of epidemiological cohort studies and specimen sample sets and development of technical guidance documents for HIV incidence assays	38
Survey of the sexual behaviour and sexual health of Australian prisoners	26
Syphilaxis: a trial of chemoprophylaxis to prevent syphilis in men who have sex with men with HIV infection	20
Syphilis point-of-care test evaluation	22
Syphilis testing in HIV positive men	21
Systematic review and meta-analyses of HIV comorbid conditions	12
TREAT Asia HIV Observational Database (TAHOD)	38
TREAT Asia Paediatric HIV Observational Database (TApHOD)	39
TREAT Asia Quality Assurance Scheme (TAQAS)	39
TREAT Asia Studies Evaluating Resistance (TASER)	38
Unprotected oral sex and sex workers	27
Uptake and outcomes of chlamydia or gonorrhoea testing programs in non-clinical settings: a systematic review	21
Using CD4 counts at diagnosis to estimate incidence	11
Using mathematical models to assess the impact of interventions to reduce sexually transmitted infections in Australia	12
Viral reservoirs	31
Women's and men's experiences of preventing mother-to-child transmission (PMTCT) in Papua New Guinea	40
Young Women's Reproductive Health Study	9

About NCHECR

The National Centre in HIV Epidemiology and Clinical Research (NCHECR) was established in 1986 by the Australian Government to fulfil a number of key roles in Australia's fight against HIV/AIDS.

NCHECR is affiliated with the Faculty of Medicine, University of New South Wales.

NCHECR's primary functions relate to the co-ordination of national surveillance programs, clinical research and clinical trials. While its original focus was exclusively on HIV/AIDS, NCHECR's work has expanded to encompass hepatitis B and C, and sexually transmissible infections. NCHECR also conducts research into the transmission, prevention and natural history of these infections.

NCHECR's research program has increasingly taken on a regional focus, with major collaborative programs in Thailand and Cambodia. NCHECR conducts research through nine programs. Dissemination of NCHECR's research output is undertaken through publication in scientific journals and a range of surveillance reports. This publication was funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government.

ISSN No. 1441-2640

National Centre in HIV Epidemiology and Clinical Research has three locations:

Director's Unit and the Immunovirology and Pathogenesis Program:
Level 4, 405 Liverpool Street, Darlinghurst NSW 2010 Australia

Therapeutic and Vaccine Research Program; Biostatistics and Databases Program; Sexual Health Program;
Aboriginal and Torres Strait Islander Health Program; and Public Health Interventions Research Group:
UNSW Cliffbrook Campus, 45 Beach Street, Coogee NSW 2034

HIV Epidemiology and Prevention Program; Viral Hepatitis Epidemiology and Prevention Program; Viral
Hepatitis Clinical Research Program; Surveillance and Evaluation Program for Public Health; Administration,
and Finance:

The CFI Building, corner Boundary and West Streets, Darlinghurst NSW 2010

Postal address: The CFI Building, Corner Boundary and West Streets, Darlinghurst NSW 2010

Telephone +61 (2) 9385 0900

Web: <http://www.nchecr.unsw.edu.au/>

Fax +61 (2) 9385 0920

Email: recpt@nchecr.unsw.edu.au

National Centre in HIV Epidemiology and Clinical Research Annual Report 2010

Editor: Louise Wright

Design: Luke Gover/Gadfly

Images: Claire Reynolds

